

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113571 A2

- (51) International Patent Classification⁷: C12Q 1/68 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/IB2004/002394
- (22) International Filing Date: 25 June 2004 (25.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/482,595 26 June 2003 (26.06.2003) US
- (71) Applicant (for all designated States except US): EXON-HIT THERAPEUTICS SA [FR/FR]; 26, rue Brunel, F-75017 Paris (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EINSTEIN, Richard [US/US]; 12421 Galesville Dr., Gaithersburg, MD 20878 (US). MCGOWAN, Kevin, M. [US/US]; 15132 Winesap Drive, N. Potomac, MD 20878 (US). PANDO, Matthew, P. [US/US]; 2004 N. Cleveland Street, Arlington, VA 22201 (US).
- (74) Agents: BECKER, Philippe et al.; Becker & Associés, 35 rue des Mathurins, F-75008 Paris (FR).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE CANCER THERAPY AND DIAGNOSIS

(57) Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.

**PROSTATE SPECIFIC GENES AND THE
USE THEREOF AS TARGETS FOR PROSTATE CANCER
THERAPY AND DIAGNOSIS**

5

FIELD OF THE INVENTION

The present invention relates to the identification of DNA sequences that correspond to alternatively spliced events in genes expressed on the surface of prostate cancer cells. These genes or their corresponding proteins are to be targeted for the treatment, prevention and/or diagnosis of cancers wherein these genes are differentially regulated and/or spliced, particularly in prostate cancer.

10

BACKGROUND OF THE INVENTION

Genetic detection of human disease states is a rapidly developing field (Taparowsky et al., 1982; Slamon et al., 1989; Sidransky et al., 1992; Miki et al., 1994; Dong et al., 1995; Morahan et al., 1996; Lifton, 1996; Barinaga, 1996). However, some problems exist with this approach. A number of known genetic lesions merely predispose an individual to the development of specific disease states. Individuals carrying the genetic lesion may not develop the disease state, while other individuals may develop the disease state without possessing a particular genetic lesion. In human cancers, genetic defects may potentially occur in a large number of known tumor suppresser genes and proto-oncogenes.

20

Genetic detection of cancer has a long history. Some of the earliest genetic lesions shown to predispose to cancer were transforming point mutations in the ras oncogenes (Taparowsky et al., 1982). Transforming ras point mutations may be detected in the stool of individuals with benign and malignant colorectal tumors (Sidransky et al., 1992). However, only 50% of such tumors contained a ras mutation (Sidransky et al., 1992). Similar results have been obtained with amplification of HER-2/neu in breast and prostate cancer (Slamon et al., 1989), deletion and mutation of p53 in bladder cancer (Sidransky et al., 1991), deletion of DCC in colorectal cancer (Fearon et al., 1990) and mutation of BRCA1 in breast and prostate cancer (Miki et al., 1994).

25

None of these genetic lesions are capable of predicting a majority of individuals with cancer and most require direct sampling of a suspected tumor, and make screening difficult. Further, none of the markers described above are capable of distinguishing between metastatic

30

and non-metastatic forms of cancer. In effective management of cancer patients, identification of those individuals whose tumors have already metastasized or are likely to metastasize is critical. Because metastatic cancer kills 560,000 people in the U.S. each year (ACS home page), identification of markers for metastatic prostate cancer would be an important advance.

5 A particular problem in cancer detection and diagnosis occurs with prostate cancer. Carcinoma of the prostate is the most frequently diagnosed cancer among men in the United States (Veltri et al., 1996). Prostate cancer was diagnosed in approximately 189,500 men in 1998 and about 40,000 men succumbed to the malignancy (Landis et al, 1998). Although relatively few prostate tumors progress to clinical significance during the lifetime of the
10 patient, those which are progressive in nature are likely to have metastasized by the time of detection. Survival rates for individuals with metastatic prostate cancer are quite low. Between these extremes are patients with prostate tumors that will metastasize but have not yet done so, for whom surgical prostate removal is curative. Determination of which group a patient falls within is critical in determining optimal treatment and patient survival.

15 The FDA approval of the serum prostate specific antigen (PSA) test in 1984 changed the way that prostate disease was managed (Allhoff et al., 1989; Cooner et al., 1990; Jacobson et al, 1995; Orozco et al., 1998). PSA is widely used as a serum biomarker to detect and monitor therapeutic response in prostate cancer patients (Badalament et al., 1996; O'Dowd et al., 1997). Several modifications in PSA assays (Partin and Oesterling, 1994; Babian et al.,
20 1996; Zlotta et al, 1997) have resulted in earlier diagnoses and improved treatment.

 Although PSA has been widely used as a clinical marker of prostate cancer since 1988 (Partin and Oesterling, 1994), screening programs utilizing PSA alone or in combination with digital rectal examination (DRE) have not been successful in improving the survival rate for men with prostate cancer (Partin and Oesterling, 1994). Although PSA is specific to prostate
25 tissue, it is produced by normal and benign as well as malignant prostatic epithelium, resulting in a high false-positive rate for prostate cancer detection (Partin and Oesterling, 1994).

 While an effective indicator of prostate cancer when serum levels are relatively high, PSA serum levels are more ambiguous indicators of prostate cancer when only modestly elevated, for example when levels are between 2-10 ng/ml. At these modest elevations, serum
30 PSA may have originated from non-cancerous disease states such as BPH (benign prostatic hyperplasia), prostatitis or physical trauma (McCormack et al, 1995). Although application of

the lower 2.0 ng/ml cancer detection cutoff concentration of serum PSA has increased the diagnosis of prostate cancer, especially in younger men with nonpalpable early stage tumors (Stage T1c) (Soh et al., 1997; Carter and Coffey, 1997; Harris et al., 1997; Orozco et al., 1998), the specificity of the PSA assay for prostate cancer detection at low serum PSA levels remains
5 a problem.

Several investigators have sought to improve upon the specificity of serologic detection of prostate cancer by examining a variety of other biomarkers besides serum PSA concentration (Ralph and Veltri, 1997). One of the most heavily investigated of these other biomarkers is the ratio of free versus total PSA (f/t PSA) in a patient's blood. Most PSA in
10 serum is in a molecular form that is bound to other proteins such as alpha1-antichymotrypsin (ACT) or alpha2-macroglobulin (Christensson et al, 1993; Stenman et al., 1991; Lilja et al., 1991). Free PSA is not bound to other proteins. The ratio of free to total PSA (f/tPSA) is usually significantly higher in patients with BPH compared to those with organ confined prostate cancer (Marley et al., 1996; Oesterling et al., 1995; Pettersson et al., 1995). When an
15 appropriate cutoff is determined for the f/tPSA assay, the f/tPSA assay can help distinguish patients with BPH from those with prostate cancer in cases in which serum PSA levels are only modestly elevated (Marley et al., 1996; Partin and Oesterling, 1996). Unfortunately, while f/tPSA may improve on the detection of prostate cancer, information in the f/tPSA ratio is insufficient to improve the sensitivity and specificity of serologic detection of prostate cancer
20 to desirable levels.

Other markers that have been used for prostate cancer detection include prostatic acid phosphatase (PAP) and prostate secreted protein (PSP). PAP is secreted by prostate cells under hormonal control (Brawn et al., 1996). It has less specificity and sensitivity than does PSA. As a result, it is used much less now, although PAP may still have some applications for
25 monitoring metastatic patients that have failed primary treatments. In general, PSP is a more sensitive biomarker than PAP, but is not as sensitive as PSA (Huang et al., 1993). Like PSA, PSP levels are frequently elevated in patients with BPH as well as those with prostate cancer.

Another serum marker associated with prostate disease is prostate specific membrane antigen (PSMA) (Horoszewicz et al., 1987; Carter and Coffey, 1996; Murphy et al., 1996).
30 PSMA is a Type II cell membrane protein and has been identified as Folic Acid Hydrolase (FAH) (Carter and Coffey, 1996). Antibodies against PSMA react with both normal prostate

tissue and prostate cancer tissue (Horoszewicz et al., 1987). Murphy et al. (1995) used ELISA to detect serum PSMA in advanced prostate cancer. As a serum test, PSMA levels are a relatively poor indicator of prostate cancer. However, PSMA may have utility in certain circumstances. PSMA is expressed in metastatic prostate tumor capillary beds (Silver et al., 5 1997) and is reported to be more abundant in the blood of metastatic cancer patients (Murphy et al., 1996). PSMA messenger RNA (mRNA) is down-regulated 8-10 fold in the LNCaP prostate cancer cell line after exposure to 5-alpha-dihydroxytestosterone (DHT) (Israeli et al., 1994).

Two relatively new potential biomarkers for prostate cancer are human kallekrein 2 10 (HK2) (Piironen et al., 1996) and prostate specific transglutaminase (pTGase) (Dubbink et al., 1996). HK2 is a member of the kallekrein family that is secreted by the prostate gland (Piironen et al., 1996). Prostate specific transglutaminase is a calcium-dependent enzyme expressed in prostate cells that catalyzes post-translational cross-linking of proteins (Dubbink et al., 1996). In theory, serum concentrations of HK2 or pTGase may be of utility in prostate 15 cancer detection or diagnosis, but the usefulness of these markers is still being evaluated.

Interleukin 8 (IL-8) has also been reported as a marker for prostate cancer. (Veltri et al., 1999). Serum IL-8 concentrations were reported to be correlated with increasing stage of prostate cancer and to be capable of differentiating BPH from malignant prostate tumors. (Id.) The wide-scale applicability of this marker for prostate cancer detection and diagnosis is still 20 under investigation.

In addition to these protein markers for prostate cancer, several genetic changes have been reported to be associated with prostate cancer, including: allelic loss (Bova, et al., 1993; Macoska et al., 1994; Carter et al., 1990); DNA hypermethylation (Isaacs et al., 1994); point mutations or deletions of the retinoblastoma (Rb), p53 and KAI1 genes (Bookstein et al., 25 1990a; Bookstein et al., 1990b; Isaacs et al., 1991; Dong et al., 1995); and aneuploidy and aneusomy of chromosomes detected by fluorescence in situ hybridization (FISH) (Macoska et al., 1994; Visakorpi et al., 1994; Takahashi et al., 1994; Alcaraz et al., 1994). None of these have been reported to exhibit sufficient sensitivity and specificity to be useful as general screening tools for asymptomatic prostate cancer.

30 In current clinical practice, the serum PSA assay and digital rectal exam (DRE) is used to indicate which patients should have a prostate biopsy (Lithrup et al., 1994; Orozco et al.,

1998). Histological examination of the biopsied tissue is used to make the diagnosis of prostate cancer. Based upon the 189,500 cases of diagnosed prostate cancer in 1998 (Landis, 1998) and a known cancer detection rate of about 35% (Parker et al., 1996), it is estimated that in 1998 over one-half million prostate biopsies were performed in the United States (Orozco et al., 1998; Veltri et al., 1998). Clearly, there would be much benefit derived from a serological test that was sensitive enough to detect small and early stage prostate tumors that also had sufficient specificity to exclude a greater portion of patients with noncancerous or clinically insignificant conditions.

There remain deficiencies in the prior art with respect to the identification of the genes linked with the progression of prostate cancer and the development of diagnostic methods to monitor disease progression. Likewise, the identification of genes, which are differentially expressed in prostate cancer, would be of considerable importance in the development of a rapid, inexpensive method to diagnose cancer. Although a few prostate specific genes have been cloned (PSA, PSMA, HK2, pTGase, etc.), these are typically not upregulated in prostate cancer. The identification of a novel, prostate specific gene that is differentially expressed in prostate cancer, compared to non-malignant prostate tissue, would represent a major, unexpected advance for the diagnosis, prognosis and treatment of prostate cancer.

The use of therapeutic antibodies for treatment of cancers that target surface proteins is known. Examples thereof include RITUXAN® that targets CD20 on B cell lymphoma, Campath® that targets a surface antigen CD52 expressed by chronic lymphocytic leukemia, Herceptin® that targets erbB2 on breast and other cancers and Mybtara that targets CD33 surface antigen expressed on leukemia cells. However, to date, a monoclonal antibody for treatment of prostate cancer has not been approved for therapeutic use.

SUMMARY OF THE INVENTION

The present invention relates to the identification of novel nucleic acid and amino acid sequences that are characteristic of prostate cancer cell or tissue, and which represent targets for therapy or diagnosis of such a condition in a subject.

The invention more specifically discloses 159 specific, isolated nucleic acid molecules that encode novel expression sequences. Of these, 122 are expressed sequence tags that are differentially spliced and correspond to SEQ ID NOS 1-65, 74, 80, 85, 102-134, 136, 141, 146,

150-165, 167, 168. In addition, 42 specific isoforms of known genes have been identified corresponding to SEQ ID NOS. 67-72, 75-77, 81-83, 86-90, 92, 93, 95-98, 100, 101, 137-139, 143, 144, 147-149, 169-173, 175, 177, 179, and 181. These novel sequences were found to be differentially expressed between normal prostate and prostate cancer. The expressed sequence tag represent novel exons that are alternatively spliced in prostate cancer, and as such, directly identify distinct isoforms. These sequences and molecules represent targets and valuable information to develop methods and materials for the detection, diagnosis, and treatment of prostate cancer.

10 It is an object of the invention to provide methods and materials for treatment and diagnosis of prostate cancer.

 It is a more specific object of the invention to identify novel exons (novel splice variants) that are expressed by prostate cancer tissue which are potential gene targets for treatment and diagnosis of prostate cancer.

15 It is a specific object of the invention to develop novel therapies for treatment of prostate cancer involving the administration or use of anti-sense oligonucleotides corresponding to novel gene targets that are specifically expressed by the prostate cancer.

 It is another specific object of the invention to identify exons and the corresponding protein domain encoded by those exons specifically upregulated in prostate cancer cells.

20 It is another specific object of the invention to produce ligands that bind antigens encoded by the exons, expressed as a protein domain by certain prostate cancers, including, but not limited to, monoclonal antibodies.

 It is another specific object of the invention to provide novel therapeutic regimens for the treatment of prostate cancer that involve the administration or use of antigens expressed by certain prostate cancers, alone or in combination with adjuvants that elicit an antigen-specific cytotoxic T-cell lymphocyte response against cancer cells that express such antigen.

25 It is another object of the invention to provide novel therapeutic regimens for the treatment of prostate cancer that involve the administration or use of ligands, especially monoclonal antibodies that specifically bind novel antigens that are expressed by certain prostate cancers.

30

It is an other object of this invention to provide pharmaceutical compositions comprising a ligand or antigen as defined above, in combination with a pharmaceutically acceptable carrier or excipient and/or an adjuvant.

It is another object of the invention to provide a novel method for diagnosis of prostate cancer by using ligands, e.g., monoclonal antibodies, which specifically bind to antigens that are specifically expressed by certain prostate cancers, in order to detect whether a subject has or is at increased risk of developing prostate cancer.

It is another object of the invention to provide a novel method of detecting persons having, or at increased risk of developing prostate cancer by use of labeled DNAs that hybridize to novel gene targets expressed by certain prostate cancers.

It is yet another object of the invention to provide diagnostic test kits for the detection of persons having or at increased risk of developing prostate cancer that comprise a ligand, e.g., monoclonal antibody that specifically binds to an antigen expressed by prostate cancer cells, and a detectable label, e.g. indicator enzymes, a radiolabels, fluorophores, or paramagnetic particles.

It is another object of the invention to provide diagnostic kits for detection of persons having or at risk of developing prostate cancer that comprise DNA primers or probes specific for novel gene targets specifically expressed by prostate cancer cells, and a detectable label, e.g. indicator enzymes, a radiolabels, fluorophores, or paramagnetic particles.

It is another object of this invention to provide methods for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising a determination of whether a candidate compound binds, preferably selectively, an antigen or a polynucleotide as disclosed in the present application. Such compounds represent drug candidates or leads for treating cancer diseases, particularly prostate cancer.

It is another object of the invention to identify genes that are expressed in altered forms in prostate cancer cells. These forms represent splice variants of the gene, where the DATASTM fragment either 1) indicates the splice event occurring within the gene, or 2) points to a gene that is actively spliced to produce different gene products. These different splice variants or isoforms can be targets for therapeutic intervention.

LEGEND TO THE FIGURES

Figure 1 : Expression of Sequence ID: No. 92 in normal human tissue. Primers were designed to detect the DATAS clone sequence and RT-PCR analysis was performed for 30 cycles. Lane 1, Prostate; lane 2, Heart; lane 3, Lung; lane 4, Kidney; lane 5, Liver; lane 6, Brain; lane 7, Placenta; lane 8, Sk. Muscle; lane 9, Pancreas; lane 10, Spleen; lane 11, Thymus; lane 12, Testis; lane 13, Ovary; lane 14, Sm. Intestine; lane 15, Colon; lane 16 Leukocyte.

Figure 2 : Expression of clone (SEQ ID NO 92) in normal and tumor prostate samples. Primers were designed to detect the DATAS clone and RT-PCR analysis was performed for 40 cycles. Individual RNA samples (normal and tumor) were tested both as pooled and as individual samples. The pooled RNA samples were used to produce cDNA using either an oligo dT approach (dT) or through a random primer protocol (RP). Individual patient cDNA samples (lanes 9-12) were prepared through the random primed protocol. Lane 1, prostate tumor pool 1 (RP cDNA); lane 2, normal prostate pool 1 (RP cDNA); lane 3, prostate tumor pool 2 (RP cDNA); lane 4, normal prostate pool 2 (RP cDNA); lane 5, prostate tumor pool 1 (dT cDNA); lane 6, normal prostate pool 1 (dT cDNA); lane 7, normal prostate pool 2 (dT cDNA); lane 8, NTC; lane 9, Patient 1 (OHK); lane 10, Patient 2 (T523); lane 11, Patient 3 (82B) ; lane 12, Patient 4 (4BK).

Figure 3 : Alignment of the different isoforms isolated from structural analysis of clone (DATAS clone number). The sequences isolated from the DATAS derived events were mapped using Blat against the Human genome to annotate the gene and determine the each unique splicing event. Five events are mapped with AK092666, an EST that closely resembles the five events.

Figure 4 : Western blot analysis for the expression of STEAP2 isoforms. Protein extracts from prostate cancer cell lines were separated on SDS_PAGE gels and transferred to nitrocellulose, and probed with an antibody raised against a peptide sequence present in the N-terminal portion of the wild type STEAP2 protein. Five different cell lines were analyzed: lane 1) LNCaP; 2) 22Rv1 3) MDA-PCa2b; 4) PC3; 5) DU145. The blot was developed using standard chemiluminescence reagents.

DETAILED DESCRIPTION OF THE INVENTION

DATAS (Different Analysis of Transcripts with Alternative Splicing) analyzes structural differences between expressed genes and provides systematic access to alterations in RNA splicing (disclosed in U.S. Patent No.6,251,590, the disclosure of which is
5 incorporated by reference in its entirety). Having access to these spliced sequences, which are critical for cellular homeostasis, represents a useful advance in functional genomics.

The DATAS Technology generates two libraries when comparing two samples, such as
10 normal vs. tumor tissue. Each library specifically contains clones of sequences that are present and more highly expressed in one sample. For example, library A will contain sequences that are present in genes in the normal samples but absent in the tumor samples. These sequences are identified as being removed or spliced out from the genes in the tumor samples. In contrast, library B will contain sequences that are present only in the tumor samples and not
15 present in the normal samples. These represent exons/introns that are alternatively spliced into genes expressed *only* in the tumor samples.

The present invention is based in part on the identification of exons that are isolated using DATAS and then determined to be differentially regulated or expressed in prostate
20 tumor samples. Specifically, 122 expressed sequence tags were identified through DATAS and confirmed to be differentially expressed between normal prostate tissue and prostate tumor tissue. These DATAS fragments (DF) are small sections of genes that are selected for inclusion or exclusion in one sample but not the other. These small sections are part of the expressed gene transcript, and can consist of sequences derived from several different regions
25 of the gene, including, but not limited to, portions of single exons, several exons, sequence from introns, and sequences from exons and introns. This alternative usage of exons in different biological samples produces different gene products from the same gene through a process well known in the art as alternative RNA splicing. In particular, 37 alternatively spliced isoforms have been identified from the DATAS fragment sequences, and produce
30 alternate gene products that fit all the descriptions of targets and gene products below.

Alternatively spliced mRNA's produced from the same gene contain different ribonucleotide sequence, and therefore translate into proteins with different amino acid sequences. Nucleic acid sequences that are alternatively spliced into or out of the gene products can be inserted or deleted in frame or out of frame from the original gene sequence. This leads to the translation of different proteins from each variant. Differences can include simple sequence deletions, or novel sequence information inserted into the gene product. Sequences inserted out of frame can lead to the production of an early stop codon and produce a truncated form of the protein. Alternatively, in-frame insertions of nucleic acid may cause an additional protein domain to be expressed from the mRNA. The end stage target is a novel protein containing either a novel epitope or function. Many variations of known genes have been identified and produce protein variants that can be agonistic or antagonistic with the original biological activity of the protein.

DATAS fragments thus identify genes and proteins which are subject to differential regulation and alternative splicing(s) in prostate cancer cells. DATAS fragments thus allow the definition of target molecules suitable for diagnosis or therapy of prostate cancers, which target molecules comprise all or a portion of genes or RNAs comprising the sequence of a DATAS fragment, or of genes or RNA from which the sequence of a DATAS fragment derives, as well as corresponding polypeptides or proteins, and variants thereof.

A first type of target molecule is a target nucleic acid molecule comprising the sequence of a full gene or RNA molecule comprising the sequence of a DATAS fragment as disclosed in the present application. Indeed, since DATAS identifies genetic deregulations associated with prostate tumor, the whole gene or RNA sequence from which said DATAS fragment derives can be used as a target of therapeutic intervention or diagnosis.

Similarly, another type of target molecule is a target polypeptide molecule comprising the sequence of a full-length protein comprising the amino acid sequence encoded by a DATAS fragment as disclosed in the present application.

A further type of target molecule is a target nucleic acid molecule comprising a fragment of a gene or RNA as disclosed above. Indeed, since DATAS identifies genes and RNAs that are altered in prostate tumor cells, portions of such genes or RNAs, including portions that do not comprise the sequence of a DATAS fragment, can be used as a target for therapeutic intervention or diagnosis. Examples of such portions include : DATAS fragments, portions

thereof, alternative exons or introns of said gene or RNA, exon-exon, exon-intron or intron-intron junction sequences generated by splicing(s) in said RNA, etc. Particular portions comprise a sequence encoding a extra-cellular domain of a polypeptide.

Similarly, another type of target molecule is a fragment of a protein comprising the amino acid
5 sequence encoded by a DATAS fragment as disclosed in the present application. Such fragments may comprise or not the DATAS sequence, and may comprise newly generated amino acid sequence resulting, for instance, from a frame shift, a novel exon-exon or exon-intron junction, the creation of new stop codon, etc.

10 These target molecules (including genes, fragments, proteins and their variants) can serve as diagnostic agents and as targets for the development of therapeutics. For example, these therapeutics may modulate biological processes associated with prostate tumor viability. Agents may also be identified that are associated with the induction of apoptosis (cell death) in prostate tumor cells. Other agents can also be developed, such as monoclonal antibodies, that
15 bind to the protein or its variant and alter the biological processes important for cell growth. Alternatively, antibodies can deliver a toxin which can inhibit cell growth and lead to cell death.

Specifically, the invention provides sequences that are expressed in a variant protein
20 and are prostate tumor specific or prostate specific. These sequences are portions of genes identified to be in the plasma membrane of the cell through bioinformatic analysis, and the specific sequences of the invention are expressed on the extracellular region of the protein, so that the sequences may be useful in the preparation of prostate tumor vaccines, including prophylatic and therapeutic vaccines.

25 Based thereon, it is anticipated that the disclosed genes that are associated with the differentially expressed sequences and the corresponding variant proteins should be suitable targets for prostate cancer therapy, prevention or diagnosis, e.g. for the development of antibodies, small molecular inhibitors, anti-sense therapeutics, and ribozymes. The potential therapies are described in greater detail below.

30 Such therapies will include the synthesis of oligonucleotides having sequences in the antisense orientation relative to the subject nucleic acids which appear to be up-regulated in

prostate cancer. Suitable therapeutic antisense oligonucleotides will typically vary in length from two to several hundred nucleotides in length, more typically about 50-70 nucleotides in length or shorter. These antisense oligonucleotides may be administered as naked nucleic acids or in protected forms, e.g., encapsulated in liposomes. The use of liposomal or other
5 protected forms may be advantageous as it may enhance *in vivo* stability and thus facilitate delivery to target sites, i.e., prostate tumor cells.

Also, the subject novel genes may be used to design novel ribozymes that target the cleavage of the corresponding mRNAs in prostate tumor cells. Similarly, these ribozymes may be administered in free (naked) form or by the use of delivery systems that enhance stability
10 and/or targeting, e.g., liposomes.

Also, the present invention embraces the administration of use of nucleic acids that hybridize to the novel nucleic acid targets identified *infra*, attached to therapeutic effector moieties, e.g., radiolabels, (e.g., ^{90}Y , ^{131}I) cytotoxins, cytotoxic enzymes, and the like in order to selectively target and kill cells that express these nucleic acids, i.e., prostate tumor cells.

15 Also, the present invention embraces the treatment and/or diagnosis of prostate cancer by targeting altered genes or the corresponding altered protein particularly splice variants that are expressed in altered form in prostate tumor cells. These methods will provide for the selective detection of cells and/or eradication of cells that express such altered forms thereby minimizing adverse effects to normal cells.

20 Still further, the present invention encompasses non-nucleic acid based therapies. For example, the invention encompasses the use of a DNA containing one of the novel cDNAs corresponding to novel antigen identified herein. It is anticipated that the antigens so encoded may be used as therapeutic or prophylactic anti-tumor vaccines. For example, a particular contemplated application of these antigens involves their administration with adjuvants that
25 induce a cytotoxic T lymphocyte response.

Administration of the subject novel antigens in combination with an adjuvant may result in a humoral immune response against such antigens, thereby delaying or preventing the development of prostate cancer.

These embodiments of the invention will comprise administration of one or more of
30 the subject novel prostate cancer antigens, ideally in combination with an adjuvant, e.g., PROVAX™ (as disclosed U.S. Patents Nos. 5,709,860, 5,695,770, and 5,585,103, which

comprises a microfluidized adjuvant containing Squalene, Tween and Pluronic), ISCOM'S[®], DETOX[®], SAF, Freund's adjuvant, Alum[®], Saponin[®], among others. This composition will be administered in an amount sufficient to be therapeutically or prophylactically effective, e.g. on the order of 50 to 20,000 mg/kg body weight, 100 to 5000 mg/kg body weight.

5 Yet another embodiment of the invention will comprise the preparation of monoclonal antibodies against the antigens encoded by the novel genes containing the nucleic acid sequences disclosed infra. Such monoclonal antibodies may be produced by conventional methods and include human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies, single chain antibodies, e.g., scFv's and antigen-binding
10 antibody fragments such as Fab and Fab' fragments. Methods for the preparation of monoclonal antibodies are known in the art. In general, preparation of monoclonal antibodies will comprise immunization of an appropriate (non-homologous) host with the subject prostate cancer antigens, isolation of immune cells therefrom, use of such immune cells to isolate monoclonal antibodies and screening for monoclonal antibodies that specifically bind to either
15 of such antigens. Antibody fragments may be prepared by known methods, e.g., enzymatic change of monoclonal antibodies.

These monoclonal antibodies and fragments will be useful for passive anti-tumor immunotherapy, or may be attached to therapeutic effector moieties, e.g., radiolabels, cytotoxins, therapeutic enzymes, agents that induce apoptosis, and the like in order to provide
20 for targeted cytotoxicity, i.e., killing of human prostate tumor cells. Given the fact that the subject genes are apparently not significantly expressed by many normal tissues this should not result in significant adverse side effects (toxicity to non-target tissues).

In one embodiment, of the present invention such antibodies or fragments will be administered in labeled or unlabeled form, alone or in conjunction with other therapeutics,
25 e.g., chemotherapeutics such as cisplatin, methotrexate, adriamycin, and the like suitable for prostate cancer therapy. The administered composition will also typically include a pharmaceutically acceptable carrier, and optionally adjuvants, stabilizers, etc., used in antibody compositions for therapeutic use.

Preferably, the subject monoclonal antibodies will bind the target antigens with high
30 affinity, e.g., possess a binding affinity (Kd) on the order of 10^{-6} to 10^{-12} M.

As noted, the present invention also embraces diagnostic applications that provide for detection of the expression of prostate specific splice variants disclosed herein. This will comprise detecting the expression of one or more of these genes at the RNA level and/or at the protein level.

5 For nucleic acids, expression of the subject genes will be detected by known nucleic acid detection methods, e.g., Northern blot hybridization, strand displacement amplification (SDA), catalytic hybridization amplification (CHA), and other known nucleic acid detection methods. Preferably, a cDNA library will be made from prostate cells obtained from a subject to be tested for prostate cancer by PCR using primers corresponding to the novel isoforms
10 disclosed in this application.

The presence or absence of prostate cancer can be determined based on whether PCR products are obtained, and the level of expression. The levels of expression of such PCR product may be quantified in order to determine the prognosis of a particular prostate cancer patient (as the levels of expression of the PCR product often will increase or decrease
15 significantly as the disease progresses.) This may provide a method for monitoring the status of a prostate cancer patient.

Alternatively, the status of a subject to be tested for prostate cancer may be evaluated by testing biological fluids, e.g., blood, urine, lymph, and the like with an antibody or antibodies or fragment that specifically binds to the novel prostate tumor antigens disclosed
20 herein.

Methods for using antibodies to detect antigen expression are well known and include ELISA, competitive binding assays, and the like. In general, such assays use an antibody or antibody fragment that specifically binds the target antigen directly or indirectly bound to a label that provides for detection, e.g. indicator enzymes, a radiolabels, fluorophores, or
25 paramagnetic particles.

Patients which test positive for the enhanced presence of the antigen on prostate cells will be diagnosed as having or being at increased risk of developing prostate cancer. Additionally, the levels of antigen expression may be useful in determining patient status, i.e., how far disease has advanced (stage of prostate cancer).

30 As noted, the present invention provides novel splice variants that encode antigens that correlate to human prostate cancer. The present invention also embraces variants thereof. As

used herein "variants" means sequences that are at least about 75% identical thereto, more preferably at least about 85% identical, and most preferably at least 90% identical and still more preferably at least about 95-99% identified when these DNA sequences are compared to a nucleic acid sequence encoding the subject DNAs or a fragment thereof having a size of at least about 50 nucleotides. This includes allelic and splice variants of the subject genes. The present invention also encompasses nucleic acid sequences that hybridize to the subject splice variants under high, moderate or low stringency conditions e.g., as described *infra*.

Also, the present invention provides for primer pairs that result in the amplification of DNAs encoding the subject novel genes or a portion thereof in an mRNA library obtained from a desired cell source, typically human prostate cell or tissue sample. Typically, such primers will be on the order of 12 to 50 nucleotides in length, and will be constructed such that they provide for amplification of the entire or most of the target gene.

Also, the invention embraces the antigens encoded by the subject DNAs or fragments thereof that bind to or elicits antibodies specific to the full-length antigens. Typically, such fragments will be at least 10 amino acids in length, more typically at least 25 amino acids in length.

As noted, the subject DNA fragments are expressed in a majority of prostate tumor samples tested. The invention further contemplates the identification of other cancers that express such genes and the use thereof to detect and treat such cancers. For example, the subject DNA fragments or variants thereof may be expressed on other cancers, e.g., breast, ovary, pancreas, lung or prostate cancers. Essentially, the present invention embraces the detection of any cancer wherein the expression of the subject novel genes or variants thereof correlate to a cancer or an increased likelihood of cancer. To facilitate under-study of the invention, the following definitions are provided.

"Isolated tumor antigen or tumor protein" refers to any protein that is not in its normal cellular environment. This includes by way of example compositions comprising recombinant proteins encoded by the genes disclosed *infra*, pharmaceutical compositions comprising such purified proteins, diagnostic compositions comprising such purified proteins, and isolated protein compositions comprising such proteins. In preferred embodiments, an isolated prostate tumor protein according to the invention will comprise a substantially pure protein, in that it is substantially free of other proteins, preferably that is at least 90% pure, that comprises the

amino acid sequence contained herein or natural homologues or mutants having essentially the same sequence. A naturally occurring mutant might be found, for instance, in tumor cells expressing a gene encoding a mutated protein according to the invention.

“Native tumor antigen or tumor protein” refers to a protein that is a non-human primate
5 homologue of the protein having the amino acid sequence contained infra.

“Isolated prostate tumor gene or nucleic acid sequence” refers to a nucleic acid molecule that encodes a tumor antigen according to the invention which is not in its normal human cellular environment, e.g., is not comprised in the human or non-human primate chromosomal DNA. This includes by way of example vectors that comprise a gene according
10 to the invention, a probe that comprises a gene according to the invention, and a nucleic acid sequence directly or indirectly attached to a detectable moiety, e.g. a fluorescent or radioactive label, or a DNA fusion that comprises a nucleic acid molecule encoding a gene according to the invention fused at its 5’ or 3’ end to a different DNA, e.g. a promoter or a DNA encoding a detectable marker or effector moiety. Also included are natural homologues or mutants having
15 substantially the same sequence. Naturally occurring homologies that are degenerate would encode the same protein including nucleotide differences that do not change the corresponding amino acid sequence. Naturally occurring mutants might be found in tumor cells, wherein such nucleotide differences may result in a mutant tumor antigen. Naturally occurring homologues containing conservative substitutions are also encompassed.

“Variant of prostate tumor antigen or tumor protein” refers to a protein possessing an amino acid sequence that possess at least 90% sequence identity, more preferably at least 91% sequence identity, even more preferably at least 92% sequence identity, still more preferably at least 93% sequence identity, still more preferably at least 94% sequence identity, even more preferably at least 95% sequence identity, still more preferably at least 96% sequence identity,
25 even more preferably at least 97% sequence identity, still more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity, to the corresponding native tumor antigen wherein sequence identity is as defined infra. Preferably, this variant will possess at least one biological property in common with the native protein.

“Variant of prostate tumor gene or nucleic acid molecule or sequence” refers to a
30 nucleic acid sequence that possesses at least 90% sequence identity, more preferably at least 91%, more preferably at least 92%, even more preferably at least 93%, still more preferably at

least 94%, even more preferably at least 95%, still more preferably at least 96%, even more preferably at least 97%, even more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity, to the corresponding native human nucleic acid sequence, wherein "sequence identity" is as defined infra.

5 "Fragment of prostate antigen encoding nucleic acid molecule or sequence" refers to a nucleic acid sequence corresponding to a portion of the native human gene wherein said portion is at least about 50 nucleotides in length, or 100, more preferably at least 150 nucleotides in length.

"Antigenic fragments of prostate tumor antigen" refer to polypeptides corresponding to
10 a fragment of a prostate protein or a variant or homologue thereof that when used itself or attached to an immunogenic carrier elicits antibodies that specifically bind the protein. Typically such antigenic fragments will be at least 8-15 amino acids in length, and may be much longer.

Sequence identity or percent identity is intended to mean the percentage of the same
15 residues shared between two sequences, referenced to human protein A or protein B or gene A or gene B, when the two sequences are aligned using the Clustal method [Higgins et al, Cabios 8:189-191 (1992)] of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI), or alignment programs available from the Genetics
Computer Group (GCG Wisconsin package, Accelrys, San Diego, CA). In this method,
20 multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid
25 change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment=10; gap length penalty for multiple alignment=10; k-tuple value in pairwise alignment=1; gap penalty in pairwise alignment=3; window value in pairwise alignment=5; diagonals saved in pairwise
30 alignment=5. The residue weight table used for the alignment program is PAM250

[Dayhoff et al., in Atlas of Protein Sequence and Structure, Dayhoff, Ed., NDRF, Washington, Vol. 5, suppl. 3, p. 345, (1978)].

Percent conservation is calculated from the above alignment by adding the percentage of identical residues to the percentage of positions at which the two residues represent a conservative substitution (defined as having a log odds value of greater than or equal to 0.3 in the PAM250 residue weight table). Conservation is referenced to human Gene A or gene B when determining percent conservation with non-human Gene A or gene B, e.g. mgene A or gene B, when determining percent conservation. Conservative amino acid changes satisfying this requirement include: R-K; E-D, Y-F, L-M; V-I, Q-H.

10

Polypeptide Fragments

The invention provides polypeptide fragments of the disclosed proteins. Polypeptide fragments of the invention can comprise at least 8, more preferably at least 25, still more preferably at least 50 amino acid residues of the protein or an analogue thereof. More particularly such fragment will comprise at least 75, 100, 125, 150, 175, 200, 225, 250, 275 residues of the polypeptide encoded by the corresponding gene. Even more preferably, the protein fragment will comprise the majority of the native protein, e.g. about 100 contiguous residues of the native protein.

20 *Biologically Active Variants*

The invention also encompasses mutants of the novel prostate proteins disclosed infra which comprise an amino acid sequence that is at least 80%, more preferably 90%, still more preferably 95-99% similar to the native protein.

Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity can be found using computer programs well known in the art, such as DNASTAR or software from the Genetics Computer Group (GCG). Preferably, amino acid changes in protein variants are conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine,

25
30

leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.

5 A subset of mutants, called muteins, is a group of polypeptides in which neutral amino acids, such as serines, are substituted for cysteine residues which do not participate in disulfide bonds. These mutants may be stable over a broader temperature range than native secreted proteins. See Mark *et al.*, U.S. Patent 4,959,314.

10 It is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological properties of the resulting secreted protein or polypeptide variant.

15 Protein variants include glycosylated forms, aggregative conjugates with other molecules, and covalent conjugates with unrelated chemical moieties. Also, protein variants also include allelic variants, species variants, and muteins. Truncations or deletions of regions which do not affect the differential expression of the gene are also variants. Covalent variants can be prepared by linking functionalities to groups which are found in the amino acid chain or at the N- or C-terminal residue, as is known in the art.

20 It will be recognized in the art that some amino acid sequence of the prostate proteins of the invention can be varied without significant effect on the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there are critical areas on the protein which determine activity. In general, it is possible to replace residues that form the tertiary structure, provided that residues performing a similar function are used. In other instances, the type of residue may be completely unimportant if the alteration occurs at a non-critical region of the protein. The replacement of amino acids can
25 also change the selectivity of binding to cell surface receptors. Ostade *et al.*, *Nature* 361:266-268 (1993) describes certain mutations resulting in selective binding of TNF-alpha to only one of the two known types of TNF receptors. Thus, the polypeptides of the present invention may include one or more amino acid substitutions, deletions or additions, either from natural
30 mutations or human manipulation.

The invention further includes variations of the prostate proteins disclosed infra which show comparable expression patterns or which include antigenic regions. Such mutants include deletions, insertions, inversions, repeats, and site substitutions. Guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

Of particular interest are substitutions of charged amino acids with another charged amino acid and with neutral or negatively charged amino acids. The latter results in proteins with reduced positive charge to improve the characteristics of the disclosed protein. The prevention of aggregation is highly desirable. Aggregation of proteins not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be immunogenic. (Pinckard et al., *Clin. Exp. Immunol.* 2:331-340 (1967); Robbins et al., *Diabetes* 36:838-845 (1987); Cleland et al., *Crit. Rev. Therapeutic Drug Carrier Systems* 10:307-377 (1993)).

Amino acids in the polypeptides of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244: 1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as binding to a natural or synthetic binding partner. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., *J Mol. Biol.* 224:899-904 (1992) and de Vos et al. *Science* 255: 306-312 (1992)).

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein. Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of substitutions for any given polypeptide will not be more than 50, 40, 30, 25, 20, 15, 10, 5 or 3.

Fusion Proteins

Fusion proteins comprising proteins or polypeptide fragments of the subject prostate tumor antigen can also be constructed. Fusion proteins are useful for generating antibodies against amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with a protein of the invention or which interfere with its biological function. Physical methods, such as protein affinity chromatography, or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can also be used for this purpose. Such methods are well known in the art and can also be used as drug screens. Fusion proteins comprising a signal sequence and/or a transmembrane domain of a protein according to the invention or a fragment thereof can be used to target other protein domains to cellular locations in which the domains are not normally found, such as bound to a cellular membrane or secreted extracellularly.

A fusion protein comprises two protein segments fused together by means of a peptide bond. As noted, these fragments may range in size from about 8 amino acids up to the full length of the protein.

The second protein segment can be a full-length protein or a polypeptide fragment. Proteins commonly used in fusion protein construction include β -galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags can be used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP 16 protein fusions.

These fusions can be made, for example, by covalently linking two protein segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises a coding sequence encoding a possible antigen according to the invention or a fragment thereof in proper reading frame with a nucleotide encoding the second protein segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion

proteins are available from companies that supply research labs with tools for experiments, including, for example, Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), Clontech (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

Proteins, fusion proteins, or polypeptides of the invention can be produced by recombinant DNA methods. For production of recombinant proteins, fusion proteins, or polypeptides, a sequence encoding the protein can be expressed in prokaryotic or eukaryotic host cells using expression systems known in the art. These expression systems include bacterial, yeast, insect, and mammalian cells.

The resulting expressed protein can then be purified from the culture medium or from extracts of the cultured cells using purification procedures known in the art. For example, for proteins fully secreted into the culture medium, cell-free medium can be diluted with sodium acetate and contacted with a cation exchange resin, followed by hydrophobic interaction chromatography. Using this method, the desired protein or polypeptide is typically greater than 95% pure. Further purification can be undertaken, using, for example, any of the techniques listed above.

It may be necessary to modify a protein produced in yeast or bacteria, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain a functional protein. Such covalent attachments can be made using known chemical or enzymatic methods.

A protein or polypeptide of the invention can also be expressed in cultured host cells in a form which will facilitate purification. For example, a protein or polypeptide can be expressed as a fusion protein comprising, for example, maltose binding protein, glutathione-S-transferase, or thioredoxin, and purified using a commercially available kit. Kits for expression and purification of such fusion proteins are available from companies such as New England BioLabs, Pharmacia, and Invitrogen. Proteins, fusion proteins, or polypeptides can also be tagged with an epitope, such as a "Flag" epitope (Kodak), and purified using an antibody which specifically binds to that epitope.

The coding sequence of the protein variants identified through the sequences disclosed herein can also be used to construct transgenic animals, such as mice, rats, guinea pigs, cows, goats, pigs, or sheep. Female transgenic animals can then produce proteins, polypeptides, or

fusion proteins of the invention in their milk. Methods for constructing such animals are known and widely used in the art.

Alternatively, synthetic chemical methods, such as solid phase peptide synthesis, can be used to synthesize a secreted protein or polypeptide. General means for the production of peptides, analogs or derivatives are outlined in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins -- A Survey of Recent Developments, B. Weinstein, ed. (1983).
5 Substitution of D-amino acids for the normal L-stereoisomer can be carried out to increase the half-life of the molecule.

Typically, homologous polynucleotide sequences can be confirmed by hybridization
10 under stringent conditions, as is known in the art. For example, using the following wash conditions: 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2 x SSC, 0.1% SDS, 50 °C once, 30 minutes; then 2 x SSC, room temperature twice, 10 minutes each, homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous
15 nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

The invention also provides polynucleotide probes which can be used to detect complementary nucleotide sequences, for example, in hybridization protocols such as Northern or Southern blotting or *in situ* hybridizations. Polynucleotide probes of the invention comprise
20 at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, or 40 or more contiguous nucleotides of the nucleic acid sequences provided herein. Polynucleotide probes of the invention can comprise a detectable label, such as a radioisotopic, fluorescent, enzymatic, or chemiluminescent label.

Isolated genes corresponding to the cDNA sequences disclosed herein are also provided. Standard molecular biology methods can be used to isolate the corresponding genes
25 using the cDNA sequences provided herein. These methods include preparation of probes or primers from the nucleotide sequence disclosed herein for use in identifying or amplifying the genes from mammalian, including human, genomic libraries or other sources of human genomic DNA.

Polynucleotide molecules of the invention can also be used as primers to obtain
30 additional copies of the polynucleotides, using polynucleotide amplification methods. Polynucleotide molecules can be propagated in vectors and cell lines using techniques well

known in the art. Polynucleotide molecules can be on linear or circular molecules. They can be on autonomously replicating molecules or on molecules without replication sequences. They can be regulated by their own or by other regulatory sequences, as is known in the art.

5 *Polynucleotide Constructs*

Polynucleotide molecules comprising the coding sequences of the gene variants identified through the sequences disclosed herein can be used in a polynucleotide construct, such as a DNA or RNA construct. Polynucleotide molecules of the invention can be used, for example, in an expression construct to express all or a portion of a protein, variant, fusion
10 protein, or single-chain antibody in a host cell. An expression construct comprises a promoter which is functional in a chosen host cell. The skilled artisan can readily select an appropriate promoter from the large number of cell type-specific promoters known and used in the art. The expression construct can also contain a transcription terminator which is functional in the host cell. The expression construct comprises a polynucleotide segment which encodes all or a
15 portion of the desired protein. The polynucleotide segment is located downstream from the promoter. Transcription of the polynucleotide segment initiates at the promoter. The expression construct can be linear or circular and can contain sequences, if desired, for autonomous replication.

Also included are polynucleotide molecules comprising the promoter and UTR
20 sequences of the subject novel genes, operably linked to the associated protein coding sequence and/or other sequences encoding a detectable or selectable marker. Such promoter and/or UTR-based constructs are useful for studying the transcriptional and translational regulation of protein expression, and for identifying activating and/or inhibitory regulatory proteins.

25

Host Cells

An expression construct can be introduced into a host cell. The host cell comprising the expression construct can be any suitable prokaryotic or eukaryotic cell. Expression systems in bacteria include those described in Chang *et al.*, *Nature* 275:615 (1978); Goeddel *et al.*, *Nature* 281: 544 (1979); Goeddel *et al.*, *Nucleic Acids Res.* 8:4057 (1980); EP 36,776;
30

U.S. 4,551,433; deBoer *et al.*, *Proc. Natl. Acad. Sci. USA* 80: 21-25 (1983); and Siebenlist *et al.*, *Cell* 20: 269 (1980).

Expression systems in yeast include those described in Hinnen *et al.*, *Proc. Natl. Acad. Sci. USA* 75: 1929 (1978); Ito *et al.*, *J Bacteriol* 153: 163 (1983); Kurtz *et al.*, *Mol. Cell. Biol.* 6: 142 (1986); Kunze *et al.*, *J Basic Microbiol.* 25: 141 (1985); Gleeson *et al.*, *J. Gen. Microbiol.* 132: 3459 (1986), Roggenkamp *et al.*, *Mol. Gen. Genet.* 202: 302 (1986)); Das *et al.*, *J Bacteriol.* 158: 1165 (1984); De Louvencourt *et al.*, *J Bacteriol.* 154:737 (1983), Van den Berg *et al.*, *Bio/Technology* 8: 135 (1990); Kunze *et al.*, *J. Basic Microbiol.* 25: 141 (1985); Cregg *et al.*, *Mol. Cell. Biol.* 5: 3376 (1985); U.S. 4,837,148; U.S. 4,929,555; Beach and Nurse, *Nature* 300: 706 (1981); Davidow *et al.*, *Curr. Genet.* 10: 380 (1985); Gaillardin *et al.*, *Curr. Genet.* 10: 49 (1985); Ballance *et al.*, *Biochem. Biophys. Res. Commun.* 112: 284-289 (1983); Tilburn *et al.*, *Gene* 26: 205-22 (1983); Yelton *et al.*, *Proc. Natl. Acad. Sci. USA* 81: 1470-1474 (1984); Kelly and Hynes, *EMBO J.* 4: 475479 (1985); EP 244,234; and WO 91/00357.

Expression of heterologous genes in insects can be accomplished as described in U.S. 4,745,051; Friesen *et al.* (1986) "The Regulation of Baculovirus Gene Expression" in: THE MOLECULAR BIOLOGY OF BACULOVIRUSES (W. Doerfler, ed.); EP 127,839; EP 155,476; Vlak *et al.*, *J. Gen. Virol.* 69: 765-776 (1988); Miller *et al.*, *Ann. Rev. Microbiol.* 42: 177 (1988); Carbonell *et al.*, *Gene* 73: 409 (1988); Maeda *et al.*, *Nature* 315: 592-594 (1985); Lebacqz-Verheyden *et al.*, *Mol. Cell Biol.* 8: 3129 (1988); Smith *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 8404 (1985); Miyajima *et al.*, *Gene* 58: 273 (1987); and Martin *et al.*, *DNA* 7:99 (1988). Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow *et al.*, *Bio/Technology* (1988) 6: 47-55, Miller *et al.*, in GENETIC ENGINEERING (Setlow, J.K. *et al.* eds.), Vol. 8, pp. 277-279 (Plenum Publishing, 1986); and Maeda *et al.*, *Nature*, 315: 592-594 (1985).

Mammalian expression can be accomplished as described in Dijkema *et al.*, *EMBO J.* 4: 761(1985); Gorman *et al.*, *Proc. Natl. Acad. Sci. USA* 79: 6777 (1982b); Boshart *et al.*, *Cell* 41: 521 (1985); and U.S. 4,399,216. Other features of mammalian expression can be facilitated as described in Ham and Wallace, *Meth Enz.* 58: 44 (1979);

Expression constructs can be introduced into host cells using any technique known in the art. These techniques include transferrin-polycation-mediated DNA transfer, transfection

with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun," and calcium phosphate-mediated transfection.

The invention can also include hybrid and modified forms thereof including fusion
5 proteins, fragments and hybrid and modified forms in which certain amino acids have been deleted or replaced, modifications such as where one or more amino acids have been changed to a modified amino acid or unusual amino acid.

Also included within the meaning of substantially homologous is any human or non-human primate protein which may be isolated by virtue of cross-reactivity with antibodies to
10 proteins encoded by a gene described herein or whose encoding nucleotide sequences including genomic DNA, mRNA or cDNA may be isolated through hybridization with the complementary sequence of genomic or subgenomic nucleotide sequences or cDNA of a gene herein or fragments thereof. It will also be appreciated by one skilled in the art that degenerate DNA sequences can encode a tumor protein according to the invention and these are also
15 intended to be included within the present invention as are allelic variants of the subject genes.

Preferred is a prostate protein according to the invention prepared by recombinant DNA technology. By "pure form" or "purified form" or "substantially purified form" it is meant that a protein composition is substantially free of other proteins which are not the desired protein.

20 The present invention also includes therapeutic or pharmaceutical compositions comprising a protein according to the invention in an effective amount for treating patients with disease, and a method comprising administering a therapeutically effective amount of the protein. These compositions and methods are useful for treating cancers associated with the subject proteins, e.g. prostate cancer. One skilled in the art can readily use a variety of assays
25 known in the art to determine whether the protein would be useful in promoting survival or functioning in a particular cell type.

Anti-Prostate Antigen Antibodies

As noted, the invention includes the preparation and use of anti-prostate antigen antibodies and fragments for use as diagnostics and therapeutics. These antibodies may be
30 polyclonal or monoclonal. Polyclonal antibodies can be prepared by immunizing rabbits or other animals by injecting antigen followed by subsequent boosts at appropriate intervals. The

animals are bled and sera assayed against purified protein usually by ELISA or by bioassay based upon the ability to block the action of the corresponding gene. When using avian species, e.g., chicken, turkey and the like, the antibody can be isolated from the yolk of the egg. Monoclonal antibodies can be prepared after the method of Milstein and Kohler by
5 fusing splenocytes from immunized mice with continuously replicating tumor cells such as myeloma or lymphoma cells. [Milstein and Kohler, *Nature* 256:495-497 (1975); Gutfre and Milstein, *Methods in Enzymology: Immunochemical Techniques* 73:1-46, Langone and Banatis eds., Academic Press, (1981) which are incorporated by reference]. The hybridoma cells so formed are then cloned by limiting dilution methods and supernates assayed for antibody
10 production by ELISA, RIA or bioassay.

The unique ability of antibodies to recognize and specifically bind to target proteins provides an approach for treating an overexpression of the protein. Thus, another aspect of the present invention provides for a method for preventing or treating diseases involving overexpression of the protein by treatment of a patient with specific antibodies to the protein.

15 Specific antibodies, either polyclonal or monoclonal, to the protein can be produced by any suitable method known in the art as discussed above. For example, by recombinant methods, preferably in eukaryotic cells murine or human monoclonal antibodies can be produced by hybridoma technology or, alternatively, the protein, or an immunologically active fragment thereof, or an anti-idiotypic antibody, or fragment thereof can be administered to an
20 animal to elicit the production of antibodies capable of recognizing and binding to the protein. Such antibodies can be from any class of antibodies including, but not limited to IgG, IgA, IgM, IgD, and IgE or in the case of avian species, IgY and from any subclass of antibodies.

The availability of isolated protein allows for the identification of small molecules and low molecular weight compounds that inhibit the binding of protein to binding partners,
25 through routine application of high-throughput screening methods (HTS). HTS methods generally refer to technologies that permit the rapid assaying of lead compounds for therapeutic potential. HTS techniques employ robotic handling of test materials, detection of positive signals, and interpretation of data. Lead compounds may be identified via the incorporation of radioactivity or through optical assays that rely on absorbance, fluorescence or
30 luminescence as read-outs. [Gonzalez, J.E. *et al.*, *Curr. Opin. Biotech.* 9:624-631 (1998)].

Model systems are available that can be adapted for use in high throughput screening for compounds that inhibit the interaction of protein with its ligand, for example by competing with protein for ligand binding. Sarubbi *et al.*, *Anal. Biochem.* 237:70-75 (1996) describe cell-free, non-isotopic assays for discovering molecules that compete with natural ligands for binding to the active site of IL-1 receptor. Martens, C. *et al.*, *Anal. Biochem.* 273:20-31 (1999) describe a generic particle-based nonradioactive method in which a labeled ligand binds to its receptor immobilized on a particle; label on the particle decreases in the presence of a molecule that competes with the labeled ligand for receptor binding.

Antibody Preparation

10 (i) Starting Materials and Methods

Immunoglobulins (Ig) and certain variants thereof are known and many have been prepared in recombinant cell culture. For example, see U.S. Pat. No. 4,745,055; EP 256,654; EP 120,694; EP 125,023; EP 255,694; EP 266,663; WO 30 88/03559; Faulkner *et al.*, *Nature*, 298: 286 (1982); Morrison, J. *Immunol.*, 123: 793 (1979); Koehler *et al.*, *Proc. Natl. Acad. Sci. USA*, 77: 2197 (1980); Raso *et al.*, *Cancer Res.*, 41: 2073 (1981); Morrison *et al.*, *Ann. Rev. Immunol.*, 2: 239 (1984); Morrison, *Science*, 229: 1202 (1985); and Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, 81: 6851 (1984). Reassorted immunoglobulin chains are also known. See, for example, U.S. Pat. No. 4,444,878; WO 88/03565; and EP 68,763 and references cited therein. The immunoglobulin moiety in the chimeras of the present invention may be obtained from IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA, IgE, IgD, or IgM, but preferably from IgG-1 or IgG-3.

(ii) Polyclonal Antibodies

Polyclonal antibodies to the subject prostate antigens are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues),

glutaraldehyde or succinic anhydride.

Animals are immunized against the polypeptide or fragment, immunogenic conjugates, or derivatives by combining about 1 mg or 1 .µg of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer to the antigen or a fragment thereof. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same polypeptide or fragment thereof, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

(iii) Monoclonal Antibodies

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.

For example, monoclonal antibodies using for practicing this invention may be made using the hybridoma method first described by Kohler and Milstein, *Nature*, 256: 495 (1975), or may be made by recombinant DNA methods (Cabilly et al., *supra*).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the antigen or fragment thereof used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 [Academic Press, 1986]).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, Calif. USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Md. USA.

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the prostate antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107: 220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *supra*). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies of the invention is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are

capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., *Curr. Opin. in Immunol.*, 5: 256-262 (1993) and Pluckthun, *Immunol. Revs.*, 130: 151-188 (1992).

The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (Morrison, et al., *Proc. Natl. Acad. Sci. USA*, 81: 6851 [1984]), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, "chimeric" or "hybrid" antibodies are prepared that have the binding specificity of an anti-prostate antigen monoclonal antibody herein.

Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for prostate antigen according to the invention and another antigen-combining site having specificity for a different antigen.

Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.

(iv) Humanized Antibodies

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be

essentially performed following the method of Winter and co-workers (Jones et al., *Nature* 321, 522-525 [1986]; Riechmann et al., *Nature* 332, 323-327 [1988]; Verhoeyen et al., *Science* 239, 1534-1536 [1988]), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (Cabilly et al., *supra*), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

10 The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., *J. Immunol.*, 151: 2296 [1993]; Chothia and Lesk, *J. Mol. Biol.*, 196: 901 [1987]). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., *Proc. Natl. Acad. Sci. USA*, 89: 4285 [1992]; Presta et al., *J. Immunol.*, 151: 2623 [1993]).

20 It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target

antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

(v) Human Antibodies

Human monoclonal antibodies can be made by the hybridoma method. Human
5 myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor, J. Immunol. 133, 3001 (1984); Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86-95 (1991).

10 It is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production.
15 Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90: 2551 (1993); Jakobovits et al., Nature, 362: 255-258 (1993); Bruggermann et al., Year in Immuno., 7: 33 (1993).

Alternatively, the phage display technology (McCafferty et al., Nature, 348: 552-553
20 [1990]) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from non-immunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous
25 particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats; for their review see, e.g., Johnson and Chiswell, Curr. Op. Struct. Biol., 3: 564-571 (1993). Several sources of V-gene segments can
30 be used for phage display. Clackson et al., Nature, 352: 624-628 (1991) isolated a diverse array

of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from non-immunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol., 222: 581-597 (1991), or Griffith et al., EMBO J., 12: 725-734 (1993).

In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin are preferentially replicated and differentiated during subsequent antigen challenge. This natural process can be mimicked by employing the technique known as "chain shuffling" (Marks et al., Bio/Technology, 10: 779-783 [1992]). In this method, the affinity of "primary" human antibodies obtained by phage display can be improved by sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from non-immunized donors. This technique allows the production of antibodies and antibody fragments with affinities in the nM range. A strategy for making very large phage antibody repertoires has been described by Waterhouse et al., Nucl. Acids Res., 21: 2265-2266 (1993).

Gene shuffling can also be used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as "epitope imprinting", the heavy or light chain V domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable capable of restoring a functional antigen-binding site, i.e., the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is obtained (see PCT WO 93/06213, published Apr. 1, 1993). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.

(vi) Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the

binding specificities will be to a prostate antigen according to the invention. Methods for making bispecific antibodies are known in the art.

Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains
5 have different specificities (Milstein and Cuello, *Nature*, 305: 537-539 [1983]). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar
10 procedures are disclosed in WO 93/08829 published May 13, 1993, and in Traunecker et al., *EMBO J.*, 10: 3655-3659 (1991).

According to a different and more preferred approach, antibody-variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant-domain sequences. The fusion preferably is with an
15 immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1), containing the site necessary for light-chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
20 This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the production of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of
25 no particular significance. In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin
30 chain combinations, as the presence of an immunoglobulin light chain in only one half of the

bispecific molecule provides for a facile way of separation.

For further details of generating bispecific antibodies, see, for example, Suresh et al., *Methods in Enzymology*, 121: 210 (1986).

(vii) Heteroconjugate Antibodies

- 5 Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/00373; and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods.
- 10 Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

- The polynucleotides and polypeptides of the present invention may be utilized in gene delivery vehicles. The gene delivery vehicle may be of viral or non-viral origin (*see generally*, Jolly, *Cancer Gene Therapy* 1:51-64 (1994); Kimura, *Human Gene Therapy* 5:845-852
- 15 (1994); Connelly, *Human Gene Therapy* 1:185-193 (1995); and Kaplitt, *Nature Genetics* 6:148-153 (1994)). Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic according to the invention can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches. Expression of such coding sequences can be induced using endogenous mammalian or heterologous
- 20 promoters. Expression of the coding sequence can be either constitutive or regulated. Preferred vehicles for gene therapy include retroviral and adeno-viral vectors.

- Representative examples of adenoviral vectors include those described by Berkner, *Biotechniques* 6:616-627 (Biotechniques); Rosenfeld *et al.*, *Science* 252:431-434 (1991); WO 93/19191; Kolls *et al.*, *P.N.A.S.* 215-219 (1994); Kass-Bisleret *et al.*, *P.N.A.S.* 90: 11498-11502
- 25 (1993); Guzman *et al.*, *Circulation* 88: 2838-2848 (1993); Guzman *et al.*, *Cir. Res.* 73: 1202-1207 (1993); Zabner *et al.*, *Cell* 75: 207-216 (1993); Li *et al.*, *Hum. Gene Ther.* 4: 403-409 (1993); Cailaud *et al.*, *Eur. J. Neurosci.* 5: 1287-1291 (1993); Vincent *et al.*, *Nat. Genet.* 5: 130-134 (1993); Jaffe *et al.*, *Nat. Genet.* 1: 372-378 (1992); and Levrero *et al.*, *Gene* 101: 195-202 (1992). Exemplary adenoviral gene therapy vectors employable in this invention also
- 30 include those described in WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO

95/11984 and WO 95/00655. Administration of DNA linked to kill adenovirus as described in Curiel, *Hum. Gene Ther.* 3: 147-154 (1992) may be employed.

Other gene delivery vehicles and methods may be employed; including polycationic condensed DNA linked or unlinked to kill adenovirus alone, for example Curiel, *Hum. Gene Ther.* 3: 147-154 (1992); ligand-linked DNA, for example see Wu, *J. Biol. Chem.* 264: 16985-16987 (1989); eukaryotic cell delivery vehicles cells, for example see U.S. Serial No. 08/240,030, filed May 9, 1994, and U.S. Serial No. 08/404,796; deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun, as described in U.S. Patent No. 5,149,655; ionizing radiation as described in U.S. Patent No. 5,206,152 and in
10 WO 92/11033; nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip, *Mol. Cell Biol.* 14:2411-2418 (1994), and in Woffendin, *Proc. Natl. Acad. Sci.* 91:1581-1585 (1994).

Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Patent No. 5,580,859. Uptake efficiency may be
15 improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm. Liposomes that can act as gene delivery vehicles are described in U.S. Patent No. 5,422,120, PCT Patent Publication Nos. WO 95/13
20 796, WO 94/23697, and WO 91/14445, and EP No. 0 524 968.

Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al., *Proc. Natl. Acad. Sci. USA* 91(24): 11581-11585 (1994). Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional
25 methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Patent No. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Patent No. 5,206,152 and PCT Patent Publication No. WO 92/11033.

The subject antibodies or antibody fragments may be conjugated directly or indirectly
30 to effective moieties, e.g., radionuclides, toxins, chemotherapeutic agents, prodrugs, cytoslatic agents, enzymes and the like. In a preferred embodiment the antibody or fragment will be

attached to a therapeutic or diagnostic radiolabel directly or by use of a chelating agent. Examples of suitable radiolabels are well known and include ^{90}Y , ^{125}I , ^{131}I , ^{111}I , ^{105}Rh , ^{153}Sm , ^{67}Cu , ^{67}Ga , ^{166}Ho , ^{177}Lu , ^{186}Re and ^{188}Re .

5 Examples of suitable drugs that may be coupled to antibodies include methotrexate, adriamycine and lymphokines such as interferons, interleukins and the like. Suitable toxins which may be coupled include ricin, cholera and diphtheria toxin.

In a preferred embodiment, the subject antibodies will be attached to a therapeutic radiolabel and used for radioimmunotherapy.

Anti-sense Oligonucleotides

10 In certain circumstances, it may be desirable to modulate or decrease the amount of the protein expressed by a prostate cell. Thus, in another aspect of the present invention, anti-sense oligonucleotides can be made and a method utilized for diminishing the level of expression a prostate antigen according to the invention by a cell comprising administering one or more anti-sense oligonucleotides. By anti-sense oligonucleotides reference is made to
15 oligonucleotides that have a nucleotide sequence that interacts through base pairing with a specific complementary nucleic acid sequence involved in the expression of the target such that the expression of the gene is reduced. Preferably, the specific nucleic acid sequence involved in the expression of the gene is a genomic DNA molecule or mRNA molecule that encodes the gene. This genomic DNA molecule can comprise regulatory regions of the gene,
20 or the coding sequence for the mature gene.

The term complementary to a nucleotide sequence in the context of antisense oligonucleotides and methods therefor means sufficiently complementary to such a sequence as to allow hybridization to that sequence in a cell, *i.e.*, under physiological conditions. Antisense oligonucleotides preferably comprise a sequence containing from about 8 to about
25 100 nucleotides and more preferably the antisense oligonucleotides comprise from about 15 to about 30 nucleotides. Antisense oligonucleotides can also contain a variety of modifications that confer resistance to nucleolytic degradation such as, for example, modified internucleoside linkages [Uhlmann and Peyman, *Chemical Reviews* 90:543-548 (1990); Schneider and Banner, *Tetrahedron Lett.* 31:335, (1990) which are incorporated by reference],
30 modified nucleic acid bases as disclosed in 5,958,773 and patents disclosed therein, and/or sugars and the like.

Any modifications or variations of the antisense molecule which are known in the art to be broadly applicable to antisense technology are included within the scope of the invention.

Such modifications include preparation of phosphorus-containing linkages as disclosed in U.S. Patents 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361, 5,625,050 and 5,958,773.

The antisense compounds of the invention can include modified bases. The antisense oligonucleotides of the invention can also be modified by chemically linking the oligonucleotide to one or more moieties or conjugates to enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. Such moieties or conjugates include lipids such as cholesterol, cholic acid, thioether, aliphatic chains, phospholipids, polyamines, polyethylene glycol (PEG), palmityl moieties, and others as disclosed in, for example, U.S. Patents 5,514,758, 5,565,552, 5,567,810, 5,574,142, 5,585,481, 5,587,371, 5,597,696 and 5,958,773.

Chimeric antisense oligonucleotides are also within the scope of the invention, and can be prepared from the present inventive oligonucleotides using the methods described in, for example, U.S. Patents 5,013,830, 5,149,797, 5,403,711, 5,491,133, 5,565,350, 5,652,355, 5,700,922 and 5,958,773.

In the antisense art a certain degree of routine experimentation is required to select optimal antisense molecules for particular targets. To be effective, the antisense molecule preferably is targeted to an accessible, or exposed, portion of the target RNA molecule. Although in some cases information is available about the structure of target mRNA molecules, the current approach to inhibition using antisense is via experimentation. mRNA levels in the cell can be measured routinely in treated and control cells by reverse transcription of the mRNA and assaying the cDNA levels. The biological effect can be determined routinely by measuring cell growth or viability as is known in the art.

Measuring the specificity of antisense activity by assaying and analyzing cDNA levels is an art-recognized method of validating antisense results. It has been suggested that RNA from treated and control cells should be reverse-transcribed and the resulting cDNA populations analyzed. [Branch, A. D., *T.I.B.S.* 23:45-50 (1998)].

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable route known in the art including for example intravenous,

subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of slow release formulation.

Additionally, the subject prostate tumor proteins can also be linked or conjugated with
5 agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, the protein can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and administered by intravenous injection (see, for example, Friden et al., *Science* 259:373-377 (1993) which is incorporated by reference). Furthermore, the subject protein A or protein B
10 can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties. [See, for example, Davis et al., *Enzyme Eng.* 4:169-73 (1978); Buruham, *Am. J. Hosp. Pharm.* 51:210-218 (1994) which are incorporated by reference].

The compositions are usually employed in the form of pharmaceutical preparations.
15 Such preparations are made in a manner well known in the pharmaceutical art. See, e.g. Remington Pharmaceutical Science, 18th Ed., Merck Publishing Co. Eastern PA, (1990). One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be
20 used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. The subject prostate tumor antigens, fragments or variants thereof can also be incorporated into a solid or semi-solid biologically compatible matrix which can be
25 implanted into tissues requiring treatment.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or
30 penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parental administration in either unit dosage or

multi-dose form or for direct infusion into the cerebrospinal fluid by continuous or periodic infusion.

Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

5 It is also contemplated that certain formulations containing the subject antibody or nucleic acid antagonists are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose,
10 polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the
15 active ingredients after administration to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be
20 calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity disclosed herein in assay preparations of target cells. Exact dosages are determined in conjunction with standard dose-
25 response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

30 In one embodiment of this invention, the protein may be therapeutically administered by implanting into patients vectors or cells capable of producing a biologically-active form of

the protein or a precursor of protein, *i.e.*, a molecule that can be readily converted to a biological-active form of the protein by the body. In one approach, cells that secrete the protein may be encapsulated into semipermeable membranes for implantation into a patient. The cells can be cells that normally express the protein or a precursor thereof or the cells can
5 be transformed to express the protein or a precursor thereof. It is preferred that the cell be of human origin and that the protein be a human protein when the patient is human. However, it is anticipated that non-human primate homologues of the protein discussed *infra* may also be effective.

Detection of Subject Prostate Proteins or Nucleic Acids

10 In a number of circumstances it would be desirable to determine the levels of protein or corresponding mRNA in a patient. Evidence disclosed *infra* suggests the subject prostate proteins may be expressed at different levels during some diseases, e.g., cancers, provides the basis for the conclusion that the presence of these proteins serves a normal physiological function related to cell growth and survival. Endogenously produced protein according to the
15 invention may also play a role in certain disease conditions.

The term "detection" as used herein in the context of detecting the presence of protein in a patient is intended to include the determining of the amount of protein or the ability to express an amount of protein in a patient, the estimation of prognosis in terms of probable outcome of a disease and prospect for recovery, the monitoring of the protein levels over a
20 period of time as a measure of status of the condition, and the monitoring of protein levels for determining a preferred therapeutic regimen for the patient, e.g. one with prostate cancer.

To detect the presence of a prostate protein according to the invention in a patient, a sample is obtained from the patient. The sample can be a tissue biopsy sample or a sample of blood, plasma, serum, CSF, urine or the like. It has been found that the subject proteins are
25 expressed at high levels in some cancers. Samples for detecting protein can be taken from prostate tissues. When assessing peripheral levels of protein, it is preferred that the sample be a sample of blood, plasma or serum. When assessing the levels of protein in the central nervous system a preferred sample is a sample obtained from cerebrospinal fluid or neural tissue. The sample may be obtained by non-invasive methods, such as from tissue collection(s)
30 or culture(s), or using directly available tissue material (urine, saliva, stools, hair, etc.).

In some instances, it is desirable to determine whether the gene is intact in the patient or in a tissue or cell line within the patient. By an intact gene, it is meant that there are no alterations in the gene such as point mutations, deletions, insertions, chromosomal breakage, chromosomal rearrangements and the like wherein such alteration might alter production of the corresponding protein or alter its biological activity, stability or the like to lead to disease processes. Thus, in one embodiment of the present invention a method is provided for detecting and characterizing any alterations in the gene. The method comprises providing an oligonucleotide that contains the gene, genomic DNA or a fragment thereof or a derivative thereof. By a derivative of an oligonucleotide, it is meant that the derived oligonucleotide is substantially the same as the sequence from which it is derived in that the derived sequence has sufficient sequence complementarity to the sequence from which it is derived to hybridize specifically to the gene. The derived nucleotide sequence is not necessarily physically derived from the nucleotide sequence, but may be generated in any manner including for example, chemical synthesis or DNA replication or reverse transcription or transcription.

Typically, patient genomic DNA is isolated from a cell sample from the patient and digested with one or more restriction endonucleases such as, for example, TaqI and AluI. Using the Southern blot protocol, which is well known in the art, this assay determines whether a patient or a particular tissue in a patient has an intact prostate gene according to the invention or a gene abnormality.

Hybridization to a gene would involve denaturing the chromosomal DNA to obtain a single-stranded DNA; contacting the single-stranded DNA with a gene probe associated with the gene sequence; and identifying the hybridized DNA-probe to detect chromosomal DNA containing at least a portion of a gene.

The term "probe" as used herein refers to a structure comprised of a polynucleotide that forms a hybrid structure with a target sequence, due to complementarity of probe sequence with a sequence in the target region. Oligomers suitable for use as probes may contain a minimum of about 8-12 contiguous nucleotides which are complementary to the targeted sequence and preferably a minimum of about 20.

A gene according to the present invention can be DNA or RNA oligonucleotides and can be made by any method known in the art such as, for example, excision, transcription or chemical synthesis. Probes may be labeled with any detectable label known in the art such as,

for example, radioactive or fluorescent labels or enzymatic marker. Labeling of the probe can be accomplished by any method known in the art such as by PCR, random priming, end labeling, nick translation or the like. One skilled in the art will also recognize that other methods not employing a labeled probe can be used to determine the hybridization. Examples
5 of methods that can be used for detecting hybridization include Southern blotting, fluorescence in situ hybridization, and single-strand conformation polymorphism with PCR amplification.

Hybridization is typically carried out at 25° - 45° C, more preferably at 32° -40° C and more preferably at 37° - 38° C. The time required for hybridization is from about 0.25 to about 96 hours, more preferably from about one to about 72 hours, and most preferably from about 4
10 to about 24 hours.

Gene abnormalities can also be detected by using the PCR method and primers that flank or lie within the gene. The PCR method is well known in the art. Briefly, this method is performed using two oligonucleotide primers which are capable of hybridizing to the nucleic acid sequences flanking a target sequence that lies within a gene and amplifying the target
15 sequence. The terms "oligonucleotide primer" as used herein refers to a short strand of DNA or RNA ranging in length from about 8 to about 30 bases. The upstream and downstream primers are typically from about 20 to about 30 base pairs in length and hybridize to the flanking regions for replication of the nucleotide sequence. The polymerization is catalyzed by a DNA-polymerase in the presence of deoxynucleotide triphosphates or nucleotide analogs to
20 produce double-stranded DNA molecules. The double strands are then separated by any denaturing method including physical, chemical or enzymatic. Commonly, a method of physical denaturation is used involving heating the nucleic acid, typically to temperatures from about 80°C to 105°C for times ranging from about 1 to about 10 minutes. The process is repeated for the desired number of cycles.

25 The primers are selected to be substantially complementary to the strand of DNA being amplified. Therefore, the primers need not reflect the exact sequence of the template, but must be sufficiently complementary to selectively hybridize with the strand being amplified.

After PCR amplification, the DNA sequence comprising the gene or a fragment thereof is then directly sequenced and analyzed by comparison of the sequence with the sequences
30 disclosed herein to identify alterations which might change activity or expression levels or the like.

In another embodiment, a method for detecting a tumor protein according to the invention is provided based upon an analysis of tissue expressing the gene. Certain tissues such as prostate tissues have been found to overexpress the subject gene. The method comprises hybridizing a polynucleotide to mRNA from a sample of tissue that normally
5 expresses the gene. The sample is obtained from a patient suspected of having an abnormality in the gene.

To detect the presence of mRNA encoding the protein, a sample is obtained from a patient. The sample can be from blood or from a tissue biopsy sample. The sample may be treated to extract the nucleic acids contained therein. The resulting nucleic acid from the
10 sample is subjected to gel electrophoresis or other size separation techniques.

The mRNA of the sample is contacted with a DNA sequence serving as a probe to form hybrid duplexes. The use of a labeled probes as discussed above allows detection of the resulting duplex.

When using the cDNA encoding the protein or a derivative of the cDNA as a probe,
15 high stringency conditions can be used in order to prevent false positives, that is the hybridization and apparent detection of the gene nucleotide sequence when in fact an intact and functioning gene is not present. When using sequences derived from the gene cDNA, less stringent conditions could be used, however, this would be a less preferred approach because of the likelihood of false positives. The stringency of hybridization is determined by a number
20 of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. These factors are outlined in, for example, Sambrook et al. [Sambrook et al. (1989), *supra*].

In order to increase the sensitivity of the detection in a sample of mRNA encoding the protein A or protein B, the technique of reverse transcription/ polymerization chain reaction
25 (RT/PCR) can be used to amplify cDNA transcribed from mRNA encoding the prostate tumor antigen. The method of RT/PCR is well known in the art, and can be performed as follows. Total cellular RNA is isolated by, for example, the standard guanidium isothiocyanate method and the total RNA is reverse transcribed. The reverse transcription method involves synthesis of DNA on a template of RNA using a reverse transcriptase enzyme and a 3' end primer.
30 Typically, the primer contains an oligo(dT) sequence. The cDNA thus produced is then amplified using the PCR method and gene A or gene B specific primers. [Belyavsky et al.,

Nucl. Acid Res. 17:2919-2932 (1989); Krug and Berger, *Methods in Enzymology*, 152:316-325, Academic Press, NY (1987) which are incorporated by reference].

The polymerase chain reaction method is performed as described above using two oligonucleotide primers that are substantially complementary to the two flanking regions of the DNA segment to be amplified. Following amplification, the PCR product is then electrophoresed and detected by ethidium bromide staining or by phosphoimaging.

The present invention further provides for methods to detect the presence of the protein in a sample obtained from a patient. Any method known in the art for detecting proteins can be used. Such methods include, but are not limited to immunodiffusion, immunoelectrophoresis, immunochemical methods, binder-ligand assays, immunohistochemical techniques, agglutination and complement assays. [*Basic and Clinical Immunology*, 217-262, Sites and Terr, eds., Appleton & Lange, Norwalk, CT, (1991), which is incorporated by reference]. Preferred are binder-ligand immunoassay methods including reacting antibodies with an epitope or epitopes of the prostate tumor antigen protein and competitively displacing a labeled prostate antigen according to the invention or derivative thereof.

As used herein, a derivative of the subject prostate tumor antigen is intended to include a polypeptide in which certain amino acids have been deleted or replaced or changed to modified or unusual amino acids wherein the derivative is biologically equivalent to gene and wherein the polypeptide derivative cross-reacts with antibodies raised against the protein. By cross-reaction it is meant that an antibody reacts with an antigen other than the one that induced its formation.

Numerous competitive and non-competitive protein binding immunoassays are well known in the art. Antibodies employed in such assays may be unlabeled, for example as used in agglutination tests, or labeled for use in a wide variety of assay methods. Labels that can be used include radionuclides, enzymes, fluorescers, chemilumescers, enzyme substrates or co-factors, enzyme inhibitors, particles, dyes and the like for use in radioimmunoassay (RIA), enzyme immunoassays, *e.g.*, enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassays and the like.

A further aspect of this invention relates to a method for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising a determination of whether a candidate compound binds, preferably selectively, a target molecule as disclosed above. Such target molecules include nucleic acid sequences, polypeptides and fragments thereof, typically prostate-specific antigens, even more preferably extracellular portions thereof. Binding may be assessed in vitro or in vivo, typically in vitro, in cell based or acellular systems. Typically, the target molecule is contacted with the candidate compound in any appropriate device, and the formation of a complex is determined. The target molecule and/or the candidate compound may be immobilized on a support. The compounds identified or selected represent drug candidates or leads for treating cancer diseases, particularly prostate cancer.

While the invention has been described supra, including preferred embodiments, the following examples are provided to further illustrate the invention.

EXAMPLE

Tissue Sources:

Appropriate patient samples were procured for evaluation of research protocol. Samples were provided with relevant clinical parameters, and patient consent. Histological assessment was performed on all samples and diagnosis by pathology confirmed the presence and/or absence of malignancy within each sample. Clinical data generally included patient history, physiopathology, and parameters relating to prostate cancer physiology. Ten normal and ten malignant samples were procured along with available clinical information. In addition, ten samples from organs other than normal prostate and prostate cancer were procured to determine the tissue specific expression profile of epitopes. RNA derived from normal tissue samples was obtained from known commercial sources.

Generation of the DATAS Library

Samples were pooled based on their pathological diagnosis (normal vs. tumor). Samples were pooled based on equivalent amounts of total RNA to produce total pooled RNA samples of 100ug. DATAS libraries were constructed as previously disclosed in U.S. Patent

No. 6,251,590, the disclosure of which is incorporated by reference in its entirety. Briefly, total RNA was isolated from the normal and tumor pooled samples and mRNA was subsequently purified from the total RNA for each pooled sample. Synthesis of cDNA was performed using a biotinylated oligo (dT) primer. The biotinylated cDNA was hybridized with the mRNA of the opposite sample to form heteroduplexes between the cDNA and the mRNA. For example, the biotinylated cDNA of the pooled normal prostate sample was hybridized with prostate tumor mRNA. Similarly, prostate tumor biotinylated cDNA was hybridized with prostate normal RNA to generate the second DATAS library. Streptavidin coated beads were used to purify the complexes by binding the biotin present on the cDNA. The heteroduplexes were digested with RNase H to degrade the RNA that was complementary to the cDNA. All mRNA sequences that were different from the cDNA remained intact. These single stranded RNA fragments or "loops" were subsequently amplified with degenerate primers and cloned into either pGEM-Tor pCR II TOPO vector (Company source) to produce the DATAS library.

15 **Clone sequencing and Bioinformatics Analysis:**

The DATAS library was used to transform *E. coli* so that individual clones could be isolated using standard molecular biology techniques. From these libraries, 10,665 individual clones were isolated and sequenced using an automated Applied Biosystems 3100 sequencer. The nucleotide sequences that were obtained were submitted to the bioinformatics pipeline for analysis. As the DATAS library is prepared with PCR amplified DNA, many copies of the same sequence are present in the clones isolated from the libraries. Therefore it is important to reduce the redundancy of the clones to identify the number of unique, nonrepeating sequences that are isolated. From this large set of DATAS fragments, 1699 unique, nonredundant sequences were identified and each DATAS fragment was annotated with a candidate gene. The annotation was performed by aligning the DATAS fragment to the human genome sequence by two methods; 1) a publicly available alignment and genome viewer tool, Blat (Kent et al., 2002); and 2) a commercially available genomic alignment and viewer tool, Prophecy (Doubletwise). Each DATAS fragment sequence was annotated with a corresponding gene that overlapped the genomic sequence containing the DATAS fragment. Genes were annotated with either the RefSeq accession number, or a hypothetical gene prediction from different algorithms, for example, Genscan, Twinscan, or Fgenesh++.

Identified genes were either matched to the sequence of the DATAS fragment (in case of exon to fragment match), or overlapped with the DATAS fragment (in case of intron to fragment match), and the full length sequence of the gene was identified. These sequences were further analyzed to detect all potential membrane spanning proteins. Membrane proteins were predicted through the use of different algorithms publicly available. For example, TMHMM (CBS) was used to identify membrane-spanning domains present within the amino acid sequence of the candidate gene. DATAS fragments were located within the sequence in an attempt to determine whether the spliced event affected intracellular or extracellular domains. Genes associated with the sequence were ranked in order to maximize the identification of successful therapeutic targets. The highest priority genes had characteristics where the gene was a known membrane protein, the function of the gene was known, and the DATAS fragment mapped to an intron on the extracellular domain of the protein, indicating that the DATAS fragment would be presented outside the cell, and available for therapeutic intervention by monoclonal antibodies.

- Based on the bioinformatic analysis, clones were prioritized in three groups:
- A) Known transmembrane genes with DATAS fragments located in introns on the extracellular domain.
 - B) Known and predicted transmembrane genes with DATAS fragments located in exons in either the extracellular or intracellular domain.
 - C) DATAS fragments that did not match the genome

Expression Monitoring:

A valid epitope target for prostate cancer requires that the expression of the epitope be limited to prostate tissue, or preferably to prostate tumors. Assessment of the expression profile for each prioritized sequence was performed by RT-PCR, a procedure well known in the art. A protocol known as touchdown PCR was used, described in the user's manual for the GeneAmp PCR system 9700, Applied Biosystems. Briefly, PCR primers were designed to the DATAS fragment and used for end point RT-PCR analysis. Each RT reaction contained 5 µg of total RNA and was performed in a 100 µl volume using Archive RT Kit (Applied Biosystems). The RT reactions were diluted 1:50 with water and 4 µl of the diluted stock was used in a 50 µl PCR reaction consisting of one cycle at 94°C for 3 min, 5 cycles at 94°C for 30

seconds, 60°C for 30 seconds and 72°C for 45 seconds, with each cycle reducing the annealing temperature by 0.5 degree. This was followed by 30 cycles at 94°C for 30 seconds, 55°C for 30 seconds, and 72 °C for 45 seconds. 15 µl was removed from each reaction for analysis and the reactions were allowed to proceed for an additional 10 cycles. This produced reactions for analysis at 30 and 40 cycles, and allowed the detection of differences in expression where the 40 cycle reactions had saturated. The level of expression profile of the DATAS fragment was determined in normal and tumor prostate total RNA, as well as total RNA from normal samples of brain, heart, liver, lung, kidney, colon, bone marrow, muscle, spleen, and testis. Expression profiles were prioritized accordingly for specific expression in prostate tumor and low expression found in normal tissues, including normal prostate.

Verification of RNA Structure:

DATAS identifies sequences that are altered between the experimental samples. However, the exact sequence of the junctions or borders that the DATAS fragment represents can not be determined directly from the isolated DATAS fragment sequence. The DATAS fragment was used, however, to design experiments that elucidate the sequence of each transcript present in each sample. Primers were designed to amplify a region of the gene larger than the proposed DATAS fragment sequence. These amplicons were subsequently cloned and sequenced for the identification of the exact junctions of all exons and introns. This required partial cloning of the isoforms from an identified sample to verify the primary structure (sequence) of the isoforms. All twenty samples (10 normal and 10 tumor samples) initially used to generate the DATAS libraries were used for the verification of the mRNA structure of the prioritized genes.

Isolation of full-length clones of isoforms:

Isolation of the full-length clones containing both isoforms was accomplished utilizing the information and DNA fragments generated during the structure validation process. Several methods are applicable to isolation of the full length clone. Where full sequence information regarding the coding sequence is available, gene specific primers were designed from the sequence and used to amplify the coding sequence directly from the total RNA of the tissue samples. An RT-PCR reaction was set up using these gene specific primers. The RT reaction

was performed as described infra, using oligo dT to prime for cDNA. Second strand was produced by standard methods to produce double stranded cDNA. PCR amplification of the gene was accomplished using gene specific primers. PCR consisted of 30 cycles at 94°C for 30 seconds, 55°C for 30 seconds, and 72 °C for 45 seconds. The reaction products were analyzed on 1% agarose gels and the amplicons were ligated into prepared vectors with A overhangs for amplicon cloning. 1 µl of the ligation mixture was used to transform E. coli for cloning and isolation of the amplicon. Once purified, the plasmid containing the amplicon was sequenced on an ABI 3100 automated sequencer.

Where limited sequence information was available, the oligo pulling method was utilized. Briefly, a gene-specific oligonucleotide was designed based on the DATAS fragment. The oligonucleotide was labeled with biotin and used to hybridize with a single stranded plasmid DNA library prepared from either normal prostate tissue or prostate tumor tissue following the procedures of Sambrook et al (1989). The hybridized cDNA was separated by streptavidin conjugated beads and eluted by heating. The eluted cDNA was converted to double strand plasmid DNA and used to transform E. coli cells and the longest cDNA clone was subjected to DNA sequencing.

RESULTS

Using methods described above, 1699 DNA fragments have been identified that putatively correspond to exons (novel splice variants) expressed exclusively or at an increased level in prostate tumor tissue when compared to matched normal prostate tissue.

These sequences were used to search public databases containing human genomic sequences to identify related genes. This search identified 122 fragments that correspond to exons of either known or potential cell surface proteins.

Additionally, thirty seven distinct alternatively spliced isoforms were identified from the initial sequence tags that appear to contain novel sequence information of cell surface proteins.

These DNA sequences are disclosed in the Sequence Listing as well as in Table 1, and correspond to the nucleic acid sequences having SEQ ID NOS: 1-173, 175, 177, 179, and 181. Oligonucleotide primers were designed to each DATAS fragment to determine the specific

expression of the mRNA in a panel of normal human tissue. An example is shown in figure 1, where the clone corresponding to Sequence ID: No. 92 displays specific expression in prostate with very low levels detected in kidney (lane 4) and pancreas (lane 9). All clones that were found to be either specifically expressed in prostate or highly expressed in prostate compared to other tissues were analyzed for expression in tumor samples.

Figure 2 illustrates the expression profile of one DATAS clone in normal and tumor prostate tissue. Expression of this clone is upregulated in two of the three tumor pooled samples and is highly expressed in three of the four individual tumor samples. The high expression of this splice event in tumor samples as compared to normal prostate, and the low expression in other normal human tissues is an example of one candidate that has utility for development as a novel epitope for prostate cancer.

The splice events for DATAS clones that displayed a specific expression profile for prostate and a high differential expression profile for prostate tumors were isolated and the sequences for each event was determined. An example is shown in figure 3, where the sequence of the isolated event was mapped to the genome in Blat, and genomic viewer developed by the bioinformatics department at UCSC (Kent et al., 2002). Five distinct clones were isolated that mapped to the gene locus for STEAP2. One expressed sequence tag (EST), AK092666, contained many similar domains as the splice events that were isolated using DATAS. The sequences and predicted protein translations for all five clones are described in SEQ NOS. 173 – 182 and are graphically illustrated in figure 3. The length of the open reading frame and the predicted protein size for each isoform is described in Table 2. The EST, AK092666 contains a large deletion in exon 5, the terminal 3' exon of STEAP2, with two novel exons in the 5' region of the transcript. The nomenclature for the DATAS derived events was based on AK092666 because of higher similarity when compared to the RefSeq sequence for STEAP2. The first isoform identified, AK092666_01 (SEQ ID NO 173), contains a novel C-terminal exon when compared to AK092666, and therefore generates a novel junction, and a novel sequence for translation and generates a unique amino acid sequence (SEQ ID NO 183). The same novel sequence was generated by isoform AK092666_03 (SEQ ID NO 177), which contains the same novel exon with an additional splicing event of an in frame truncation of exon 4, and by isoform AK092666_05 (SEQ ID NO 181), which contains a single codon deletion from AK092666_01. AK092666_02 (SEQ ID

NO 175) skipped exon 6 of AK092666 and generated the novel amino acid sequence in SEQ ID NO 184. AK092666_04 (SEQ ID NO 179) contains a short out of frame truncation of exon 4, which results in the creation of 8 novel amino acids before encountering a premature stop codon (SEQ ID NO 185).

5

Table 2. Length of the open reading frame and the predicted protein size for each novel isoform.

Clone Name	ORF length (bp)	Protein size (KD)
STEAP2	1473	56
AK092666	1365	51.7
AK092666_01	1389	52.7
AK092666_02	1260	47.8
AK092666_03	900	34.1
AK092666_04	705	26.7
AK092666_05	1386	52.5

10 The novel amino acids found in SEQ ID NOS 183 and 184 represent novel epitopes that are specifically expressed in prostate cancer in a membrane protein. These epitopes are targets for monoclonal antibody immunotherapy for the treatment of prostate cancer. To illustrate the different isoforms present, an antibody was generated from the invariant sequence present in the 5' region (or the amino terminal portion of the protein) that recognizes all the
15 different isoforms.

An antibody was generated against an amino acid sequence that was common to all five isoforms, as well as present in STEAP2 and AK092666. Prostate cancer cell lines were analyzed by western blot to determine what different isoforms would be expressed at the protein level. Figure 4 illustrates two bands that were specifically detected by the antibody.
20 Band A potentially represents the glycosylated, wild type STEAP2 and band B indicates isoforms AK092666, AK092666_01, or AK092666_05, which is unresolvable in the gel analysis. In addition, multiple bands of the proper size were detected suggesting that isoforms of the STEAP2 locus are expressed and represent targets for the immunotherapy in prostate cancer.

25

Table 1. Sequence information of the DATAS fragments and the alternatively spliced isoforms.

- Sequence ID: No. 1
 5 Accession #: NM_005656
 Genomic sequence: chr21:39407238-39450894
 Sequence definition: transmembrane protease serine 2
- Sequence ID: No. 2
 10 Accession #: NM_001423
 Genomic sequence: chr12:13265134-13265266
 Sequence definition: Homo sapiens epithelial membrane protein 1 EMP1
- Sequence ID: No. 3
 15 Accession #: NM_000484
 Genomic sequence: chr21:23832850-24123073
 Sequence definition: beta amyloid A4
- Sequence ID: No. 4
 20 Accession #: NM_002841
 Genomic sequence: chr3:62548596-63240788_1
 Sequence definition: protein tyrosine phosphatase G-type
- Sequence ID: No. 5
 25 Accession #: NM_022124
 Genomic sequence: chr10:74968313-75112962
 Sequence definition: cadherin related 23 isoform 1 precursor
- Sequence ID: No. 6
 30 Accession #: NM_033056
 Genomic sequence: chr10:55940286-56920530_02
 Sequence definition: protocadherin 15 precursor
- Sequence ID: No. 7
 35 Accession #: NM_002847
 Genomic sequence: chr7:158586667-159621018_01
 Sequence definition: protein tyrosine phosphatase receptor type N
- Sequence ID: No. 8
 40 Accession #: NM_002222
 Genomic sequence: chr3:5000696-5354641_1
 Sequence definition: ITPR inositol 145-triphosphate receptor type 1
- Sequence ID: No. 9
 45 Accession #: AC078864.20
 Genomic sequence: chr12:52201280-52201714
 Sequence definition: Genscan prediction
- Sequence ID: No. 10
 50 Accession #: NM_014554; NM_001844; NT_009785.3
 Genomic sequence: chr12:45785273-45856561
 Sequence definition: chr12_498 potential fusion of SENP1 and Collagen 2A;
 also overlaps GS prediction
- Sequence ID: No. 11
 55 Accession #: AB064665
 Genomic sequence: chrM:9411-9524
 Sequence definition: Homo sapiens mRNA for OK/SW-CL.16

- Sequence ID: No. 12
Accession #: NM_024029
Genomic sequence: chr19:10880041-10883719
5 Sequence definition: hypothetical protein MGC3262
- Sequence ID: No. 13
Accession #: NT_008748.79
Genomic sequence: chr10:80881918-80882092
10 Sequence definition: Genscan prediction
- Sequence ID: No. 14
Accession #: AB002360
Genomic sequence: chr13:112761227-112761344
15 Sequence definition: KIAA0362
- Sequence ID: No. 15
Accession #: AK057572
Genomic sequence: chr16:14547315-14547422
20 Sequence definition: FLJ33010
- Sequence ID: No. 16
Accession #: NT_034410.56/NM_033102.1
Genomic sequence: chr1:203503646-203554883/chr1:192169879-192474008
25 Sequence definition: Genscan - Elk4/LOC85414 - Homo sapiens protein LOC85414
- Sequence ID: No. 17
Accession #: NT_019696.29
Genomic sequence: chrX:64173951-64275396
30 Sequence definition: Genscan prediction
- Sequence ID: No. 18
Accession #: NT_007834.17
Genomic sequence: chr7:71656530-71727938
35 Sequence definition: Genscan prediction
- Sequence ID: No. 19
Accession #: NT_005403.1000
Genomic sequence: chr2:208067141-208067324
40 Sequence definition: Genscan prediction
- Sequence ID: No. 20
Accession #: NT_009654.19
Genomic sequence: chr12:116716120-116840364
45 Sequence definition: Genscan prediction
- Sequence ID: No. 21
Accession #: AC126564.7
Genomic sequence: chr12:131440407-131440735
50 Sequence definition: genomic match
- Sequence ID: No. 22
Accession #: NT_006171.64
Genomic sequence: chr4:172269202-172299375
55 Sequence definition: Genscan prediction
- Sequence ID: No. 23
Accession #: NM_025149.1
Genomic sequence: chr17:61361324-61409903
60 Sequence definition: FLJ20920

- Sequence ID: No. 24
Accession #: NT_026437.145
Genomic sequence: chr14:72272372-72462407
Sequence definition: Genscan prediction
- 5 Sequence ID: No. 25
Accession #: NT_030059.13
Genomic sequence: chr10:103933731-103955924
Sequence definition: Genscan prediction
- 10 Sequence ID: No. 26
Accession #: AK058112
Genomic sequence: chr19:1815692-1822319
Sequence definition: FLJ25383
- 15 Sequence ID: No. 27
Accession #: NM_002205.1
Genomic sequence: chr12:55541534-55565494
Sequence definition: Homo sapiens integrin alpha 5 fibronectin receptor
alpha polypeptide
- 20 Sequence ID: No. 28
Accession #: NM_004716.1
Genomic sequence: chr11:117114115-117114448
Sequence definition: Homo sapiens proprotein convertase subtilisin/kexin
type 7 PCSK7 mRNA
- 25 Sequence ID: No. 29
Accession #: NM_030774
Genomic sequence: chr11:5003431-5021099
Sequence definition: prostate specific G-protein coupled receptor [Homo
sapiens]
- 30 Sequence ID: No. 30
Accession #: AB007932
Genomic sequence: chr1:204846394-204846755
Sequence definition: Homo sapiens plexin A2 PLXNA2 mRNA
- 35 Sequence ID: No. 31
Accession #: AB023177
Genomic sequence: chr7:11157196-11157402
Sequence definition: Homo sapiens mRNA for KIAA0960 protein
- 40 Sequence ID: No. 32
Accession #: NT_004858.23
Genomic sequence: chr1:147688399-147725025
Sequence definition: Genscan prediction
- 45 Sequence ID: No. 33
Accession #: NT_004873.61
Genomic sequence: chr1:14678698-14732191
Sequence definition: Genscan prediction
- 50 Sequence ID: No. 34
Accession #: NT_029860.99
Genomic sequence: chr1:110751286-110854188
Sequence definition: Genscan prediction
- 55 Sequence ID: No. 35
Accession #: NM_032385.1
Genomic sequence: chr5:170086201-170251515
Sequence definition: Homo sapiens chromosome 5 open reading frame 4
- 60

C5orf4

- Sequence ID: No. 36
Accession #: NM_014752.1
5 Genomic sequence: chr11:73182947-73211393
Sequence definition: KIAA0102
- Sequence ID: No. 37
Accession #: NP_000295
10 Genomic sequence: chr17:15500091-15500332
Sequence definition: Homo sapiens peripheral myelin protein 22
- Sequence ID: No. 38
Accession #: NM_020433
15 Genomic sequence: chr20:42528457-42528759
Sequence definition: Homo sapiens junctophilin 2
- Sequence ID: No. 39
Accession #: NT_999999.2
20 Genomic sequence: chrM:9411-9524
Sequence definition: Genscan Gene Predictions
- Sequence ID: No. 40
Accession #: NT_004754.1
25 Genomic sequence: chr1:117988850-117989247
Sequence definition: Genscan Gene Predictions
- Sequence ID: No. 41
Accession #: NT_011568.108
30 Genomic sequence: chrX:47583156-47583796
Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- Sequence ID: No. 42
Accession #: NP_061116
35 Genomic sequence: chr7:140900079-140900876
Sequence definition: transient receptor potential cation channel
- Sequence ID: No. 43
Accession #: NT_011295.163
40 Genomic sequence: chr19:19799239-19804450
Sequence definition: Genscan prediction
- Sequence ID: No. 44
Accession #: NP_056051
45 Genomic sequence: chr4:62284401-62284770
Sequence definition: lectomedin-3
- Sequence ID: No. 45
Accession #: NT_033927.57
50 Genomic sequence: chr11:75518014-75562375
Sequence definition: Genscan prediction
- Sequence ID: No. 46
Accession #: NM_030774
55 Genomic sequence: chr11:5003431-5021099
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens
- Sequence ID: No. 47
Accession #: NM_022119
60 Genomic sequence: chr16:2939532-2939842
Sequence definition: protease serine 22

- Sequence ID: No. 48
Accession #: NP_000155
Genomic sequence: chr19:46824678-46824801
5 Sequence definition: Homo sapiens gastric inhibitory polypeptide receptor
- Sequence ID: No. 49
Accession #: NM_001627
Genomic sequence: chr3:104784804-104787209
10 Sequence definition: activated leukocyte cell adhesion molecule
- Sequence ID: No. 50
Accession #: NP_056343
Genomic sequence: chr17:5263335-5263632
15 Sequence definition: Homo sapiens DKFZP566H073 protein
- Sequence ID: No. 51
Accession #: NT_033275.9
Genomic sequence: chr15:19767754-19767842
20 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- Sequence ID: No. 52
Accession #: NT_004511.105
Genomic sequence: chr1:37657082-37657508
25 Sequence definition: Genscan Gene Predictions
- Sequence ID: No. 53
Accession #: NT_007819.76
Genomic sequence: chr7:2293638-2293859
30 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- Sequence ID: No. 54
Accession #: NT_008046.179
Genomic sequence: chr8:101509107-101509191
35 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- Sequence ID: No. 55
Accession #: NP_001668
Genomic sequence: chr1:166712801-166712951
40 Sequence definition: ATPase Na+/K+ transporting beta 1 polypeptide
- Sequence ID: No. 56
Accession #: NP_061332
Genomic sequence: chr7:105724807-105753208
45 Sequence definition: B-cell receptor-associated protein BAP29
- Sequence ID: No. 57
Accession #: NT_008251.42
Genomic sequence: chr8:36531104-36531405
50 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- Sequence ID: No. 58
Accession #: NT_008984.116
Genomic sequence: chr11:97792879-97792961
55 Sequence definition: Genscan Gene Predictions
- Sequence ID: No. 59
Accession #: NT_011176.84
Genomic sequence: chr19:11151260-11154382
60 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- Sequence ID: No. 60

- Accession #: ENST00000255124
Genomic sequence: chr20:46047371-46047445
Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- 5 Sequence ID: No. 61
Accession #: ENST00000262657
Genomic sequence: chr20:29935469-29937596
Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions
- 10 Sequence ID: No. 62
Accession #: NT_033903.44
Genomic sequence: chr11:58671001-58671164
Sequence definition: Genscan Gene Predictions
- 15 Sequence ID: No. 63
Accession #: NP_000360
Genomic sequence: chr14:78989775-78989913
Sequence definition: Homo sapiens thyroid stimulating hormone receptor
- 20 Sequence ID: No. 64
Accession #: NP_005219
Genomic sequence: chr7:54724858-54725037
Sequence definition: Homo sapiens epidermal growth factor receptor
erythroblastic leukemia viral v-erb-b oncogene homolog avian
- 25 Sequence ID: No. 65
Accession #: NP_149093
Genomic sequence: chr1:203548697-203549088
Sequence definition: Homo sapiens prostatein protein
- 30 Sequence ID: No. 66
Accession #: NM_030774
Genomic sequence: chr11:5003431-5021099
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens
- 35 Sequence ID: No. 67
Accession #: NM_030774
Genomic sequence: chr11:5004995-5010301
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens
- 40 Sequence ID: No. 68
Accession #: NM_030774
Genomic sequence: chr11:5004983-5010305
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens
- 45 Sequence ID: No. 69
Accession #: NM_030774
Genomic sequence: chr11:5004983-5010305
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens
- 50 Sequence ID: No. 70
Accession #: NM_030774
Genomic sequence: chr11:4667240-4678100
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens
- 55 Sequence ID: No. 71
Accession #: NM_030774

Genomic sequence: chr11:4677792-4677987
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens

5 Sequence ID: No. 72
Accession #: NM_030774
Genomic sequence: chr11:5003430-5007773
Sequence definition: prostate specific G-protein coupled receptor Homo sapiens

10 Sequence ID: No. 73
Accession #: AK075546
Genomic sequence: chr11:36643617-36930167
Sequence definition: predicted protein

15 Sequence ID: No. 74
Accession #: AK075546
Genomic sequence: chr11:36643626-36931023
Sequence definition: predicted protein

20 Sequence ID: No. 75
Accession #: AK075546
Genomic sequence: chr11:36643617-36929351
Sequence definition: predicted protein

25 Sequence ID: No. 76
Accession #: AK075546
Genomic sequence: chr11:36643617-36929351
Sequence definition: predicted protein

30 Sequence ID: No. 77
Accession #: AK075546
Genomic sequence: chr11:36643617-36929351
Sequence definition: predicted protein

35 Sequence ID: No. 78
Accession #: NT_033927.57
Genomic sequence: chr11:75518014-75562375
Sequence definition: Genscan prediction

40 Sequence ID: No. 79
Accession #: NM_000300
Genomic sequence: chr1:19337078-19342056
Sequence definition: phospholipase A2 group IIA platelets synovial

45 Sequence ID: No. 80
Accession #: NM_000300
Genomic sequence: chr1:19337078-19342056
Sequence definition: phospholipase A2 group IIA platelets synovial

50 Sequence ID: No. 81
Accession #: NM_000300
Genomic sequence: chr1:19337078-19342056
Sequence definition: phospholipase A2 group IIA platelets synovial

55 Sequence ID: No. 82
Accession #: NM_000300
Genomic sequence: chr1:19337078-19342056
Sequence definition: phospholipase A2 group IIA platelets synovial

60 Sequence ID: No. 83
Accession #: NM_000300

- Genomic sequence: chr1:19337078-19342056
Sequence definition: phospholipase A2 group IIA platelets synovial
- Sequence ID: No. 84
5 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102 - refseq
- Sequence ID: No. 85
10 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102
- Sequence ID: No. 86
15 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102
- Sequence ID: No. 87
20 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102
- Sequence ID: No. 88
25 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102
- Sequence ID: No. 89
30 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102
- Sequence ID: No. 90
35 Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102
- Sequence ID: No. 91
40 Accession #: AK092666
Genomic sequence: chr7:88376306-88402240
Sequence definition: STEAP2/AK092666
- Sequence ID: No. 92
45 Accession #: AK092666
Genomic sequence: chr7:88376306-88402240
Sequence definition: STEAP2/AK092666
- Sequence ID: No. 93
50 Accession #: AK092666
Genomic sequence: chr7:88376306-88402240
Sequence definition: STEAP2/AK092666
- Sequence ID: No. 94
55 Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
Sequence definition: TMPRSS2
- Sequence ID: No. 95
60 Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
Sequence definition: TMPRSS2

- Sequence ID: No. 96
Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
5 Sequence definition: TMPRSS2
- Sequence ID: No. 97
Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
10 Sequence definition: TMPRSS2
- Sequence ID: No. 98
Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
15 Sequence definition: TMPRSS2
- Sequence ID: No. 99
Accession #: NM_004476
Genomic sequence: chr11:50361918-50423952
20 Sequence definition: PSMA/FOLH1
- Sequence ID: No. 100
Accession #: NM_004476
Genomic sequence: chr11:50361918-50423952
25 Sequence definition: PSMA/FOLH1
- Sequence ID: No. 101
Accession #: NM_004476
Genomic sequence: chr11:50361918-50423952
30 Sequence definition: PSMA/FOLH1
- Sequence ID: No. 102
Accession #: no match to index
Genomic sequence: No match BLAT
35 Sequence definition: No match BLAT
- Sequence ID: No. 103
Accession #: AC105101.8
Genomic sequence: chr18:45441503-45442177
40 Sequence definition: genomic match
- Sequence ID: No. 104
Accession #: BC043509
Genomic sequence: chr2:7566735-7567210
45 Sequence definition: genomic match
- Sequence ID: No. 105
Accession #: no match to index
Genomic sequence: No match BLAT
50 Sequence definition: No match BLAT
- Sequence ID: No. 106
Accession #: NT_007914.345
Genomic sequence: chr7:150965224-150965948
55 Sequence definition: Genscan prediction
- Sequence ID: No. 107
Accession #: NM_002474
Genomic sequence: chr16:15123743-15124024
60 Sequence definition: smooth muscle myosin heavy chain 11 isoform
- Sequence ID: No. 108

Accession #: no match to index
Genomic sequence: No match BLAT
Sequence definition: No match BLAT

- 5 Sequence ID: No. 109
 Accession #: AL450472.14
 Genomic sequence: chrX:132596913-132597349
 Sequence definition: genomic match
- 10 Sequence ID: No. 110
 Accession #: no match to index
 Genomic sequence: No match BLAT
 Sequence definition: No match BLAT
- 15 Sequence ID: No. 111
 Accession #: NM_024490
 Genomic sequence: chr15:18676827-18681314
 Sequence definition: ATPase Class V type 10A
- 20 Sequence ID: No. 112
 Accession #: NT_007741.24
 Genomic sequence: chr7:154483727-154484200
 Sequence definition: Genscan prediction
- 25 Sequence ID: No. 113
 Accession #: NT_010168.1
 Genomic sequence: chr14:100136759-100137109
 Sequence definition: Genscan prediction
- 30 Sequence ID: No. 114
 Accession #: AK074158
 Genomic sequence: chr7:2347770-2347996
 Sequence definition: Homo sapiens mRNA for FLJ00231 protein
- 35 Sequence ID: No. 115
 Accession #: no match to index
 Genomic sequence: No match BLAT
 Sequence definition: No match BLAT
- 40 Sequence ID: No. 116
 Accession #: AL549429
 Genomic sequence: chr11:9027915-9028089
 Sequence definition: genomic match
- 45 Sequence ID: No. 117
 Accession #: NM_015541
 Genomic sequence: chr3:65899978-65900329
 Sequence definition: leucine-rich repeats and immunoglobulin-like
- 50 Sequence ID: No. 118
 Accession #: NM_024897
 Genomic sequence: chr1:151978744-151978881
 Sequence definition: hypothetical protein FLJ22672
- 55 Sequence ID: No. 119
 Accession #: NM_006598
 Genomic sequence: chr5:1165896-1168793
 Sequence definition: solute carrier family 12 potassium/chloride
- 60 Sequence ID: No. 120
 Accession #: NM_021569
 Genomic sequence: chr9:131740238-131740388

Sequence definition: NMDA receptor 1 isoform NR1-2 precursor

Sequence ID: No. 121

Accession #: AL445467.6

- 5 Genomic sequence: chrX:15985515-15985779
Sequence definition: genomic match

Sequence ID: No. 122

Accession #: BM976799

- 10 Genomic sequence: chr1:54049149-54049432
Sequence definition: genomic/EST match

Sequence ID: No. 123

Accession #: no match to index

- 15 Genomic sequence: No match BLAT
Sequence definition: No match BLAT

Sequence ID: No. 124

Accession #: NT_007933.414

- 20 Genomic sequence: chr7:98285605-98286140
Sequence definition: Genscan prediction

Sequence ID: No. 125

Accession #: NM_020428

- 25 Genomic sequence: chr19:10964586-10965036
Sequence definition: Homo sapiens CTL2 gene CTL2 mRNA

Sequence ID: No. 126

Accession #: no match to index

- 30 Genomic sequence: No match BLAT
Sequence definition: No match BLAT

Sequence ID: No. 127

Accession #: NM_006292

- 35 Genomic sequence: chr11:19444265-19444422
Sequence definition: Homo sapiens tumor susceptibility gene 101 TSG101 mRNA

Sequence ID: No. 128

Accession #: NM_052932

- 40 Genomic sequence: chr11:102306433-102306907
Sequence definition: Homo sapiens pro-oncosis receptor inducing membrane injury gene PORIMIN mRNA

- 45 Sequence ID: No. 129

Accession #: NM_000014

Genomic sequence: chr12:9416444-9416720

Sequence definition: Homo sapiens alpha-2-macroglobulin A2M mRNA

- 50 Sequence ID: No. 130

Accession #: NM_002337

Genomic sequence: chr4:3426547-3433294

Sequence definition: low density lipoprotein-related

- 55 Sequence ID: No. 131

Accession #: AL834445

Genomic sequence: chr20:23304135-23304477

Sequence definition: Homo sapiens mRNA; cDNA DKFZp761J109

- 60 Sequence ID: No. 132

Accession #: NM_004986

Genomic sequence: chr14:49879277-49880762

Sequence definition: kinectin 1

Sequence ID: No. 133

Accession #: NM_024295

5 Genomic sequence: chr8:124092754-124095061

Sequence definition: hypothetical protein MGC3067

Sequence ID: No. 134

Accession #: AC018457.14

10 Genomic sequence: chr3:165236534-165236724

Sequence definition: genomic match

Sequence ID: No. 135

Accession #: NM_004753

15 Genomic sequence: chr1:12208898-12258427

Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

Sequence ID: No. 136

20 Accession #: NM_004753

Genomic sequence: chr1:12221576-12258383

Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

25 Sequence ID: No. 137

Accession #: NM_004753

Genomic sequence: chr1:12221576-12258383

Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

30

Sequence ID: No. 138

Accession #: NM_004753

Genomic sequence: chr1:12221576-12258383

Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

35

Sequence ID: No. 139

Accession #: NM_004753

Genomic sequence: chr1:12221576-12258383

40 Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

Sequence ID: No. 140

Accession #: D87438

45 Genomic sequence: chr16:14996279-15058862

Sequence definition: Human mRNA for KIAA0251 gene partial cds

Sequence ID: No. 141

Accession #: D87438

50 Genomic sequence: chr16:15018972-15027737

Sequence definition: Human mRNA for KIAA0251 gene partial cds

Sequence ID: No. 142

Accession #: AB007932

55 Genomic sequence: chr1:204843635-205060532

Sequence definition: Homo sapiens plexin A2 long form PLXNA2 mRNA

Sequence ID: No. 143

Accession #: AB007932

60 Genomic sequence: chr1:204843635-205060532

Sequence definition: Homo sapiens plexin A2 long form PLXNA2 mRNA

- Sequence ID: No. 144
Accession #: AB007932
Genomic sequence: chr1:204843635-205060532
Sequence definition: Homo sapiens plexin A2 long form PLXNA2 mRNA
- 5 Sequence ID: No. 145
Accession #: AB037745
Genomic sequence: chr1:108833848-108851509
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds
- 10 Sequence ID: No. 146
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds
- 15 Sequence ID: No. 147
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds
- 20 Sequence ID: No. 148
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds
- 25 Sequence ID: No. 149
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds
- 30 Sequence ID: No. 150
Accession #: NM_002253
Genomic sequence: chr4:55795152-55795458
Sequence definition: Homo sapiens kinase insert domain receptor a type
III receptor tyrosine kinase KDR mRNA
- 35 Sequence ID: No. 151
Accession #: NM_004879
Genomic sequence: chr11:125479160-125481382
Sequence definition: Homo sapiens etoposide induced 2.4 mRNA EI24 mRNA
- 40 Sequence ID: No. 152
Accession #: BC041788
Genomic sequence: chr8:144841449-144841809
Sequence definition: Homo sapiens Similar to RIKEN cDNA 1110025J15 gene
clone MGC:32881 IMAGE:4738372 mRNA complete cds
- 45 Sequence ID: No. 153
Accession #: AB033073
Genomic sequence: chr20:46925235-46925516
Sequence definition: Homo sapiens mRNA for KIAA1247 protein partial cds
- 50 Sequence ID: No. 154
Accession #: NT_011520.136
Genomic sequence: chr22:21548074-21562329
Sequence definition: Genscan prediction
- 55 Sequence ID: No. 155
Accession #: NM_005581
Genomic sequence: chr19:49998069-49998792
Sequence definition: Homo sapiens Lutheran blood group Auberger b antigen
included LU mRNA
- 60

- Sequence ID: No. 156
Accession #: NM_004355
Genomic sequence: chr5:149769000-149775442
5 Sequence definition: Homo sapiens CD74 antigen invariant polypeptide of major histocompatibility complex class II antigen-associated CD74 mRNA
- Sequence ID: No. 157
Accession #: NM_000484
10 Genomic sequence: chr21:26174980-26175131
Sequence definition: Homo sapiens amyloid beta A4 precursor protein protease nexin-II Alzheimer disease APP mRNA
- Sequence ID: No. 158
Accession #: NM_005745
15 Genomic sequence: chrX:150566783-150575554
Sequence definition: Homo sapiens accessory protein BAP31 BCAP31 mRNA
- Sequence ID: No. 159
Accession #: NM_005570
20 Genomic sequence: chr18:56780509-56781078
Sequence definition: Homo sapiens lectin mannose-binding 1 LMAN1 mRNA
- Sequence ID: No. 160
Accession #: NT_029218.14
25 Genomic sequence: chr1:19080562-19080917
Sequence definition: Genscan prediction
- Sequence ID: No. 161
Accession #: NT_011387.8
30 Genomic sequence: chr20:410654-410816
Sequence definition: Genscan prediction
- Sequence ID: No. 162
Accession #: NM_002587
35 Genomic sequence: chr5:141227996-141231527
Sequence definition: Homo sapiens protocadherin 1 PDCH1
- Sequence ID: No. 163
Accession #: NT_035036.5
40 Genomic sequence: chr10:51263955-51274232
Sequence definition: Genscan prediction
- Sequence ID: No. 164
Accession #: NM_007176
45 Genomic sequence: chr14:74107662-74107815
Sequence definition: Homo sapien Chr 14 open reading frame
- Sequence ID: No. 165
Accession #: AP000531.1
50 Genomic sequence: chr22:14703272-14703359
Sequence definition: poor genomic match to repeat
- Sequence ID: No. 166
Accession #: NM_020182
55 Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA
- Sequence ID: No. 167
Accession #: NM_020182
60 Genomic sequence: chr20:56850452-56936716

Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA

- Sequence ID: No. 168
5 Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA
- 10 Sequence ID: No. 169
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA
- 15 Sequence ID: No. 170
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA
- 20 Sequence ID: No. 171
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA
- Sequence ID: No. 172
Accession #: NM_020182
30 Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced RNA TMEPAI mRNA
- Sequence ID: No. 173
Accession #: AK092666_01
35 Sequence definition: Novel spliced isoform of STEAP2
- Sequence ID: No. 174
Accession #: AK092666_01
40 Sequence definition: Protein translation of novel spliced isoform of STEAP2
- Sequence ID: No. 175
Accession #: AK092666_02
45 Sequence definition: Novel spliced isoform of STEAP2
- Sequence ID: No. 176
Accession #: AK092666_02
50 Sequence definition: Protein translation of novel spliced isoform of STEAP2
- Sequence ID: No. 177
Accession #: AK092666_03
55 Sequence definition: Novel spliced isoform of STEAP2
- Sequence ID: No. 178
Accession #: AK092666_03
Sequence definition: Protein translation of novel spliced isoform of STEAP2
- 60 Sequence ID: No. 179
Accession #: AK092666_04

Sequence definition: Novel spliced isoform of STEAP2

Sequence ID: No. 180

Accession #: AK092666_04

5 Sequence definition: Protein translation of novel spliced isoform of STEAP2

Sequence ID: No. 181

Accession #: AK092666_05

10 Sequence definition: Novel spliced isoform of STEAP2

Sequence ID: No. 182

Accession #: AK092666_05

Sequence definition: Novel spliced isoform of STEAP2

15

Sequence ID: No. 183

Accession #: AK092666_01aa

Sequence definition: Novel amino acids generated by spliced isoforms
AK092666_01, AK092666_03, AK092666_05

20

Sequence ID: No. 184

Accession #: AK092666_02aa

Sequence definition: Novel amino acids generated by spliced isoform
AK092666_02

25

Sequence ID: No. 185

Accession #: AK092666_04aa

Sequence definition: Novel amino acids generated by spliced isoform
AK092666_04

30

REFERENCES

- Alcaraz et al., *Cancer Res.*, 55:3998-4002, 1994.
- 5 Allhoff et al., *World J. Urol.*, 7:12-16, 1989.
- An et al., *Proc. Amer. Assn. Canc. Res.*, 36:82, 1995.
- An et al., *Molec. Urol.*, 2: 305-309, 1998.
- 10 Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988.
- Babian et al., *J. Urol.*, 156:432-437, 1996.
- 15 Badalament et al., *J. Urol.*, 156:1375-1380, 1996.
- Baichwal and Sugden, In: *Gene Transfer*, Kucherlapati (Ed.), Plenum Press, New York, pp 117-148, 1986.
- 20 Bangham et al., *J. Mol. Biol.* 13: 238-252, 1965.
- Barinaga, *Science*, 271: 1233, 1996.
- 25 Bedzyk et al., *J. Biol. Chem.*, 265:18615, 1990
- Bell et al., "Gynecological and Genitourinary Tumors," In: *Diagnostic Immunopathology*, Colvin, Bhan and McCluskey (Eds.), 2nd edition, Ch. 31, Raven Press, New York, pp 579-597, 1995.
- 30 Bellus, *J Macromol. Sci. Pure Appl. Chem.*, A31(1):1355-1376, 1994.
- Benvenisty and Neshif, *Proc. Nat. Acad Sci. USA*, 83:9551-9555, 1986.
- Bittner et al., *Methods in Enzymol*, 153:516-544, 1987.
- 35 Bookstein et al., *Science*, 247:712-715, 1990a.
- Bookstein et al., *Proc. Nat'l Acad. Sci. USA*, 87:7762-7767, 1990b.
- 40 Bova et al., *Cancer Res.*, 53:3869-3873, 1993
- Brawn et al., *The Prostate*, 28:295-299, 1996.
- Campbell, In: *Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology*, Burden and Von Knippenberg (Eds.), Vol.13:75-83, Elsevier, Amsterdam, 1984.
- 45 Capaldi et al., *Biochem. Biophys. Res. Comm*, 76:425, 1977.
- 50 Carter and Coffey, In: *Prostate Cancer: The Second Tokyo Symposium*, J. P. Karr and H. Yamanak

- (Eds.), Elsevier, New York, pp 19-27, 1989.
- Carter and Coffey, Prostate, 16:3948, 1990.
- 5 Carter et al., Proc. Nat'l Acad Sci. USA, 87:8751-8755, 1990.
- Carter et al., Proc. Nat'l Acad Sci. USA 93: 749-753, 1996.
- Carter et al., J. Urol., 157:2206-2209, 1997.
- 10 Cech et al., Cell, 27:487-496, 1981.
- Chang et al., Hepatology, 14: 124A, 1991.
- 15 Chaudhary et al., Proc. Nat'l Acad. Sci., 87:9491, 1990.
- Chen and Okayama, Mol Cell Biol., 7:2745-2752, 1987.
- Chen et al., Clin. Chem., 41:273-282, 1995a.
- 20 Chen et al., Proc. Am. Urol. Assn, 153:267A, 1995.
- Chinault and Carbon, "Overlap Hybridization Screening: Isolation and Characterization of Overlapping DNA Fragments Surrounding the LEU2 Gene on Yeast Chromosome III," Gene, 5:111-126, 1979.
- 25 Chomczynski and Sacchi, Anal. Biochem., 162:156-159, 1987.
- Christensson et al., J. Urol., 150:100-105, 1993.
- 30 Coffin, In: Virology, Fields et al. (Eds.), Raven Press, New York, pp 1437-1500, 1990.
- Colberre-Garapin et al., J. Mol. Biol., 150:1, 1981.
- 35 Colvin et al., Diagnostic Immunopathology, 2nd edition, Raven Press, New York, 1995.
- Cooner et al., J. Urol., 143:1146-1154, 1990.
- Couch et al., Am. Rev. Resp. Dis., 88:394-403, 1963.
- 40 Coupar et al., Gene, 68:1-10, 1988.
- Culver et al., Science, 256:1550-1552, 1992.
- 45 Davey et al., EPO No. 329 822.
- Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," In: Liposomes, M. Ostro (Ed.), 1983.
- 50 Diamond et al., J. Urol., 128:729-734, 1982.

- Donahue et al., J. Biol. Chem., 269:8604-8609, 1994.
- Dong et al., Science, 268:884-886, 1995.
- 5 Dubensky et al., Proc. Nat. Acad. Sci. USA, 81:7529-7533, 1984.
- Dumont et al., J. Immunol., 152:992-1003, 1994.
- Elledge et al., Cancer Res. 54:3752-3757, 1994
- 10 European Patent Application EPO No. 320 308
- Fearon et al., Science, 247:47-56, 1990.
- 15 Fechheirner et al., Proc. Natl. Acad. Sci. USA, 84:8463-8467, 1987.
- Forster and Symons, Cell, 49:211-220, 1987.
- Fraley et al., Proc. Natl. Acad. Sci USA, 76:3348-3352, 1979.
- 20 Friedmann, Science, 244:1275-1281, 1989.
- Freifelder, In: Physical Biochemistry Applications to Biochemistry and Molecular Biology, 2nd ed., Wm. Freeman and Co., New York, N.Y., 1982.
- 25 Frohman, In: PCR Protocols: A Guide to Methods and Applications, Academic Press, New York, 1990.
- Geffer et al., Somatic Cell Genet., 3:231-236, 1977.
- 30 Gerlach et al., Nature (London), 328:802-805, 1987.
- Ghosh-Choudhury et al., EMBO J., 6:1733-1739, 1987.
- 35 Gingeras et al., PCT Application WO 88/10315.
- Ghosh and Bachhawat, In: Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands, Wu et al. (Eds.), Marcel Dekker, New York, pp 87-104, 1991.
- 40 Goding, In: Monoclonal Antibodies: Principles and Practice, 2nd ed., Academic Press, Orlando, Fla., pp 60-61, 65-66, 71-74, 1986.
- Gomez-Foix et al., J. Biol. Chem., 267:25129-25134, 1992.
- 45 Gopal, Mol. Cell Biol., 5:1188-1190, 1985.
- Graham et al., J. Gen. Virol., 36:59-72, 1977.
- Graham and van der Eb, Virology, 52:456-467, 1973.
- 50 Graham and Prevec, In: Methods in Molecular Biology: Gene Transfer and Expression Protocols 7,

- E. J. Murray (Ed.), Humana Press, Clifton, N.J., pp 205-225, 1991.
- Gregoriadis (ed.), In: Drug Carriers in Biology and Medicine, pp 287-341, 1979.
- 5 Grunhaus and Horwitz, Sem. Virol., 3:237-252, 1992.
- Harland and Weintraub, J. Cell Biol., 101:1094-1099, 1985.
- Harris et al., J. Urol., 157:1740-1743, 1997.
- 10 Heng et al., Proc. Nat. Acad. Sci. USA, 89: 9509-9513, 1992.
- Hermonat and Muzycska, Proc. Nat. Acad. Sci USA, 81:6466-6470, 1984.
- 15 Hersdorffer et al., DNA Cell Biol., 9:713-723, 1990.
- Herz and Gerard, Proc. Natl Acad Sci. USA, 90:2812-2816, 1993.
- Hess et al., J. Adv. Enzyme Reg., 7:149, 1968.
- 20 Hitzeman et al., J. Biol. Chem., 255:2073, 1980.
- Holland et al., Biochemistry, 17:4900, 1978.
- 25 Horoszewicz, Kawinski and Murphy, Anticancer Res., 7:927-936, 1987.
- Horwich, et al., J. Virol., 64:642-650, 1990.
- Huang et al., Prostate, 23: 201-212, 1993.
- 30 Innis et al., In: PCR Protocols, Academic Press, Inc., San Diego Calif., 1990.
- Inouye et al., Nucl. Acids Res., 13:3101-3109, 1985.
- 35 Isaacs et al., Cancer Res., 51:4716-4720, 1991.
- Isaacs et al., Sem. Oncol., 21:1-18, 1994.
- Israeli et al., Cancer Res., 54:1807-1811, 1994.
- 40 Jacobson et al., JAMA, 274:1445-1449, 1995.
- Johnson et al., In: Biotechnology and Pharmacy, Pezzuto et al., (Eds.), Chapman and Hall, New York, 1993.
- 45 Jones, Genetics, 85:12, 1977.
- Jones and Shenk, Cell, 13:181-188, 1978.
- 50 Joyce, Nature, 338:217-244, 1989.

- Kaneda et al., Science, 243:375-378, 1989.
- Kato et al., J. Biol. Chem., 266:3361-3364, 1991.
- 5 Kent, et al., Genome Res. 12:996-1006 (2002).
- Kim and Cech, Proc. Natl. Acad. Sci. USA, 84:8788-8792, 1987.
- Kingsman et al., Gene, 7:141, 1979.
- 10 Klein et al., Nature, 327:70-73, 1987.
- Kohler and Milstein, Nature, 256:495-497, 1975.
- 15 Kohler and Milstein, Eur. J. Immunol., 6:511-519, 1976.
- Kwoh et al., Proc. Nat. Acad. Sci. USA, 86:1173, 1989.
- Landis et al., CA Cancer J. Clin., 48: 6-29, 1998.
- 20 Le Gal La Salle et al., Science, 259:988-990, 1993.
- Levrero et al., Gene, 10 1: 195-202, 1991.
- 25 Liang and Pardee, Science, 257:967-971, 1992.
- Liang and Pardee, U.S. Pat. No. 5,262,311, 1993.
- Liang et al., Cancer Res., 52:6966-6968, 1992.
- 30 Lifton, Science, 272:676, 1996.
- Lilja et al., Clin. Chem., 37:1618-1625, 1991.
- 35 Lithrup et al., Cancer, 74:3146-3150, 1994.
- Lowy et al., Cell, 22:817, 1980.
- Macoska et al., Cancer Res., 54:3824-3830, 1994.
- 40 Mann et al., Cell, 33:153-159, 1983.
- Markowitz et al., J. Virol., 62:1120-1124, 1988.
- 45 Marley et al., Urology, 48(6A): 16-22, 1996.
- McCormack et al., Urology, 45:729-744, 1995.
- Michel and Westhof, J. Mol. Biol. 216:585-610, 1990.
- 50 Miki et al., Science, 266:66-71, 1994.

- Miller et al., PCT Application, WO 89/06700.
- Mok et al., Gynecol. Oncol., 52:247-252, 1994.
- 5 Morahan et al., Science 272:1811, 1996.
- Mulligan et al., Proc. Nat'l Acad. Sci. USA, 78:2072, 1981.
- 10 Mulligan, Science, 260:926-932, 1993.
- Murphy et al., Cancer, 78: 809-818, 1996.
- Murphy et al., Prostate, 26:164-168, 1995.
- 15 Nakamura et al., In: Handbook of Experimental Immunology, (4th Ed.), Weir, E., Herzenberg, L. A., Blackwell, C., Herzenberg, L. (Eds.), Vol. 1, Chapter 27, Blackwell Scientific Publ., Oxford, 1987.
- 20 Nicolas and Rubinstein, In: Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Rodriguez and Denhardt (Eds.), Butterworth, Stoneham, p 494-513, 1988.
- Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190, 1982.
- 25 O'Dowd et al., J. Urol., 158:687-698, 1997.
- O'Hare et al., Proc. Nat'l Acad. Sci. USA, 78:1527, 1981.
- Oesterling et al., J. Urol., 154:1090-1095, 1995.
- 30 Ohara et al., Proc. Nat'l Acad. Sci. USA, 86:5673-5677, 1989.
- Orozco et al., Urology, 51:186-195, 1998.
- 35 Parker et al., CA Cancer J. Clin., 65:5-27, 1996.
- Partin and Oesterling, Urology, 48 (6A):1-3, 1996.
- Partin and Oesterling, J. Urol., 152:1358-1368, 1994.
- 40 Partin and Oesterling (Eds.), Urology, 48(6A) Supplement:1-87, 1996.
- Paskind et al., Virology, 67:242-248, 1975.
- 45 PCT Application No. PCT/US87/00880
- Pettersson et al., Clin. Chem., 41(10):1480-1488, 1995.
- Piironen et al., Clin. Chem. 42:1034-1041, 1996.
- 50 Potter et al., Proc. Nat. Acad. Sci. USA, 81:7161-7165, 1984.

- Racher et al., *Biotechnology Techniques*, 9:169-174, 1995.
- Ragot et al., *Nature*, 361:647-650, 1993.
- 5 Ralph and Veltri, *Advanced Laboratory*, 6:51-56, 1997.
- Ralph et al., *Proc. Natl. Acad. Sci. USA*, 90(22):10710-10714, 1993.
- 10 Reinhold-Hurek and Shub, *Nature*, 357:173-176, 1992.
- Renan, *Radiother. Oncol.*, 19:197-218, 1990.
- Ribas de Pouplana and Fothergill-Gilmore, *Biochemistry*, 33:7047-7055, 1994.
- 15 Rich et al., *Hum. Gene Ther.*, 4:461-476, 1993.
- Ridgeway, In: *Vectors: A Survey of Molecular Cloning Vectors and Their Uses*, Rodriguez R L, Denhardt D T (Eds.), Butterworth, Stoneham, pp 467-492, 1988.
- 20 Rippe et al., *Mol. Cell Biol.*, 10:689-695, 1990.
- Rosenfeld et al., *Science*, 252:431-434, 1991.
- 25 Rosenfeld et al., *Cell*, 68:143-155, 1992.
- Roux et al., *Proc. Nat'l Acad. Sci. USA*, 86:9079-9083, 1989.
- Sager et al., *FASEB J.*, 7:964-970, 1993.
- 30 Sambrook et al., (ed.), In: *Molecular Cloning*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.
- Santerre et al., *Gene*, 30: 147-156, 1984.
- 35 Sarver, et al., *Science*, 247:1222-1225, 1990.
- Scanlon et al., *Proc Natl Acad Sci USA*, 88:10591-10595, 1991.
- 40 Sidransky et al., *Science*, 252:706-709, 1991.
- Sidransky et al., *Cancer Res.*, 52:2984-2986, 1992.
- Silver et al., *Clin. Cancer Res.*, 3:81-85, 1997.
- 45 Slamon et al., *Science*, 224:256-262, 1984.
- Slamon et al., *Science*, 235:177-182, 1987.
- 50 Slamon et al., *Science*, 244:707-712, 1989.

- Smith, U.S. Pat. No. 4,215,051.
- Soh et al., J. Urol., 157:2212-2218, 1997.
- 5 Stenman et al., Cancer Res., 51:222-226, 1991.
- Stinchcomb et al., Nature, 282:39, 1979.
- 10 Stratford-Perricaudet and Perricaudet, In: Human Gene Transfer, O. Cohen-Haguenauer et al., (Eds.), John Libbey Eurotext, France, pp 51-61, 1991.
- Stratford-Perricaudet et al., Hum. Gene. Ther., 1:241-256, 1990.
- Sun and Cohen, Gene, 137:127-132, 1993.
- 15 Szoka and Papahadjopoulos, Proc. Nat'l. Acad. Sci. USA, 75: 4194-4198, 1978.
- Szybalska et al., Proc. Nat'l Acad. Sci. USA, 48:2026, 1962.
- 20 Takahashi et al., Cancer Res., 54:3574-3579, 1994.
- Taparowsky et al., Nature, 300:762-764, 1982.
- 25 Temin, In: Gene Transfer, Kucherlapati R. (Ed.), Plenum Press, New York, pp 149-188:, 1986.
- Tooze, In: Molecular Biology of DNA Tumor Viruses, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1991.
- 30 Top et al., J. Infect. Dis., 124:155-160, 1971.
- Tschemper et al., Gene, 10:1 57, 1980.
- Tur-Kaspa et al., Mol. Cell Biol., 6:716-718, 1986.
- 35 U.S. patent application Ser. No. 08/692,787
- U.S. Pat. No. 4,196,265
- U.S. Pat. No. 4,215,051
- 40 U.S. Pat. No. 4,683,195
- U.S. Pat. No. 4,683,202
- 45 U.S. Pat. No. 4,800,159
- U.S. Pat. No. 4,883,750
- U.S. Pat. No. 5,354,855
- 50 U.S. Pat. No. 5,359,046

- Varmus et al., Cell, 25:23-36, 1981.
- Veltri et al., J. Cell Biochem., 19(suppl):249-258, 1994.
- 5 Veltri et al., Urology, 48: 685-691, 1996.
- Veltri et al., Sem. Urol. Oncol., 16:106-117, 1998.
- 10 Veltri et al., Urology, 53:139-147, 1999.
- Visakorpi et al., Am. J. Pathol., 145:1-7, 1994.
- Wagner et al., Science, 260:1510-1513, 1993.
- 15 Walker et al., Proc. Nat'l Acad. Sci. USA, 89:392-396, 1992.
- Watson et al., Cancer Res., 54:4598-4602, 1994.
- 20 Welsh et al., Nucl. Acids Res., 20:4965-4970, 1992.
- Wigler et al., Cell, 11:223, 1977.
- Wigler et al., Proc. Nat'l Acad. Sci. USA, 77:3567, 1980.
- 25 Wingo et al., CA Cancer J. Clin., 47: 239-242, 1997.
- WO 90/07641, filed Dec. 21, 1990.
- 30 Wong et al., Int. J. Oncol., 3:13-17, 1993.
- Wu and Wu, J. Biol. Chem., 262: 4429-4432, 1987.
- Wu and Wu, Biochemistry, 27: 887-892, 1988.
- 35 Wu and Wu, Adv. Drug Delivery Rev., 12: 159-167, 1993.
- Wu et al., Genomics, 4:560, 1989.
- 40 Yang et al., Proc. Natl. Acad. Sci. USA, 87:9568-9572, 1990.
- Yokoda et al., Cancer Res. 52, 3402-3408, 1992.
- Zlotta et al, J. Urol., 157:1315-1321, 1997.
- 45

WHAT IS CLAIMED IS:

1. An isolated nucleic acid sequence that is expressed by human prostate cancer
5 cells, selected from the group consisting of:
 - (i) the nucleic acid sequence contained in SEQ ID NOS.: 1 to 173, 175, 177, 179, 181;
 - (ii) variants thereof, wherein such variants have a nucleic acid sequence that is at least 70% identical to the sequence of (i) when aligned without allowing for
10 gaps; and
 - (iii) fragments of (i) or (ii) having a size of at least 20 nucleotides in length.
2. The nucleic acid sequence of Claim 1 which comprises the nucleic acid
sequence contained in any one of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or a fragment
15 thereof.
3. A primer mixture that comprises primers that result in the specific amplification
of one of the nucleic acid sequences of Claim 1.
- 20 4. A method of detecting prostate cancer comprising determining whether a human prostate cell sample expresses a target nucleic acid molecule, wherein said target nucleic acid molecule comprises the sequence of a gene or RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or of a fragment of said gene or RNA having a size of at least 20 nucleotides in length.
25
5. The method of Claim 4, wherein said method comprises detecting the expression of said target nucleic acid molecule using a nucleic acid sequence that specifically hybridizes thereto.
- 30 6. The method of Claim 5, wherein said method comprises detecting the expression of said target nucleic acid molecule using primers that result in the amplification thereof.

7. The method of Claim 5, wherein the expression of said target nucleic acid molecule is detected by assaying for the antigen encoded by said nucleic acid.

5 8. The method of Claim 7, wherein said assay involves the use of a monoclonal antibody or fragment that specifically binds to said antigen.

9. The method of Claim 8, wherein said assay comprises an ELISA or competitive binding assay.
10

10. An antigen expressed by human prostate cancer cells, wherein said antigen is selected from the group consisting of:

- (i) the antigen encoded by a nucleic acid sequence having at least 90% sequence identity in SEQ ID NOS.: 1 to 173, 175, 177, 179, 181;
- 15 (ii) an antigen derived from a protein comprising a sequences having at least 90% identity in SEQ ID NOS. 174, 176, 178, 180, 182-185; and
- (iii) an antigenic fragment of (i) or (ii).

11. A prostate antigen comprising (i) the amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or (ii) an amino acid sequence selected from SEQ ID NOS. : 174, 176, 178, 180, and 182-185, or (iii) an antigenic fragment of (i) or (ii).
20

12. A monoclonal antibody or antigen-binding fragment thereof that specifically binds to a target polypeptide molecule selected from:
25

- (i) a polypeptide encoded by a nucleic acid molecule comprising the sequence of a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, or by a fragment of said gene or RNA having a size of at least 20 nucleotides in length, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185
30
- (ii) an antigen according to Claim 10 or 11, and

(iii) an antigenic fragment of (i) or (ii).

13. A monoclonal antibody or fragment thereof that specifically binds the antigen of Claim 11.

5

14. The antigen of Claim 10 or 11 which is attached directly or indirectly to a detectable label.

15. The antibody of Claim 12 or 13 which is attached directly or indirectly to a detectable label.

10

16. A diagnostic kit for detection of prostate cancer which comprises a DNA according to Claim 1 and a detectable label.

15

17. A diagnostic kit for detection of prostate cancer which comprises primers according to Claim 3 and a diagnostically acceptable carrier.

18. A diagnostic kit for detection of prostate cancer which comprises a monoclonal antibody according to Claim 12 or 13 and a detectable label.

20

19. A method for treating prostate cancer, which comprises administering to a subject a therapeutically effective amount of a ligand which specifically binds a target molecule selected from (i) a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (ii) a protein or polypeptide encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185.

25

20. The method of claim 19, wherein the ligand is a ribozyme or antisense

30

oligonucleotide that inhibits the expression of a gene having a DNA sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or a fragment, or variant thereof, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185.

5 21. The method of claim 19 or 20, wherein the ligand is directly or indirectly attached to an effector moiety.

 22. The method of Claim 21, wherein said effector moiety is a therapeutic radiolabel, enzyme, cytotoxin, growth factor, or drug.

10

 23. A method for treating prostate cancer comprising administering to a subject a therapeutically effective amount of an antigen according to Claim 10 or 11, and optionally an adjuvant that elicits a humoral or cytotoxic T-lymphocyte response to said antigen.

15

 24. A method for treating prostate cancer comprising administering to a subject a therapeutically effective amount of a ligand which specifically binds to a protein encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or a fragment, or variant thereof, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185 optionally directly or indirectly attached to a

20

 25. The method of Claim 24, wherein said effector moiety is a radiolabel, enzyme, cytotoxin, growth factor, or drug.

25

 26. The method of Claim 25 wherein the radiolabel is yttrium.

 27. The method of Claim 25 wherein the radiolabel is indium.

 28. The method of claim 24 wherein said ligand is a monoclonal antibody or
30 fragment thereof.

29. The method of claim 24 wherein said ligand is a small molecule.

30. The method of claim 24 wherein said ligand is a peptide.

5 31. The method of claim 24, wherein said ligand binds an extracellular domain of said protein.

32. A molecule, selected from:

- 10 (i) a polypeptide comprising the sequence of an extracellular domain of a protein encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 185; and
- (ii) a nucleic acid molecule encoding a polypeptide of (i).

15 33. The molecule of claim 32, wherein said polypeptide has 8 to 100 amino acids in length.

34. A method for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising contacting a candidate compound with a target molecule and determining whether the candidate compound binds said target molecule, wherein said target molecule is selected from (i) a nucleic acid molecule comprising the sequence of a gene or RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, (ii) a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (iii) a polypeptide encoded by (i) or (ii) or a polypeptide derived from SEQ ID NOS.: 174, 176, 178, 180, and 182 - 185.

20

1/2




Figure 1




Figure 2




Figure 3




Figure 4

10/560/23

Rec'd PCT/PTO 17 FEB 2006

PCT/IB2004/002394

WO 2004/113571

B0213WO seq list.ST25.txt
SEQUENCE LISTING

<110> EXONHIT THERAPEUTICALS

<120> PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE
CANCER THERAPY AND DIAGNOSIS

<130> B0213WO

<160> 185

<170> PatentIn version 3.1

<210> 1

<211> 151

<212> DNA

<213> Homo sapiens

<400> 1
ccggcccagg catgcacaca ctcttctgga gcacacgcga ccctccctag accgcctgct 60
tctcggtccc cctgcacatt agagcttctc aagacacggc ctgcacttgc cacctctgca 120
tttcccactc tcgctttgct gcctcccggc c 151

<210> 2

<211> 138

<212> DNA

<213> Homo sapiens

<400> 2
ggaggggaag ttcggtcca gccacatagg tgtgtgtcct cttatcctc tgaccaaagc 60
ttgtccttcc tacatatgct cctttgctag cactcccacc tgaatgcatc cctatgatcc 120
ttccaccttc cctgctcc 138

<210> 3

<211> 459

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 3
 ggaaccctac gaagaaccac agggagaaca ccagcattgc caccaccacc accaccacca 60
 cagagtctgt ggaagagggtg gticgagttc ctacaacagc agccagtacc cctgatgccg 120
 ttgacaagta tctcgagaca cctggggatg agaatgaaca tgcccatttc cagaaagcca 180
 aagagagggt tgaggccaag caccgagaga gaatgtccca ggtcatgaga gaatgggaag 240
 aggcagaacg tcaagcaaag aacttgccta aagctgataa gaaggcagtt atccagcatt 300
 tccaggagaa agtggaatct ttggaacagg aagcagccaa cgagagacag cagctgggtg 360
 agacacacat ggccagagtg gaagccatgc tcaatgaccg ccgccgcctg gccctggaga 420
 actacatcac cgctctgcag gctgttcctc ctcccggcc 459

<210> 4

<211> 562

<212> DNA

<213> Homo sapiens

<400> 4
 tggggggagg gcaggaaaat gaactcaatg agataaccag ggacaagatg atatgatgcc 60
 tttcttctag cactcaggga tttcggatc aaatctgaga gaggaagaa attgtgagaa 120
 gattgtaagc agagatgaaa cagaaaagat acctgaaact ctgatcttgg agcttttctt 180
 ccgtgatata agatctaaca ggggccactg catagagctg ttgtgaggat gacaagagat 240
 cactaacact gtaaaacttc aatccacagc cttcacataa ctgggtctca agacatgccc 300
 tctcccttct cctctgcact tcttcatgtg ttttaaggag aatgtgggga ggggcttatg 360
 taaaataggg gactacaggt atcagactga accaatccta cttgttgaac tttatctact 420
 ggatggccaa gggtataagg aacaccacca ctttctcatg ccctgggggt ccctagagaa 480
 aggtaagcag accaagggtc tcagactccc tgtggaagaa agaccactgc acccaagctt 540
 taaaaacgca tccctcggcc gt 562

<210> 5

<211> 328

<212> DNA

<213> Homo sapiens

<400> 5
 gggcacccta gctgcaaggg aggttagaaa aaatgaggga caggattatc atggtcagca 60
 tattacttgg gggccagata tatcacttcc cacacaaaag caggcctctg tcagtgagga 120

B0213WO seq list.ST25.txt

agaagtggag aatggatttg ggggtgggcat ctgacagcat ttgccacact gccctcccca 180
 atcctaattgc aggccagtca acgcaccacc cccactcccc acccacactc caacccccac 240
 agtcctaggg tctctcaggg agaccatcgg tggaatccat aacattctaa gaccctgcag 300
 tttgtaggca aaatcaggct tccttttg 328

<210> 6

<211> 168

<212> DNA

<213> Homo sapiens

<400> 6
 gacctcgaat tacaggcatg agccaccgtg cctggccttt tcttttcttt taagctactt 60
 tttaatatat agtaatgact gttaatatag tatatactat gctattcatc aatgctgtaa 120
 ctttcttagt ttcattttct cactcaattg aagtccaggt acccaggt 168

<210> 7

<211> 317

<212> DNA

<213> Homo sapiens

<400> 7
 agaaccctgg agcacttgag ggaccagaga cccggcatgg tccagacgaa ggtactgtca 60
 gtctctcctc cgggacgcag acccattcaa ggtgcctctc tgcggccgtg ttcctgagag 120
 gagcacgggg agggcctggt ttaatgtgag ccgcacaccg attgctctgc tctgaccgac 180
 ctcgtccatg ccggccttgc atgggcgggg tcacttctgg gcccccaaag gtccactggc 240
 gtttcttgca acacctccag atgcagccac atctcaagtc ctaggaactc gatccactgg 300
 ctctttccat tcactag 317

<210> 8

<211> 277

<212> DNA

<213> Homo sapiens

<400> 8
 ggggtgcgagg attcttgggc ctcatcctac agcacagctt tagtaagctg ggttgacaga 60
 gtcctggcgt cagtatatat ggaaacaata agtctgatga acatccccct cgtaagaat 120
 ccctgagacc aactttcatt ttacagatga aaaaactgag accggtaggg gtaaaatgcc 180

B0213WO seq list.ST25.txt

```
acagtcatga tcatgccgct agtaggtggc agagtgccat ctacaattca tttgtcatct 240
gagcttgact ggggctcctc ttaccacttc ctccctcg 277
```

<210> 9

<211> 441

<212> DNA

<213> Homo sapiens

```
<400> 9
gggggcagga gatagccaga tgtggtggca caccctgta gtcccagcta ctggggaggc 60
tgagatagga ggatcacttg agcccaggag tttgagacta gaatgagcca tgattgtgcc 120
actgcactcc agcctggtga aagagtgata cctgttttc ataagaaaa aataacaaaa 180
acaaaaacaa gaaaggagag agttggctaa gctttatcac ctttgtgggt ttggaaccct 240
tacttgatcc ttcactaaag tacttcttgg gcatccagtg aggttcagtg tgtattgaga 300
ggatggtgag gatggcagcc aggcgtggga tctgtattca agaagaagct gcccactcg 360
ctggccatct atggatttcc agccaacaag catttccaac cacctatgga tttccaacaa 420
ctgagaactc atgagactgg c 441
```

<210> 10

<211> 508

<212> DNA

<213> Homo sapiens

```
<400> 10
aggctatgag ttgaaaattg gctctccttg gacagtcctc aagcactaca tttttttcag 60
tgactctcac cagaccaca gatgaattta cttctctgc gtatgccttt tgactggttc 120
tgtttcaggg aaccgcaagc tcaataagct cactgttct accaagctgg acaaacagcc 180
acgtctctgt tctcttgcc agaccctgag gcctggagt ctgccttcag gaattccaga 240
attctagaaa gttagagcta gacaagacct cagccttcac ctagtcttgc tccaaccact 300
gtgcggatgg ggaacaagg catgggctgg ggatgactta aggggtataa aatgttgggc 360
tttcttttgt caagcccagc atgtgcctcc tataggcacc agtggctctt gcaagtcctg 420
gcctgctggc ctgcagcca cagagagctc ggactctctc aggcagctca cttcattgct 480
ggaacaatag caatgttctt cctaattgc 508
```

<210> 11

<211> 135

<212> DNA

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 11
agaagcgta tacgggggag gctggagtgg taaaaggctc agaaaaatcc tgcgaagaaa 60
aaaactttctg aggtaataaa taggattatc ccgtatcgaa ggcctttttg gacagggtgg 120
gtgtggtggc ctgcg 135

<210> 12

<211> 248

<212> DNA

<213> Homo sapiens

<400> 12
gaggatgagg tggaggagga gaggacaag gccgcgctcc tgcaggagca gcagcagcag 60
cagcagccgg gattctggac cttcagctac tatcagagct tctttgacgt ggacacctca 120
caggctcctgg accggatcaa aggtcactg ctgccccggc ctggccacaa ctttgtgcgg 180
caccatctgc ggaatcggcc ggatctgtat ggcccccttct ggatctgtgc cacgttggcc 240
tttgtcct 248

<210> 13

<211> 183

<212> DNA

<213> Homo sapiens

<400> 13
cccgccgacc tggcaggagc atgcttagga aaagatgggtg tcaacagacc cacaacacag 60
aaccacactg tggggtgggg aagcagagag gcgggaccag ccacttccag caggaagttt 120
ccaacctgga ctgggttggg acggtgaggg gatagtcatc tgccatcagt ttacataggt 180
ggt 183

<210> 14

<211> 124

<212> DNA

<213> Homo sapiens

<400> 14
cggcaggcat cacacaagag ggtgtcccta agatgcatca cgtccgtgga gaaaacaaag 60

B0213WO seq list.ST25.txt

caggacacac gtgtgagtcg tcacaccctt ggtcaccggt cttggccgtc acacatgcct 120
ccct 124

<210> 15
<211> 132
<212> DNA
<213> Homo sapiens

<400> 15
gtaggggagg gaaccagcta ctagatgggt cgattagtct ttcgccccta taccaggtc 60
ggacgaccga tttgcacgtc aggaccgcta cggacctcca ccagagtttc ctctggcttc 120
gccctggggc cg 132

<210> 16
<211> 124
<212> DNA
<213> Homo sapiens

<400> 16
cacaccttgg ggacaggcat gaggaacaga ttaatgtgag atattctaga ggtacatgca 60
tcaggccatg gtgaccaatt gtctgtggag ggtgaggcag aaggaattgt tgaggatgac 120
tgag 124

<210> 17
<211> 489
<212> DNA
<213> Homo sapiens

<400> 17
gggaggcaat cattgagaga taatagctga gagtttttca gaaaggaaaa gaggtatgag 60
tttcaggggag aaagggcggg ccaaggacta agccaaataa ataaaataag tctataccta 120
gacactttgt gggaaattca cagaccatca aagataaggg aaaaacctca tgggctacag 180
cagaaaagag acccattcta cacaaagaac aagttcacaa tatgagacag agccacgcac 240
agaggatgac tgctatgacc tgacgacggg gaagtgtctt gttctctggt aagccgcctc 300
taaagatggc caaagacatg gtttttccta ggtttgaggt gcactacttc agggttcctg 360
cttacctcct gctcgttctc tggccctcat tgtgaccatg cttcactctc ccacctctgtg 420
ctgggacaac catttttctt tccttattgc tgctactgca gagtgaggta gggctgtggc 480

B0213WO seq list.ST25.txt

ctcgcaccg 489

<210> 18
 <211> 244
 <212> DNA
 <213> Homo sapiens

<400> 18
 cgggtgggagg cggccccgca ctaaggtagg gacccagatg gaaatgggac gctctctgca 60
 ccatgggagg caaaaataca aattccatca ccaagagggc acgccatgcg gtgttggtcc 120
 ataaggggtga gcaaagctgc caggcccaca ggagagagag cccacaggag ccctggatcc 180
 tgtgggactt tggatcctac acagtgagtg atctcagaac ttgcaaggc tgaggcaggg 240
 agac 244

<210> 19
 <211> 195
 <212> DNA
 <213> Homo sapiens

<400> 19
 gggcgggacc agtgagagaa aggatagagc gtgtgagatg aaagggctgg tcttattaag 60
 ccctacaata ctctggggtc caagcaatcc tgctgtggga ccctgctaag tgaacataat 120
 gccgaggaag aacagctctc ctctttttgc caaagcctgc caaggtgtca aggcttgaga 180
 aagagtgggtg gccta 195

<210> 20
 <211> 346
 <212> DNA
 <213> Homo sapiens

<400> 20
 ccggtgcagg cattgtgata atagttggaa tgcagaggtg aattaaagag tatgggcttg 60
 tctatataaa taaataaata tatatgtata tgggtgtgtat aaccctatta tatatattat 120
 gtattaggtg gtgttgata tatatgttta tatatgtgtg tgtttatgta taagtatata 180
 tgtgataaga gtttataatc ctatatagag acagatgtat taaaatggat tttttttttt 240
 tgagacagag tcttactctg tcatcaaagc tggagtgcag tggtgcaatc taggctcaca 300
 gtgacctaca cctcccatgt tcaaacgatt ctctgcctc ggccgg 346

B0213WO seq list.ST25.txt

<210> 21
 <211> 168
 <212> DNA
 <213> Homo sapiens

<400> 21
 cgctgggagg ctgtgcgtgt ttgcttttgt tgatctgttt aactgcagcc cgatttatgt 60
 ttctggatcc tggaaattgag ttgacactat cggtagtatg aaagtgcag acaccaggat 120
 gaagtcactc ttgtcagacc cagaggaaac agggtcagga ggcctggg 168

<210> 22
 <211> 435
 <212> DNA
 <213> Homo sapiens

<400> 22
 agccggcagg actgtatcat caacgcaagt ctcttgagat gccttggtga tcggtagatc 60
 aagttatagc ctcggtttct gattttgctg tggtgatact ggatgtagca ttcaaggagt 120
 aaatggagaa tccacaaaat aactttccca aggattataa ccgtctgaac tttcaatggg 180
 tttgtgtaat ttcttgggca cttgtcctca ttgggattag gataagaaca aagcacacct 240
 gttaaaaatg ctaaaacaac aaacacgaga tgaataaacc acagaagatt cactatgatg 300
 actgtaggaa gaggatggaa tcgggggtcta aagtgcgctt gtaatgagtg gtgtgggaga 360
 agctgggcat ccagaagtgg gtcgtcttca atactctggg tgatatccaa ggaaccgtcc 420
 tccatcctgc cgcgg 435

<210> 23
 <211> 199
 <212> DNA
 <213> Homo sapiens

<400> 23
 cggggaaagg acaggcctgc tgctttattc acagatttag atgtcgttcc atctgctctc 60
 gaagtttgaa tttctggatc ttctctgaaa tggtagaggg gtagtttggtg acaaacacga 120
 tgtacttcgg aatcttgaag tgagagatct tccctttgca gaaagctttt atctcctcca 180
 ccgtggtctc ctctcggcg 199

<210> 24

B0213WO seq list.ST25.txt

<211> 258

<212> DNA

<213> Homo sapiens

<400> 24
 gggcgcaggc tatggaggag accgtggtgg tggcagtggc tacggtggag accgaagtgg 60
 aggctatgga ggagacagga gtggtggcgg ctatggagga gaccgaggtg ggggctacgg 120
 aggagaccga ggtggtctatg gagggcaaat gggaggaaga aacgactaca gaaatgatca 180
 gcgcaaccga ccatactgat gactgttttg aatgttcctt tgtctctgac atgatccata 240
 gtgaaattgc cagagttt 258

<210> 25

<211> 171

<212> DNA

<213> Homo sapiens

<400> 25
 ggttcaggca ggtcagcaag gaacacaaag gcatctgcc cctgagcaag tatcgaacac 60
 catcacctgc atccttcaag ggttccaggt agatctccag cctctttag gagagaacca 120
 agttgaaaag gtcaaacgct ggggacttgg taggaaaagg tggagactcc a 171

<210> 26

<211> 223

<212> DNA

<213> Homo sapiens

<400> 26
 cagtgcgagg agccgtcact ctgctaagcc tgtatctgct gttcggctac ggagcgtctc 60
 tgctgtgcaa tctcatcgga tttgtgtacc ccgcatatgc ctcaatcaaa gctatcgaga 120
 gcccaagcaa ggacgacgac actgtgtggc tcacctactg ggtggtgtac gccctgtttg 180
 ggctggccga gttcttcagc gatctactcc tgtcctgccc ccc 223

<210> 27

<211> 249

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 27
 tggggagagg tgagcagctt tgaacttttt cttagggagt gtcagaacga ggccagtctg 60
 cctttatgcc atgtggcctc aggcacctac agtgaagtct taaaaccagt ggatgctctc 120
 tacagtgcct tctagctgtg gtagtctgtg tctccaagga ccaacccttc catttctgag 180
 gcttcagaat aaattctggc agttatttct tctctcagac tctatttcag aaaagtgtac 240
 ctgccccca 249

<210> 28
 <211> 334
 <212> DNA
 <213> Homo sapiens

<400> 28
 caggctggag tgtggtagca tgagcatggc tctactgcaat ctccacctcc caggctcaag 60
 cgatcctccc acctcaccct ccccggtagt gggaccacag gtgcacacca ccacacctgg 120
 ctatatgctt cttttgagat tgcttttttc actcacataa tttgcttgaa atttatccac 180
 cagcattttt taaaaattaa ctgtgcatca tcttcagtga gatgtgtgca tttcgtcttt 240
 gttcatgcct tttccactgc ctagaatgcc ctctaccaac cctgtctacc gatctgtatt 300
 catttccttc agtgtgtctc actgctgtgt gcct 334

<210> 29
 <211> 226
 <212> DNA
 <213> Homo sapiens

<400> 29
 aggtccaaag tggaaagatg gaaaagctca gatgatacag gcctacagac tagatttttt 60
 gtttatttgt ttctgtacac tactactaca aaggatagca aatagagctg aaggaaaagg 120
 atggagatac tcaaagtcct aaaaatggaa aggagaaaag ggaatgtcaa cctcaaggac 180
 aactgagatg ttcacagaac ttctgcagat tcttgtcccc cacctc 226

<210> 30
 <211> 372
 <212> DNA
 <213> Homo sapiens

<400> 30

B0213WO seq list.ST25.txt

```

gggatagggg agagaagaag aagctgggga gctgggaaca tcatctcagg ctggaggaca      60
agcctgcgac aggaccggtt ccacagagga gtcaaaagag ttaaagccca gaaggcagct    120
ggaagagaag gcaaagctgg aaaaggaagt aaaagcagca gctgttctga ttttgaagga    180
gagtaaattg gcttatttgc tttatggtct aaggagcaga gaaaactcat tctcctctgg    240
ttataaatc ccgagttgca gaaggaagtc tcctaactac tgatcggttc ctcttgggggt    300
gggaaaatct ctgagctaca gtgagtcatt cccaggatgc caacaatggc ctccacttct    360
ccctctgccc ct                                                         372

```

<210> 31

<211> 207

<212> DNA

<213> Homo sapiens

```

<400> 31
cctctgttct tccagcttgg cttggagaag aactggcaga tgaacacgtc ctgcatggtg      60
gaatgccctg tgaactgtca gctttctgat tgggtctcctt ggtcagaatg ttctcaaaca    120
tgtggcctca caggtttggt tgtaccataa cttatattag gctcctggtc aaggaatatg    180
aaataaaata tccctcttgc tttaacc                                         207

```

<210> 32

<211> 179

<212> DNA

<213> Homo sapiens

```

<400> 32
tggtagggagg tcaactgctg aaggagtcac atagacgtgg tgtgtgacac ttgtgcccac      60
ttcctgtgcc tgatgtgtag caaagaaagg ttgcatgctc ccttgctccc tggtctcttc    120
cagaccgtct atgaccagta tttcatcacc ctgtataaca tcgtgtacac ctaacgccc      179

```

<210> 33

<211> 484

<212> DNA

<213> Homo sapiens

```

<400> 33
tgaggagggtg aaggaccgga tcctggagaa catctcgctg tcggtgaaga agttgcagag      60
ctatcttctgct gcatgtgagg atgagacccc tgccatccgg aacctgaca aggtcctaca    120

```

B0213WO seq list.ST25.txt

gcgtctgtgt gagcacctgg accacgccct gctgtacgga ctgcaagacc tctcctctgg 180
 ctactgggtg ctctgtgtgc attttactcg gagagaggcc atcaagcaga tcgaggtgct 240
 gcagcacgtg gccaccaacc tggggcgag cctgcctgg ctgtacctgg ccctcaacga 300
 gaactccttg gagagctacc tgcggtgtt ccaggagaac ctgggcctgc tgcataagta 360
 ctacgtcaag aatgccctgg tctgcagcca cgatcacctg acgctcttcc tgaccttgg 420
 gtccgggcta gagttcattc gtttcgagct ggatctggat gccccttacc tagacctccc 480
 cagc 484

<210> 34

<211> 443

<212> DNA

<213> Homo sapiens

<400> 34
 ggggaggtga ttccatccag agtcatatct gttgtcacc caataagtcg atcagcaagg 60
 ctgacaggct gtgaggaaac cccggccttg tagcctgtca cctctggggg gatgatgact 120
 gcctggcaga cgtaggctgt gatagatttg gagaaccctg actcaccctc aggaatccgg 180
 aggtcagtga cattgtcggg gcacacagac attttctac cctgggttcc acagagactg 240
 agggtaaagt gatggaagta tttcaaccct ttggaagtga agcttgggcc tccagcaaga 300
 gtgacgggtg ttgccaaagc ggagaagttg tagttgaaag tcctgggttg agtggtgcgt 360
 gagaaggtgc aatcattgta gcacagagag tggatcttgt tgttcttggg ccctggacca 420
 cagggcacac agacctcgcc gca 443

<210> 35

<211> 272

<212> DNA

<213> Homo sapiens

<400> 35
 ggacaggggt ctctccacca tttgaggaag ggatagagga agaccacat ggggaaagat 60
 atcatgcact ggttgaaaag aactgtgcgg atagactggc gcagtttcac aggatccaca 120
 ggttcattct tgccgacctg aattcggtag cgagagatga agttaggttt tcctgttgtg 180
 tcaaccacca atagaagccc attgaagctc cagaagaaga gacaaggcac ttggatggca 240
 cctataaaga agaggatcca ctcttccct ac 272

<210> 36

<211> 224

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

```

<400> 36
gatggaaagg ctgtagtggg gctggtggtg cttccaactg cgggacagga agtggccgta    60
gcggcttggt ggataagtgg aagatagatg ataagcctgt aaaaattgac aagtgggatg    120
gatcagctgt gaaaaactct ttggatgatt ctgccaaaaa ggtacttctg gaaaaataca    180
aatatgtgga gaattttggt ctaattgatg gtcgccttgt aacc                    224

```

<210> 37

<211> 342

<212> DNA

<213> Homo sapiens

```

<400> 37
tgtcttgagg cactgtagta tcaatcagac caggaatatc cttctctcct ttttttacia    60
tagccaagtt gcaatgcaac cgcgaactga ttttctcttt ctttctccag gtctccttgg    120
tcttctctaa caatcaacag caacccccac ctccactgct ttctgttttg tttggtttga    180
gtttgggatt ttgggctagc tcttttttct ttgtctgctt tctggtttcc cttcctccct    240
tccctatgta cgctcagagc ctccagacaga ccgtctgggc gcctcattcg cgtgagaagg    300
gccaggggga aggccaccag gccaggatgt aggcgaaacc gt                        342

```

<210> 38

<211> 315

<212> DNA

<213> Homo sapiens

```

<400> 38
tcgggggagg tgggacctga gcatgctgtg ttccagaaaa ggctggagca cagactcaga    60
gagagagaga gtgggggtgga cgaggctgga gagattggca aagcccagat tatgagggtt    120
ttgtgggtca cagtgaggag cttgaacttc atccttctag tagattctag gctaccctt    180
cagacactcc ttaggaccag ggacacattc cccgagctgc caggagtgtt agcagctgac    240
agatcctggc tgggtatttc tctccaacaa agggagctgc ctccttcaca tctaatagact    300
gtaatgacct accac                    315

```

<210> 39

<211> 127

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 39
 tgcttttgag gctggagtgg taaaaggctc agaaaaatcc tgcgaagaaa aaaacttctg 60
 aggtaataaa taggattatc ccgtatcgaa ggcctttttg gacagggtgg gtgtggtggc 120
 ctggccc 127

<210> 40

<211> 408

<212> DNA

<213> Homo sapiens

<400> 40
 gggggaggca cattctcact gaagataaag aactccgcat gccatcaccc cttcctcacc 60
 acaaccccg c gaaacaaaag ctataaacac acacaagtca gaggatctat aaaccagtgg 120
 gagaaaaaaa attagatgaa ggtaaccat taaaaagctg cagttgggaa aacacacact 180
 cgattgttac atcagaaagt gccgtgggga gaagagccgt gtgctggtaa acatgtccgc 240
 gctcagaact tgacatgcag aaaagagaga gcgccaagtc ccacctgaga ttagagagga 300
 ctggttttta gtgtaacaca ctttgtttta aaatatcact gtcctcttct tgccccaatt 360
 gctcctagaa cgctcctctg tcaactcccct cccgggccag cctctccg 408

<210> 41

<211> 314

<212> DNA

<213> Homo sapiens

<400> 41
 ggcgtggagg tacaagcagt cagttctcgg caggggccga ccgggcaact tcccccttg 60
 tgtccctcta ccctgctttg gagggccggg ccctcattca gcagatgtcc ccctctgcct 120
 ttggtctgaa tgactgggat gatgatgaga tcctagcttc ggtgctggca gtgtcccaac 180
 aggaatacct agacagtatg aagaaaaaca aagtgcacag agacccgccc ccagacaaga 240
 gttgatggag acccagggat tggacacat ctccaaccc cagtactcct gctctccggt 300
 gccacctcac cgcc 314

<210> 42

<211> 352

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 42
 tctggggagg tggccccat gtctgtcgta ggacagcaac aggttgtaca tctggcaggc 60
 aaaggttttg ttgggctgga ggatgaggat gtgtaacact gtgtttccca gggagtcctg 120
 ggcccggatg tcagctccat gctcaatgag cagccgcacg atctcctcac tgttcacaca 180
 ggcagcaaag gacaaagggt gctcccaaaa gtagatgagg ttgcagggaac tacggcgga 240
 ggcagtgcct gtggctctgg cagagacact ggcctgcgg gcaagcaggg ctcgcaccag 300
 gttcatgttc tgggtcacaa cagcgatgtg cagtgcagtc tgacctccat cc 352

<210> 43

<211> 292

<212> DNA

<213> Homo sapiens

<400> 43
 ggctgggggt aaggaccctg acagggcctc aggtggggac ttgcgcttca ggccggggtc 60
 aggtgctgtg aagctgcctg tggagctggc cttggcttcc cggaactcct ccagcttctg 120
 tcggtagtac ttgtaccctt ggctattggg ctcatacaga aagctgaatg cctggttctc 180
 acggttggtc tggagggcaa tggtttccac ctcgggaccc ccgtccgcta tgaacctggc 240
 caacttttct gcaaggttct tgacctcttc gtctctggg ggtgaaactt tc 292

<210> 44

<211> 372

<212> DNA

<213> Homo sapiens

<400> 44
 ttcttagttt aagtgccagt gatcctgctt tgtacctctt caactatgat tcagttttta 60
 caagtgaggt tcaattaagc tgagatgtag ttgaaatatt tgagcaccag aatcaccttc 120
 tgaactccca atcatctggg gcttaggtgt agttacctcc caggaacaga tctcccagcc 180
 caaggtccca cattgtacct tgatgtttct ttactgccta tcaaatgag ccccaggtag 240
 ctacgttatt actgggtttt gctctccaat ttctttattt tcccttgctc ccaaccacat 300
 caacagaaca acaacaaaaa gaatccttta tcttcatgca aactacagt agtacagagc 360
 aaagaactgg tg 372

B0213WO seq list.ST25.txt

<210> 45
 <211> 158
 <212> DNA
 <213> Homo sapiens

<400> 45
 aggcctgaga ggaagtttc tggagttcag atactctctg ttgggaacag gacatctcaa 60
 cagtctcagg ttcgatcagt gggctctttg gcactttgaa ccttgaccac agggaccaag 120
 aagtggcaat gaggacacct gcaggagggg ctagcctt 158

<210> 46
 <211> 157
 <212> DNA
 <213> Homo sapiens

<400> 46
 gagggcctaa gaaagtaccc agctctgggt ccaataaaga ctcttggtat ctgtcagcac 60
 tgcatgtggt agcatgggca aaaggcatta agaaagtaaa tatacgtccc tgtgttcccc 120
 ttgctctccc tccatgcctg ctcttttctt caccctg 157

<210> 47
 <211> 310
 <212> DNA
 <213> Homo sapiens

<400> 47
 aggacagcac tgacagcgag tggccctgga tcgtgagcat ccagaagaat gggacccacc 60
 actgcgcagg ttctctgctc accagccgct gggatgacac tgctgcccac tgtttcaagg 120
 agtatgtaca gccggcctgg ggcacttgat cttctaaggc cctgggcttt gtgccccagg 180
 ccctgggctc cctttacagg ctctgcttcc gggcctctgt tcaatcttgg tgccccctga 240
 ttctacctag aagcctctcc tgccttcagg ggccttcaca cccatgctgt tccccaggt 300
 acctctctcc 310

<210> 48
 <211> 124
 <212> DNA
 <213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 48
 cccggcacct ggggaagggg gagtagagct aagagataga aaaactctag actcaccgat 60
 caccaagctc atttggtcgg tagggcccgc ccaccggact tgagaacaca cacattctct 120
 aagg 124

<210> 49
 <211> 191
 <212> DNA
 <213> Homo sapiens

<400> 49
 aatctcctaa tattaatggc aggtattata gtaaaattat catttcccct gaagagaatg 60
 ttacattaac ttgcacagca gaaaaccaac tggagagaac agtaaaactcc ttgaatgtct 120
 ctgctaataa aaacagagaa aaggatgaatg accaggcaaa actaattgtg ggaatcgttg 180
 ttggtctcct c 191

<210> 50
 <211> 305
 <212> DNA
 <213> Homo sapiens

<400> 50
 ccgaagtttt tctgtcacct gtgttaggct ccgtccccct tccgcgtttt atccccgtac 60
 cagaaaagga tacatttagt gcctcccacc cagctccact aaacgggttg gatattctcat 120
 tctttgagtt ggtgttcctt ccccgcgccc cccatgtagc tgggaagtgg gacctggggg 180
 tggttggacc cctgggatcc taaaggaggg gcaggaggg cgcagaactc cgcttctgct 240
 ccttgcctacc aggacgcgcg gcctcctcag cctctttcct cccgctgcca tgcaccctac 300
 gctcg 305

<210> 51
 <211> 108
 <212> DNA
 <213> Homo sapiens

<400> 51
 ggctgacagg gtgggattct cgctccttca ttccagggtta ctcgttcttc agcaagttgg 60

B0213WO seq list.ST25.txt
caaaacagac atcatgctgg tgagtgccac gttactcccc tggggtgc 108

<210> 52

<211> 439

<212> DNA

<213> Homo sapiens

<400> 52
cgcggcgagg ggagaggtct ccttgagtcc cacctgagct gcctcagtgc cccccagctg 60
ctgcaggtga gggcctgtca ccatcaagcc atcagtggga caaaaaactt gggccctcaa 120
cccaccagca ctgctctgca ttctctgaag ccctggagat aagctgggga ccatggcccc 180
cacactctca gacacagatg acacaagtgg gaccattctg agcctaagag attttaccaa 240
aaatacctca atatggtttg gctacgtccc caccxaaatc ttatcttgaa ttgtaatcgc 300
cgtaatcccc acgtgttgag ggagggatcc agtggaaggt gattaggtca tggagggtgt 360
tttcccatg ctgttctcat gatagtgagg gagttttcac aagatctgat ggttttataa 420
gccagtttcc cctccggcc 439

<210> 53

<211> 234

<212> DNA

<213> Homo sapiens

<400> 53
ccgagacagg accaactcac acacctgcca gaaagcctca ctctccagcc tcaggaccaa 60
cttacacacc tgccagaaag ctcactctc cagcctcagg accaacttac acacctgcca 120
gaaagcctca ctctccagcc tcaggaccaa cttacacacc tgctagaaag ctcactctc 180
cagcctcagg accaacttac acacctgcca gaaagcctca ctctcctccc cggg 234

<210> 54

<211> 92

<212> DNA

<213> Homo sapiens

<400> 54
gcctgcgagg agctttattc ttccagctta atatggttgc tgcgggaaca ctgcaggatg 60
aaactgactt tttttgtggt gatgtttctc ct 92

<210> 55

B0213WO seq list.ST25.txt

<211> 164

<212> DNA

<213> Homo sapiens

<400> 55
 cgggggtacc tgtaccgtgg aacatggaag ggaagaggag gcaagtacag cagtcctggg 60
 tctacattca caaatcagca tactgatagc ttgctggata ttatatcaag acataaaaaat 120
 tgacacacac ggtctctctt tctctctctc atggagggtc ctgc 164

<210> 56

<211> 202

<212> DNA

<213> Homo sapiens

<400> 56
 tggggtggac caggagaaac tgaaaactga attaaggaag acttcagatg ccctttctaa 60
 ggcacaaaat gatgtgatgg aaatgaagat gcagtcagag agattttcga aagaatatga 120
 tcaactcctg aaagaacact ctgaacttca ggttttgtc tattctactt aactacctcc 180
 ttatgaggaa gtggtctctc ca 202

<210> 57

<211> 314

<212> DNA

<213> Homo sapiens

<400> 57
 cagggggagg agttcagagc ttacggtgag ccgccatcac gctattgcac tccaacttgg 60
 gtgacagacc gagatcctag cttaaaaaaa aaaagaagtt ggtggggaaa atgggaaaat 120
 aggggtgccat gaaaaagaaa aagaaaaaca caccataatg gcattgtaag ttgggcttac 180
 aactgttggt tactttctta aagttttctg aggatgtaag aggaaaaaaa tattgtaaac 240
 cttcaagatc tacttgtaat taaaattccc tgctgcttaa aaaagagtga aatctttgga 300
 aggtcctccc ccca 314

<210> 58

<211> 92

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 58
 ggacgggacc acagttctaa acgaataaac gaatgagacg caaatttttt atgttcagtc 60
 ctttcatctc tatgaaaacc ctatatgggc gt 92

<210> 59
 <211> 179
 <212> DNA
 <213> Homo sapiens

<400> 59
 cggggccagg atcccagagc cacagccaac atcaagaacg atcttgcct tgaagtcggt 60
 gtggttttgc aggatggcgc gctggtaggc gcctgtccgt ttttagtcct gcatcatgtt 120
 ctgctgctgg gacaggtagc cataaaactg gaagtacttc ttgcagaag actcctctt 179

<210> 60
 <211> 89
 <212> DNA
 <213> Homo sapiens

<400> 60
 tcgcggggag gcgtgaatat tgtggggctg aatcctcagg gccgtggggg gctgcatggc 60
 tgatgacat gaggactggc ctcccgcc 89

<210> 61
 <211> 169
 <212> DNA
 <213> Homo sapiens

<400> 61
 tgggggttcc aggtatagga gggcaggctg agcatgcttg aagatgtgca tgatgaagat 60
 ggtaaggccc aggccgaaga tgtaggctgc aaagctggtg tagaagtagg tgtgggtatt 120
 cttcttcaag ctgatgtcaa agcgcagcag caaggcaatg aagatccat 169

<210> 62
 <211> 171
 <212> DNA
 <213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 62
 cagcgggtacc atagttcact aggaaaggca ctcatccacc aagttcagag aggtggccat 60
 ccgcattgct aaacagaata aaacaaaaat tcactttgtc attttcctga cattggcctt 120
 gctataagat agcctcataa actgcctgaa aggccttatt tttttcaaag g 171

<210> 63
 <211> 140
 <212> DNA
 <213> Homo sapiens

<400> 63
 aaggcaattc ttaggtactc tcgtgattga acctctgcac caaagaggga aaagtataag 60
 ttagaaagga atttataagc accatacaca aaaatagcca tgactcaggc ctccacatct 120
 catttgtgct gtcacttccc 140

<210> 64
 <211> 195
 <212> DNA
 <213> Homo sapiens

<400> 64
 tatttggagg ggggtatggg agggaaagag cttaggaaac ggctctccct gcaaagtcca 60
 accaaacttt aacgttaacc aaaccattaa tgttgccatg aatttgaagt gaaccagagg 120
 gaggtggcag aagaagctta atggggaata gttccggtag agaaatgagg cttaagatga 180
 actacccttc tcca 195

<210> 65
 <211> 397
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (364)..(364)
 <223> n = a t c or g

B0213WO seq list.ST25.txt

<400> 65
 tgccagctga ataaactcag tcacctggtt tcccatctct aagcccctta acctgcagct 60
 tcgtttaatg tagctcttgc atgggagttt ctaggatgaa aactcctcc atgggatttg 120
 aacatatgaa agttatttgt aggggaagag tcctgagggg caacacacaa gaaccagggtc 180
 ccctcagccc acagcactgt ctttttgctg atccaccccc ctcttacctt ttatcaggat 240
 gtggcctgtt ggtccttctg ttgccatcac agagacacag gcatttaaatt atttaactta 300
 tttatttaac aaagtagaag ggaatccatt gctagctttt ctgtgttggt gtctaataatt 360
 tgngtagggg tgggggatcc ccaacaatca ggtcccc 397

<210> 66

<211> 2799

<212> DNA

<213> Homo sapiens

<400> 66
 ctcacacacc ctgaagacac agtgagttag caccaccacc aggaattggc cttttagctc 60
 tgtgcctgtc tccagtcagg ctggaataag tctcctcata ttgcaagct cggccctccc 120
 ctggaatcta aagcctctc agccttctga gtcagcctga aaggaacagg ccgaactgct 180
 gtatgggctc tactgccagt gtgacctcac cctctccagt caccctcct cagttccagc 240
 tatgagttcc tgcaacttca cacatgccac ctttgtgctt attggtatcc caggattaga 300
 gaaagcccat ttctgggttg gcttccccct cttttccatg tatgtagtgg caatgttttg 360
 aaactgcac gtggtcttca tcgtaaggac ggaacgcagc ctgcacgctc cgatgtacct 420
 ctttctctgc atgcttgca ccatgacct ggccttatcc acatccacca tgcctaagat 480
 ccttgccctt ttctgggttg attcccgaga gattagcttt gaggcctgtc ttaccagat 540
 gttctttatt catgccctct cagccattga atccaccatc ctgctggcca tggcctttga 600
 ccgttatgtg gccatctgcc acccactgcg ccatgctgca gtgctcaaca atacagtaac 660
 agcccagatt ggcatcgtgg ctgtggtccg cggatccctc ttttttttcc cactgcctct 720
 gctgatcaag cggtgacctc tctgccactc caatgtcctc tcgcactcct attgtgtcca 780
 ccaggatgta atgaagtgg cctatgcaga cactttgccc aatgtggtat atggtcttac 840
 tgccattctg ctggtcatgg gcgtggacgt aatgttcac tccttgctcct attttctgat 900
 aatacgaacg gttctgcaac tgccttccaa gtcagagcgg gccaaggcct ttggaacctg 960
 tgtgtcacac attggtgtgg tactcgcctt ctatgtgcca cttattggcc tctcagttgt 1020
 acaccgcttt ggaacagacc ttcattccat tgtgcgtgtt gtcaggggtg acatctacct 1080
 gctgctgcct cctgtcatca atcccatcat ctatggtgcc aaaaccaaac agatcagaac 1140
 acgggtgctg gctatgttca agatcagctg tgacaaggac ttgcaggctg tgggaggcaa 1200

B0213WO seq list.ST25.txt

```

gtgaccctta acactacact tctccttatac tttattggct tgataaacat aattatttct 1260
aacactagct tatttccagt tgcccataag cacatcagta cttttctctg gctggaatag 1320
taaactaaag tatggtacat ctacctaaag gactattatg tggaataata cataactaatg 1380
aagtattaca tgatttaaag actacaataa aaccaaacat gcttataaca ttaagaaaaa 1440
caataaagat acatgattga aaccaagttg aaaaatagca tatgccttgg aggaaatgtg 1500
ctcaaattac taatgattta gtgtgtgtccc tacttttctt ctcttttttc tttctttttt 1560
ttttattatg gttagctgtc acatacaact tttttttttt tgagatgggg tctcgtctctg 1620
tcaccaggct ggagtgcagt ggcgcgatct cggctcactg caacctccac atcccatgtt 1680
gaagtaattc ttctgcctca gcctcccgag tagctgggac tagaggaacg tgccaccatg 1740
actggctaata tttctgtatt ttttagtaga gacagagttt caccatgttg gccaggatgg 1800
tctcgatctc ctgaccttgt gatccacccg cctcagcctc ccaaagtgtt gggattacag 1860
gtgtgaacca ctgtgcccgg cctgtgtaca acttttttaa tagggaatat gatagcttcg 1920
catggtgggtg tgcacctata gccccactg cctggaaagc tgaggtggga gaatcgcttg 1980
agtccaggag tttgaggtta cagtgatcca cgatcgatcc actacactcc agcctgggca 2040
acggagcaag accctgtctc aaagcataaa atggaataac atatcaaag aaacagggaa 2100
aatgaagctg acaatttatg gaagccaggg cttgtcacag tctctactgt tattatgcat 2160
tacctgggaa tttatataag cccttaataa taatgccaat gaacatctca tgtgtgctca 2220
caatgttctg gcactattat aagtgttca caggttttat gtgttcttcg taactttatg 2280
gagtaggtac catttggtgc tctttattat aagtgagaga aatgaagttt atattatcaa 2340
ggggactaaa gtcacacggc ttgtgggcac tgtgccaaaga tttaaaatta aatttgatgg 2400
ttgaatacag ttacttaatg accatgttat attgcttcct gtgtaacatc tgccatttat 2460
ttcctcagct gtacaaatcc tctgttttct ctctgttaca cactaacatc aatggctttg 2520
tacttgtgat gagagataac cttgccctag ttgtgggcaa cacatgcaga ataatcctgt 2580
tttacagctg cttttcgtga tcttattgct tgcttttttc cagattcagg gagaatgttg 2640
ttgtctatct gtctcttaca tctccttgat catgtcttca ttttttaatg tgctctgtac 2700
ctgtcaaaaa ttttgaatgt acaccacatg ctattgtctg aacctgagta taagataaaa 2760
taaaatttta ttttaattt taataaaaaa aaaaaaaa 2799

```

<210> 67
 <211> 1982
 <212> DNA
 <213> Homo sapiens

<400> 67
 tactcaagct cctaaaaatg gaaaggagaa aagggaaatgt caacctcaag gacaactgag 60

B0213WO seq list.ST25.txt

atgttcacag aacttctgca gattctcgtc cccacacctca cctcacaat gctaacctgt	120
ggacagtcct cctgtccaac agtcctggca gcttataagc ttccatctat aggaaattgg	180
taatgtagac accgagactg ggtgggttgc agaacaaatg tcatgctctg accaagatgg	240
ataagctcac aatgagttgg ggactttcct aaaagccagg gcactagtag tcacatggcc	300
actggttag ctacgtgaac atggtagtgg tgggtgaagat ggaaataaga ggaaacatgc	360
aaaagatttt tagaaggaaa aatagacaag atcggttgaa taattggatg tgaaggatga	420
ggaaatgcta tgtatcttaa gttcctgtct cacatgacta aattcataag cacttccact	480
tcgtcctcct caaattcacc ctccaacag cttctggaat agcaatctga aacacatgtc	540
tagttgtgat gtccctgctt aaaaccattt attcacctcc caattcctac aggatgaagt	600
ccttgagttc acagcatatc atcagttcac atccattgac ctctccagtt tctctttcct	660
ttttggttga ctctatgctt cagccaagct acaactcttc gtaattcttc tatagaaaat	720
tctgtttcct tcatgatttt ctgcctgctg aaataccctc tttttggacc caccatga	780
ctaaataaat acccttctca agttcctata aaaatctgtg gcattcactg ctctttcata	840
ccatttcagg tttgtttggg taggtgtgta tgaccacctt gaaggcaagg actttgtctt	900
attcacctct ggcaccctaa actcagcaca gtgcctgcac aaaactagcc ttgagaatgt	960
gcttattaca caatgaatga attaattaac tccattgcc a gatatagatg accaataaat	1020
acttaatggc tgatggaagt acttctgttt ctgtgttcaa agattacagt gacaatgaca	1080
aagcaagact catgtgtgag gcatacttag aaaggatggc agatagaaca ggttagtggt	1140
aaatattaat aaagtatgaa ggtaaccctg ctgggtatga cgtaggggac acgtcactgg	1200
aagacagcca tcaagcatca tgaggtactg aggatactc aatatcctgg agaaggtagt	1260
tggggtagt tttttttatc tattttgctt ataacattgt aagcctttga caaacatttg	1320
tttaatgtga ataaacagtc ggaataacctg gttctccaac caatattatc actaattaac	1380
tatatgacct aggacaaaaa gctgtcatat catctgggct ttatctgtaa tctaggagca	1440
atgaagagca gctttgatac attagggct gttttgttaa ccagaagaaa ggtaggggaa	1500
agatatggag aattgcatgc ccctattttg aattatggaa ctatactttt gtatttttag	1560
agaggatgca aactcctaaa gcccaaggac catgcctagt cacatatgat gtctgctggt	1620
catgggcgtg gacgtaatgt tcatctcctt gtcctatttt ctgataatac gaacggttct	1680
gcaactgcct tccaatcaga gcgggccaag gcctttggaa cctgtgtgtc acacattggg	1740
gtggtactcg ccttctatgt gccacttatt ggcctctcag tggtagaccg ctttggaac	1800
agccttcac ccattgtgcg tgttgtcatg ggtgacatct acctgctgct gcctcctgtc	1860
atcaatcca tcattctatgg tgccaaaacc aaacagatca gaacacgggt gctggctatg	1920
ttcaagatca gctgtgacaa ggacttgca gctgtgggag gcaagtgacc cttaacacta	1980
ca	1982

B0213WO seq list.ST25.txt

<211> 2306

<212> DNA

<213> Homo sapiens

<400> 68
 gagataactca aagtcctaaa aatggaaagg agaaaaggga atgtcaacct caaggacaac 60
 tgagatgttc acagaacttc tgcagattct cgtcccccac ctcacctcac aaatgctaac 120
 ctgggacagt cctcctgtcc aacagtcctg gcagcttata agcttccatc tataggaaat 180
 tggtaatgta gacaccgaga ctgggtgggt tgcagaacaa atgtcatgct ctgaccaaga 240
 tggataagct cacaatgagt tggggacttt cctaaaagcc agagcactag tagtcacatg 300
 gccactgttg tagctacgtg aacatggtag tgggtggtgaa gatggaaata agaggaaaca 360
 tgcaaaagat ttttagaagg aaaaatagac aagatcggtt gaataattgg atgtgaagga 420
 tgaggaaatg ctatgtatct taagttcctg tctcacatga ctaaattcat aagcacttcc 480
 acttcgtcct cctcaaattc accctcccaa cagcttctgg aatagcaatc tgaaacacat 540
 gtctagtgtg gatgtccctg cttaaaacca tttattcacc tcccaattcc tacaggatga 600
 agtccttgag ttcacagcat atcatcagtt cacatccatt gacctctcca gtttctcttt 660
 cctttttggt tgactctatg cttcagccaa gctacaactc ttcgtaattc ttctatagaa 720
 aattctgttt ctttcatgat tttctgcctg ctgaaatacc ctcttttttg acccacccaa 780
 tgactaaata aatacccttc tcaagttcct ataaaaatct gtggcattca ctgctctttc 840
 ataccatttc aggtttgttt gggtaggtgt gtatgaccac cctgaaggca aggacttgt 900
 cttattcacc tctggcacc taaactcagc acagtgcctg cacaaaagta gccttgagaa 960
 tgtgcttatt acacaatgaa tgaattaatt aactccattg ccagatatag atgaccaata 1020
 aataactaat ggctgatgga agtacttctg tttctgtgtt caaagattac agtgacaatg 1080
 acaaagcaag actcatgtgt gaggcatact tagaaaggat ggcagataga acaggttagt 1140
 gttaaatatt aataaagtat gaaggttaacc ctgctgggta tgacgtaggg gacacgtcac 1200
 tggaagacag ccatcaagca tcatgaggta ctgaggatac atcaatatcc tggagaaggt 1260
 agttgggact gccagtgtga cctcacctc tccagtcacc cctcctcagt tccagctatg 1320
 agttcctgca acttcacaca tgccaccttt gtgcttattg gtatcccagg attagagaaa 1380
 gccattttct gggtagctt cccctcctt tccatgtatg tagtggcaat gtttggaac 1440
 tgcacgtgg tcttcatcgt aaggacggaa cgcagcctgc acgctccgat gtacctcttt 1500
 ctctgcatgc ttgcagccat tgacctggcc ttatccacat ccacatgcc taagatcctt 1560
 gcccttttct ggtttgattc ccgagagatt agctttgagg cctgtcttac ccagatgttc 1620
 tttattcatg ccctctcagc cattgaatcc accatcctgc tggccatggc ctttgaccgt 1680
 tatgtggcca tctgccacc actgcgccat gctgcagtgc tcaacaatac agtaacagcc 1740

B0213WO seq list.ST25.txt

cagattggca tcgtggctgt ggtccgcgga tccctctttt ttttcccact gcctctgctg	1800
atcaagcggc tggccttctg ccactccaat gtcctctcgc actcctattg tgtccaccag	1860
gatgtaatga agttggccta tgcagacact ttgcccaatg tggatatatgg tcttactgcc	1920
attctgctgg tcatgggcgt ggacgtaatg ttcattctct tgcctatttt tctgataata	1980
cgaacgggtc tgcaactgcc ttccaagtca gagcggggcca aggccttttg aacctgtgtg	2040
tcacacattg gtgtgggtact cgccttctat gtgccactta ttggcctctc agttgtacac	2100
cgctttggaa acagccttca tcccattgtg cgtgtgtgtca tgggtgacat ctacctgtg	2160
ctgcctctctg tcatcaatcc catcatctat ggtgccaata ccaaacagat cagaacacgg	2220
gtgctggcta tgttcaagat cagctgtgac aaggacttgc aggctgtggg aggcaagtga	2280
cccttaacac tacacttctc cttatc	2306

<210> 69

<211> 2767

<212> DNA

<213> Homo sapiens

<400> 69	
gagatactca aagtcctaaa aatggaaagg agaaaaggga atgtcaacct caaggacaac	60
tgagatgttc acagaacttc tgcagattct cgccccccac ctcacctcac aaatgctaac	120
ctgtggacag tcctctgtgc caacagtcct ggcagcttat aagcttccat ctataggaaa	180
ttggtaatgt agacaccgag actgggtggg ttgcagaaca aatgtcatgc tctgaccaag	240
atggataagc tcacaatgag ttggggactt tcctaaaagc cagagcacta gtagtcacat	300
ggccactgtt gtagctacgt gaacatggta gtggtggtga agatggaaat aagaggaaac	360
atgcaaaaga tttttagaag gaaaaataga caagatcggg tgaataattg gatgtgaagg	420
atgaggaaat gctatgtatc ttaagttcct gtctcacatg actaaattca taagcacttc	480
cacttcgtcc tcctcaaatt caccctccca acagcttctg gaatagcaat ctgaaacaca	540
tgtctagttg tgatgtccct gcttaaagcc atttattcac ctcccaattc ctacaggatg	600
aagtccttga gttcacagca tatcatcagt tcacatccat tgacctctcc agtttctctt	660
tccttttttg ttgactctat gcttcagcca agctacaact cttcgttaatt cttctataga	720
aaattctgtt tctttcatga ttttctgcct gctgaaatac cctctttttg gacccacca	780
atgactaaat aaataccctt ctcaagttcc tataaaaatc tgtggcattc actgctcttt	840
cataccattt caggtttgtt tgggtagggtg tgtatgacca ccctgaaggc aaggactttg	900
tcttattcac ctctggcacc ctaaaactcag cacagtgcct gcacaaaagt agccttgaga	960
atgtgcttat tacacaatga atgaattaat taactccatt gccagatata gatgaccaat	1020
aaatgcttaa tggctgatgg aagtacttct gtttctgtgt tcaaagatta cagtgacaat	1080

B0213WO seq list.ST25.txt

gacgaagcaa gactcatgtg tgaggcatatc ttagaaagga tggcagatag aacagggttag 1140
 tgttaaatat taataaagta tgaaggtaac cctgctgggt atgacgtagg ggacacgtca 1200
 ctggaagaca gccatcaagc atcatgaggt actgaggata catcaatatc ctggagaagg 1260
 tagttggggg gagttttttt tatctatttt gcttataaca ttgtaagcct ttgacaaaca 1320
 tttgtttaat gtgaataaac agtcggaata cctggttctc caaccaatat tatcactaat 1380
 tagctatatg acctaggaca aaaagctgtc atatcatctg ggctttatct gtaatctagg 1440
 agcaatgaag agcagctttg atacattaag ggctggtttg ttaaccagaa gaaagggttag 1500
 ggaaagatat ggagaattgc atgcccctat tttgaattat ggaactatac ttttgtattt 1560
 ttagagagga tgcaaactcc taaagcccaa ggaccatgcc tagtcacata tgatgtctgc 1620
 tgcgtctagc agagtggcac atgaagaaac aactaatcc tgtggctgac tgtgtgtgct 1680
 tggtttagct tggagaagtg ggagcagatt gtcgagagcc ctgtatatac tgccagtgtg 1740
 acctcaccct ctccagtcac cctcctcag ttccagctat gatttctgc aacttcacac 1800
 atgccacctt tgtgcttatt ggtatcccag gattagagaa agcccatttc tgggttggt 1860
 tccccctcct ttccatgtat gtagtggaac tgtttggaaa ctgcatcgtg gtcttcacg 1920
 taaggacgga acgcagcctg cacgctccga tgtacctctt tctctgcatg cttgcagcca 1980
 ttgacctggc cttatccaca tccaccatgc ctaagatcct tgcccttttc tggtttgatt 2040
 cccgagagat tagctttgag gcctgtctta cccagatgtt ctttattcat gccctctcag 2100
 ccattgaatc caccatcctg ctggccatgg cctttgaccg ttatgtggcc atctgccacc 2160
 cactgcgcca tgctgcagtg ctcaacaata cagtaacagc ccagattggc atcgtggctg 2220
 tgggtccgcg atccctcttt tttttccac tgctctgct gatcaagcgg ctggccttct 2280
 gccactccaa tgctctctg cactcctatt gtgtccacca ggatgtaatg aagttggcct 2340
 atgcagacac tttgccaat gtggtatatg gtcttactgc cattctgctg gtcattggcg 2400
 tggacgtaat gttcatctcc ttgtcctatt ttctgataat acgaacgggt ctgcaactgc 2460
 cttccaagtc agagcgggcc aaggcctttg gaacctgtgt gtcacacatt ggtgtggtac 2520
 tcgccttcta tgtgccactt attggcctct cagtgggtaca ccgctttgga aacagccttc 2580
 atccattgt gcgtgttgtc atgggtgaca tctacctgct gctgcctcct gtcacatc 2640
 ccatcatcta tggtgccaaa accaaacaga tcagaacacg ggtgctgggt atgttcaaga 2700
 tcagctgtga caaggacttg caggctgtgg gaggaagtg acccttaaca ctacattct 2760
 ccttatac 2767

<210> 70

<211> 322

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 70
 tgtgaacatc tcagttgtcc ttgaggttga cattcccttt tctcctttcc atttttagga 60
 ctttgagtat ctccgtgtgg gtgagaaagt ccaattcatc tagagtcaag cattttcact 120
 gaacaaaaca gttttactta cagagcccat acagcagttc ggcctgttcc tttcaggctg 180
 actcagaagg ctgaggaggc tttagattcc aggggagggc cgagcttgca aatatgagga 240
 gacttatcc agcctgactg gagacaggca cagagctgaa aggccaatc ctggtggtgg 300
 tgctaactca ctgtgtcttc ag 322

<210> 71
 <211> 206
 <212> DNA
 <213> Homo sapiens

<400> 71
 gaatctaaag ctcctcagc ccaccatacc aacatctaata ctaattctgc acattgtgag 60
 gaaattactc cctgtgggtg agaaagtcca attcatctag agtcaagcat tttcattgaa 120
 caaaacagtt ttacttacag agcccatata gcagttcggc ctgttccttt caggctgact 180
 cagaaggctg aggaggcttt agattc 206

<210> 72
 <211> 4344
 <212> DNA
 <213> Homo sapiens

<400> 72
 ctgggtccca tttctctgga acacagtggc ctagtgatct gacctctctt cagggaaggc 60
 tccttagttc tgccccatat atttcagtat gatttgttta aagttctata tccccctccc 120
 caagctatga cggatacaga aatggatgga tggatgcaag atgcaaacta tcttgatct 180
 cactaaagga tgcaatcatc tgcttctgaa aagggtcttt catgttctga tagcaactgg 240
 gagccaaata tgggatttaa tatttgtaa ggagcttagc tgttttgtct gcacaagttc 300
 tgaagggtgga gaagagaaaa tacaggcaga agtatgggtt ttgtaacctt caaaccccaa 360
 atctgtcctt ctttgcttat ccaagatggg gagaatccag ttcaaatctc tttgtactaa 420
 ttttatcata ttgtacttta agatcactgg tatctaacc ctctacatta aggccaaact 480
 gaagggcatc tcccagctgc agtaagaact cagatgatga gtgaagaatt ctgggggttg 540
 gggagtgcaa tataagcaag ctaacctgtt tcaatgaaac agatgatcaa tgaagacact 600
 gcatcatttg tttccaaaag ttaggccttg cagccaaggc tttggctttt tagagaaaat 660

B0213WO seq list.ST25.txt

tagctctaaa gaccagggca cctaggcaac cttagcagaga agaagtttca tgaagtcaga	720
gcccagggtgt ttgggtgagg gtagggagt ttgggcaaagc aacactgggc ttctaaaaaa	780
gaaatgtctc ccctgagatg aatgacttgt tggcacaagt ttcaggaaag acaaagctct	840
aaaaatatca ttgtaaaatt aataatactt ctccaaaagta aggactcaac tcaaactatc	900
cttgatgca attaaaatgg ccttggaaga agctttcagg tgcggaggta ctcaccagt	960
tcctgccagc acctcatct ctgaagaagt catcgagggg agccactacc ttgattttat	1020
gaccacagat gagtttcctt taatccgaaa gagattgact ttggcattt ttttcttagt	1080
ttttgtttat ttatatctt ttaagcttta aaaaaaagtg tcattgctgt gcttcttatt	1140
cctctggctg actttagaat tgaggactgg gaatcctgaa aatttgcaa gttatctcct	1200
atcctcactg ccttggaaca cccattattc cactctgtct aatttctact catgtttcaa	1260
gtctaaacag gaagattcct ctgtgatcat gcctctccct ttctcatgaa ttaaatgcat	1320
atattatgct agtaatgctt ctggaatgaa tgaataatag aaagaaagaa agtgggggga	1380
gggaagcagg gaaagtaaaa tgagaaaggc agccttatct ggaaggagct cccaaaagt	1440
tatctcttaa cacctatcag aaaaaaagg gccacaat atccaggcaa cgaaggatg	1500
gaccagtagg aagaatctga gggaattaca ttttggaaaa agcattgctc tcccaagatt	1560
cccttttaaa aatttaata aaccttgaga gtagtgatgc ataaatgaat ttgatctgtc	1620
acagtccgc ctttggaaga gggcctcaga gcttatgaaa gaccctaagt gggggtggga	1680
gaagacaaaa ggggtgggat gtcagtttca agtttccagg gcattctctg attgtgctct	1740
atgtccctgc agactgccag tgtgacctca cctctccag tcaccctcc tcagttccag	1800
ctatgagttc ctgcaactc acacatgcca ctttgtgct tattggtatc ccaggattag	1860
agaaagccca tttctgggtt ggcttcccc tcctttccat gtatgtagtg gcaatgtttg	1920
gaaactgcat cgtggtcttc atcgtaaagga cggaaacgag cctgcacgct ccgatgtacc	1980
tctttctctg catgcttgca gccattgacc tggccttatc cacatccacc atgcctaaga	2040
tccttgccct tttctggtt gattcccag agattagctt tgaggcctgt cttaccaga	2100
tgttctttat tcatgccctc tcagccattg aatccaccat cctgctggcc atggcctttg	2160
accgttatgt ggccatctgc caccactgc gccatgctgc agtgctcaac aatacagtaa	2220
cagcccagat tggcatcgtg gctgtgtgcc gcggatccct ctttttttc cactgcctc	2280
tgctgatcaa gcggctggcc ttctgccact ccaatgtcct ctgcactcc tattgtgtcc	2340
accaggatgt aatgaagttg gcctatgag acactttgcc caatgtggta tatggtctta	2400
ctgccattct gctggtcatg ggcgtggacg taatgttcat ctcttgtcc tattttctga	2460
taatacgaac ggttctgcaa ctgccttcca agtcagagcg ggccaaggcc tttggaacct	2520
gtgtgtcaca cattgggtgtg gtactgcct tctatgtgcc acttattggc ctctcagtgg	2580
tacaccgctt tggaaacagc cttcatccca ttgtgcgtgt tgcatgggt gacatctacc	2640
tgctgctgcc tcctgtcatc aatcccatca tctatggtgc caaaacaaa cagatcagaa	2700

B0213WO seq list.ST25.txt

cacgggtgct ggctatgttc aagatcagct gtgacaagga cttgcaggct gtgggaggca	2760
agtgaccctt aacactacac ttctccttat ctttattggc ttgataaaca taattatttc	2820
taactactagc ttatttccag ttgcccataa gcacatcagt acttttctct ggctggaata	2880
gtaaactaaa gtatggtaca tctacctaaa ggactattat gtggaataat acataactaat	2940
gaagtattac atgatttaaa gactacaata aaaccaaaca tgcttataac attaagaaaa	3000
acaataaaga tacatgattg aaaccaagtt gaaaaatagc atatgccttg gaggaaatgt	3060
gctcaaatta ctaatgattt agtggtgtcc ctactttctc tctctttttt ctttcttttt	3120
tttttattat ggtagctgt cacatacaac tttttttttt tttagatgg ggtctcgctc	3180
tgccaccagg ctggagtgca gtggcgcgat ctcggctcac tgcaacctcc acatcccatg	3240
ttgaagtaat tcttctgcct cagcctcccg agtagctggg actagaggaa cgtgccacca	3300
tgactggcta attttctgta ttttttagta gagacagagt ttcacatgt tggccaggat	3360
ggtctcgatc tcctgacctt gtgatccacc cgcctcagcc tcccaaagtg ttgggattac	3420
agggtgaac cactgtgccc ggctgtgta caacttttta aatagggaat atgatagctt	3480
cgcaggtggg tgtgcaccta tagccccac tgcctggaaa gctgaggtgg gagaatcgct	3540
tgagtccagg agtttgaggt tacagtgatc cacgatcgta ccactacact ccagcctggg	3600
caacagagca agaccctgtc tcaaagcata aaatggaata acatatcaa tgaaacaggg	3660
aaaatgaagc tgacaattta tgggaagccag ggctgtgcac agtctctact gttattatgc	3720
attacctggg aatttatata agcccttaat aataatgcca atgaacatct catgtgtgct	3780
cacaatgttc tggcactatt ataagtgtt cacaggtttt atgtgttctt cgtaacttta	3840
tggagtaggt accatttgtg tctctttatt ataagtgaga gaaatgaagt ttatattatc	3900
aaggggacta aagtcacacg gcttgtgggc actgtgccaa gatttaaaat taaatttgat	3960
ggttgaatac agttacttaa tgaccatgtt atattgcttc ctgtgtaaca tctgccattt	4020
atttcctcag ctgtacaaat cctctgtttt ctctctgtta cacactaaca tcaatggctt	4080
tgtacttgtg atgagagata accttgccct agttgtgggc aacacatgca gaataatcct	4140
gttttacagc tgcctttcgt gatcttattg cttgcttttt tccagattca gggagaatgt	4200
tgttgtctat ttgtctctta catctccttg atcatgtctt ctttttttaa tgtgctctgt	4260
acctgtcaaa aattttgaat gtacaccaca tgctattgtc tgaacttgag tataagataa	4320
aataaaattt tattttaaat ttg	4344

<210> 73

<211> 2969

<212> DNA

<213> Homo sapiens

<400> 73

B0213WO seq list.ST25.txt

agcaacgacg ccgggcagcg ggagcggcgg ccgcgccatg tggctgctgg ggccgctgtg	60
cctgctgctg agcagcgccg cggagagcca gctgctcccc gggaacaact tcaccaatga	120
gtgcaacata ccaggcaact tcatgtgcag caatggacgg tgcattcccg gcgcctggca	180
gtgtgacggg ctgcctgact gtttcgacaa gagtgatgag aaggagtgcc ccaaggctaa	240
gtcgaaatgt ggcccaacct tcttccctg tgccagcggc atccattgca tcattggtcg	300
cttccggtgc aatgggtttg aggactgtcc cgatggcagc gatgaagaga actgcacagc	360
aaacctctg ctttgtcca ccgcccgtc cactgcaag aacggcctct gtattgacaa	420
gagcttcac tgcatggac agaataactg tcaagacaac agtgatgagg aaagctgtga	480
aagttctcaa gaaccggca gtgggcagggt gtttgtgact tcagagaacc aacttgtgta	540
ttacccagc atcacctatg ccatcatcgg cagctccgtc atttttgtgc tgggtggtggc	600
cctgctggca ctggtcttgc accaccagcg gaagcggaaac aacctcatga cgctgcccgt	660
gcaccggctg cagcacctg tgctgctgtc ccgcctggtg gtcctggacc acccccacca	720
ctgcaacgtc acctacaacg tcaataatgg catccagtat gtggccagcc aggcggagca	780
gaatgcgtcg gaagtaggct cccaccctc ctactccgag gccttgcctg accagaggcc	840
tgctggtat gaccttcctc caccgccccta ctcttctgac acggaatctc tgaaccaagc	900
cgactgccc ccctaccgct ccggtcccg gagtgccaac agtgccagct cccaggcagc	960
cagcagctc ctgagcgtgg aagacaccag ccacagcccg gggcagcctg gccccagga	1020
gggactgct gagcccaggg actctgagcc cagccagggc actgaagaag tataagtccc	1080
agttattcca aagtccatat gggtaaatct gctctgactt gttgccattc taacaatttg	1140
tgctcatggg aagctcttta agcacctgta aggatgtctc aagttacagt ttgggatatt	1200
aactatctct gattccccct cctccccag acttcagaga tgtttttctg gcgtctcagt	1260
tgacatgatc tgtgtgcgt cttttctgtc aggtcactct tcccttggga cccgagatca	1320
cacctcatt ttccacatta ttctgtttct gttggagaga cagcatataa aacagtattg	1380
aaataggctg ggagagagca atgtttctgt gctatattgg atgctcagaa gtgcaggaga	1440
cgctggacc aattctctct gctgggtagt taccttatag ctttgggga tttgggttag	1500
atgatctaac caggaggcca tcttggtatg gtcaccccc caaaaaaatt ccatttgagc	1560
atcaaacct gcttgcaca atcctatttg atgccccag ttcagcagag tcagtggcca	1620
aagaaaactt tggacgtgag taacaccctt cagcagtcgc aacgttattt tggttttgtg	1680
aaggactctg aaaccatcta ccctgtataa attctggctt tagaaatttg cccaagaatg	1740
ctcattctga gagctttcct cagcagcata tatcatcagc ctcatcctaa aataggcagg	1800
gagccccctc catgagttta tccaagttct cagctcctaa aatgcaggct gccaagaccc	1860
tacacctgcc ctggctctac agccacttac ctggtttctg gactgtcacc ctcccagctg	1920
acctgcccgt agccaaggaa tgaggacctt acttgagttg gcccaaagtc tgacctggct	1980
gtatgtccct gtggcccaca cccagcctgt cttgctcatt catgcagcct caacactggc	2040

B0213WO seq list.ST25.txt

ctccaaagtt cccttaacac ttgcaaagtc ctttttacct gtgcatttgg acttgaggac 2100
 actggtttct atcacagggtg agagccatgt tcaatacctc cagcaagctc tcctggctcc 2160
 ctgcactgtg cagctcctc ttcccaaggt cccaatacca gcacctctag ttagagttag 2220
 ggtcagggtc aggcctctcc caacatccca gtagtttctc ctctgagaca catgggcaag 2280
 agacaatttg gagtcaagat tttccatttg gatctatttt aaatctttta gaaatgcatt 2340
 tgaaacagtg tgtttgtttt ttcccttcta gttaagggtac tatttatatg tgtataggaa 2400
 agctgtctct ttttttgttt ttcccttaac aagggtccaa gaaagatgca aaaggagatc 2460
 acacccttgc cccgctgagc cccgtgataa caagtcactc cagactaacc tgtgtgccag 2520
 acatttggtc attgtgtcac tttaggttga ttatttatca agttcttgaa ggaagcagaa 2580
 agagggtac ctctctccct ccgtgtatag tctctatgtt tgtgctagtt tttctttttt 2640
 ttctctgtgt ccagtcagcc acagggcccg cctccctgca ggaataaggg gtaaaacgtt 2700
 aggtgttgtt tggcaagaaa ccacactgac tgatgagggg taaaatggaa ccaggtagag 2760
 ccactccggg cagctgtcac ccattcagaa cttctttccg cagctgaaga aatgttcagt 2820
 aacctgtttg acgctaatta aaacagagcc tgcaggaagt ggggctaaag tggcattcag 2880
 tgatcctgtt ctgtagactt ttctttcttt ttttaaccaa atccaaagga tgttacagaa 2940
 aagctagcca ctggtatttt gttttgttt 2969

<210> 74

<211> 350

<212> DNA

<213> Homo sapiens

<400> 74

gccagtcac acagtgtaac taatttaatg ctaaaataaa acacggatct catttgagaa 60
 aaaaagagat gagactatct tctggttggc gtagatttag gcaatgtata aaaaagcttc 120
 ctggttgtaa tgagttaaaa aatattgctg gacactaatg tgccatcttg agttggaaaa 180
 caaacccct ccccccaaaa aaaaccctgc cgctttggtg tcctatttat atatttttaa 240
 aaacattcat taaaaaaatc aaatctataa taaaatgtc cctgtttggt ttaaaaaagc 300
 attagtaggc atcccttatc tactaaaacc atttgttttt cctaagatgc 350

<210> 75

<211> 2006

<212> DNA

<213> Homo sapiens

<400> 75

B0213WO seq list.ST25.txt

agcaacgacg ccgggcagcg ggagcggcgg ccgcgccatg tggctgctgg ggccgctgtg	60
cctgctgctg agcagcgccg cggccaaggc taagtcgaaa tgtggcccaa ccttcttccc	120
ctgtgccagc ggcattcatt gcatcattgg tcgcttcgg tgcaatgggt ttgaggactg	180
tcccgatggc agcgatgaag agaactgcac agcaaaccct ctgctttgct ccaccgccc	240
ctaccactgc aagaacggcc tctgtattga caagagcttc atctgcgatg gacagaataa	300
ctgtcaagac aacagtgatg aggaaagctg tgaaagtctt caagaaccg gcagtgggca	360
gggtgtttgtg acttcagaga accaacttgt gtattacccc agcatcacct atgccatcat	420
cggcagctcc gtcatttttg tgctgggtgg ggccctgctg gcactgggtct tgcaccacca	480
gcggaagcgg aacaacctca tgacgctgcc cgtgcaccgg ctgcagcacc ctgtgctgct	540
gtcccgctg tggtctctgg accaccccca cactgcaac gtcacctaca acgtcaataa	600
tggcatccag tatgtggcca gccaggcggg gcagaatgcg tcggaagtag gctccccacc	660
ctcctactcc gaggccttgc tggaccagag gcctgcgtgg tatgaccttc ctccaccgcc	720
ctactcttct gacacggaat ctctgaacca agccgacctg cccccctacc gctcccggtc	780
cgggagtgcc aacagtgcc gctcccaggc agccagcagc ctctgagcg tggaagacac	840
cagccacagc ccggggcagc ctggcccca ggagggcact gctgagccca gggactctga	900
gcccagccag ggcactgaag aagtataagt ccagttatt ccaaagtcca tatgggttaa	960
tctgctctga cttgttgcca ttctaacaat ttgtgctcat gggaagctct ttaagcacct	1020
gtaaggatgt ctcaagttac agtttgggat attaaactatc tctgcattcc cctcctcccc	1080
cagacttcag agatgttttt ctggcgtctc agttgacatg atctgttgtg cgtcttttct	1140
gtcaggtcac tcttccttg ggacccgaga tcacacctc atttttcaca ttattctgtt	1200
tctgttggag agacagcata taaaacagta ttgaaatagg ctgggagaga gcaatgtttc	1260
tgtgctatat tggatgctca gaagtgcagg agacgctgga cccaattctc tctgctgggt	1320
agttacctta tagcatttgg ggatttgggt tagatgatct aaccaggagg ccatcactgg	1380
atggtcacc ccccaaaaaa attccatttg agcatcaaaa cctgctttgc acaatcctat	1440
ttgatgcccc cagttcagca gagtcagtgg ccaaagaaaa ctttggacgt gagtaacacc	1500
cttcagcagt cgcaacgtta ttttggtttt gtgaaggact ctgaaaccat ctaccctgta	1560
taaattctgg ctttagaaat ttgccaaga atgctcattc tgagagcttt cctcagcagc	1620
atatatcatc agcctcatcc taaaataggc agggagcccc tcccatgagt ttatccaagt	1680
tctcagctcc taaaatgcag gctgccaaga ccctacacct gccctggctc tacagccact	1740
tacctggttt ctggactgtc accctcccag ctgacctgcc cgtagccaag gaatgaggac	1800
ctaaacttgag ttggcccaaa gtctgacctg gctgtatgtc cctgtggccc acaccagcc	1860
tgtcttgctc attcatgcag cctcaacact ggcctccaaa gttcccttaa cacttgcaaa	1920
gtccttttta cctgtgcatt tggacttgag gacactggtt tctatcacag gtgagagcca	1980
tgttcaatac ctccagcaag ctctcc	2006

B0213WO seq list.ST25.txt

<210> 76
 <211> 3094
 <212> DNA
 <213> Homo sapiens

```

<400> 76
agcaacgacg ccgggcagcg ggagcggcgg ccgcgccatg tggctgctgg ggccgctgtg      60
cctgctgctg agcagcgccg cgggtctgtg actactttgc tccaatacca agatggacag      120
aacagccctt tgattacca gggagactgt caagtttgca tctggtcaat ctctgtttta      180
tatataagga aactgaggca cagggaggag agccagctgc tccccgggaa caacttcacc      240
aatgagtgcg acataccagg caacttcatt tgcagcaatg gacgggtgat cccgggcgcc      300
tggcagtgtg acgggctgcc tgactgcttc gacaagagtg atgagaagga gtgccccaaag      360
gctaagtcga aatgtggccc aaccttcttc ccctgtgcca gcggcatcca ttgcatcatt      420
ggtcgcttcc ggtgcaatgg gtttgaggac tgtcccgatg gcagcgatga agagaactgc      480
acagcaaacc ctctgctttg ctccaccgcc cgctaccact gcaagaacgg cctctgtatt      540
gacaagagct tcattctgca tggacagaat aactgtcaag acaacagtga tgaggaaagc      600
tgtgaaagtt ctcaagaacc cggcagtggg caggtgtttg tgacttcaga gaaccaactt      660
gtgtattacc ccagcatcac ctatgccatc atcggcagct ccgtcatttt tgtgctggtg      720
gtggccctgc tggcactggg ctgacaccac cagcgggaagc ggaacaacct catgacgctg      780
cccgtgcacc ggctgcagca ccctgtgctg ctgtcccgcc tggtggtcct ggaccacccc      840
caccactgca acgtcaccta caacgtcaat aatggcatcc agtatgtggc cagccaggcg      900
gagcagaatg cgtcgggaag aggtcccca ccctcctact ccgaggcctt gctggaccag      960
aggcctgcgt ggtatgacct tcctccaccg ccctactctt ctgacacgga atctctgaac     1020
caagccgacc tgcccccta ccgctcccgg tccgggagtg ccaacagtgc cagctcccag     1080
gcagccagca gcctcctgag cgtggaagac accagccaca gcccggggca gcctggcccc     1140
caggagggca ctgctgagcc cagggactct gagcccagcc agggcactga agaagtataa     1200
gtcccagtta ttccaaagtc catatgggtt aatctgctct gacttggtgc cattctaaca     1260
atattgtctc atgggaagct ctttaagcac ctgtaaggat gtctcaagtt acagtttggg     1320
atattaacta tctctgcatt cccctcctcc ccagacttc agagatgttt ttctggcgtc     1380
tcagttgaca tgatctgttg tgcgtctttt ctgtcaggtc actcttccct tgggaccgca     1440
gatcacaccc tcatttttca cattattctg tttctgttgg agagacagca tataaaacag     1500
tattgaaata ggctgggaga gagcaatgtt tctgtgctat attggatgct cagaagtgca     1560
ggagacgctg gacccaattc tctctgctgg gtagttacct tatagcattt ggggatttgg     1620
gttagatgat ctaaccagga ggccatcact ggatggtcac cccccaaaaa aaattccatt     1680

```


B0213WO seq list.ST25.txt

tgagcatcaa aacctgcttt gcacaatcct atttgatgcc cccagttcag cagagtcagt	1740
ggccaaagaa aacttttgac gtgagtaaca cccttcagca gtcgcaacgt tattttgggt	1800
ttgtgaagga ctctgaaacc atctaccctg tataaattct ggctttagaa atttgcccaa	1860
gaatgtcat tctgagagct ttcctcagca gcatatatca tcagcctcat cctaaaatag	1920
gcaggagacc cctcccatga gtttatccaa gtctcagct cctaaaatgc aggtgccaa	1980
gaccctacac ctgccctggc tctacagcca cttacctggg ttctggactg tcacctccc	2040
agctgacctg cccgtagcca aggaatgagg acctaacctg agttggccca aagtctgacc	2100
tggtgtatg tccctgtggc ccacaccag cctgtcttgc tcattcatgc agcctcaaca	2160
ctggcctcca aagtccctt aacacttgca aagtcctttt tacctgtgca tttggacttg	2220
aggacactgg tttctatcac aggtgagagc catgttcaat acctccagca agctctctg	2280
gctccctgca ctgtgcacgc tcctcttccc aagggtccca taccagcacc tctagttaga	2340
gttagggta gggtcaggcc tctcccaaca tcccagtagt ttctcctctg agacacatgg	2400
gcaagagaca atttggagtc aagatthtcc atttggatct attttaaatc ttttagaat	2460
gcatttgaaa cagtgtgttt gttttttccc ttctagttaa gggactattt atatgtgtat	2520
aggaaagctg tctctttttt tgtttttctt ttaacaaggc ccaaagaaag atgcaaaagg	2580
agatcacacc cttgccccgc tgagccccgt gataacaagt cactccagac taacctgtgt	2640
gccagacatt tgtgcattgt tgcacttga gggtattatt tatcaagttc ttgaaggaag	2700
cagaaagagg gactcctctc tccctccgtg tatagtctct atgtttgtgc tagtttttct	2760
tttttttctc tgtgtccagt cagccacagg gccgcctcc ctgcaggaat aaggggtaaa	2820
acgttaggtg ttgtttggca agaaaccaca ctgactgatg aggggtaaaa tggaaccagg	2880
tagagccact ccgggcagct gtcaccatt cagaacttct ttccgcagct gaagaaatgt	2940
tcagtaacct gtttgacgt aattaaaaca gagcctgcag gaagtggggc taaagtggca	3000
ttcagtgatc ctgttctgta gacttttctt tcttttttta accaaatcca aaggatgtta	3060
cagaaaagct agccactggg atttgtttt gttt	3094

<210> 77

<211> 3024

<212> DNA

<213> Homo sapiens

<400> 77	
ctggggccgc tgtgcctgct gctgagcagc gccgcgggaa agtgcctgga aaaatagatg	60
acagccagaa agagagcttg gagaaaaaaa tgactccaag gagaagggtg tcatttccta	120
gagtctggct tgtcagttag agccagctgc tccccgggaa caacttcacc aatgagtgca	180
acataccagg caacttcatt tgcagcaatg gacggtgcat cccgggcgcc tggcagtgtg	240

B0213WO seq list.ST25.txt

acgggctgcc tgactgcttc gacaagagtg atgagaagga gtgcccacag gctaagtcga	300
aatgtggccc aaccttcttc ccctgtgcca gcggcatcca ttgcatcatt ggtcgcttcc	360
ggtgcaatgg gtttgaggac tgtcccgatg gcagcgatga agagaactgc acagcaaacc	420
ctctgctttg ctccaccgcc cgctaccact gcaagaacgg cctctgtatt gacaagagct	480
tcctctgcga tggacagaat aactgtcaag acaacagtga tgaggaaagc tgtgaaagtt	540
ctcaagaacc cggcagtggg caggtgtttg tgacttcaga gaaccaactt gtgtattacc	600
ccagcatcac ctatgccatc atcggcagct ccgtcatttt tgtgctgggtg gtggccctgc	660
tggcactggt cttgaccac cagcggaagc ggaacaacct catgacgctg cccgtgcacc	720
ggctgcagca ccctgtgctg ctgtcccgcc tgggtggctct ggaccacccc caccactgca	780
acgtcaccta caacgtcaat aatggcatcc agtatgtggc cagccaggcg gagcagaatg	840
cgctggaagt aggtctccca ccctcctact ccgaggcctt gctggaccag aggcctgcgt	900
ggtatgacct tcctccaccg ccctactctt ctgacacgga atctctgaac caagccgacc	960
tgcccccta ccgctcccg tccgggagtg ccaacagtgc cagctcccag gcagccagca	1020
gcctcctgag cgtggaagac accagccaca gcccggggca gcctggcccc caggaggga	1080
ctgctgagcc cagggactct gagcccagcc agggcactga agaagtataa gtcccagtta	1140
ttccaaagtc catatgggtt aatctgctct gacttgttgc cattctaaca atttgtgctc	1200
atgggaagct ctttaagcac ctgtaaggat gtctcaagtt acagtttggg atattaacta	1260
tctctgcatt cccctcctcc ccagacttc agagatgttt ttctggcgtc tcagttgaca	1320
tgatctgttg tgcgtctttt ctgtcaggtc actcttccct tgggacccga gatcaccccc	1380
tcatttttca cattattctg tttctgttgg agagacagca tataaacag tattgaaata	1440
ggctgggaga gagcaatgtt tctgtgctat attggatgct cagaagtga ggagacgctg	1500
gaccaattc tctctgctgg gtagttacct tatagcattt ggggatttgg gttagatgat	1560
ctaaccagga ggccatcact ggatggtcac cccccaaaa aaattccatt tgagcatcaa	1620
aacctgcttt gcacaatcct atttgatgcc ccagttcag cagagtcagt ggccaaagaa	1680
aactttggac gtgagtaaca cccttcagca gtcgcaacgt tattttgggtt ttgtgaagga	1740
ctctgaaacc atctaccctg tataaattct ggcttttagaa atttgccccaa gaatgctcat	1800
tctgagagct ttcttcagca gcatatatca tcagcctcat cctaaaatag gcagggagcc	1860
cctcccatga gtttatccaa gttctcagct cctaaaatgc aggtgccaa gaccctacac	1920
ctgccctggc tctacagcca cttacctggg ttctggactg tcaccctccc agctgacctg	1980
cccgtagcca aggaatgagg acctaacctg agttggcca aagtctgacc tggctgtatg	2040
tccctgtggc ccacaccag cctgtcttgc tcattcatgc agcctcaaca ctggcctcca	2100
aagttccctt aaccttgca aagtcctttt tacctgtgca tttggacttg aggacactgg	2160
tttctatcac aggtgagagc catgttcaat acctccagca agctctcctg gctccctgca	2220
ctgtgcacgc tcctcttccc aaggtcccaa taccagcacc tctagttaga gttagggtca	2280

B0213WO seq list.ST25.txt

```

gggtcaggcc tctcccaaca tcccagtagt ttctcctctg agacacatgg gcaagagaca 2340
atttggagtc aagattttcc atttggatct attttaaatc ttttagaaat gcatttgaaa 2400
cagtgtgttt gttttttccc ttctagttaa gggactattt atatgtgtat aggaaagctg 2460
tctctttttt tgtttttcct ttaacaaggt ccaaagaaag atgcaaaaagg agatcacacc 2520
cttgccccgc tgagccccgt gataacaagt cactccagac taacctgtgt gccagacatt 2580
tgtgcattgt tgcactttga gggtattatt tatcaagttc ttgaaggaag cagaaagagg 2640
gactcctctc tccctccgtg tatagtctct atgtttgtgc tagtttttct tttttttctc 2700
tgtgtccagt cagccacagg gccgcctcc ctgcaggaat aaggggtaaa acgttaggtg 2760
ttgtttggca agaaaccaca ctgactgatg aggggtaaaa tggaaccagg tagagccact 2820
ccgggcagct gtcaccatt cagaacttct ttccgcagct gaagaaatgt tcagtaacct 2880
gtttgacgct aattaaaaca gaggctgcag gaagtggggc taaagtggca ttcagtgatc 2940
ctgttctgta gacttttctt tcttttttta accaaatcca aaggatgtta cagaaaagct 3000
agccactggt attttgtttt gttt 3024

```

<210> 78

<211> 1668

<212> DNA

<213> Homo sapiens

```

<400> 78
atgggtcctg gggcgcggt ggcggcgctg ctggcggtgc tggcgctcgg gacaggagac 60
ccagaaaggg ctgcggctcg gggcgacacg ttctcggcgc tgaccagcgt ggcgcgcgcc 120
ctggcgcccg agcgccggct gctggggctg ctgaggcggc acctgcgcgg ggaggaggcg 180
cggctgcggg acctgactag attctacgac aaggtaactt ctttgcatga ggattcaaca 240
acctctgtgg ctaacctctt gcttgcatth actctcatca aacgcctgca gtctgactgg 300
aggaatgtgg tacatagtct ggaggccagt gagaacatcc gagctctgaa ggatggctat 360
gagaagggtg agcaagacct tccagccttt gaggaccttg agggagcagc aagggccctg 420
atgcggtcgc aggacgtgta catgctcaat gtgaaaggcc tggcccaggg tgtctttcag 480
agagtcactg gctctgccat cactgacctg tacagcccca aacggctctt ttctctcaca 540
ggggatgact gcttccaagt tggcaagggt gcctatgaca tgggggatta ttaccatgcc 600
attccatggc tggaggaggc tgctagctctc ttccgaggat cttacggaga gtggaagaca 660
gaggatgagg caagtctaga agatgccttg gatcacttgg cttttgctta tttccgggta 720
agggagccag ttaggagatt tgaaagatct agtggagcca agaataaatt agcttccaat 780
tctctgggga agaataaggtt gggtcctttt gcaataggct ttggctttct ggacttctct 840
ttcattgcac ttatcatatt ttgttgccca gataataaga ggatggccag gaatgtcttg 900

```

B0213WO seq list.ST25.txt

```

aaatatgaaa ggctcttggc agagagcccc aaccacgtgg tagctgaggc tgtcatccag    960
aggcccaata taccacacct gcagaccaga gacacctacg aggggctatg tcagaccctg    1020
ggttcccagc cactctctta ccagatccct agcctctact gttcctatga gaccaattcc    1080
aacgcctacc tgctgctcca gcccatccgg aaggagggtca tccacctgga gccctacatt    1140
gctctctacc atgacttcgt cagtgactca gaggctcaga aaattagaga acttgcagaa    1200
ccatggctac agaggctcgt ggtggcatca ggggagaagc agttacaagt ggagtaccgc    1260
atcagcaaaa gtgcctggct gaaggacact gttgacccaa aactggtgac cctcaaccac    1320
cgcattgctg ccctcacagg ccttgatgtc cggcctccct atgcagagta tctgcagggtg    1380
gtgaactatg gcatcggagg acactatgag cctcactttg accatgctac gctgagctcg    1440
gtggaagctg gaggagccac agccttcac tatgccaacc tcagcgtgcc tgtggtagg    1500
aatgcagcac tgttttggtg gaacctgcac aggagtgggtg aaggggacag tgacacactt    1560
catgctggct gtcctgtcct ggtgggagat aagtgggtgg ccaacaagtg gatacatgag    1620
tatggacagg aattccgcag accctgcagc tccagccctg aagactga    1668

```

<210> 79

<211> 997

<212> DNA

<213> Homo sapiens

```

<400> 79
gaaggaaaaa gagcaacaga tccagggagc attcacctgc cctgtctcca aacagccttg    60
tgcctcacct accccaacc tcccagaggg agcagctatt taaggggagc aggagtgcag    120
aacaacaag acggcctggg gatacaactc tggagtctc tgagagagcc accaaggagg    180
agcaggggag cgacggccgg ggcagaagtt gagaccacc agcagaggag ctaggccagt    240
ccatctgcat ttgtcaccca agaactctta ccatgaagac cctcctactg ttggcagtga    300
tcatgatctt tggcctactg caggcccatg ggaatttggg gaatttccac agaattgatca    360
agttgacgac aggaaaggaa gccgcactca gttatggctt ctacggctgc cactgtggcg    420
tgggtggcag aggatcccc aaggatgcaa cggatcgctg ctgtgtcact catgactgtt    480
gctacaaacg tctggagaaa cgtggatgtg gcaccaaatt tctgagctac aagtttagca    540
actcggggag cagaatcacc tgtgcaaac aggactcctg cagaagtcaa ctgtgtgagt    600
gtgataaggc tgctgccacc tgttttgcta gaaacaagac gacctacaat aaaaagtacc    660
agtactattc caataaacac tgcagaggga gcaccctcg ttgctgagtc ccctcttccc    720
tggaacctt ccaccagtg ctgaatttcc ctctctcata ccctccctcc ctaccctaac    780
caagttcctt ggccatgcag aaagcatccc tcaccatcc tagaggccag gcaggagccc    840
ttctataccc acccagaatg agacatccag cagatttcca gccttctact gctctcctcc    900

```

B0213WO seq list.ST25.txt

acctcaactc cgtgcttaac caaagaagct gtactccggg gggctctctc tgaataaagc 960
aattagcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 997

<210> 80

<211> 260

<212> DNA

<213> Homo sapiens

<400> 80
tgagaggtgg gtgtgatcac tcatttgctg tttaaaggcc cagaaaggag acagagaagg 60
gatggacaga gagggagaag ggggaactgag cgagaaggtc aaggagtcag taaggaaatg 120
gttagcaagg gccaaagtga caggaggatcc tccatgaaaa gggccaacaa ggctccccctg 180
gatgttgagg cagaaacgca tgagggactc aggggaagct gtttccatgg agtcggggggg 240
gcaaagccag attagaccag 260

<210> 81

<211> 201

<212> DNA

<213> Homo sapiens

<400> 81
ttcctttcct gtcgtcaact tgatcattca aagatcatga tcaactgcaa cagtaggagg 60
gtcttcatgg taagagttct tgggtgacaa atgcagatgg actggcctag ctctctgct 120
gggtggtctc aacttctgcc ccggccgtcg ctccccctgct cctccttggg ggctctgttt 180
ggagacaggg caggtgaatg a 201

<210> 82

<211> 272

<212> DNA

<213> Homo sapiens

<400> 82
tcattcacct gccctgtctc caacagggtg gatgggagag catgtctgtg tgtctcagag 60
ccaccaagga ggagcagggg agcgacggcc ggggcagaag ttgagaccac ccagcagagg 120
agctaggcca gtccatctgc atttgtcacc caagaactct taccatgaag accctcctac 180
tgttggcagt gatcatgac tttggcctac tgcaggccca tgggaatttg gtgaatttcc 240
acagaatgat caagttgacg acaggaaagg aa 272

B0213WO seq list.ST25.txt

<210> 83
 <211> 258
 <212> DNA
 <213> Homo sapiens

<400> 83
 tcattcacct gccctgtctc caaacagagc caccaaggag gagcagggga gcgacggccg 60
 gggcagaagt tgagaccacc cagcagagga gctaggccag tccatctgca tttgtcacc 120
 aagaactctt accatgaaga ccctcctact gttggcagt atcatgatct ttggcctact 180
 gcaggcccat gggaatttgg tgaatttcca cagaatgac aagttgacga caggaaagga 240
 agccgcactc agttatga 258

<210> 84
 <211> 2226
 <212> DNA
 <213> Homo sapiens

<400> 84
 ggcagcatgg cgtctttccg gcttctccaa acccttgcca aaaactttat tggcaaagct 60
 atcagagaac ggacagtgtg cccactgagg cggccaaagc ttaactggat cagggcagga 120
 tgacatgacc ttgtggtaga tcccagaact gagggcccag gatgacagaa caggagaccc 180
 tggccctact ggaagtgaag aggtctgatt ccccagagaa gagctcacc caggccttgg 240
 ttcccaatgg ccggcagcca gaaggggaag gtggggccga atccccggga gctgagtccc 300
 tcagagtggg gtcttcagct ggatctccca cagccataga gggggctgag gatggtctag 360
 acagcacagt aagtgaggct gccaccttgc cctgggggac tggccctcag cccagtgtc 420
 cgttcccga tccccctggc tggcgggaca ttgaaccaga gccccctgag tcagaaccac 480
 ttaccaagct agaggagctg cccgaagacg atgccaacct gctgcctgag aaagcggccc 540
 gtgccttcgt gcctattgac ctacagtga ttgagcggca gccccaagaa gaccttatcg 600
 tgcgctgtga ggcaggcgag ggcgagtgcc gaaccttcat gcccccccg gtcaccacc 660
 ccgacccac tgagcgcaag tgggctgagg cagtggtag gccgcctggc tgttcctgtg 720
 ggggctgcgg gagctgtgga gaccgtgagt ggctaagggc tgtggcctcc gtgggagccg 780
 cactcattct ctcccttgc ctactatacg gggcatatgc cttcctgccg tttgatgtcc 840
 cacggctgcc caccatgagt tccgcctga tctacacact gcgctgcggg gtctttgcca 900
 ccttcccat tgtgctggg atcctggtgt acgggctgag cctgttatgc ttttctgccc 960
 ttcggccctt tggggagcca cggcgggagg tggagatcca ccggcgatat gtggcccagt 1020

B0213wo seq list.ST25.txt

cgggccagct ctttattctc tacttcttca acctggccgt gctttccact tacctgcccc 1080
 aggataccct caaactgctc cctctgctca ctggctctct tgccgtctcc cggtgatct 1140
 actggctgac ctttgccgtg ggccgctcct tccgaggctt cggctacggc ctgacgtttc 1200
 tgccactgct gtcgatgctg atgtggaacc tctactacat gtctgtggtg gagccggagc 1260
 gcatgctcac tgccaccgag agccgcctgg actaccgga ccacgcccgc tcggcctccg 1320
 actacaggcc ccgcccctgg ggctgagcct ctccgccctc gccctcggag tagggggtag 1380
 cggcttggtt ctgacacatc tttgaacctt gtggccaggc ctggacttcg cccccaggcc 1440
 taggaccgag gtgggtggaa ccctgctact gccccaacag ggactccaat caatcgagat 1500
 tctccccttg ccggagctgc ctttcacctt tggggcccga gacagtcata agggatggac 1560
 ttagttttct tgcaaggaaa aagggtggaca gccgtgtttc ttaaggatgc tgagggcatg 1620
 gggccaggac caggggagag gcacagctcc ttcctgagca gcctctcacc actgccacaa 1680
 ggctccctaa tgctgtgtct tgctccactc cccggcttcc cgtgaggcag gaggcagagc 1740
 cacagccaag gccctgacca cttctgtgcc agttgtctaa gcagagcgcc tcagggacgc 1800
 tggaaatgcc ttaaggatag aggtgggca tcacatcaaa tgggactgtg gtgtttggtg 1860
 aaaaccttcc tgaggatctg gattcaggac cctccatgac tggcctattt actgtttaca 1920
 gctggccagt gcagagctgc tgctctttta ctttttagg cccctgtaac ttcccacctt 1980
 taaactgccc agaaggcatg cctctccac aggaagaggg gagcagacag ggaaatctgc 2040
 ctaccaagag ggggtgtgtg gtctttgtgc ccacacgtgg tggctgggga gtgcctggat 2100
 ggtgcggtgg ttgatgttaa ctagtgtgtg gtgtgtgtgt gtgtgtgtgt gtgtgtaaca 2160
 ataaattact accagtcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220
 aaaaaa 2226

<210> 85

<211> 328

<212> DNA

<213> Homo sapiens

<400> 85
 tgaggccgcc tggctgttcc tgtgggggct gcgggagctg tggagaccgt gagtggctaa 60
 gggctgtggc ctccgtggga gccgactca ttctcttccc ttgcctacta tacggggcat 120
 atgccttcct gccgtttgat gtcccacggc tgcccacat gagttcccgc ctgatctaca 180
 cactgcgctg cgggggtctt gccaccttcc ccattgtgct ggggatcctg gtgtacgggc 240
 tgagcctgtt atgcttttct gcccttcggc cttttgggga gccacggcgg gaggtggaga 300
 tccaccggcg atatgtggcc cagtcggt 328

<210> 86

B0213WO seq list.ST25.txt

<211> 1469

<212> DNA

<213> Homo sapiens

<400> 86
 cagagaacgg acagtgtacc cactgaggcg gccaaagctt aactggatca gggcaggatg 60
 acatgacctt gtggtagatc ccagaactga ggccccagga tgacagaaca ggagaccctg 120
 gccctactgg aagtgaagag gtctgattcc ccagagaaga gctcacccca ggccttggtt 180
 cccaatggcc ggcagccaga aggggaaggt gggggcgaat ccccgaggc tgagtccctc 240
 agagtgggtt cttcagctgg atctcccaca gccatagagg gggctgagga tggcttagac 300
 agcacagtaa gtgaggctgc caccttgccc tgggggactg gccctcagcc cagtgtccg 360
 ttcccgatc cccctggctg gcgggacatt gaaccagagc cccctgagtc agaaccactt 420
 accaagctag aggagctgcc cgaagacgat gccaacctgc tgcctgagaa agcggcccg 480
 gccttcgtgc ctattgacct acagtgcatt gagcggcagc cccaagaaga ccttatcgtg 540
 cgctgtgagg caggcgaggg cgagtgccga accttcacgc cccccgggt caccaccccc 600
 gacccactg agcgcaagtg ggctgaggca gtggtgaggc cgcttggtg ttcctgtggg 660
 ggctgcggga gctgtggaga ccgtgagtgg ctaagggtg tggcctccgt gggagccgca 720
 ctcatctct tcccttgctt actatacggg gcatatgcct tcctgccgtt tgatgtccca 780
 cggctgcccc ccatgagttc ccgctgatc tacacactgc gctgcggggt ctttgccacc 840
 ttcccatctg tgctgggtga gccygtgaga agaaagggg catcgggaag tggacttgag 900
 gagggcaggg cctgcctggt gtggggagca ggaggatttc ccttcacttg acctgggccc 960
 ctcagggtct cccacccctt gccagtctgc atgccatct cctcccagga ccacctccac 1020
 cccactgtgt agagcccatg cactgcccac agtgaatctg ccccagctt actgcctctt 1080
 gtgcccttcc cctgcctttt ctgaccctac ccygtttccc aactccacc aggatcctg 1140
 gtgtacgggc tgagcctgtt atgcttttct gcccttcggc cctttgggga gccacggcgg 1200
 gaggtggaga tccaccggcg atatgtggcc cagtccgtcc agctctttat tctctacttc 1260
 ttcaacctgg ccgtgctttc cacttacctg cccagagata ccctcaaact gctccctctg 1320
 ctactgggtc tctttgccgt ctcccggctg atctactggc tgacctttgc cgtgggccgc 1380
 tccttccgag gcttcggcta cggcctgacg tttctgccac tgctgtcgat gctgatgtgg 1440
 aacctctact acatgttcgt ggtggagcc 1469

<210> 87

<211> 180

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 87
 tcagagaacg gacagtgtac ccactgaggc ggccaaagct taactggatc agggcaggct 60
 gatctactgg ctgacctttg ccgtgggccg ctccttccga ggcttcggct acggcctgac 120
 gtttctgcc a ctgctgtcga tgctgatgtg gaacctctac tacatgttcg tggaggagcc 180

<210> 88

<211> 477

<212> DNA

<213> Homo sapiens

<400> 88
 cagagaacgg acagtgtacc cactgaggcg gccaaagctt aactggatca gggcaggatg 60
 acatgacctt gtggtagatc ccagaactga ggccccagga tgacagaaca ggagaccctg 120
 gccctactgg aagtgaagag ggatcctggg gtacgggctg agcctgttat gcttttctgc 180
 ccttcggccc tttggggagc cacggcgagg ggtggagatc caccggcgat atgtggccca 240
 gtcggtccaa ctctttattc tctacttctt caacctggcc gtgctttcca cttacctgcc 300
 ccaggatacc ctcaaactgc tccctctgct cactgggtctc ttgcccgtct cccggctgat 360
 ctactggctg acctttgccg tgggcccgtc cttccgaggc ttcggctacg gcctgacgtt 420
 tctgccactg ctgtcgtatg tgatgtggaa cctctactac atgttcgtgg tggagcc 477

<210> 89

<211> 1013

<212> DNA

<213> Homo sapiens

<400> 89
 cagagaacgg acagtgtacc cactgaggcg gccaaagctt aactggatca gggcaggatg 60
 acatgacctt gtggtagatc ccagaactga ggccccagga tgacagaaca ggagaccctg 120
 gccctactgg aagtgaagag gtctgattcc ccagagaaga gctcacccca ggccttggtt 180
 cccaatggcc ggagccagga aggggaaggt gggggcgaat ccccgaggagc tgagtcctc 240
 agagtggggt cttcagctgg atctcccaca gccatagagg gggctgagga tggcttagac 300
 agcacagtaa gtgaggctgc cgccttgccc tgggggactg gccctcagcc cagtgtccg 360
 ttcccggatc cccctggctg gcgggacatt gaaccagagc cccctgagtc agaaccactt 420
 accaagctag aggagctgcc cgaagacgat gccaacctgc tgcctgagaa agcggcccgt 480
 gccttcgtgc ctattgacct acagtgcatt gagcggcagc cccaagaaga ccttatcatg 540

B0213WO seq list.ST25.txt

```

cgctgtgagg cagggcaggg cgagtgccga accttcatgc cccccgggt caccacccc 600
gacccactg agcgcaagtg ggctgaggca gtggtgaggc cgcctggctg ttcctgtggg 660
ggctgcggga gctgtggaga cggatctggt gtacggctga cctgttatgc tttctgcctt 720
cgccctttg gggagccacg gcgggagggt gagatccacc ggcgatatgt ggcccagtcg 780
gtccagctct ttattctcta cttcttcaac ctggcgtgc ttccactta cctgccccag 840
gataccctca aactgctccc tctgctcact ggtctctttg ccgtctcccg gctgatctac 900
tggtgacct ttgccgtggg ccgtccttc cgaggcttcg gctacggcct gacgtttctg 960
ccactgctgt cgatgctgat gtggaacctc tactacatgt tcgtggtgga gcc 1013

```

<210> 90

<211> 737

<212> DNA

<213> Homo sapiens

<400> 90

```

ccccaggatg acagaacagg agaccctggc cctactggaa gtgaagagtg cattgagcgg 60
cagccccaag aagaccttat cgtgcgtgtg gaggcaggcg agggcgagtg ccgaaccttc 120
atgccccccc gggtcaccca ccccgacccc actgagcgca agtgggctga ggcagtgggtg 180
aggccgcctg gctgttcctg tgggggctgc gggagctgtg gagaccgtga gtggctaagg 240
gctgtggcct ccgtgggagc cgcactcatt ctcttccctt gcctactata cggggcatat 300
gccttcctgc cgtttgatgt cccacggctg cccaccatga gttccgcct gatctacaca 360
ctgcgctgcg gggctcttgc caccttcccc attgtgctgg ggatcctggt gtacgggctg 420
agcctgttat gcttttctgc ctttcggccc ttggggagc cacggcggga ggtggagatc 480
caccggcgat atgtggccca gtcggtccag ctctttattc tctacttctt caacctggcc 540
gtgctttcca cttacctgcc ccaggatacc ctcaactgc tccctctgct cactggcttc 600
tttgccgtct cccggctgat ctactggctg acctttgccg tgggcccgtc cttccgaggc 660
ttcggctacg gcctgacgtt tctgccactg ctgtcgatgc tgatgtggaa cctctactac 720
atgttcgtgg tggagcc 737

```

<210> 91

<211> 2469

<212> DNA

<213> Homo sapiens

<400> 91

```

agcgttcctc gggccctcgg cgccacaagc tgtccgggca cgcagcccct agcggcgcgt 60

```

B0213WO seq list.ST25.txt

cgctgccaag ccggcctccg cgcgccctccc tccttccttc tcccctggct gttcgcgatc	120
cagcttgggt aggcggggaa gcagctggag tgcgaccgcc acggcagcca cctgcaacc	180
gccagtcgga ggtgcagtcc gtaggccctg gccccgggt gggcccttg ggagtcggcg	240
ccgctcccga ggagctgcaa ggctcgcccc tgcccgccgt ggagggcgcg gggggcgcg	300
aggatattct tggatgattt ggaagtgtcc gtatcatgga atcaatctct atgatgggaa	360
gccctaagag ccttagtgaa acttggttac ctaatggcat aaatggtatc aaagatgcaa	420
ggaaggtcac ttaggtgtg attggaagtg gagattttgc caaatccttg accattcgac	480
ttattagatg cggctatcat gtggtcatag gaagtagaaa tcctaagttt gcttctgaat	540
tttttcctca tgtggtagat gtcactcatc atgaagtgc tctcacaaaa acaaatataa	600
tatttggtgc tatacacaga gaacattata cctccctgtg ggacctgaga catctgcttg	660
tgggtaaaat cctgattgat gtgagcaata acatgaggat aaaccagtac ccagaatcca	720
atgctgaata tttggcttca ttattcccag attctttgat tgtcaaagga tttaatgttg	780
tctcagcttg ggcacttcag ttaggacctt aggatgccag ccggcagggt tatatatgca	840
gcaacaatat tcaagcgca caacagggtt ttgaacttgc ccgccagttg aatttcattc	900
ccattgactt gggatcctta tcatcagcca gagagattga aaatttacct ctacgactct	960
ttactctctg gagaggcca gtggtggtag ctatgagctt ggccacattt ttttccttt	1020
attcctttgt cagagatgtg attcatccat atgctagaaa ccaacagagt gacttttaca	1080
aaattcctat agagattgtg aataaaacct tacctatagt tgccattact ttgctctccc	1140
tagtatacct tgcaggctct ctggcagctg cttatcaact ttattacggc accaagtata	1200
ggagatttcc accttggttg gaaacctggt tacagtgtag aaaacagctt ggattactaa	1260
gttttttctt cgctatggtc catgttgctt acagcctctg cttaccgatg agaaggctag	1320
agagatattt gtttctcaac atggcttctc agcagggtca tgcaaatatt gaaaactctt	1380
ggaatgagga agaagtttg agaattgaaa tgtatatctc ctttggcata atgagccttg	1440
gcttactttc cctcctggca gtcacttcta tcccttcagt gagcaatgct ttaaactgga	1500
gagaattcag ttttattcag tctacacttg gatatgtcgc tctgctcata agtactttcc	1560
atgttttaat ttatggatgg aaacgagctt ttgaggaaga gtactacaga ttttatacac	1620
caccaaactt tgttcttgct cttgttttgc cctcaattgt aattctggat cttttgcagc	1680
tttgagata cccagactga gctggaactg gaatttgtct tcctattgac tctacttctt	1740
taaaagcggc tgcccattac attcctcagc tgccttgca gttaggtgta catgtgactg	1800
agtgttggcc agtgagatga agtctcctca aaggaaggca gcatgtgtcc tttttcatcc	1860
cttcatcttg ctgctgggat tgtggatata acaggagccc tggcagctgt ctccagagga	1920
tcaaagccac acccaaagag taaggcagat tagagaccag aaagaccttg actacttccc	1980
tacttccact gctttttcct gcatttaagc cattgtaaat ctgggtgtgt tacatgaagt	2040
gaaaattaat tctttctgcc cttcagttct ttatcctgat accatttaac actgtctgaa	2100

B0213WO seq list.ST25.txt

ttaactagac tgcaataatt ctttcttttg aaagctttta aaggataatg tgcaattcac	2160
attaaaattg attttccatt gtcaattagt tatactcatt ttcctgcctt gatctttcat	2220
tagatatttt gtatctgctt ggaatatatt atcttctttt taactgtgta attggtaatt	2280
actaaaactc tgtaatctcc aaaatattgc tatcaaatta cacaccatgt tttctatcat	2340
tctcatagat ctgccttata aacattttaa taaaaagtac tatttaatga ttttaacttct	2400
gttttgaaat gttgtataca cgtggatttt tttctcatta aataataatt ctagtaaaaa	2460
aaaaaaaaag	2469

<210> 92

<211> 2562

<212> DNA

<213> Homo sapiens

<400> 92	
agcgttcctc gggccctcgg cgccacaagc tgtccgggca cgcagcccct agcggcgcgt	60
cgctgccaa gggccctcgg cgccctccc tccttccttc tcccctggct gttcgcgatc	120
cagcttgggt aggcggggaa gcagctggag tgcgaccgcc acggcagcca ccctgcaacc	180
gccagtcgga ggtgcagtcc gtaggccctg gccccgggt gggcccttgg ggagtcggcg	240
ccgctccga ggagctgcaa ggctcgcccc tgcccggcgt ggagggcgcg gggggcgcgg	300
aggatattct tggtagtctt ggaagtgtcc gtatcatgga atcaatctct atgatgggaa	360
gccctaagag ccttagtgaa acttgtttac ctaatggcat aaatggatc aaagatgcaa	420
ggaaggtcac tgtaggtgtg attggaagtg gagattttgc caaatccttg accattcgac	480
ttattagatg cggctatcat gtggtcatag gaagtagaaa tcctaagttt gcttctgaat	540
tttttctca tgtggtagat gtcactcatc atgaagatgc tctcacaaaa acaaatataa	600
tatttggtgc tatacacaga gaacattata cctccctgtg ggacctgaga catctgcttg	660
tgggtaaaat cctgattgat gtgagcaata acatgaggat aaaccagtac ccagaatcca	720
atgctgaata ttggcttca ttattcccag attctttgat tgtcaaagga tttaatgttg	780
tctcagcttg ggcacttcag ttaggaccta aggatgccag ccggcagggt tatatatgca	840
gcaacaatat tcaagcgcga caacaggta ttgaacttgc ccgccagttg aatttcattc	900
ccattgactt gggatcctta tcatcagcca gagagattga aaatttacc ctacgactct	960
ttactctctg gagagggccg gtggtggtag ctatgagctt ggccacattt ttttctctt	1020
attcctttgt cagagatgtg attcatccat atgctagaaa ccaacagagt gacttttaca	1080
aaattcctat agagattgtg aataaaacct tacctatagt tgccattact ttgctctccc	1140
tagtatacct tgcaggtcct ctggcagctg cttatcaact ttattacggc accaagtata	1200
ggagatttcc accttggttg gaaacctggt tacagtgtag aaaacagctt ggattactaa	1260

B0213WO seq list.ST25.txt

gttttttctt cgctatgggc catgttgcct acagcctctg cttaccgatg agaagggtcag	1320
agagatatatt gtttctcaac atggcttatc agcaggttca tgcaaatatt gaaaactctt	1380
ggaatgagga agaagtttgg agaattgaaa tgtatatctc ctttggcata atgagccttg	1440
gcttactttc cctcctggca gtcacttcta tcccttcagt gagcaatgct ttaaactgga	1500
gagaattcag tttattcag tctacacttg gatatgtcgc tctgctcata agtactttcc	1560
atgttttaat ttatggatgg aaacgagctt ttgaggaaga gtactacaga tttatacac	1620
caccaaactt tgttcttgct cttgttttgc cctcaattgt aattctggta gagacggagt	1680
ttcaccgtgt tagccaggat ggtctcgatc tcctgacctc gtgatccgcc cgccttgccc	1740
tccaaagtgc tgggattaca gatcttttgc agctttgcag ataccagac tgagctggaa	1800
ctggaatttg tcttctatt gactctactt ctttaaaagc ggctgcccac tacattcctc	1860
agctgtcctt gcagttaggt gtacatgtga ctgagtgttg gccagtgaga tgaagtctcc	1920
tcaaaggaag gcagcatgtg tcctttttca tcccttcacg ttgctgctgg gattgtggat	1980
ataacaggag ccctggcagc tgtctccaga ggatcaaagc cacacccaaa gagtaaggca	2040
gattagagac cagaaagacc ttgactactt ccctacttcc actgcttttt cctgcattta	2100
agccattgta aatctgggtg tgttacatga agtgaaaatt aattctttct gcccttcagt	2160
tccttatcct gataccattt aacactgtct gaattaacta gactgcaata attctttctt	2220
ttgaaagctt ttaaaggata atgtgcaatt cacattaata ttgattttcc attgtcaatt	2280
agttatactc attttctgc cttgatcttt cattagatat tttgtatctg cttggaatat	2340
attatcttct ttttaactgt gtaattggta attactaaa ctctgtaac tccaaaatat	2400
tgctatcaaa ttacacacca tgttttctat cattctcata gatctgcctt ataaacattt	2460
aaataaaaag tactatttaa tgatttaact tctgttttga aatgttgtat acacgtggat	2520
ttttttctca ttaaataata attctagtaa aaaaaaaaa ag	2562

<210> 93

<211> 2321

<212> DNA

<213> Homo sapiens

<400> 93	
agcgttcctc gggccctcgg cgccacaagc tgtccgggca cgcagcccct agcggcgct	60
cgctgccaag ccggcctccg cgcgcctccc tccttccttc tcccctggct gttcgcgatc	120
cagcttgggt aggcggggaa gcagctggag tgcgaccgcc acggcagcca ccctgcaacc	180
gccagtcgga ggtgcagtcc gtaggccctg gccccgggt gggcccttgg ggagtcggcg	240
ccgctcccga ggagctgcaa ggctcgcccc tgccccgct ggagggcgcg gggggcgcg	300
aggatattct tggatgattt ggaagtgtcc gtatcatgga atcaatctct atgatgggaa	360

B0213WO seq list.ST25.txt

```

gccctaagag ccttagtgaa acttggtttac ctaatggcat aaatggtatc aaagatgcaa 420
ggaaggtcac ttagggtgtg attggaagtg gagatTTTgc caaatccttg accattcgac 480
ttattagatg cggctatcat gtggtcatag gaagtagaaa tcctaagttt gcttctgaat 540
TTTTcctca tgtggtagat gtcactcatc atgaagatgc tctcacaaaa acaaatataa 600
tatttgttgc tatacacaga gaacattata cctccctgtg ggacctgaga catctgcttg 660
tgggtaaaat cctgattgat gtgagcaata acatgaggat aaaccagtac ccagaatcca 720
atgctgaata tttggcttca ttattcccag attctttgat tgtcaaagga tttaatgttg 780
tctcagcttg ggcacttcag ttaggaccta aggatgccag ccggcagggt tataatatgca 840
gcaacaatat tcaagcgcga caacagggtta ttgaacttgc ccgccagggt aatttcattc 900
ccattgactt gggatcctta tcatcagcca gagagattga aaatttacct ctacgactct 960
ttactctctg gagagggcca gtggtggtag ctatgagctt ggccacattt ttttccttt 1020
attcctttgt cagagatgtg attcatccat atgctagaaa ccaacagagt gacttttaca 1080
aaattcctat agagattgtg aataaaacct tacctatagt tgccattact ttgctctccc 1140
tagtatacct tgcagggtct ctggcagctg cttatcaact ttattacggc accaagtata 1200
ggagatttcc accttggttg gaaacctgggt tacagtgtag aaaacagctt ggattactaa 1260
gttttttctt cgctatggtc catgttgctt acagcctctg cttaccgatg agaaggtcag 1320
agagatattt gtttctcaac atggcttatc agcagggttca tgcaaattt gaaaactctt 1380
ggaatgagga agaagtttg agaattgaaa tgtatatctc ctttggcata atgagccttg 1440
gcttactttt cctcctggca gtcacttcta tcccttcagt gagcaatgct ttaaactgga 1500
gagaattcag ttttattcag atcttttgca gctttgcaga taccagact gagctggaac 1560
tggaatttgt cttcctattg actctacttc tttaaaagcg gctgcccatt acattcctca 1620
gctgtccttg cagttagggt tacatgtgac tgagtgttg ccagtgagat gaagtctcct 1680
caaaggaagg cagcatgtgt ctttttcat cccttcact tgcgtctggg attgtggata 1740
taacaggagc cctggcagct gtctccagag gatcaaagcc acacccaaag agtaaggcag 1800
attagagacc agaaagacct tgactacttc cctacttcca ctgctttttc ctgcatttaa 1860
gccattgtaa atctgggtgt gttacatgaa gtgaaaatta attctttctg cccttcagtt 1920
ctttatcctg ataccattta acactgtctg aattaactag actgcaataa ttctttcttt 1980
tgaaagcttt taaaggataa tgtgcaattc acattaaaat tgattttcca ttgtcaatta 2040
gttatactca ttttcctgcc ttgatctttc attagatatt ttgtatctgc ttggaatata 2100
ttatcttctt tttaaactgt taattggtta ttactaaaac tctgtaatct ccaaaatatt 2160
gctatcaaat tacacaccat gttttctatc attctcatag atctgcctta taaacattta 2220
aataaaaagt actatttaat gatttaactt ctgttttgaa atgttgtata cacgtggatt 2280
tttttctcat taaataataa ttctagtata aaaaaaaaaa g 2321

```

B0213WO seq list.ST25.txt

<211> 3226

<212> DNA

<213> Homo sapiens

<400> 94
 cgcgagctaa gcaggaggcg gaggcggagg cggagggcgga ggggcgggga gcgccgcctg 60
 gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa 120
 cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca 180
 tggatacaca ccggaaaacc cctatcccg cagagccact gtggtcccca ctgtctacga 240
 ggtgcatccg gctcagtact acccgctccc cgtgccccag tacgccccga gggctcctgac 300
 gcaggcttcc aaccccgtcg tctgcacgca gcccaaatcc ccatccggga cagtgtgcac 360
 ctcaaagact aagaaagcac tgtgcatcac cttgacctg gggaccttcc tcgtgggagc 420
 tgcgtgggcc gctggcctac tctggaagt catgggcagc aagtgtcca actctgggat 480
 agagtgcgac tcctcaggta cctgcatcaa cccctctaac tgggtgatg gcgtgtcaca 540
 ctgccccggc ggggaggacg agaatcgggtg tgttcgcctc tacggacca acttcacct 600
 tcagatgtac tcattcaga ggaagtcctg gcacctgtg tgccaagacg actggaacga 660
 gaactacggc cgggcggcct gcagggacat gggctataag aataattttt actctagcca 720
 aggaatagt gatgacagcg gatccaccag ctttatgaaa ctgaacaca gtgccggcaa 780
 tgtcgatac tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc 840
 ttacgctgt atagcctgcg gggcaactt gaactcaagc cgccagagca ggatcgtggg 900
 cggtagagc gcgctcccg gggcctggcc ctggcaggtc agcctgcagc tccagaacgt 960
 ccacgtgtgc ggaggctcca tcaccacccc cgagtggatc gtgacagccg cccactgcgt 1020
 ggaaaaacct cttaacaatc catggcattg gacggcattt gcggggattt tgagacaatc 1080
 tttcatgttc tatggagccg gataccaagt agaaaaagt atttctcatc caaattatga 1140
 ctccaagacc aagaacaatg acattgcgct gatgaagctg cagaagcctc tgactttcaa 1200
 cgacctagt aaaccagtgt gtctgcccc cccaggcatg atgctgcagc cagaacagct 1260
 ctgctggatt tccgggtggg gggccaccga ggagaaagg aagacctcag aagtgtgaa 1320
 cgctgccaag gtgcttctca ttgagacaca gagatgcaac agcagatatg tctatgaca 1380
 cctgatcaca ccagccatga tctgtgccg cttcctgcag gggaacgtcg attcttgcca 1440
 gggtagacgt ggagggcctc tggtcacttc gaagaacaat atctggtggc tgatagggga 1500
 tacaagctgg ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat 1560
 ggtattcacg gactggattt atcgacaaat gagggcagac ggctaatacca catggctctc 1620
 gtccttgacg tcgttttaca agaaaacaat ggggctggtt ttgcttcccc gtgcatgatt 1680
 tactcttaga gatgattcag aggtcacttc atttttatta aacagtgaac ttgtctggct 1740

B0213WO seq list.ST25.txt

ttggcactct ctgccattct gtgcaggctg cagtggctcc cctgcccagc ctgctctccc	1800
taacccttg tccgaagg gtgatggccg gctggttgtg ggcactggcg gtcaagtgtg	1860
gaggagaggg gtggaggctg cccattgag atcttcctgc tgagtccttt ccaggggcca	1920
attttgatg agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg	1980
agagacatgg aaaggagac agccagggtg cacctgcagc ggctgccctc tggggccact	2040
tggtagtgtc cccagcctac ctctccaca ggggattttg ctgatgggtt cttagagcct	2100
tagcagccct ggatggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg	2160
tagtcacttg taaggggaac agaaacattt ttgttcttat ggggtgagaa tatagacagt	2220
gcccttggtg cgagggaagc aattgaaaag gaacttgccc tgagcactcc tgggtcaggt	2280
ctccacctgc acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc	2340
cctgaccctg ctcttagcac cctggagagt gcacatgccc ctgggtcctg gcagggcgcc	2400
aagtctggca ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg	2460
gggaaatcaa ggatgctcag ttttaaggtag actgtttcca tgttatgttt ctacacattg	2520
ctacctcagt gtccttgga acttagcttt tgatgtctcc aagtagtcca ctttcattta	2580
actctttgaa actgtatcac ctttgccaag taagagtgggt ggcctatttc agctgctttg	2640
acaaaatgac tggctcctga cttaacgttc tataaatgaa tgtgtgaag caaagtggcc	2700
atggtggcgg cgaagaagag aaagatgtgt tttgttttg actctctgtg gtcccttcca	2760
atgctgtggg tttccaacca ggggaagggt cctttttgca ttgccaagtg ccataaccat	2820
gagcactact ctaccatggt tctgcctcct ggccaagcag gctggtttgc aagaatgaaa	2880
tgaatgattc tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca	2940
ggatccgtct gtgcacatgc ctctgtagag agcagcattc ccagggacct tggaaacagt	3000
tggcactgta aggtgcttgc tcccaagac acatcctaaa aggtgttgta atggtgaaaa	3060
cgtcttcctt ctttattgcc ctttcttatt tatgtgaaca actgtttgtc tttttttgta	3120
tcttttttaa actgtaaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga	3180
tttttttttc aaagcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa	3226

<210> 95

<211> 3106

<212> DNA

<213> Homo sapiens

<400> 95

cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg	60
gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa	120
cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca	180

B0213WO seq list.ST25.txt

tggtataccaa ccggaaaacc cctatcccgc acagcccact gtggtcccca ctgtctacga	240
ggtgcatccg gctcagtact acccgtcccc cgtgcccag tacgcccga gggtcctgac	300
gcaggcttcc aaccccgtcg tctgcacgca gcccaaatcc ccatccggga cagtgtgcac	360
ctcaaagact aagaaagcac tgtgcatcac cttgaccctg gggaccttcc tcgtgggagc	420
tgcgctggcc gctggcctac tctggaagtt cattcgctc tacggacca acttcacct	480
tcagatgtac tcatctcaga ggaagtcctg gcaccctgtg tgccaagacg actggaacga	540
gaactacggg cgggcggcct gcagggacat gggctataag aataattttt actctagcca	600
aggaatagtg gatgacagcg gatccaccag ctttatgaaa ctgaacacaa gtgccggcaa	660
tgtcgatatc tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc	720
tttacgctgt atagcctgcg ggggtcaactt gaactcaagc cgccagagca ggatcgtggg	780
cggtgagagc gcgctcccgg gggcctggcc ctggcaggtc agcctgcacg tccagaacgt	840
ccacgtgtgc ggaggtcca tcatcacccc cgagtggatc gtgacagccg cccactgcgt	900
ggaaaaacct cttacaatc catggcattg gacggcattt gcggggattt tgagacaatc	960
tttcatgttc tatggagccg gataccaagt agaaaaagt atttctcatc caaattatga	1020
ctccaagacc aagaacaatg acattgctg gatgaagctg cagaagcctc tgactttcaa	1080
cgacctagtg aaaccagtgt gtctgcccga cccaggcatg atgctgcagc cagaacagct	1140
ctgctggatt tccgggtggg gggccaccga ggagaaagg aagacctcag aagtgtgaa	1200
cgctgccaa ggtcttctca ttgagacaca gagatgcaac agcagatatg tctatgaca	1260
cctgatcaca ccagccatga tctgtgccg cttcctgcag ggaacgtcg attcttgcca	1320
gggtgacagt ggagggcctc tggtcacttc gaagaacaat atctggtggc tgatagggga	1380
tacaagctgg ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat	1440
ggtattcacg gactggattt atcgacaaat gagggcagac ggctaatacca catggtcttc	1500
gtccttgacg tcgttttaca agaaaacaat ggggctggtt ttgcttcccc gtgcatgatt	1560
tactcttaga gatgattcag aggtcacttc atttttatta aacagtgaac ttgtctggct	1620
ttggcactct ctgccattct gtgcaggctg cagtggctcc cctgcccagc ctgctctccc	1680
taacccttg tccgaagggt gtgatggccg gctggtgtg ggcactggcg gtcaagtgtg	1740
gaggagaggg gtggaggctg cccattgag atcttcctgc tgagtccttt ccaggggcca	1800
attttgatg agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg	1860
agagacatgg aaaggagac agccagggtg cacctgcagc ggctgccctc tggggccact	1920
tggtagtgtc cccagcctac ctctccacaa ggggattttg ctgatgggtt cttagagcct	1980
tagcagccct ggtggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg	2040
tagtcacttg taagggaac agaaacattt ttgttcttat ggggtgagaa tatagacagt	2100
gcccttggtg cgagggaagc aattgaaaag gaacttgccc tgagcactcc tgggtgcagg	2160
ctccacctgc acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc	2220

B0213WO seq list.ST25.txt

```

cctgaccctg ctccctagcac cctggagagt gcacatgccc ctgggtcctg gcagggcgcc 2280
aagtctggca ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg 2340
gggaaatcaa ggatgctcag ttttaaggtag actgtttcca tggtatgttt ctacacattg 2400
ctacctcagt gtccttgga acttagcttt tgatgtctcc aagtagtcca ccttcattta 2460
actctttgaa actgtatcac ctttgccaag taagagtggg ggcctatttc agctgctttg 2520
acaaaatgac tggctcctga cttaacgttc tataaatgaa tgtgctgaag caaagtggcc 2580
atggtggcgg cgaagaagag aaagatgtgt ttgttttgg actctctgtg gtcccttcca 2640
atgctgtggg ttccaacca ggggaagggt cccttttgca ttgccaagt ccataaccat 2700
gagcactact ctaccatggg tctgcctcct ggccaagcag gctggtttgc aagaatgaaa 2760
tgaatgattc tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca 2820
ggatccgtct gtgcacatgc ctctgtagag agcagcattc ccaggacct tggaaacagt 2880
tggcactgta aggtgcttgc tccccaagac acatcctaaa aggtgttgta atggtgaaaa 2940
cgtcttcctt ctttattgcc ctttcttatt tatgtgaaca actgtttgtc tttttttgta 3000
tcttttttaa actgtaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga 3060
tttttttttc aaagcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 3106

```

<210> 96

<211> 3003

<212> DNA

<213> Homo sapiens

```

<400> 96
cgcgagctaa gcaggaggcg gagggcgagg cggaggggcga ggggcgggga gcgccgcctg 60
gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa 120
cagcaagatg gctttgaact caagactaag aaagcactgt gcatcacctt gaccctgggg 180
accttcctcg tgggagctgc gctggccgct ggcctactct ggaagtcat gggcagcaag 240
tgctccaact ctgggataga gtgcgactcc tcaggtagct gcatcaaccc ctctaactgg 300
tgtgatggcg tgtcactctg ccccgccggg gaggacgaga atcgggtgtg tcgcctctac 360
ggaccaaact tcaccttca gatgtactca tctcagagga agtcctggca ccctgtgtgc 420
caagacgact ggaacgagaa ctacgggcgg gcggcctgca gggacatggg ctataagaat 480
aatTTTTtact ctagccaagg aatagtggat gacagcggat ccaccagctt tatgaaactg 540
aacacaagtg ccggcaatgt cgatatctat aaaaaactgt accacagtga tgctgtttct 600
tcaaaagcag tggtttcttt acgctgtata gcctgcgggg tcaacttgaa ctcaagccgc 660
cagagcagga tcgtgggcgg tgagagcgcg ctcccggggg cctggccctg gcaggtcagc 720
ctgcacgtcc agaacgtcca cgtgtgcgga ggctccatca tcaccccgga gtggatcgtg 780

```

B0213WO seq list.ST25.txt

acagccgccc actgcgtgga aaaacctctt aacaatccat ggcattggac ggcatttgcg	840
gggattttga gacaatcttt catgttctat ggagccggat accaagtaga aaaagtgatt	900
tctcatccaa attatgactc caagaccaag aacaatgaca ttgcgctgat gaagctgcag	960
aagcctctga ctttcaacga cctagtgaac ccagtgtgtc tgcccaaccc aggcatgatg	1020
ctgcagccag aacagctctg ctggatttcc ggggtggggg ccaccgagga gaaaggggaag	1080
acctcagaag tgctgaacgc tgccaagggtg cttctcattg agacacagag atgcaacagc	1140
agatatgtct atgacaacct gatcacacca gccatgatct gtgccggcctt cctgcagggg	1200
aacgtcgatt cttgccaggg tgacagtggg gggcctctgg tcacttcgaa gaacaatatc	1260
tggtggctga taggggatac aagctggggg tctggctgtg ccaaagctta cagaccagga	1320
gtgtacggga atgtgatggg attcacggac tggatttatc gacaaatgag ggcagacggc	1380
taatccacat ggtcttcgct cttgacgtcg ttttacaaga aaacaatggg gctggttttg	1440
cttccccgtg catgattttac tcttagagat gattcagagg tcacttcatt tttattaaac	1500
agtgaacttg tctggctttg gcactctctg ccattctgtg caggctgcag tggctcccct	1560
gcccagcctg ctctccctaa ccccttgctc gcaaggggtg atggccggct ggttgtgggc	1620
actggcggtc aagtgtggag gagaggggtg gaggctgccc cattgagatc ttcctgctga	1680
gtcctttcca ggggccaatt ttggatgagc atggagctgt cacctctcag ctgctggatg	1740
acttgagatg aaaaaggaga gacatggaaa gggagacagc cagggtggac ctgcagcggc	1800
tgccctctgg ggccacttgg tagtgtcccc agcctacctc tccacaaggg gattttgctg	1860
atgggttctt agagccttag cagccctgga tgggtggccag aaataaaggg accagccctt	1920
catgggtggg gacgtggtag tcacttgtaa ggggaacaga aacatttttg ttcttatggg	1980
gtgagaatat agacagtgcc cttggtgcca ggggaagcaat tgaaaaggaa cttgccctga	2040
gcactcctgg tgcaggtctc cacctgcaca ttgggtgggg ctctctggag ggagactcag	2100
ccttcctcct catcctccct gaccctgctc ctgacacctt ggagagtga catgcccctt	2160
ggtcctggca gggcgccaag tctggcacca tgttggcctc ttcaggcctg ctagtactg	2220
gaaattgagg tccatggggg aaatcaagga tgctcagttt aaggtacact gtttccatgt	2280
tatgtttcta cacattgcta cctcagtgtc cctggaaact tagcttttga tgtctccaag	2340
tagtccacct tcatttaact ctttgaact gtatcacctt tgccaagtaa gagtgggtggc	2400
ctatttcagc tgctttgaca aaatgactgg ctctgactt aacgttctat aaatgaatgt	2460
gctgaagcaa agtggccatg gtggcggcga agaagagaaa gatgtgtttt gttttggact	2520
ctctgtggtc cttccaatg ctgtgggttt ccaaccaggg gaagggtccc ttttgattg	2580
ccaagtcca taaccatgag cactactcta ccatggttct gcctcctggc caagcaggct	2640
ggtttgcaag aatgaaatga atgattctac agctaggact taaccttgaa atggaaagtc	2700
ttgcaatccc atttgagga tccgtctgtg cacatgcctc tgtagagagc agcattccca	2760
gggaccttgg aaacagttgg cactgtaagg tgcttgctcc ccaagacaca tcctaaaagg	2820

B0213WO seq list.ST25.txt

tggtgtaatg gtgaaaacgt cttccttctt tattgcccct tcttatttat gtgaacaact	2880
gtttgtcttt ttttgtatct tttttaaact gtaaagttca attgtgaaaa tgaatatcat	2940
gcaaataaat tatgcgattt ttttttcaaa gcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3000
aaa	3003

<210> 97

<211> 3102

<212> DNA

<213> Homo sapiens

<400> 97	
cgcgagctaa gcaggaggcg gaggcggagg cggaggggcga ggggcgggga gcgccgcctg	60
gagcgcgga ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa	120
cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca	180
tggataccaa ccggaaaacc cctatcccgc acagcccact gtggtcccca ctgtctacga	240
gagactaaga aagcactgtg catcaccttg accctgggga ccttcctcgt gggagctgcg	300
ctggccgctg gcctactctg gaagttcatg ggcagcaagt gctccaactc tgggatagag	360
tgcgactcct caggtagctg catcaacccc tctaactggt gtgatggcgt gtcacactgc	420
cccggcgggg aggacgagaa tcggtgtgtt cgctctacg gaccaaactt catccttcag	480
atgtactcat ctacagaggaa gtcctggcac cctgtgtgcc aagacgactg gaacgagaac	540
tacgggcggg cggcctgcag ggacatgggc tataagaata atttttactc tagccaagga	600
atagtggatg acagcggatc caccagcttt atgaaactga acacaagtgc cggcaatgtc	660
gatatttata aaaaactgta ccacagtgat gcctgttctt caaaagcagt ggtttcttta	720
cgctgtatag cctgccccgt caacttgaac tcaagccgcc agagcaggat cgtgggcggt	780
gagagcgcg tcccgggggc ctggccctgg caggtcagcc tgcacgtcca gaacgtccac	840
gtgtgcggag gctccatcat ccccccgag tggatcgtga cagccgcca ctgcgtggaa	900
aaacctctta acaatccatg gcattggacg gcatttgcgg ggattttgag acaatctttc	960
atgttctatg gagccggata ccaagtagaa aaagtgattt ctcatccaaa ttatgactcc	1020
aagaccaaga acaatgacat tgcgctgatg aagctgcaga agcctctgac tttcaacgac	1080
ctagtgaac cagtgtgtct gcccaacca ggcatgatgc tgcagccaga acagctctgc	1140
tggatttccg ggtggggggc caccgaggag aaagggaaga cctcagaagt gctgaacgct	1200
gccaagtgct ttctcattga gacacagaga tgcaacagca gatatgtcta tgacaacctg	1260
atcacaccag ccatgatctg tgccggcttc ctgcagggga acgtcgattc ttgccagggt	1320
gacagtggag ggcctctggt cacttcgaag aacaatatct ggtggctgat aggggataca	1380
agctgggggt ctggctgtgc caaagcttac agaccaggag tgtacgggaa tgtgatggta	1440

B0213WO seq list.ST25.txt

```

ttcacggact ggatttatcg acaaatgagg gcagacggct aatccacatg gtcttcgtcc 1500
ttgacgtcgt tttaacaagaa aacaatgggg ctggttttgc ttccccgtgc atgatttact 1560
cttagagatg attcagaggt cacttcattt ttattaaaca gtgaacttgt ctggctttgg 1620
cactctctgc cattctgtgc aggtcgcagt ggctcccctg cccagcctgc tctccctaac 1680
cccttgctcg caaggggtga tggccggctg gttgtgggca ctggcgggtca agtgtggagg 1740
agaggggtgg aggtgcctcc attgagatct tcctgtctgag tcctttccag gggccaattt 1800
tggatgagca tggagctgtc acctctcagc tgctggatga cttgagatga aaaaggagag 1860
acatggaaag ggagacagcc aggtggcacc tgcagcggct gccctctggg gccacttggt 1920
agtggtccca gcctacctct ccacaagggg attttctga tgggttctta gaggccttagc 1980
agccctggat ggtggccaga aataaaggga ccagcccttc atgggtgggtg acgtggtagt 2040
cacttgtaag gggaacagaa acatttttgt tcttatgggg tgagaatata gacagtcccc 2100
ttggtgcgag ggaagcaatt gaaaaggaac ttgccctgag cactcctggt gcaggtctcc 2160
acctgcacat tgggtggggc tcctgggagg gagactcagc ctctctctc atcctccctg 2220
accctgctcc tagcacctg gagagtgcac atgcccttg gtcctggcag ggcgccaagt 2280
ctggcaccat gttggcctct tcaggcctgc tagtcaactg aaattgaggt ccatggggga 2340
aatcaaggat gctcagttta aggtacactg tttccatgtt atgtttctac acattgctac 2400
ctcagtgtct ctggaaactt agcttttgat gtctccaagt agtccacctt catttaactc 2460
tttgaaactg tatcaccttt gccaaagtaag agtggtggcc tatttcagct gctttgacaa 2520
aatgactggc tcctgactta acgttctata aatgaatgtg ctgaagcaaa gtgcccattg 2580
tggcggcgaa gaagagaaa atgtgttttg ttttgactc tctgtggtcc cttccaatgc 2640
tgtgggtttc caaccagggg aagggtccct ttgtcattgc caagtccat aaccatgagc 2700
actactctac catggttctg cctcctggcc aagcaggctg gtttgcaaga atgaaatgaa 2760
tgattctaca gctaggactt aaccttgaaa tggaaagtct tgcaatccca ttgacaggat 2820
ccgtctgtgc acatgcctct gtagagagca gcattcccag ggaccttga aacagttggc 2880
actgtaagggt gcttgctccc caagacacat cctaaaagggt gttgtaatgg tgaaaacgtc 2940
ttccttcttt attgccccct cttatttatg tgaacaactg tttgtctttt ttgtatctt 3000
ttttaaactg taaagttcaa ttgtgaaaat gaatatcatg caaataaatt atgcgatttt 3060
tttttcaaag caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 3102

```

<210> 98

<211> 2916

<212> DNA

<213> Homo sapiens

<400> 98

B0213WO seq list.ST25.txt

cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg	60
gagcgcgga ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa	120
cagcaagatg gctttgaact catgggcagc aagtgtcca actctgggat agagtgcgac	180
tcctcaggta cctgcatcaa cccctctaac tgggtgatg gcgtgtcaca ctgccccggc	240
ggggaggacg agaatcgggtg tgttcgcctc tacggaccaa acttcaccc tcatgtgtac	300
tcattctcaga ggaagtccctg gcaccctgtg tgccaagacg actggaacga gaactacggg	360
cgggcggcct gcagggacat gggctataag aataattttt actctagcca aggaatagtg	420
gatgacagcg gatccaccag ctttatgaaa ctgaacacaa gtgccggcaa tgtcgatatac	480
tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc tttacgctgt	540
atagcctgcg gggcctaactt gaactcaagc cgccagagca ggatcgtggg cgggtgagagc	600
gcgctccccg gggcctggcc ctggcaggtc agcctgcacg tccagaacgt ccacgtgtgc	660
ggaggctcca tcatcacccc cgagtggatc gtgacagccg cccactgcgt ggaaaaacct	720
cttaacaatc catggcattg gacggcattt gcggggattt tgagacaatc tttcatgttc	780
tatggagccg gataccaagt agaaaaagtg atttctcatc caaattatga ctccaagacc	840
aagaacaatg acattgcgct gatgaagctg cagaagcctc tgactttcaa cgacctagtg	900
aaaccagtgt gtctgccccaa cccaggcatg atgctgcagc cagaacagct ctgctggatt	960
tccgggtggg gggccaccga ggagaaaggg aagacctcag aagtgtgaa cgctgccaag	1020
gtgcttctca ttgagacaca gagatgcaac agcagatatg tctatgacaa cctgatcaca	1080
ccagccatga tctgtgccg cttcctgcag gggaacgtc attcttgcca gggtgacagt	1140
ggagggcctc tggctacttc gaagaacaat atctgtggc tgatagggga tacaagctgg	1200
ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat ggtattcacg	1260
gactggattt atcgacaaat gagggcagac ggctaatacca catggtcttc gtccttgacg	1320
tcgttttaca agaaaacaat ggggctgggt ttgcttcccc gtgcatgatt tactcttaga	1380
gatgattcag aggtcacttc atttttatta aacagtgaac ttgtctggct ttggcactct	1440
ctgccattct gtgcaggctg cagtggctcc cctgccagc ctgctctccc taaccccttg	1500
tccgcaaggg gtgatggccg gctggttgtg ggcactggcg gtcaagtgtg gaggagaggg	1560
gtggaggctg ccccatagag atcttcctgc tgagtccttt ccaggggcca attttggatg	1620
agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg agagacatgg	1680
aaagggagac agccagggtg cacctgcagc ggctgccctc tggggccact tggtagtgtc	1740
cccagcctac ctctccacaa ggggattttg ctgatgggtt cttagagcct tagcagccct	1800
ggatggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg tagtcacttg	1860
taaggggaac agaacaattt ttgttcttat ggggtgagaa tatagacagt gcccttggtg	1920
cgaggggaagc aattgaaaag gaacttggcc tgagcactcc tgggtgcaggc ctccacctgc	1980
acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc cctgaccctg	2040

B0213WO seq list.ST25.txt

```

ctcctagcac cctggagagt gcacatgccc cttggtcctg gcagggcgcc aagtctggca 2100
ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg gggaaatcaa 2160
ggatgctcag ttttaaggtag actgtttcca tgttatgttt ctacacattg ctacctcagt 2220
gctcctggaa acttagcttt tgatgtctcc aagtagtcca cttcattta actctttgaa 2280
actgtatcac ctttgccaag taagagtggg ggcctatttc agctgctttg acaaaatgac 2340
tggctcctga cttaacgttc tataaatgaa tgtgctgaag caaagtgcc atggtggcgg 2400
cgaagaagag aaagatgtgt tttgttttgg actctctgtg gtcccttcca atgctgtggg 2460
tttccaacca ggggaagggg cctttttgca ttgccaagt ccataaccat gagcactact 2520
ctaccatggg tctgcctcct ggccaagcag gctggtttgc aagaatgaaa tgaatgattc 2580
tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca ggatccgtct 2640
gtgcacatgc ctctgtagag agcagcattc ccagggacct tggaaacagt tggcactgta 2700
aggtgcttgc tccccaagac acatcctaaa aggtgttgta atggtgaaaa cgtcttcctt 2760
ctttattgcc cttctttatt tatgtgaaca actgtttgtc tttttttgta tcttttttaa 2820
actgtaaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga ttttttttc 2880
aaagcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 2916

```

<210> 99

<211> 2653

<212> DNA

<213> Homo sapiens

```

<400> 99
ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg 60
attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc caggtctgga 120
gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac 180
cccgcctggg tggttggagg gcgcgcagta gagcagcagc acaggcgagg gtcccgggag 240
gccggctctg ctgcgcgcca gatgtggaat ctccttcacg aaaccgactc ggctgtggcc 300
accgcgcgcc gccgcgctg gctgtgcgct ggggcgctgg tgctggcggg tggcttcttt 360
ctcctcggtt tcctcttcgg gtggtttata aaatcctcca atgaagctac taacattact 420
ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc 480
ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca 540
aagcaaattc aatcccagtg gaaagaattt ggcttgatt ctgttgagct agcacattat 600
gatgtcctgt tgcctaccc aaataagact catcccaact acatctcaat aattaatgaa 660
gatggaaatg agattttcaa cacatcatta tttgaaccac ctcctccagg atatgaaaat 720
gtttcgata ttgtaccacc tttcagtgtt ttctctctc aaggaatgcc agagggcgat 780

```

B0213WO seq list.ST25.txt

ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa	840
atcaattgct ctgggaaaaat tgtaattgcc agatatggga aagttttcag aggaaataag	900
gttaaaaatg cccagctggc aggggccaaa ggagtcattc tctactccga ccctgctgac	960
tactttgctc ctggggtgaa gtcctatcca gatggttgga atcttcctgg aggtggtgct	1020
cagcgtggaa atatcctaaa tctgaatggt gcaggagacc ctctcacacc aggttaccca	1080
gcaaatgaat atgcttatag gcgtggaatt gcagaggctg ttggtcttcc aagtattcct	1140
gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca	1200
ccaccagata gcagctggag aggaagtctc aaagtgccct acaatgttgg acctggcttt	1260
actggaaact tttctacaca aaaagtcaag atgcacatcc actctacca tgaagtgaca	1320
agaatttaca atgtgatagg tactctcaga ggagcagtg aaccagacag atatgtcatt	1380
ctgggaggtc accgggactc atgggtgttt ggtggtattg accctcagag tggagcagct	1440
gttggtcatg aaattgtgag gagctttgga aactgaaaa aggaagggtg gagacctaga	1500
agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg ttctactgag	1560
tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat taatgctgac	1620
tcacttatag aaggaaaact cactctgaga gttgattgta caccgctgat gtacagcttg	1680
gtacacaacc taacaaaaga gctgaaaagc cctgatgaag gctttgaagg caaatctctt	1740
tatgaaagt ggactaaaaa aagtccttcc ccagagttca gtggcatgcc caggataagc	1800
aaattgggat ctggaaatga ttttgaggtg ttcttccaac gacttggaaat tgcttcaggc	1860
agagcacggt atactaaaaa ttgggaaaca aacaaattca gcggctatcc actgtatcac	1920
agtgtctatg aaacatatga gttggtggaa aagttttatg atccaatgtt taaatatcac	1980
ctcactgtgg cccaggttcg aggagggatg gtggttgagc tagccaattc catagtgtc	2040
ccttttgatt gtcgagatta tgctgtagtt ttaagaaagt atgctgacaa aatctacagt	2100
atttctatga aacatccaca ggaaatgaag acatacagt tatcatttga ttacttttt	2160
tctgcagtaa agaattttac agaaattgct tccaagttca gtgagagact ccaggacttt	2220
gacaaaagca acccaatagt attaagaatg atgaatgat aactcatgtt tctggaaaga	2280
gcattttattg atccattagg gttaccagac aggccttttt ataggcatgt catctatgct	2340
ccaagcagcc acaacaagta tgcaggggag tcattcccag gaatttatga tgctctgttt	2400
gatattgaaa gcaaagtgga cccttccaag gcctggggag aagtgaagag acagatttat	2460
gttgagcct tcacagtgc ggcagctgca gagactttga gtgaagtagc ctaaggaggat	2520
tcttttagaga atccgtattg aatttggtg gtatgtcact cagaaagaat cgtaatgggt	2580
atattgataa attttaaaat tggatatatt gaaataaagt tgaatattat atataaaaaa	2640
aaaaaaaaa aaa	2653

<210> 100

<211> 2466

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

```

<400> 100
ctcaaaagg gcccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg    60
attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc caggtctgga    120
gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac    180
cccgccgtgg tggttggagg gcgcgcagta gagcagcagc acaggcgcggt gtcccgggag    240
gccggctctg ctgcgcgccg gatgtggaat ctcttcacg aaaccgactc ggctgtggcc    300
accgcgcgcc gcccgcgctg gctgtgcgct ggggcgctgg tgcctggcggg tggcttcttt    360
ctcctcggct tcctcttcgg gtggtttata aaatcctcca atgaagctac taacattact    420
ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc    480
ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca    540
aagcaaattc aatcccagtg gaaagaattt ggcctggatt ctgttgagct agcacattat    600
gatgtcctgt tgcctaccc aaataagact catcccaact acatctcaat aattaatgaa    660
gatggaaatg agattttcaa cacatcatta tttgaaccac ctctccagg atatgaaaat    720
gtttcggata ttgtaccacc tttcagtgct tctctcctc aaggaatgcc agagggcgat    780
ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa    840
atcaattgct ctgggaaaat tgtaattgcc agatatggga aagttttcag aggaaataag    900
aatatgctta taggcgtgga attgcagagg ctgttggtct tccaagtatt .cctgttcac    960
caattggata ctatgatgca cagaagctcc tagaaaaaat ggggtggctca gcaccaccag   1020
atagcagctg gagaggaagt ctcaaagtc cctacaatgt tggacctggc ttacttgaa    1080
acttttctac acaaaaagtc aagatgcaca tccactctac caatgaagtg acaagaattt    1140
acaatgtgat aggtactctc agaggagcag tgaaccaga cagatatgtc attctgggag    1200
gtcaccggga ctcatgggtg tttggtggtg ttgacctca gagtggagca gctgtgttc    1260
atgaaattgt gaggagcttt ggaacactga aaaaggaagg gtggagacct agaagaacaa    1320
ttttgtttgc aagctgggat gcagaagaat ttggtcttct tggttctact gagtgggcag    1380
aggagaattc aagactcctt caagagcgtg gcgtggctta tattaatgct gactcatcta    1440
tagaaggaaa ctacactctg agagttgatt gtacaccgct gatgtacagc ttggtacaca    1500
acctaacaaa agagctgaaa agccctgatg aaggctttga aggcaaatct ctttatgaaa    1560
gttggtacta aaaaagtcct tccccagagt tcagtggcat gccaggata agcaaattgg    1620
gatctggaaa tgattttgag gtgttcttcc aacgacttgg aattgcttca ggcagagcac    1680
ggtatactaa aaattgggaa acaaacaaat tcagcggcta tccactgtat cacagtgtct    1740
atgaaacata tgagttgggtg gaaaagtttt atgatccaat gtttaaatat cacctcactg    1800

```

B0213WO seq list.ST25.txt

```

tggcccaggt tcgaggaggg atggtgtttg agctagccaa ttccatagtg ctcccttttg 1860
attgtcgaga ttatgctgta gttttaagaa agtatgctga caaaatctac agtatttcta 1920
tgaaacatcc acaggaaatg aagacataca gtgtatcatt tgattcactt ttttctgcag 1980
taaagaattt tacagaaatt gcttccaagt tcagtgcagag actccaggac tttgacaaaa 2040
gcaacccaat agtattaaga atgatgaatg atcaactcat gtttctggaa agagcattta 2100
ttgatccatt aggggtacca gacaggcctt tttataggca tgatcatctat gctccaagca 2160
gccacaacaa gtatgcaggg gagtcattcc caggaattta tgatgctctg tttgatattg 2220
aaagcaaagt ggacccttcc aaggcctggg gagaagtga gagacagatt tatgttgcag 2280
ccttcacagt gcaggcagct gcagagactt tgagtgaagt agcctaagag gattctttag 2340
agaatccgta ttgaatttgt gtggtatgtc actcagaaag aatcgtaatg ggtatattga 2400
taaattttta aattggtata tttgaaataa agttgaatat tatatataaa aaaaaaaaaa 2460
aaaaaa 2466

```

<210> 101

<211> 2560

<212> DNA

<213> Homo sapiens

<400> 101

```

ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgcctcg 60
attggttcag tgcactctag aaacactgct gtggtggaga aactggacc caggctctgga 120
gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac 180
cccgcctggt tggttggagg gcgcgcagta gagcagcagc acaggcgcgg gtcccgggag 240
gccggtctct ctcgcgccga gatgtggaat ctccttcacg aaaccgactc ggctgtggcc 300
accgcgcgcc gccgcgcctg gctgtgcgct ggggcgcctg tgctggcggg tggcttcttt 360
ctcctcgggt tcctcttcggt gtggtttata aaatcctcca atgaagctac taacattact 420
ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc 480
ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca 540
aagcaaattc aatcccagtg gaaagaattt ggcttgatt ctgttgagct agcacattat 600
gatgtcctgt tgcctacccc aaataagact catcccaact acatctcaat aattaatgaa 660
gatggaaatg agattttcaa cacatcatta tttgaaccac ctctccagg atatgaaaat 720
gtttcggata ttgtaccacc tttcagtgtc ttctctctc aaggaatgcc agaggcgat 780
ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa 840
atcaattgct ctgggaaaat tgtaattgcc agatatggga aagttttcag aggaaataag 900
gttaaaaatg cccagctggc aggggccaaa ggagtcattc tctactccga ccctgctgac 960

```

B0213WO seq list.ST25.txt

tactttgctc ctggggtgaa gtcctatcca gatggttga atcttcctgg aggtggtgctc 1020
cagcgtggaa atatacctaaa tctgaatggt gcaggagacc ctctcacacc aggttaccca 1080
gcaaatgaat atgcttatag gcgtggaatt gcagaggctg ttggtcttcc aagtattcct 1140
gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca 1200
ccaccagata gcagctggag aggaagtctc aaagtgccct acaatgttgg acctggcttt 1260
actggaaact tttctacaca aaaagtcaag atgcacatcc actctaccaa tgaagtgaca 1320
agaatttaca atgtgatagg tactctcaga ggagcagtgg aaccagacag atatgtcatt 1380
ctgggagggtc accgggactc atgggtgttt ggtggtattg accctcagag tggagcagct 1440
gttggtcatg aaattgtgag gagctttgga aactgaaaa aggaaggggtg gagacctaga 1500
agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg ttctactgag 1560
tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat taatgctgac 1620
tcatctatag aaggaaacta cactctgaga gttgattgta caccgctgat gtacagcttg 1680
gtacacaacc taacaaaaga gctgaaaagc cctgatgaag gctttgaagg caaatctctt 1740
tatgaaagt ggactaaaaa aagtccttcc ccagagtcca gtggcatgcc caggataagc 1800
aaattgggat ctggaaatga ttttgagggtg ttcttccaac gacttggaat tgcttcaggc 1860
agagcacggt atactaaaaa ttgggaaaca aacaaattca gcggctatcc actgtatcac 1920
agtgtctatg aaacatatga gttggtgga aagttttatg atccaatgtt taaatatcac 1980
ctcactgtgg cccaggttcg aggagggatg gtgtttgagc tagccaattc catagtgctc 2040
ccttttgatt gtcgagatta tgctgtagtt ttaagaaagt atgctgacaa aatctacagt 2100
atttctatga aacatccaca ggaaatgaag acatacagtg tatcatttga ttcacttttt 2160
tctgcagtaa agaattttac agaaattgct tccaagtcca gtgagagact ccaggacttt 2220
gacaaaagca agcatgtcat ctatgctcca agcagccaca acaagtatgc aggggagtca 2280
ttcccaggaa tttatgatgc tctgtttgat attgaaagca aagtggaccc ttccaaggcc 2340
tggggagaag tgaagagaca gatttatgtt gcagccttca cagtgcaggc agctgcagag 2400
actttgagtg aagtagccta agaggattct ttagagaatc cgtattgaat ttgtgtggtg 2460
tgtcactcag aaagaatcgt aatgggtata ttgataaatt ttaaaattgg tatatttgaa 2520
ataaagttga atattatata taaaaaaaaa aaaaaaaaaa 2560

<210> 102

<211> 212

<212> DNA

<213> Homo sapiens

<400> 102

ggagtgcacc cgctgtccac atgccgcgat ctggtggcgg tcgtgcatcg tccagcaaac 60

B0213WO seq list.ST25.txt

ggaagatgac cctgggaacg ttcaaaccgg gcgtccagca gcggctgact gtagagctcc 120
 tatctgatag ctgcgtgttc agggtagatg gtgaagtgtt cgagacgac cggccttccg 180
 acatggcgga tggatatatc tgggtcccca cg 212

<210> 103

<211> 675

<212> DNA

<213> Homo sapiens

<400> 103
 ctagactgac tgaatcaaaa tccctgggggt tgtgtgcaca tgacggttcg agaaacgcca 60
 gcctaaggga ccctctgcag tctgtccagc ttgtcccttc aacctcatgc caaccaacac 120
 actccagact caaagtgctt tctctcaacc cccgctattg aagtacctga cccaagcca 180
 gttacaagtt cattcctgtt tcattttctc tggagggctg ccatcaatga gattgttatt 240
 tatgttggtg tgcctcacc aaagtgtctg ccaggcctat cacagtcctg gagctcaggg 300
 gagacccaag caaaccaaca cacatttgcc aggcacccag gatggaccta agcaagctgt 360
 ctgggccac caggagtcc tggttgggcc aggaggacct gcctgttaca catgaactat 420
 gattcaaaac gtagacatat agtcttcaat taataataac atttaaaaaa gacaaaaagt 480
 aggtatacat tttgaatgag aatacaaatg agaaatgccc ccattcctcc aagtgcactt 540
 tgttgaaaaa tgagaaggaa agggaggtgc ctggtggttt caggggaagg aatgtgtgga 600
 acgcaggtct tccatgagca tggggctggc agtaggaaca aagactcgct tgcactgggc 660
 ttgcgcctgc gctgg 675

<210> 104

<211> 476

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (464)..(464)

<223> n = a t g o r c

<400> 104
 ctgctccctc acactctcca ttggctcact cagccccttt cctgtgcttc tttttatgtg 60
 tttgtcacac tgccttgggt tttgtggagg ccagttcacc atcctaactt ataaattctc 120

B0213WO seq list.ST25.txt

aagagcaagg accagggctt gttgtgtgtt gcattttgga ttacccaag aagcagactg	180
tgggatgaca tttaggtaca ggccatttaa caaaggagct ctttgagga acacacttgt	240
gaaagtggag gtgggagaag aagcataatt agaaagaaga agaagtcaga tgtgatggag	300
accagggac agcttcata cctgaggaat tctggagcta gctagtggtc gctggcagtt	360
gtcccaaatt gaaaagagat ggccaggcat tgataaacct gatatttaga gacagatagt	420
ggctctgggc agaaagatca tctgatggtg ttctcagcac cggngaacaa catttc	476

<210> 105

<211> 265

<212> DNA

<213> Homo sapiens

<400> 105	
gaccagaaa tcgaaggga ggcgccgc acagaacgtg gcccgatcct tgccgtgatc	60
gataccccag ggctcgtgca cggactacca gagcaggtgg ctaaagctat cgtgctggaa	120
gcgccttgaa cagcgcatga agaaaagcgc cgatgtttcc ttacgccta cagtggacca	180
gggcaagtcc ttgagcacga gcttgatctt tcaccggacg gcatggggcg gcttctagaa	240
tttctcggct tctcttttgg tggcg	265

<210> 106

<211> 726

<212> DNA

<213> Homo sapiens

<400> 106	
cgtaattgtg gaaggagtca cgggaagtgg agacaggaaa ggctgtgagg agccaaggga	60
aagaggcgaa gagaaaggcg gacaggagag aggacgagaa tgaaagagaa atcaacaggg	120
ggaaagagaa caacaggcag agggaaaagg aagtaagttt gctgaattct atattaagaa	180
actggtaaat gtctgtagg tcaataaaac cataaacttt gaggttatct ttgctattag	240
tcagaaaaaa atgagaacct tttgtcagat ttctgcaagt taaccgctaa ttttacaggg	300
ttgtaaaaca cctgggtctc aatcaattgc tagtgaaaca caattaccct tcccatgagt	360
cagatgacct tcaggtggac atgatattca cagggtgtga aacctgttt tgcccttttt	420
caaatgttag gctacttttt cctgaaaatc ctctgcatga aaaattctac cgcccttagt	480
gtgtctcaca caaggataac ttcaaccaa gctgtgttca acctggcctc caggtccctg	540
tccttagggc gggacccatc ctctgcttcc cgaataacca acactccttt ccattgcccc	600
gaaaccatcc ctgctacctc gtgaggaatt aactttaccc aaagaaaggc ctgacctctg	660

B0213WO seq list.ST25.txt

tcccaggtcc tgggagaaag tccctgaact cctagaaggt cccaagcgac aggagtgtct 720
gttcac 726

<210> 107

<211> 253

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (98)..(98)

<223> n = a t g or c

<400> 107
cggggatgag aacgtatctg ggaggagcac tgcgggcaag ggggtgctgaa ggattccatg 60
tgccggcagg gcattcccaa ccgtgaatcg tctccagnga gtccgccaac gcttcgagat 120
cctggcggcg aatgccatcc ccaaaggctt catggacggg aagcaggcct gcattctcat 180
gatcaaagcc ctggaacttg accccaactt atacaggata gggcagagca aaatcttctt 240
ccgaactggc gtc 253

<210> 108

<211> 448

<212> DNA

<213> Homo sapiens

<400> 108
ccggcaggct gttggttccc gatctccgag cgcaggctcg atcccgtggc gccgccggaa 60
cgccgcaagc gcgctctctt gccgcgcgag cttgcgagtc aacgcgtcga tctcggcgcg 120
ccgcgtgagg gcaagcgccg ctatatcttc gcggaaagcc cgttcgtccg cgcgtgtcca 180
tcttgaggta ccaccgccgg actgccggcg cttggtgcag gacgtgatcg tcatgcgctc 240
ggcgcgagct tcgatctgcc gttcaatgat gccgagatga cggcttgtct cgagaagtgc 300
atcttccatg cgcaggagta aggccgattg aggcgtgagc gacatcagaa tgccctccat 360
ggcctgacct ataacgcttc tcaatcacta gtgcggccgc ctgcaggtcg accatatggg 420
agagctccca acgcgttgga tgcatagc 448

<210> 109

<211> 437

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

```

<400> 109
cagagggttg agtgagccga gatcatgccg ctgtactgca gtctgggcga cagagcaaga    60
ttccatctca taaaaactgt gaactaggca aagtttgttt ccaggaaata atcacatccc    120
catcttaata atcccatccc tatctaata taggcacaat tcttagctgg ccccatgata    180
tccaatcctt ggtgttacat cctgtataat attctttcct tgagtgtggg tgggacctgt    240
gacttgcttc tagttgagat tatctacatt acataaggct ccatcttgga gtaagagatt    300
tctctgctgg ccctgaagta gcagctatgt tgtgaacagc caatggagaa agccatatgg    360
cagagacctg caacagaagg tggacctgaa ggtggcctct ggtcaccagc aacagcccca    420
aggaaatgaa ttctgcc                                     437

```

<210> 110

<211> 244

<212> DNA

<213> Homo sapiens

```

<400> 110
ctggcaggtc gtagcaggcc ggccctgggt agggcccat actgtcgggg ccgagcgta    60
ctatgtcgcc tctcagcgc gcaacgctgc cacctccgag agcgccgat ctgagaagaa    120
tccaagggtg cttcagcggg attccaaaga agtttgctc ctcggagggt aacggttctc    180
cgttaacgac gatcccgatc ttcccgtag ttccaccgac atcaagcgag ataacctccc    240
caga                                     244

```

<210> 111

<211> 272

<212> DNA

<213> Homo sapiens

```

<400> 111
gtgacgagaa gagcagatta aagaagatta gataccactg gtcaatcatg gtagatgcag    60
agaagccaca gaaaaactgg aaccaaaca ggaggccac gaacattgtg tttttgtaga    120
agaagtacag caccatgttg gcaagtcggg agtagacca atgccgtga agaataaga    180
gcctctccag gtatcggaat ttcggcactg caaagtcgct ggccatcact gccttcaaag    240
ggagagggat tcctgttact ggtgatgccg ac                                     272

```

B0213WO seq list.ST25.txt

<210> 112

<211> 413

<212> DNA

<213> Homo sapiens

<400> 112

```

gtggagccca cagaaaggag agggcatcaa agacacactt cgctggctgc accatttgct    60
cagggttggg cccagctccg gttacagctc cataatccat tgtgttcacc actgtttgct    120
taggtttaac tcggagttag aattctggtt ttgtttctca cttagggaaa aaaaatagct    180
ttgtaaaggg aggttactaa ataaaacttt gagaactcta ttcaccctca caggatgact    240
tttggttgct aattcaatcc ctggcagggt actgttcatt tatagaattt ccaggcgact    300
agaaggcatt tgaaaggaat tcttaccgaa cattaacctg ccttggtaac cacagaaggc    360
atttctacct gccaaagctc ggctgggagc ttgtgtgcag tccgacctgc gcc          413

```

<210> 113

<211> 541

<212> DNA

<213> Homo sapiens

<400> 113

```

gtcaggctga cctggttctt ggtcatctcc tcccgggatg ggggcagggt gtacacctgt    60
ggttctcggg gctgtccttt gggttttgag atggttttct cgatgggggc tgggagggct    120
ttgttgagga ccttgacctt gtactccttg ccgttcagcc agtcctggtg caggacggtg    180
aggacgctga ccacacggaa cgtgctggtg gactgctcct cccgcggctt tgtcttgcca    240
ttatgcacct accacgccgt ccacgttaca gttaaacttg acctcagggt cttcgtggct    300
cacgtccacc accacgcatg tgacctcagg ggtccgggag atcatgaggg tgtccttggg    360
ttttgggggg aagaggaaga actgacgggc ccccaggag ttcagggtgct gggcacggtg    420
ggcatgtgtg agttttgtca caagatttgg gctcaactct cttgtccacc atggtgttgc    480
tgggcttggtg attcactttg cagatgtaag tctcatgaat acgggttttct aattcccgcg    540
g                                     541

```

<210> 114

<211> 226

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 114
 gtggtgaggc cagggcttcc agcctcgtgc tgtctcggga ctcctgaccg tgggtgtcgt 60
 gtgtgcccac ctgtgacttt ctactcacca aggttgaaga aaggaaacgg ggaaaatcaa 120
 aaggggttca aacccacact cagtaggtgg aggggagcgc ctgccattgg ttgtattttt 180
 gttctgagtt ttcggtgccg tggtcctaac tactccatcc catgac 226

<210> 115

<211> 439

<212> DNA

<213> Homo sapiens

<400> 115
 tttagaccaa gatacggcgt atatgcaagg gtttgcgagt ttattagaag ggattgtgaa 60
 gccggtatag ctagtgtctt tttaaaaagt tgtttaaaaa agagccgtat taaacattaa 120
 tatggctctt ttttattgtt gagtttttat tattacaaaa tcaatttaaa caaataaaaag 180
 ccaattgccg ttgctaataa cgtcagcccc acatgtaacc caatcagtcc taaaccgcga 240
 agcagtttgc cgttatggat aaaggtaaat acttcagcac taaaggactt aaaagtcgtc 300
 agtccgcccc aaaaaccagt tatgacaaac aacctgacat tgggagacaa gtcgctgcac 360
 ataacgcttc tcaatcacta gtgcggccgc ctgcaggctg accatatggg agagctccca 420
 acgcgttgga tgcataagct 439

<210> 116

<211> 175

<212> DNA

<213> Homo sapiens

<400> 116
 gggagtgaag atttctcacc tcgggtcttc ctagaccttc aggtcacacg ggaattgttc 60
 tgtttataga cggcgtggc cttagtactc actctccctc tattttcctt gcttccttat 120
 aactaggttt ccctactcac ttcctcaaaa agagtgatgt aggtccacgt gtacc 175

<210> 117

<211> 521

<212> DNA

<213> Homo sapiens

<400> 117

B0213WO seq list.ST25.txt

```

gctacaacca catttgttca caggagtttt tgggtgcggg tgggaaggat ggaaggcctt    60
ggatttatat tgcacttcat agacccttag gctgctgtgc ggtgggactc cacatgcgcc    120
ggaaggagct tcagggtgagc actgctcatg tgtggatgcc cctgcaacag gcttccctgt    180
ctgtagagcc aggggtgcaa gtgccatcca cacttgcaagt gaatggcttt tccttttagg    240
tttaagtcct gtctgtctgt aaggcgtaga atctgtccgt ctgtaaggcg tagaatgagg    300
gttgtaatc catcacaagc aaaaggctcag aacagttaaa cactgccttt cctcctcctc    360
ttattttatg ataaaagcaa atgtggcctt ctcagtatca ttcgattgct atttgagact    420
tttaaattaa ggtaaaggct gctgggtgtg gtacctgtgg atttttctat actgatgttt    480
tcgttttgcc aatataatga gtattacatt ggcctctcgt a                          521

```

<210> 118

<211> 131

<212> DNA

<213> Homo sapiens

```

<400> 118
ctgaagatgc ccctatatc tgtcaaagg tggcggggg aggtgttggg gtcctttcat    60
ctggctccgt ttctggtgct tctggaagtc tctgctcagc acaggaaga actaacacga    120
ctaacctagg c                          131

```

<210> 119

<211> 212

<212> DNA

<213> Homo sapiens

```

<400> 119
gtgggtggaga tgggtgaaaa cgacatatc gctttcacct acgagaggac actaatgatg    60
gagcagaggt cgcagatgct gaagcagatg cagctgtcca agaacgagca ggagcgagag    120
gccagctga tccacgacag gaacaccgcg tcccacaccg cggcggcagc caggacccaa    180
gcgccgccta cgccagacaa ggtgcagatg ac                          212

```

<210> 120

<211> 137

<212> DNA

<213> Homo sapiens

<400> 120

B0213WO seq list.ST25.txt

accgaagggc tgcatttctt tgtgggctta ttctcgagaa aactgggggc agatccctcc 60
 tcaaggaggg gagggccacc ttggtttcca gtcaagtatt gtgaaaatta tccaacactc 120
 aggcaatcca cccaacc 137

<210> 121

<211> 265

<212> DNA

<213> Homo sapiens

<400> 121
 gtggcagtga aggaaaaatc ccacaacagc cttggaatac cagagctcct gaccgtgggt 60
 tagaatggtc ttttattatg aaggacaacc cattgaattt gagaagtcta cagtgaagc 120
 aaaatgtgtt cttaaaatgc aatactatct cgaggcagtt taaattctaa caataggagc 180
 ctacatacca gatggctttg aaatatttac aggtcctctt tgcctgaatt tttagttatc 240
 caggaacaac cattataact tatac 265

<210> 122

<211> 285

<212> DNA

<213> Homo sapiens

<400> 122
 gtcctcgcac cagcgtcatc gtgtgcaccg gcttgggggg ctggagttcc ggttttcttt 60
 gttttttctc tttattcgtc ctttctcaaa gatgggatac tgatcagaat tgctctgtat 120
 atgcttggga ctggatggaa agactttgga gcagctgtgg ggggtggggg gacaccgaca 180
 accaaacaga cgtgctggct ccagtcctgt ttttactttc aaaaaccaac aagcccgcga 240
 gtggagcctg tcccctcccg ggagggtgct catggcccca ctac 285

<210> 123

<211> 269

<212> DNA

<213> Homo sapiens

<400> 123
 gggccggatc tacgccatag attgcacatt gatttctata ctcaatagta cgtataggaa 60
 tattaanaac catacgccct tctggtaata acatacctat cgttccacaa taaattgagc 120
 gaggagatga ctctaattgt tcaatatatt tcatgggtact taatttatgt ggcggggata 180

B0213WO seq list.ST25.txt

acgcttctca atcactagtg cggccgcctg caggctcgacc atatgggaga gctcccaacg 240
cgttggatgc atagcttgag tattctata 269

<210> 124

<211> 203

<212> DNA

<213> Homo sapiens

<400> 124
gccgacgac tcctcgggtc tgcctcttca ccacaaacac cctctgtcct gacaccgtca 60
ccagcagtgt gtgttctcca aagaccacag acaggcgctt gaagggcaca ttcatgccgc 120
gggtgcggccg gaaaccgcag gctgtgctga ccagctcaga gatggcactg gctgcctgct 180
catcattctc caggccacc cga 203

<210> 125

<211> 239

<212> DNA

<213> Homo sapiens

<400> 125
atacagaaga ggggtttgct ggggatgagg acagcagggc agtcaccatc tcgaagcacc 60
tcagccactc ctttattgtt cttgaagcca ggaacacaga actgcttata gtactcaaag 120
tcccgggagc tgcgagcatt caggtagctg aggtagcggc cggggcattt ttccacgcag 180
atctggggag cgggacattg gaattccagc agaaccaggg ggctggcaca tttcacaat 239

<210> 126

<211> 461

<212> DNA

<213> Homo sapiens

<400> 126
gacgtcgcac gctcccggcc gccatggccg cgggattagc gttatcggcg gcaggcgctca 60
gtccgtatac atcaacataa gttttcgcac ggacctgtgt ttttagtaaa cagtcgcttt 120
cccctagcct ctgcgaccac ccacgcca ccaaccgcaa gagtcggcga cccaagggtg 180
ctccccatct cccaagtta cggggacaat ttgccgaatt ccttaaccac agttcaccgc 240
caagccttag tatactcaac ccaactacca gcgtcggttt cgggtacggg caacaccacc 300
actcgcttag aggtttttct cgacagcaca ggatcaccac catcaccaca aacgtggcta 360

B0213WO seq list.ST25.txt

cgcatcacgc ctcctctgca taacgcttct caatcactag tgcggccgcc tgcaggtcga	420
ccatatggga gagctcccaa cgcgttgga gcatagcttg a	461

<210> 127

<211> 284

<212> DNA

<213> Homo sapiens

<400> 127	
tcaccgaatc tactgataaa aggaagagaa gaatacttta agaagagctc aacctccagc	60
tggtatcaga gaagtcagta gaggtcactg agaccggcag tctttcttgc tttttgcatt	120
agtgccctca gctggaactg tttaacgggac agaagacgta catgcttcag gaagacatcc	180
aggtcggtac cataacgctt ctaatcacta gtgcggccgc ctgcaggctg accatatggg	240
agagctccca acgcgttgga tgcatagctt gagtattcta tagt	284

<210> 128

<211> 252

<212> DNA

<213> Homo sapiens

<400> 128	
accatgaaac ctacagcggc atctaataca acaacaccag ggatgggtctc aacaaatatg	60
acttctacca ccttaaagtc tacacccaaa acaacaagtg ttccacagaa cacatctcag	120
atatcaacat ccacaatgac cgtaaccac aatagttcag tgacatctgc tgcttcacatca	180
gtaacaatca caacaactat gcattctgaa gcaaaagaaag gatcaaaatt tgatactggg	240
agctttgttg gt	252

<210> 129

<211> 382

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (380)..(380)

<223> n = a t c or g

B0213WO seq list.ST25.txt

<400> 129
gcaggccagg aattaacctt gactataaat aggccatcaa tgacctttcc agagaatggt 60
cagagacctc aactttgttt agaggctctg tgtgggtgga acttcctgtt tgcacacaga 120
gcagcataaa gcccagttgc tttgggaagt gtttgggacc agatggattg ttgggagtag 180
gggtacaatac agtctgggtc cctccagctc cttctttctg caacatgggg aagaacaaac 240
tccttcatcc aagtctggtt cttctcctct tggctcctct cgctataacg cttctcaatc 300
actagtgcgg ccgcctgcag gtcgaccata tgggagagct cccaacgcgt tggatgcata 360
gcttgagtat tctatagtgn tc 382

<210> 130

<211> 305

<212> DNA

<213> Homo sapiens

<400> 130
ggctaatac gttctcgtgg atttcttcgg tcctgctcag ggtctccagc aggacgttgt 60
actcgtgaac tttctctttg tgatgcagga actcccgcca gagcttgtcc agttcttcgc 120
cggagaattt cccagaggtc ttcgccttgt gccacagctt ttccagcctg gggatcatcca 180
gcccgtcttc ctgggtgcca ctgagagagt tgctggtcac ctgccgagcg tccttctttc 240
cgtccagacc atacttggcc aagatgacat tgaggttgcy tatgagtctc gtttccttct 300
cccc 305

<210> 131

<211> 337

<212> DNA

<213> Homo sapiens

<400> 131
atatattatt aggtggggaa aaaaaacccc acttttctct ctgatcattt tttcataaga 60
gattctaaga gggagtgaac aagtaccaac tggactccat tccaggtctt acctctagaa 120
gacagccagc tctcatttaa gaatctcaga acttgggaagg aaggaggaaa tccacattaa 180
attctagggc ccaacagaca gagtgtcttc attgccccc ccagtagtgg ggactacagt 240
gcacctgtag tcccagtaga tgctctgaca tcacagagct tcctgctcta ccagcccacc 300
tcattgcatgt caccaccata actatagcct gcaagtc 337

<210> 132

<211> 174

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 132
 ataaaaagggt ggaaactctc atggtaccat caaaaaggca agaagcattg cccctccacc 60
 aagagactaa acaagaaagt ggatcagga agaagaaagc ttcacaaag aaacaaaaga 120
 cagaaaatgt ctctgtagat gaacccctta ttcgtgcaac tacttatatt cctc 174

<210> 133

<211> 113

<212> DNA

<213> Homo sapiens

<400> 133
 cataaagtac tgacatgatc agaggaatca tcagcaactg catatccatt gctaagccag 60
 taatcacgat gcaaatccag ttaaagagga gcatgaataa atagtctgct ggc 113

<210> 134

<211> 191

<212> DNA

<213> Homo sapiens

<400> 134
 aaattatgca tctgtgagga gagaagagag ggaaaaaaa aggaaaaaca aaccaagaaa 60
 gtatgccttt ttactttcct attatcctga atagggcata ctccattcac ccttaagggt 120
 ctagaatgaa ccagtcttac tatgtatcta taaccttgcc tttatctcta ttctaatatg 180
 gtaatctggt a 191

<210> 135

<211> 1481

<212> DNA

<213> Homo sapiens

<400> 135
 ggcacgaggg ggacgcctct ctctcctta ttcggtttac tatttattgt tcggggtggt 60
 ttttaattcc tgtattgctc ggcccgggga gtttcgcccc ctgcccggct ccgcggcgcg 120
 gaggatggtg tggaacggc tgggcgcgct ggtgatgttc cctctacaga tgatctatct 180

B0213WO seq list.ST25.txt

```

ggtggtgaaa gcagccgtcg gactggtgct gcccgcgaag ctgcgggacc tgtcgcggga 240
gaacgtcctc atcaccggcg gcgggagagg catcgggagt cagctcgccc gcgagttcgc 300
ggagcgcggc gccagaaaga ttgttctctg gggccggact gagaaatgcc tgaaggagac 360
gacggaggag atccggcaga tgggcaactga gtgccattac ttcattctgt atgtgggcaa 420
ccgggaggag gtgtaccaga cggccaaggc cgtccgggag aagggtgggtg acatcaccat 480
cctggtgaac aatgccgccg tgggtccatgg gaagagccta atggacagt atgatgatgc 540
cctcctcaag tcccaacaca tcaacacctt gggccagtgc tggaccacca aggccttcct 600
gccgcgtatg ctggagctgc agaatggcca catcgtgtgc ctcaactccg tgctggcact 660
gtctgccatc cccggtgccg tcgactactg cacatccaaa gcgtcagcct tcgccttcct 720
ggagagcctg accctggggc tgctggactg tccgggagtc agcgccacca cagtgtgcc 780
cttcacacc agcaccgaga tgttccaggg catgagagtc aggtttccca acctcttcc 840
cccactgaag ccggagacgg tggcccggag gacagtggaa gctgtgcagc tcaaccaggc 900
cctcctcctc ctcccatgga caatgcattg cctcgttatc ttgaaaagca tacttccaca 960
ggctgcactc gaggagatcc acaaattctc aggaacctac acctgcatga acactttcaa 1020
agggcgggaca tagagacagg atgaagacat gcttgaggag ccacggagtt tggggggcac 1080
agcacctggg cacacacccg agcacctgtc cattggcatg cttctgctgg gtgagcagga 1140
cagctcctgt cccagcgaa gaatccggct gccctgggc cagtcccagg acctttgcac 1200
aggactgatg ggtataactg acccccacag ggaggcagga aaacagccag aagccacctt 1260
gacacttttg aacatttcca gttctgtaga gtttattgtc aattgcttct caagtctaac 1320
cagcctcagc agtgtgcata gaccatttcc aggaggggtc gtcccagat gctctgcctc 1380
ccgttccaaa acccactcat cctcagcttg cacaaactgg ttgaacggca ggaatgaaaa 1440
ataaagagag atggcttttg tgaaaaaaaa aaaaaaaaaa a 1481

```

<210> 136

<211> 344

<212> DNA

<213> Homo sapiens

<400> 136

```

gggtgttttt taattcctgt attgctcggc ccggggagtt tcgccccctg cccgggtccg 60
cggcgcgagg gatggtgtgg aaacggctgg gcgcgtgggt gatgttcctt ctacagacga 120
tctatctggt ggtgaaagca gccgtcggac tgggtctgcc cgccaagctg cgggacctgt 180
cgcgggagaa cgtcctcatc accggcgggc ggagaggcat cgggcgtcag ctgcccgcg 240
agttcgcgga gcgcggcgcc agaattgatt ttctctgggg ccggactgag aaatgcctga 300
aggagacgac ggaggagatc cggcagatgg gactgagtg ccat 344

```


B0213WO seq list.ST25.txt

<210> 137

<211> 1088

<212> DNA

<213> Homo sapiens

<400> 137

```

tgatctatct ggtggtgaaa gcagccgtcg gactggtgct gcccgccaaag ctgcgggacc    60
tgtcgcggga gaacgtcctc atcaccggcg gcgggagagg catcgggcgt cagctcgccc    120
gcgagttcgc ggagcgcggc gccagaaaga ttgttctctg gggccggact gagaaatgcc    180
tgaaggagac gacagaggag atccggcaga tgggcactga gtgccattac ttcatctgtg    240
atgtgggcaa ccgggaggag gtgtaccaga cgccaaggc cgtccgggag aagggtgggtg    300
acatcaccat cctggtgaac aatgccgccg tggccatgg gaagagccta atggacagtg    360
atgatgatgc cctcctcaag tcccaacaca tcaacaccct gggccagttc tggaccacca    420
aggccttcct gccgcgtatg ctggagctgc agaattggca catcgtgtgc ctcaactccg    480
tgctggcact gtctgccatc cccggtgcca tcgactactg cacatccaaa gcgtcagcct    540
tcgccttcat ggagagcctg accctggggc tgctggactg tccgggagtc agcgccacca    600
cagtgtgtcc cttccacacc agcaccgaga tgttccaggg catgagagtc aggtttccca    660
acctctttcc cccactgaag ccggagacgg tggcccggag gacagtggaa gctgtgcagc    720
tcaaccaggc cctcctcctc ctcccatgga caatgcatgc cctcgttata ttgaaaagca    780
tacttccaca ggctgcactc gaggagatcc acaaattctc aggaacctac acctgcatga    840
acactttcaa agggcgagaca tagagacagg atgaagacat gcttgaggag ccacggagtt    900
tgggggccac agcacctggg cacacacccg agcacctgtc cattggcatg cttctgctgg    960
gtgagcagga cagctcctgt cccagcgaa gaatccggct gcccctgggc cagtcccagg   1020
acctttgcac aggactgatg ggtataactg acccccacag ggaggcagga aaacagccag   1080
aagccacc                                     1088

```

<210> 138

<211> 399

<212> DNA

<213> Homo sapiens

<400> 138

```

tgcattgtcc atgggaggag gaggagggcc tggttgagct gcacagcttc cactgtcctc    60
cgggccaccg tctccggctt cagtggggga aagaggttgg gaaaccttct cccggacggc    120
cttgccgctc tggtacacct cctcccgtt gccacatca cagatgaagt aatggcactc    180

```

B0213WO seq list.ST25.txt

agtgcccatc tgccggatct cctccgtcgt ctcttcagg catttctcag tccggcccca 240
 gagaacaatc tttctggcgc cgcgctccgc gaactcgcgg gcgagctgac gcccgatgcc 300
 tctcccgcgc ccggtgatga ggacgttctc ccgcgacagg tcccgcagct tggcgggcag 360
 caccagtccg acggctgctt tcaccaccag atagatcat 399

<210> 139

<211> 745

<212> DNA

<213> Homo sapiens

<400> 139
 ggtggcttct ggctgttttc ctgcctccct gtgggggtca gttacacca tcagtcctgt 60
 gcaaaggtcc tgggactggc ccaggggcag ccggattctt cgctggggac aggagctgtc 120
 ctgctcacc agcagaagca tgccaatgga cagggtgctc gggtgtgtgcc cagggtgctgt 180
 ggccccaaa ctccgtggct cctcaagcat gtcttcatcc tgtctctatg tccgcccttt 240
 gaaagtgttc atgcagggtgt aggttcctga gaatttgtgg atctcctcga gtgcagcctg 300
 tggaagtatg ctgactctca tgccctggaa catctcggtg ctggtgtgga agggcagcac 360
 tgtgtgtggc ctgactcccg gacagtccag cagccccagg gtcaggctct ccatgaaggc 420
 gaaggctgac gctttggatg tgcagtagtc gacggcaccg gggatggcag acagtgccag 480
 cacggagtgt aggcacacga tgtggccatt ctgcagctcc agcatacgcg gcaggaaggc 540
 cttggtggtc cagaactggc ccaggggtgt gatgtgttgg gacttgagga gggcatcatc 600
 atcactgtcc attaggctct tcccatggac cagggcggca ttgttcacca ggatggtgat 660
 gtcaccacc ttctcccgga cggccttggc cgtctggtac acctcctccc ggttggccac 720
 atcacagatg aagtaatggc actca 745

<210> 140

<211> 3875

<212> DNA

<213> Homo sapiens

<400> 140
 cgggggacgt cagcgtgcc agcgtggaag gagctgcggg gcgcgggagg aggaagtaga 60
 gcccgggacc gccaggccac caccggccgc ctccagcatg gacgcgtccc tggagaagat 120
 agcagacccc acgttagctg aaatgggaaa aaacttgaag gaggcagtga agatgctgga 180
 ggacagtcag agaagaacag aagaggaaaa tggaaagaag ctcatatccg gagatattcc 240
 aggccactc cagggcagtg ggcaagatat ggtgagcatc ctccagttag ttcagaatct 300

B0213WO seq list.ST25.txt

catgcatgga gatgaagatg aggagcccca gagccccaga atccaaaata ttggagaaca	360
aggtcatatg gctttgttgg gacatagtct gggagcttat atttcaactc tggacaaaga	420
gaagctgaga aaacttaca ctaggatact ttcagatacc accttatggc tatgcagaat	480
tttcagatat gaaaatgggt gtgcttattt ccacgaagag gaaagagaag gacttgcaaa	540
gatatgtagg cttgccattc attctcgata tgaagacttc gtagtggatg gcttcaatgt	600
gttatataac aagaagcctg tcatatatct tagtgctgct gctagacctg gcctgggcca	660
atacctttgt aatcagctcg gcttgccctt cccctgcttg tgccgtgtac cctgtaacac	720
tgtgtttgga tcccagcatc agatggatgt tgccttcctg gagaaactga ttaaagatga	780
tatagagcga ggaagactgc ccctgttgct tgtcgcaaat gcaggaacgg cagcagtagg	840
acacacagac aagattggga gattgaaaga actctgtgag cagtatggca tatggcttca	900
tgtggagggt gtgaatctgg caacattggc tctgggttat gtctcctcat cagtgtggc	960
tgcagccaaa tgtgatagca tgacgatgac tcctggcccg tggctgggtt tgccagctgt	1020
tcctgcggtg aactgtata aacacgatga ccctgccttg actttagtgt ctggtcttac	1080
atcaaataag cccacagaca aactccgtgc cctgcctctg tggttatctt tacaatactt	1140
gggacttgat gggtttgtgg agaggatcaa gcatgcctgt caactgagtc aacggttgca	1200
ggaaagtttg aagaaagtga attacatcaa aatcttgggt gaagatgagc tcagctcccc	1260
agtgggtgtg ttcagatttt tccaggaatt accaggctca gatccggtgt ttaaagccgt	1320
cccagtgccc aacatgacac cttcaggagt cggccgggag aggcactcgt gtgacgcgct	1380
gaatcgctgg ctgggagaac agctgaagca gctggtgcct gcaagcggcc tcacagtcac	1440
ggatctggaa gctgagggca cgtgtttgct gttcagccct ttgatgaccg cagcagtttt	1500
aggaactcgg ggagaggatg tggatcagct cgtagcctgc atagaaagca aactgccagt	1560
gctgtgctgt acgctccagt tgcgtgaaga gttcaagcag gaagtggaag caacagcagg	1620
tctcctatat gttgatgacc ctaactggtc tggaaatagg gttgtcaggt atgaacatgc	1680
taatgatgat aagagcagtt tgaaatcaga tcccgaagg gaaaacatcc atgctggact	1740
cctgaagaag ttaaatgaac tggaaatctga cctaaccctt aaaataggcc ctgagtataa	1800
gagcatgaag agctgccttt atgtcggcat ggcgagcgac aacgtcgatg ctgctgagct	1860
cgtggagacc attgcggcca cagcccggga gatagaggag aactcgaggc ttctggaaaa	1920
catgacagaa gtggttcgga aaggcattca ggaagctcaa gtggagctgc agaaggcaag	1980
tgaagaacgg cttctggaag agggggtgtt gcggcagatc cctgtagtgg gctccgtgct	2040
gaattggttt tctccggtcc aggcctttaca gaagggaaga acttttaact tgacagcagg	2100
ctctctggag tccacagaac ccatatatgt ctacaaagca caaggtgcag gagtacgct	2160
gcctccaacg ccctcgggca gtcgcaccaa gcagaggctt ccaggccaga agccttttaa	2220
aaggctccctg cgaggttcag atgctttgag tgagaccagc tcagtcagtc acattgaaga	2280
cttagaaaag gtggagcgcc tatccagtgg gccggagcag atcaccctcg aggccagcag	2340

B0213WO seq list.ST25.txt

cactgagggg caccagggg ctcccagccc tcagcacacc gaccagaccg aggccttcca 2400
 gaaaggggtc ccacaccag aagatgacca ctcacaggta gaaggaccg agagcttaag 2460
 atgagactca ttgtgtggtt tgagactgta ctgagtattg tttcagggaa gatgaagttc 2520
 tattggaaat gtgaactgtg ccacatacta atataaatta ctgttgtttg tgcttactg 2580
 ggattttggc acaaataatgt gcctgaaagg taggctttct aggaggggag tcagcttgct 2640
 taacttcatg tacatgtaga accacgtttg ctgtcctact acgacttttc cctaagttac 2700
 cataaacaca ttttattcac aaaaaacact tcgaatttca agtgtctacc agtagcacc 2760
 ttgctctttc taaacataag cctaagtata tgaggttgcc cgtggcaact ttttggtaaa 2820
 acagcttttc attagcactc tccaggttct ctgcaacact tcacagaggc gagactggct 2880
 gtatcctttg ctgtcgttct ttagtacgat caagttgcaa tatacagtgg gactgctaga 2940
 cttgaaggag agcagtgatt gtgggattgt aaataagagc atcagaagcc ctcccagct 3000
 actgctcttc gtggagactt agtaaggact gtgtctactt gagctgtggc aaggctgctg 3060
 tctgggactg tcctctgcca caaggccatt tctccatta tataccgttt gtaaagagaa 3120
 actgtaaagt ctctcctga ccatatattt ttaaatactg gcaaagcttt taaaattggc 3180
 acacaagtac agactgtgct ctttctgtt tagtatctga aaacctgata gatgctaccc 3240
 ttaagagctt gctcttccgt gtgtacgta gcaccacct gggtaaaatc tgaaaacaag 3300
 taccctttg acctgtctcc cactgaagct tctactgcc tggcagctcg cctgggcca 3360
 actcagaac aggagccagc agagcactct ctacgctga tccagccggg caccctgctt 3420
 aagtcagtag aagctcgtg gactgccc ttctacttt tccgaagtac tgcgtcactt 3480
 tgtcgtagt aatggcccct gtgccttctt aatccagcag tcaagctttt gggagacctg 3540
 aaaatgggaa aattcacact gggtttctg actgtagtat tggaagcctt agttatagta 3600
 tattaagcct ataattatac tctgatttga tgggattttt gacatttaca cttgtcaaaa 3660
 tgcagggggt ttttttggg gcagatgatt aaacagtctt ccctatttgg tgcaatgaag 3720
 tatagcagat aaaatggggg aggggtaaat tatcaccttc aagaaaatta catgttttta 3780
 tatatatttg gaattgttaa attggttttg ctgaaacatt tcacccttga gatattattt 3840
 gaatgttggg ttcaataaag gttcttgaat ttgtt 3875

<210> 141
 <211> 493
 <212> DNA
 <213> Homo sapiens

<400> 141
 aggcagtgaa gatgctggag gacagtcaga gaagaacaga agaggaaaat ggaaagaagc 60
 tcatatccgg agatattcca ggccactcc agggcagtgg gcaagatatg gtgagcatcc 120

B0213WO seq list.ST25.txt

tccagttagt tcacaatcta atgcatggag atgaagatga ggagccccag agccccagaa	180
tgcaaaatat tggagaacaa gggcatatgg ctttgttgag acatagtctg ggagcttata	240
tttcaactct ggacaaagag aagctgagaa aacttacaac taggatactt tcagatacca	300
ccttatggct atgcagaatt ttcagatatg aaaatgggtg tgcttatttc cacgaagagg	360
aaagagaagg acttgcaaag atatgtaggc ttgccattca ttctcgatat gaagacttcg	420
tagtggatgg cttcaatgtg ttatataaca agaagcctgt catatatctt agtgctgctg	480
ctagacctgg cct	493

<210> 142

<211> 6263

<212> DNA

<213> Homo sapiens

<400> 142

gtggatttgg tcgtctccct gattccgagc tgcgggcagg gagaggggccc tcgcccggcc	60
ctcagcagcc ggcggcggcc gaggtagacc gagcggggac ggaaggacag accgacgtcg	120
ccgagctgga atcatgtgag ggccaaccgg ggaagggtgga gcagatgagc acacacagga	180
gccgtctcct caccgcccgc cctctcagca tggaaacagag gcggccctgg ccccgggccc	240
tggagggtgga cagccgctct gtggtcctgc tctcagtggt ctgggtgctg ctggccccc	300
cagcagccgg catgcctcag ttcagcacct tccactctga gaatcgtgac tggaccttca	360
accacttgac cgtccaccaa gggacggggg ccgtctatgt gggggccatc aaccgggtct	420
ataagctgac aggcaacctg accatccagg tggctcataa gacagggcca gaagaggaca	480
acaagtcttg ttacccgccc ctcatcgtgc agccctgcag cgaagtgtc accctcacca	540
acaatgtcaa caagctgtc atcattgact actctgagaa ccgcctgctg gcctgtggga	600
gcctctacca gggggtctgc aagctgtctg ggctggatga cctcttcac ctggtggagc	660
catcccacaa gaaggagcac tacctgtcca gtgtcaacaa gacgggcacc atgtacgggg	720
tgatttgtcg ctctgagggt gaggatggca agctcttcac cggcacggct gtggatggga	780
agcaggatta cttcccagac ctgtccagcc ggaagctgcc ccgagaccct gagtccctcag	840
ccatgtctga ctatgagcta cacagcgatt ttgtctctc tctcatcaag atcccttcag	900
acaccctggc cctggtctcc cactttgaca tcttctacat ctacggcttt gctagtgggg	960
gctttgtcta ctttctcact gtccagccc agaccctga ggggtgtggc atcaactccg	1020
ctggagacct cttctacacc tcacgcatcg tgcggctctg caaggatgac cccaagtacc	1080
actcatagct gtccctgccc ttcggctgca cccgggccc ggtggaatac cgcctcctgc	1140
aggctgctta cctggccaag cctggggact cactggccca ggccttcaat atcaccagcc	1200
aggacgatgt actctttgcc atcttctcca aagggcagaa gcagtatcac caccgccc	1260

B0213WO seq list.ST25.txt

atgactctgc	cctgtgtgcc	ttccctatcc	gggccatcaa	cttgcatatc	aaggggcgcc	1320
tacagtccctg	ctaccagggc	gagggcaacc	tggagctcaa	ctggctgctg	gggaaggacg	1380
tccagtgcac	caaggcgcc	gtcccatc	atgataactt	ctgtggactg	gacatcaacc	1440
agcccctggg	aggctcaact	ccagtggagg	gcctgaccct	gtacaccacc	agcagggacc	1500
gcatgacctc	tgtggcctcc	tacgtttaca	acggctacag	cgtggttttt	gtggggacta	1560
agagtggcaa	gctgaaaaag	attcggggccg	acgggtcccc	ccatggtggg	gtccagtacg	1620
agatggtctc	tgtgtctcaag	gacggaagcc	ccatcctccg	ggacatggcc	ttctccattg	1680
atcagcgcta	cctgtacgtc	atgtctgaga	gacaggtcac	caggggtccc	gtggagtcac	1740
gtgagcagta	tacgacttgt	ggggagtgcc	tgagctctgg	ggaccctcac	tgtggctggt	1800
gtgccctgca	caacatgtgc	tcccgaggg	acaaatgcc	acaggcctgg	gaacctaatc	1860
gatttctgctc	cagcatcagc	cagtgtgtga	gccttgagct	gcatcccagc	agcatctcag	1920
tatctgagca	cagccggttg	cttagcctgg	tagtgagtga	tgctcctgat	ctatctgcgg	1980
gtatcgctg	tgcttttggg	aacctgacag	agggtggagg	gcagggtgtc	gggagccagg	2040
tcatctgcat	ctcacctggg	cccaaggatg	tccctgtcat	cccgtggat	caagactggt	2100
ttgggctgga	gtacagctg	agggtccaag	agacagggaa	gatatttgtc	agcaccgagt	2160
tcaagtttta	caactgcagt	gcccaccaac	tgtgcctgtc	ctgtgtcaac	agcgccttcc	2220
gctgccattg	gtgcaagtac	cgcaacctct	gcactcatga	ccccaccacc	tgctccttcc	2280
aggagggccg	gatcaatatt	tcagaggact	gtccccagct	ggtgcccaca	gaggagatct	2340
tgattccagt	cggggaggta	aagccaatca	cccttaaggc	gcgaaatctg	ccccagccgc	2400
agtccggcca	gcgaggctat	gagtgtgtcc	tcaacataca	aggagccatc	caccgggtcc	2460
ccgctctgctg	cttcaacagc	tccagcggtc	agtgtcagaa	cagctcgtac	cagtatgatg	2520
gcatggacat	cagcaatctg	gccgtggatt	tcgctgtggt	gtggaacggc	aatttcatca	2580
ttgacaaccc	tcaggacctg	aaagtccatc	tctacaagt	tgagcccag	cgggagagct	2640
gcggcctctg	cctcaaggcc	gaccggaagt	ttgagtgtgg	ctgggtgcagc	ggcgagcgca	2700
ggtgcaccct	ccaccagcac	tgtaccagcc	cttccagccc	ctggctcgac	tgggtccagcc	2760
acaatgtcaa	gtgtctcaac	cctcaaata	ccgagatttt	gacggtgtct	ggaccgccc	2820
aaggaggggac	gcgagtgacc	atccatggcg	tgaacctggg	tctggacttc	tccgagatcg	2880
cccaccatgt	gcaggtggct	ggggtgccct	gcacgcccct	cccaggggaa	tacatcatcg	2940
ctgagcagat	tgtctgtgag	atgggcatg	ccctcgtggg	aaccacctcc	gggccagtac	3000
gcctgtgtat	tggcgagtgt	aagccagagt	tcatgacgaa	gtcccatcag	cagtacacct	3060
tcgtgaaccc	ttctgtgctg	tactcaacc	caatccgagg	tcccagatca	ggaggcacta	3120
tgggtgacct	taccggccat	taccttgggg	ctgggagcag	cgtggcagtc	tacctgggca	3180
accagacctg	cgagttctac	gggaggtcaa	tgagtgagat	cgtgtgtgtc	tcaccccat	3240
catccaatgg	ccttggcccc	gtccctgttt	ctgtgagtgt	cgaccgagcc	catgtggata	3300

B0213WO seq list.ST25.txt

gcaacctgca gtttgagtac atagatgacc ctggggtcca gcgcatcgag ccagagtgga	3360
gcattgccag tggccacaca cccctgacca tcacaggctt caacctggat gtcattcagg	3420
agccaaggat ccgagtcaaa ttcaatggca aagaatctgt caatgtgtgt aaagttgtga	3480
acacaaccac cctcacctgc ctggcaccct ctctgaccac ggactaccgc cctggcctgg	3540
acactgtgga acgcccagat gagtttggat ttgtctttaa caatgtccaa tccttgctaa	3600
tttacaacga caccaagttt atctactacc ccaacccgac ctttgaactg cttagcccta	3660
ctggagtctt ggatcaaaag ccaggatcgc ccatcattct gaagggcaaa aaacctctgcc	3720
ctcctgcctc tggagggggc aaactcaact aactgtgct catcgagag accccttgtg	3780
ctgtcaccgt atctgagacc cagcttctct gcgagcctcc caacctcacc gggcagcaca	3840
aggatcatgt tcacgtgggc gggatggtgt tctcgcttg ctcggtgagt gtcattctag	3900
acagcttgct gacctgcca gccatcgtca gcatcgggc cggcggcagc ctctctctca	3960
tcacgtcat catcgtctc attgcctaca agcgcaagtc tcgagaaaat gacctactc	4020
tcaagcggct gaaatgcag atggacaatc tggagtccc tgggcttg gagtgcaagg	4080
aagcttttgc tgagctccag acggatatca atgagttgac cagtgcctg gaccgctcag	4140
gaatccctta cctggactat cgtacctacg ctatgcgagt cctgttccc ggcacgagg	4200
accaccccg cctgcgggag ctggaggtag aaggaaacgg gcagcagcac gtggagaagg	4260
ccctgaagct ctttggccag ctcatcaaca acaagggtgt cctgctgacc ttcatccgca	4320
ccctggagct gcagcgcagt ttctccatgc gcgaccggg caacgtggct tcgctcatca	4380
tgaccggcct gcagggccgc ctggaatatg cactgatgt cctcaagcag ctgtctctg	4440
acctcatcga taagaacctg gagaacaaga accaccccaa gctgtactc cggaggacag	4500
agtctgtggc tgaaaagatg ctgaccaatt ggttcgcctt cctcctgcac aagttcctaa	4560
aggagtgcgc aggggagcca ctcttcatgc tatactgtgc catcaagcag cagatggaga	4620
agggcccat tgatgccatc acgggcgagg ccgctactc cctgagcag gacaagctca	4680
tccggcagca gatcgagtac aagaccctga tcctgaactg cgtcaaccct gacaacgaga	4740
acagtccaga gatcccagtg aagggtgtta actgtgacac catcacacag gtcaaggaga	4800
agattcttga tgccgtgtat aagaatgtgc cttattccca gcggccgagg gcagtggaca	4860
tggacttgga gtggcgccaa ggccggatcg cccgggtcgt gctgcaagat gaggacatca	4920
ccaccaagat tgagggtagc tgggaagcggc tcaacacact gatgcattat cagggtgcag	4980
acaggtcggg ggtggctctg gtccccaac agacctctc ctacaacatc cctgcctctg	5040
ccagcatctc ccggacgtcc atcagcagat atgactctc cttcaggtat acgggcagcc	5100
ccgacagcct gcgggtcccg gcccgatga tcacccaga cctggaaagt ggggtcaagg	5160
tgtggcatct ggtgaagaac catgaccacg gtgaccagaa ggagggtagc cggggcagca	5220
agatggtgtc cgagatctac ctgaccggc tactggccac caagggcacc ctgcagaagt	5280
ttgtggacga cttgtttgag acctgttca gcactgtgca ccggggcagc gctctcccc	5340

B0213W0 seq list.ST25.txt

tggccatcaa gtacatgttt gatttcctag atgagcaggc agacaggcac agcatccatg 5400
 acacagatgt gcggcacacc tggaaaagca actgcctccc tctgcgcttc tgggtgaacg 5460
 tgattaagaa cccccagttc gtgtttgaca tccacaaggc cagcatcacg gacgcctgcc 5520
 tctctgtggt ggcccagacc ttcattggact cttgttcaac gtcagagcac cggctgggca 5580
 aggactcccc ctccaacaag ctgctctatg ccaaggacat cccagctac aagagctggg 5640
 tggagagata ctacgcagac atcgccaagc tcccagccat cagtgaccag gacatgaatg 5700
 cctacctcgc cgagcagtcc cgcctgcacg ccgtggagtt caacatgctg agtgccctca 5760
 atgagatcta ctctatgtc agcaagtata gtgaggagct catcggggcc ctagagcagg 5820
 atgagcaggc acggcggcag cggctggctt ataagggtga gcagctcatt aatgccatgt 5880
 ccattgagag ctgagaggag gaggctcgca ttcctgggaa gagggacctg tccaagctgt 5940
 cactctggga gtctcagatg gaaggacaag tgatggggat caggccccag agcttgctgt 6000
 cccctgagac cccatcctgg ggagagggga ggactcctct ccctacgcca gccaagtctc 6060
 gtcatagccca gtccagctg ggagagacag tgggcgtcgt ccctcctcag tgagaacacc 6120
 agagaacccg gggccgggag aagggtggtc ttcaagccga gaggcacgag ctggggacag 6180
 ttctgcctct gtgactgctg ctttgcatga aaactcattt gatgtatatt ggggaaataa 6240
 tgagaacttt atttaatttt ttt 6263

<210> 143

<211> 1725

<212> DNA

<213> Homo sapiens

<400> 143

tgtgtcaaca gcgccttccg ctgccattgg tgcaagtacc gcaacctctg cactcatgac 60
 cccaccacct gctccttcca ggagggccgg atcaatattt cagaggactg tcccagctg 120
 gtgcccacag aggagatctt gattccagtc ggggaggtaa agccaatcac ccttaaggcg 180
 cgaaatctgc cccagccgca gtccggccag cgaggctatg agtgtgtcct caacatacaa 240
 ggagccatcc accgggtccc cgctctgctc ttcaacagct ccagcgttca gtgtcagaac 300
 agctcgtacc agtatgatgg catggacatc agcaatctgg ccgtggattt cgctgtggtg 360
 tggaacggca atttcatcat tgacaaccct caggacctga aagtcctct ctacaagtgt 420
 gcagcccagc gggagagctg cggcctctgc ctcaaggccg accggaagtt tgagtgtggc 480
 tgggtgcagc gcgagcgag gtgcaccctc caccagcact gtaccagccc ttccagcccc 540
 tggctcgact ggtccagcca caatgtcaag tgctccaacc ctcaaatcac cgagattttg 600
 acggtgtctg gaccgccgga aggagggacg cgagtgaacca tccatggcgt gaacctgggt 660
 ctggacttct ccgagatcgc ccaccatgtg cagggtggctg gggtgccctg cagccccctc 720

B0213wo seq list.ST25.txt

```

ccaggggaat acatcatcgc tgagcagatt gtctgtgaga tgggccatgc cctcgtggga 780
accacctccg ggccagtacg cctgtgtatt ggcgagtgtg agccagagtt catgacgaag 840
tcccatcagc agtacacctt cgtgaaccct tctgtgtgtg cactcaaccc aatccgaggt 900
cccgagtcag gaggcactat ggtgaccatt accggccatt accttggggc tgggagcagc 960
gtggcagtct acctgggcaa ccagacctgc gagttctacg ggaggtcaat gagtgagatc 1020
gtgtgtgtct caccctcatc atccaatggc cttggcccg tccctgtttc tgtgagtgtc 1080
gaccgagccc atgtggatag caacctgcag tttgagtaca tagatgacct tcgggtccag 1140
cgcctcgagc cagagtggag cattgccagt ggccacacac ccctgacct cacaggcttc 1200
aacctggatg tcattcagga gccaaggatc cgagtcaa tcaatggcaa agaattctgtc 1260
aatgtgtgta aagttgtgaa cacaaccacc ctacactgcc tggcaccctc tctgaccacg 1320
gactaccgcc ctggcctgga cactgtggaa cgccagatg agtttggatt tgtctttaac 1380
aatgtccaat ccttgcta atacaacgac accaagtta tctactacc caaccgacc 1440
tttgaactgc ttagccctac tggagtcttg gatcaaaagc caggatcgcc catcattctg 1500
aagggcaaaa acctctgccc tcctgcctct ggaggggcca aactcaacta cactgtgctc 1560
atcgagagaga ccccttgctg tgtcaccgta tctgagacct agcttctctg cgagcctccc 1620
aacctcaccg ggcagcaca ggtcatggtt cacgtggcg ggatggtgtt ctcgcctggc 1680
tcggtgagtg tcattctcaga cagcttgctg accctgccag ccac 1725

```

<210> 144

<211> 558

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (462)..(462)

<223> n = a t c o r g

<400> 144

```

gggcccttct ccactctgtg cttgatggca cagtatagca tgaagagtgg ctccccctgcg 60
cactccttta ggaacttgtg caggaggaag gcgaaccaat tggtcagcat cttttcagcc 120
acagactctg tcctccggag tagcagcttg ggggtggttct tgttctccag gttcttatcg 180
atgaggtcag agagcagctg cttgaggaca tcagtggcat attccaggcg gccctgcagg 240
ccggtcatga tgagcgaagc cacgttggcc cggtcgcgca tggagaaact gcgctgcagc 300
tccaggtgct ggatgaaggt cagcaggaac acctgtgtgt tgatgagctg ggcaaagagc 360

```

B0213WO seq list.ST25.txt

ttcagggcct tctccacgtg ctgctgcccg tttccttgta cctccagctc ccgcaggacg	420
gggtggtcct cgatgcccgg gaacaggact cgcatagcgt angtagata gtccaggtaa	480
gggattcctg agcgggtccag gtcactgggc aactcattga tatccgtctg gagctcagca	540
aaagcttcct tgcactcc	558

<210> 145

<211> 5567

<212> DNA

<213> Homo sapiens

<400> 145

atggtggaac acgtgccc caaacatgga aacgaccgtt ctcagtggga tcaacttcga	60
gtacaagggc atgacaggct gggagggtggc tggatgacac atttacacag ctgctggagc	120
ctcagacaat gacttcatga ttctactctt ggttggtgcca ggatttagac ctccgcagtc	180
ggtgatggca gacacagaga ataaagggt ggccagaatc acatttgtct ttgagaccct	240
ctgtttctgtg aactgtgagc tctacttcat ggtgggtgtg aattctagga ccaacactcc	300
tgtggagacg tggaaagggt ccaaaggcaa acagtcctat acctacatca ttgaggagaa	360
cactaccacg agcttcacct gggccttcca gaggaccact ttcatgagg caagcaggaa	420
gtacaccaat gacgttgcca agatctactc catcaatgtc accaatgtta tgaatggcgt	480
ggcctcttac tgccgtccct gtgcccataa agcctctgat gtgggtcctt cctgcacctc	540
ttgtctgtct ggttactata ttgaccgaga ttcaggaacc tgccactcct gccccctaa	600
cacaattctg aaagcccacc agccttatgg tgtccaggcc tgtgtgccct gtggtccagg	660
gaccaagaac aacaagatcc actctctgtg ctacaatgat tgcaccttct cacgcaacac	720
tccaaccagg actttcaact acaacttctc cgctttggca aacaccgtca ctcttgctgg	780
agggccaagc ttcacttcca aagggttgaa atacttccat cactttaccc tcagtctctg	840
tggaaaccag ggtaggaaaa tgtctgtgtg caccgacaat gtcactgacc tccggattcc	900
tgagggtgag tcagggttct ccaaacttat cacagcctac gtctgccagg cagtcacatc	960
ccccccagag gtgacaggct acaaggccgg ggtttcttca cagcctgtca gccttgctga	1020
tcgacttatt ggggtgacaa cagatatgac tctggatgga atcacctccc cagctgaact	1080
tttccacctg gagtccctgg gaataccgga cgtgatcttc ttttataggc ccaatgatgt	1140
gacctcagtc tgcagttctg ggagatcaac caccatccgc gtcagggtga gtccacagaa	1200
aactgtccct ggaagtttgc tgctgccagg aacgtgtcga gatgggacct gtgatggctg	1260
caacttcac ttctgtggg agagcgggc tgctgcccgt ctctgctcag tggctgacta	1320
ccatgctatc gtcagcagct gtgtggctgg gatccagaag actacttacg tgtggcgaga	1380
acccaagcta tgctctggtg gcatttctct gcctgagcag agagtcacca tctgcaaaac	1440

B0213wo seq list.ST25.txt

catagatttc tggctgaaag tgggcatctc tgcaggcacc tgtactgcca tcctgctcac	1500
cgtcttgacc tgctactttt ggaaaaagaa tcaaaaacta gagtacaagt actccaagct	1560
ggtgatgaat gctactctca aggactgtga cctgccagca gctgacagct gcgccatcat	1620
ggaaggcgag gatgtagagg acgacctcat ctttaccagc aagaagtcac tctttgggaa	1680
gatcaaatca tttacctcca agcagccagc tcctgtcacc atctctcttt cagaggactc	1740
ctgatggatt tgactcagtg ccgctgaaga catcctcagg aggccagac atggacctgt	1800
gagaggcact gcctgcctca cctgcctcct caccttgcac agcacctttg caagcctgcg	1860
gcgatttggg tgccagcatc ctgcaacacc cactgctgga aatctcttca ttgtggcctt	1920
atcagatgtt tgaatttcag atcttttttt atagagtacc caaacctcc tttctgcttg	1980
cctcaaacct gccaaatata cccacacttt gtttgtaaat tatgcccttg cttgtatctt	2040
gtttcccaaa atggcccatc cgccagagcc atagcttcgt ctgctcataa ttcttatagc	2100
tttggaatga aaatatttct atcttcttaa gtatagaaac tatttcctct gtcctctaac	2160
ttaagggcag aaacagctgg gagttttcct cgcattgccct cagctcatga tctcttcagg	2220
agagaggctg ggtgaggagg gtgtcggggt tccttggtgg ataactttca tagcagcctg	2280
gatccatttc ccctggataa ccagctcaaa gggagtgaat atggtagtct gagggcaagg	2340
ggagcaaggc ctgggtaaga aaagccttga aaagcataaa aagaggccgg gcgcggtggc	2400
tcacgcctgt aatcccagca ctttgggagg ccgaggcggg cagatcatga ggtcgggaga	2460
ttgagaccat cctggctaac acggtgaagc cccgtctcta ctggaaatac aaaaaattag	2520
ccgggcgtgg tggcgggtgc ctgtgtgcc cagctactcg gaggctgagg cgggagaata	2580
gcgtgggcct ggaaggcgga gcttgacagtg agccgagatc gcgccactgc actccatcca	2640
gcctgggtga cagagtgaat ctctgcctca aaaaaaaaaa aaaaaagaa aagcacaag	2700
agaggcaaca aggaatgttt ttgtttttga gacaggctct cactctgtca cctaggctgg	2760
agtgcagtg cgtaatcact gttcagtgca gcctcaagct cttgggctca ggctatctc	2820
ccatctcagc ctctcaagta gctgggacta cgagtgtgca ccaccaggct cactaatttt	2880
tgtgtttttt gtagacacgg ggtttcaccg tgttgcccag gctggtctcc aactcctggg	2940
ctcaagtgat ctgtccgcct cggcctccca aactgctggg attacaggca taagccactg	3000
cactcagcct tttatttgtt ttttaaacca cgtagctcat tgccttctct taagtaaatg	3060
atagatatcc tcaactgaagc caaaggaata agttcatcaa gaaaatgccc aaagccctgg	3120
tggatacatc ctccctatct tttttttaa ccttccacta tcaactctatg aactgaaaa	3180
gaaccaggta agcccaaac ccagatgttc cagccttacc ctctattggg ttaccacaca	3240
gacatagcaa accctgtcag tgaggaaaat tccccatcct tgagtgcacc cgtcctagaa	3300
gtttgggcca tattatggaa caggggtctc ttatttgaaa agagcacaag gaggccaaga	3360
ttttaatggg gcactttagg ggatacagcc cacaatggca tgggcctgag gtggccgtga	3420
tgtctgcttc taagcttaac gcatctgctc aggcacagaa taaactgcta ggctggccaa	3480

B0213WO seq list.ST25.txt

aaaaggaact gaatcccagg cccatacgcc agcaccagaa tcaaaccagt cttcaaggaa	3540
ggaaggctag gagagtttaa caagattttc actgggcccga gcatggtggc tcacacctgt	3600
aatcccaagg cagaatggtg gcttgagctc aggagttcaa gaccagcctg ggcaacacag	3660
tgagaccctg tctctaaaaa atttaaaaat aaacaagggt ttcaccaagc tgggatactt	3720
ctcactatta agcccctatc tttctctttt tttcattctc aattgctttg tgtgataaaa	3780
aactaaagag acttctggtc caatttctgg caacatccct tctgaaagggt gagtagagt	3840
ggtgtcttct atgcccattt tccccaatth tacacaaaact attatcaatg aacttttaag	3900
tacctagaat gggtaaaacc agagcaagac tttaaattac cttcttcttt cttctactgg	3960
cagttctgcc tccatcacta tcaggctagg gtgaccttcc cttggtcaag ccccaattgc	4020
ccatgatttg tgcctgtgcc ctttctccag tgaccatttg gtgaccagat ggtagatata	4080
gaaaggggat ggcatttgca agtgactagt ctgccacaaa atgctcatct gattagccac	4140
tgctgccctg gcaatggctt tgtaagagtc aatgagaact agagccaggc tgtggtccct	4200
ggccatcaac agtgttggtg acggcaggga gtcccttttg tttataaat ccagtttttc	4260
tttggtatc caaattctcc cctccttttg taggagtcag gctctcagaa cctgtgtcca	4320
tgttggaact tccccagtg tggatgcaga tacgcagctc ctgagctcca gcctaaagtc	4380
ttctgtagcc tcagcaatac ttgggcacct gctgtctcac tgaatagctt tcttttgtga	4440
caaaggccac agacagccct tagactattc cggaacaggt aggaaaaatt acatatgtct	4500
ttgacttctt tattctgact ccactgattt tagccataat actttaagga gctacttttt	4560
actacccctt accgtgctga cttctgcagg tctgccctgt gacctgtcag gaactcctga	4620
gttacgttac tggggtcacc tgttgctccc ctagcaagtt aggcattgtca tatattttta	4680
acagctttat tgagatataa ttcacatatt atacaattca cttttaaac atacgattca	4740
atggttttca gcaaaactac agagtgtgcc gccacttga gagcaaacac atgttcaatt	4800
ttcttttctt tttttttttt gagacagagt cagctttgtc gccaggctg gagtgcagt	4860
ccatgatctt ggctcactgc agcctcccca tcctgggttc aagtgatcct tctgcttcag	4920
cctccccagt agctgggatt acaggcatgc gccaccacgc ctagctaatt tttgtgtttt	4980
tagtagagat ggggtttcac cgtgttggtc aggctggtct caaactcctg gactcaagt	5040
atccaccac ctcggcctcc caaagtgtg ggattgcagg tgtgagccac cgtgcctggc	5100
ctacgtgttc aattttctat gaacaaaggc tttagtcctt gaccagggc taaagtggc	5160
tgccaagct gttgttggtg gagggagtat gataaaatgt ttaaattctca tttggttacc	5220
ttgagtcctg gaacacgcag taactgtcat gctatagtca tcatctgtat ttggctggga	5280
atacaaatga agattgtggt gtattcaagc agtaggggtt ttgcttttgt tttgtttta	5340
gtgccaacaa aacttttttt tgtctgacta cattaaagat aagactgact atatttatac	5400
aacagaaact ttgtaataga ttttttcagc tttgtgaaat cgaatttttt ttcacaggg	5460
ctggttggtat ttccttttta ccctgtaatc caagcgtaa tagtttgta gaagatgggt	5520

B0213WO seq list.ST25.txt

tattgcatgt cacttttttt tttttgtaaa ataaaaacat accttac 5567

<210> 146

<211> 299

<212> DNA

<213> Homo sapiens

<400> 146
 gtaaaaaagga aatccaacca gccctgatga aaaaaaattc gatttcacaa agctgaaaaa 60
 atctattaca aagtttctgt tgtataaata tagtcagtct tatctttaat gtagtcagac 120
 aaaaaaaagt tttgttgga ctaaaacaaa aacaaaagca aaaaccctac tgcttgaata 180
 caccacaatc ttcatattgta ttcccagcca aatacagatg acgactatag catgacagtt 240
 actgctgtgt ccaggactca aggtaaccaa atgagattta aacattttat catactccc 299

<210> 147

<211> 1326

<212> DNA

<213> Homo sapiens

<400> 147
 gactcaggca ctgggctagg tgcttgggat acatccgtga gccacacaaa gttccccacc 60
 ccagaggagc tcttacctgg ccagaaatct ggatctctgc cccagcccc tatcctcaag 120
 gtagagtccc aaagatgtcc taaatctcac acaggctgag ttgtgcttaa tccatttctg 180
 cagacacaac tcatgtacaa atgggccaag ccgaaaatct gtagcgagga ccttgagggg 240
 gcagtgaagc tgcctgcctc tgggtgtgaag acccactgcc caccctgcaa cccaggcttc 300
 ttcaaaaacca acaacagcac ctgccagccc tgcccatatg gttcctactc caatggctca 360
 gactgtaccc gctgccctgc agggactgaa cctgctgtgg gatttgaata caaatggtgg 420
 aacacgctgc ccacaaacat ggaaacgacc gttctcagt ggatcaactt cgagtacaag 480
 ggcatgacag gctgggaggt ggctggtgat cacatttaca cagctgctgg agcctcagac 540
 aatgacttca tgattctcac tctggttctg ccaggattta gacctccgca gtcggtgatg 600
 gcagacacag agaataaaga ggtggccaga atcacatttg tctttgagac cctctgttct 660
 gtgaactgtg agctctactt catggtgggt gtgaattcta ggaccaacac tcctgtggag 720
 acgtggaaag gttccaaagg caaacagtcc tatacctaca tcattgagga gaacactacc 780
 acgagcttca cctgggcttc ccagaggacc acttttcatg aggcaagcag gaagtacacc 840
 aatgacgttg ccaagatcta ctccatcaat gtcaccaatg ttatgaatgg tgtggcctcc 900
 tactgccgtc cctgtgccct agaagcctct gatgtgggct cctcctgcac ctcttgcct 960

B0213WO seq list.ST25.txt

gctggttact atattgaccg agattcagga acctgccact cctgccccac taacacaatt 1020
 ctgaaagccc accagcctta tgggtgtccag gcctgtgtgc cctgtggtcc agggaccaag 1080
 aacaacaaga tccactctct gtgctacaac gattgcacct tctcacgcaa cactccgacc 1140
 aggactttca actacaactt ctccgctttg gcaaactctg tctactttgc tggagggcca 1200
 agcttcactt ccaaagggct gaaatacttc catcacttta ccctcagtct ctgtggaaac 1260
 cagggtagga aaatgtctgt gtgcaccgac aatgtcactg acctccggat tcctgagggg 1320
 gagtca 1326

<210> 148

<211> 698

<212> DNA

<213> Homo sapiens

<400> 148
 cttccatgat ggcgcagctg tcagctgctg gcaggtcaca gtccttgaga gtagcattca 60
 tcaccagctt ggagtacttg tactctagtt tttgattctt tttccaaaag tagcagggtca 120
 agacggtgag caggatggca gtacaggtgc ctgcagagat gccactttc agccagaaat 180
 ctatggtttt gcagatgggtg actctctgct caggcagaga aatgccacca gagcatagct 240
 tgggttctcg ccacacgtaa gtagtcttct ggatcccagc cacacagctg ctgacgatag 300
 catggtagtc agccactgag cagagcgggc aagcagccgc gctctccac aggaagtgga 360
 agttgcagcc atcacaggtc ccatctgagc acgttcctgg cagcagcaaa cttccaggga 420
 cagttttctg tggactgcac ctgacgcgga tgggtggtga tctcccagaa ctgcaggact 480
 gggtcacatc attggaccta taaaagaaga tcacgtccgg tattcccaag gactccaggt 540
 ggaaaagtgc agctggggag gtgattccat ccagagtcac atctgttgtc accccaataa 600
 gtcgatcagc aaggctgaca ggctgtgagg aaaccccggc cttgtagcct gtcacctctg 660
 gggggatgat gactgcctgg cagacgtagg ctgtgata 698

<210> 149

<211> 478

<212> DNA

<213> Homo sapiens

<400> 149
 cttccatgat ggcgcagctg tcagctgctg gcaggtcaca gtccttgaga gtagcattca 60
 tcaccagctt ggagtacttg tactctagtt tttgattctt tttccaaaag tagcagggtca 120
 agacggtgag caggatggca gtacaggtgc ctgcagagat gccactttc agccagaaat 180

B0213WO seq list.ST25.txt

ctatggtttt gcagatgggtg actctctgct caggcagaga aatgccacca gagcatagct	240
tggtttctcg ccacacgtaa gtagtcttct ggccacctct ttattctctg tgtctgccat	300
caccgactgc ggaggtctaa atcctggcac aaccagagtg agaatcatga agtcattgtc	360
tgaggctcca gtagctgtgt aaatgtgatc accagccacc tcccagcctg tcatgccctt	420
gtactcgaag ttgatccac tgagaacggt cgtttccgtg tttgtgggca gcgtgttc	478

<210> 150

<211> 315

<212> DNA

<213> Homo sapiens

<400> 150	
cgtgggtagg gcacggggtc tgttctgaaa tgtaaagggt tcagacgggg tttctggttt	60
tagaagggtg cgtggctctc gagttgggct aaagtagagt tcgttggtgct gtttctgact	120
cctaatagaga gttccttcca gaccgttacg tgtctcctgg ccaagcccca ggaaggaaat	180
gatgcagctc tggctccttg tctcccaggc tgatccttta ttcagaatac cacaagaaa	240
ggacattcag ctcaaggctc cctgccgtgt tgaagagttc tgactgcaca aaccagcttc	300
tggtttcttc tggaa	315

<210> 151

<211> 219

<212> DNA

<213> Homo sapiens

<400> 151	
tttgagggca agtagtgtct tggcacagag aagagcccag agtatagagc ggaagcaaga	60
gagttagcca cgtattgtta gtagaatttt ccagtgttgt gcttggaatg gtggagtgtt	120
ctggttcagt ctctcttgt tttatcgagt atttattcct gtgcttcagt cggtaacagc	180
ccgaattatc ggtgacccat cactacatgg agatgtttg	219

<210> 152

<211> 351

<212> DNA

<213> Homo sapiens

<400> 152	
gcctttaacc atgtacaact ggctggcggc caggaccgac agggcagcaa ggctccaggg	60

B0213WO seq list.ST25.txt

gtgctttcgc cggaagtccc cacaacagct gaggacgatg agagagatga agaacacagc 120
 ataggagaca tagtaggtcc aaacattctc ccggacaaag cccttcacct ccgcaacaga 180
 agtgaacaca gacaccgtgg acagggtcac cgacagctgc aaggctcagca ctaggaacac 240
 cttgcggatg aaggcctgtc ggatgctctt gtcatcccag ttggtggcag ggaagtcctg 300
 gttgtcatag taagatgggg gaccctcctc ctggtgaaat tgataacgct t 351

<210> 153

<211> 286

<212> DNA

<213> Homo sapiens

<400> 153
 tgagctgagg gttagtgggtg actttttgat acgaaaaaat gcattttgtg cagctgggtga 60
 ggtataatcc aaagcaaaag caggggcaaa aatggacttc ctgaagttat ctctgctcct 120
 gctggttatc ctccagaatc tgtcatgttg actgagagtg cgtgcttgct ttctcaggcc 180
 tcctggctaa tagcacaggt ctgctggaaa tcaccacat ggtttttcat tgcctgtgca 240
 gtcaggtgat gcctctatgt ttttgagggt ccacccctt actcaa 286

<210> 154

<211> 419

<212> DNA

<213> Homo sapiens

<400> 154
 gttaggtagg ctatggatga ggctgactat tactgtcagg cgtgggacag caacattgct 60
 tatgtcttcg gaactgggac caaggctacc gtcttaggtc agcccaaggc caacccact 120
 gtcactctgt tccgcctc ctctgaggag ctccaagcca acaaggccac actagtgtgt 180
 ctgatcagt acttctaccc gggagctgtg acagaggcct ggaaggcaga tggcagcccc 240
 gtcaaggcgg gagtggagac caccaaacc tcacaacaga gcaacaaca gtacgcggcc 300
 agcagctacc tgagcctgtc cataataacg cttctcaatc actagtgcgg ccgcctgcag 360
 gtcgaccata tgggagagct cccaacgcgt tggatgcata gcttgagtat tctatagt 419

<210> 155

<211> 424

<212> DNA

<213> Homo sapiens

B0213W0 seq list.ST25.txt

<400> 155
tagggggagg tctgggggct cacggcgccg aagtggaaga catggcgctt gttcccgtgg 60
gggttggagg cttcacagga gatgccatcg cggtcaggg cgctggtcac tttcagggtc 120
agagagctgc tcacccaacc ctgccgtccg gggattggct ctgcggggct gcccccaat 180
tggtccagc tgagtttggg gtctggatgg ccgcgggcag agcagatgag tgtgacttcg 240
tctccttccc tccagctgcc atctgccttg ggctctattt ccgctgtctt tagctctggc 300
gagccttga ccagcagcg gaagtcttg gtgcggctga ggaccgggac tgtgggcagg 360
gaggcctcac atacgtagg gcataggaa tcgaaggtag tagaactgag cgacagcatg 420
gggc 424

<210> 156
<211> 396
<212> DNA
<213> Homo sapiens

<400> 156
gcaggggaagg tcagaagcca gtcattgatg accagcgca ccttatctcc aacaatgagc 60
aactgcccac gctggggccg cgccctgggg ccccgagag caagtgcagc cgcggagccc 120
tgtacacagg cttttccatc ctggtgactc tgctcctcgc tggccaggcc accaccgcct 180
acttcctgta ccagcagcag ggccggctgg acaaaactgac agtcacctcc cagaacctgc 240
agctggagaa cctgcgcag aagcttccca agcctccca gcctgtgagc aagatgcgca 300
tggccacccc gctgctgatg caggcgctgc ccatgggagc cctgccccag gggcccatgc 360
agaatgccac caagtatggc aacatgacag aggacc 396

<210> 157
<211> 161
<212> DNA
<213> Homo sapiens

<400> 157
gcagaggggg ggtggggagg ggtgctctgc tggcttcaa ttaccaagaa ttctccaaa 60
caattttctg caggatgatt gtacagaatc attgcttatg acatgatcgc tttctacact 120
gtattacata aataaattaa ataaaataac cccgggtcct a 161

<210> 158
<211> 382
<212> DNA

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 158
acgtcgcggg gattgttctg gaggttcacc ttttccgtca catcatcata cticcgaatt 60
tcgcgcacgg catcgtgac caacagcaca aggatgacaa tgagaaccac aaagaagggtg 120
ttgccatagg aactaaca ctccaccagc cgggacttga aaatcttctg ccatctttta 180
ggagaaatga aggggaatgca gagaagcaac acaacaaaga cctccgcata gaggaagggtg 240
gcaactgcag tccactgcag actcatcctg ttgctagaag gtttcccaca ggaagatgtg 300
agcttgtttc cgagtttccc acagtcaacg tgcaggcccc gccgcagcaa ccgaactctc 360
ccacagcagc cccccattcc ca 382

<210> 159

<211> 292

<212> DNA

<213> Homo sapiens

<400> 159
gtacaggcag gcttgaagat gggagttttc atggcttgac catgaatgat ctcaagatga 60
tttcataaga ttaaagcca tcacgaaaat actgaaagca acaggaata atctggattc 120
agtctgtagt tgctcatgaa ccacgcgttt taataaaagg aacattaagt aaattgtagg 180
tataaaagaa tcagtgcata tctgttaatg tcattgacaa taaaaataca ttatcttctc 240
agctcagctc taaattaaca aaacacctat ttttttttcc cactcctagc ca 292

<210> 160

<211> 447

<212> DNA

<213> Homo sapiens

<400> 160
gggggggagg tggagtctgg agacgacgtg cagaaatggc acctcgaaag gggaaggaaa 60
agaaggaaga acaggtcatc agcctcggac ctgaggtggc tgaaggagag aatgtatttg 120
gtgtctgcc a tatctttgca tccttcaatg acacttttgt ccatgtcact gatctttctg 180
gcaaggaaac catctgccgt gtgactggtg ggatgaagg aaaggcagac cgagatgaat 240
cctcaccata tgctgctatg ttggctgccc aggatgtggc ccagaggtgc aaggagctgg 300
gtatcaccgc cctacacatc aaactccggg ccacaggagg aaataggacc aagaccctg 360
gacctccacc caataacgct tctcaatcac tagtgcgccc gcctgcaggt cgaccatatg 420

B0213WO seq list.ST25.txt
 ggagagctcc caacgcgttg gatgcat 447

<210> 161

<211> 239

<212> DNA

<213> Homo sapiens

<400> 161
 ttgggtaagg catcatagat aaacgtaatt gtttggggag ttaaatttaa tgaacttatt 60
 taactttgta acccatcttg gcttttagtaa ctttatcaag gtggtggctt tagtgaatat 120
 aatggtaaac tttagaggac gctaaagcct cactaaaata acgcttctca atcactagt 180
 cggccgcctg caggtcgacc atatgggaga gtcaccaacg cggttgatgc atagcttga 239

<210> 162

<211> 410

<212> DNA

<213> Homo sapiens

<400> 162
 tgctgggagg tcctcacggt ccaccgggcc ctgaacagtg ataagtccag tgttcctgtc 60
 cagtcgaaga agacgcctca caacttcggg cgcctggtgg aatgtgtatt cgatttctgc 120
 attggcacct tggctctagt cattgacctt cacctggatg accgagtggc ctatggggct 180
 attctcagat agttcggcct cataggaggg ccgctcaaac ttggggggcgt tgctattggt 240
 gtcaagcacg gtgacacgca gcagggcact gctggcgcgt ggggggctgc cgccatcctg 300
 caccttgatg gtgaggtcat aggagtccca gcgctcacgg tccagggtgc ccatcacaat 360
 gagctgtggt tgcttctect cctggctctc tgccacctcg gcccataac 410

<210> 163

<211> 327

<212> DNA

<213> Homo sapiens

<400> 163
 tgaggaaggc catgttcttg gtttcttca atcctagccg aagaccattc attgcaccaa 60
 acgcagcccc tgtcatgcaa catcctcaa tcgtaaagaa ggccagctca aatctgcccc 120
 gggttttatt agctccggtg ggtaaaataa actcatctgt atcctgcacg aggtatcgtg 180
 gatccacatt taaataagga gacagagggt tcataccagt tagcgggacg ccagccaaat 240

B0213WO seq list.ST25.txt

ccgcgtgcga gtaacctgct ccgccggctc cgaaaaagca ggccaatccc cctgtggttt 300
 tgttgccgct tccccgcct ccccca 327

<210> 164

<211> 300

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (204)..(204)

<223> n = a t c or g

<400> 164
 tagcgggaga aagatgggaa ctccgtttcc acctgcactc tctcgcgcc ctctattctt 60
 tcaccacatt gctttatcct ttacccttt tttttatttt aaattaaaga atgaactgaa 120
 aagatataac atgacgtaca attaaagaat aattttaag tgaatactac gtaactccat 180
 ccaagtcaag aaattgccag cttnccgaag cccactgtgc tcctccccct cataacgctt 240
 ctcaccttag tgcgccgcct gcagcgacca tatggagagc tccaacgcgt tggatgcata 300

<210> 165

<211> 351

<212> DNA

<213> Homo sapiens

<400> 165
 cggagccagg caatacaaaa aatgcaatta tccattgcaa tggaaccacc aaagaatgcc 60
 tcgcaaccga atataccatc ccctttttgg gtccggtttt attcgctccc aagcgcttaa 120
 tctttgagtt taagccgtcg ttaaaggatt caagtcaggc atttaaggaa cgacactacg 180
 agatgggatg aggccgaaga tgatcaattt taaaggcgcc gcccgcaaac gggcctccga 240
 caccgcctcc ccgtaataac gcttctcaat cactagtgcg gccgcctgca ggtcgaccat 300
 atgggagagc tccaacgcg ttggatgcat agcttgagta ttctatagt t 351

<210> 166

<211> 4839

<212> DNA

<213> Homo sapiens

B0213W0 seq list.ST25.txt

```

<400> 166
ggaaagctag cggcagaggc tcagccccgg cggcagcgcg cgccccgctg ccagcccatt    60
ttccggacgc caccgcggg cactgccgac gccccgggg ctgccgaggg gaggcgggg    120
gggcgcagcg gagcgcggtc ccgcgcactg agccccgcgg cgccccggga acttggcggc    180
gaccgagacc cggcgagccg gggcgcgccct cccccgccgc gcgcctcctg catgcggggc    240
cccagctccg ggcgccggcc ggagcccccc ccggccgccc ccgagcccc cgcgccccgc    300
gccgcgccgc cgcgccgtcc atgcaccgct tgatgggggt caacagcacc gccgccgccg    360
ccgccgggca gcccgaatgtc tcctgcacgt gcaactgcaa acgctctttg ttccagagca    420
tgagatcac ggagctggag tttgttcaga tcatcatcat cgtggtggtg atgatggtga    480
tggtggtggt gatcacgtgc ctgctgagcc actacaagct gtctgcacgg tccttcatca    540
gccggcacag ccaggggagg aggagagaag atgccctgtc ctcagaagga tgctgtggc    600
cctcgagag cagagtgtca ggcaacggaa tccagagcc gcaggtctac gccccgcctc    660
ggcccaccga ccgcctggcc gtgccgccct tcgcccagcg ggagcgcttc caccgcttcc    720
agcccaccta tccgtacctg cagcacgaga tcgacctgcc acccaccatc tcgctgtcag    780
acggggagga gccccaccc taccagggcc cctgcaccct ccagcttcgg gaccccgagc    840
agcagctgga actgaaccgg gagtcggtgc gcgcaccccc aaacagaacc atcttcgaca    900
gtgacctgat ggatagtgcc aggtcgggag gccctgccc cccagcagt aactcgggca    960
tcagcgccac gtgtacctg agcggcgggc gcatggaggg gccgccgccc acctacagcg   1020
aggatcatcg ccactaccg gggctcctcct tccagacca gcagagcagt gggccgccct   1080
ccttgctgga ggggacccg ctccaccaca cacacatcgc gccctagag agcgagcca   1140
tctggagcaa agagaaggat aaacagaaag gacaccctct ctagggtccc cagggggggc   1200
gggctggggc tgcgtagggtg aaaaggcaga aactccgcg cttcttagaa gaggagtga   1260
aggaaggcgg ggggcgcagc aacgcacgt gtggccctcc cctccacct ccctgtgtat   1320
aaatatttac atgtgatgtc tggctctgaat gcacaagcta agagagcttg caaaaaaaaa   1380
aagaaaaaag aaaaaaaaaa accacgtttc tttgttgagc tgtgtcttga aggcaaaaga   1440
aaaaaaaaat ctacagtagt ctttcttggt tctagttgag ctgctgctg gaatgcttat   1500
tttcttttgt ttatgataat ttcacttaac tttaaagaca tatttgcaca aaacctttgt   1560
ttaagatct gcaatattat atatataaat atatataaga taagagaaac tgtatgtgcg   1620
agggcaggag tatttttgta ttagaagagg cctattaaaa aaaaaagttg ttttctgaac   1680
tagaagagga aaaaaatggc aatttttgag tgccaagtca gaaagtgtgt attaccttgt   1740
aaagaaaaaa attacaaagc aggggtttag agttatttat ataaatgttg agattttgca   1800
ctatttttta atataaatat gtcagtgtt gcttgatgga aacttctctt gtgtctgttg   1860
agactttaag ggagaaatgt cggaatttca gagtcgcctg acggcagagg gtgagcccc   1920

```

B0213WO seq list.ST25.txt

gtggagtctg cagagaggcc ttggccagga gcggcgggct ttcccaggag gccactgtcc 1980
 ctgcagagtg gatgcttctg cctagtgaca ggttatcacc acgttatata ttccctaccg 2040
 aaggagacac cttttccccc ctgaccacaga acagccttta aatcacaagc aaaataggaa 2100
 agttaaccac ggaggcaccg agttccagggt agtggttttg cctttcccaa aaatgaaaat 2160
 aaactgttac cgaaggaatt agtttttctt cttctttttt ccaactgtga aggtccccgt 2220
 ggggtggagc atggtgcccc tcacaagccg cagcggctgg tgcccgggct accagggaca 2280
 tgccagaggg ctgatgact tgtctctgca gggcgctttg gtggttgttc agctggctaa 2340
 aggttcaccg gtgaaggcag gtgcggtaac tgccgactg gaccctagga agccccaggt 2400
 attcgcaatc tgacctctc ctgtctgttt ccttcacgg atcaattctc acttaagagg 2460
 ccaataaaca acccaacatg aaaagggtgac aagcctgggt ttctcccagg atagggtgaaa 2520
 ggggttaaaat gagtaaagca gttgagcaaa caccaaccgg agcttcgggc gcagaattct 2580
 tcaccttctc ttcccccttc catctccttt ccccgcgga acaacgcttc cttctgtgtg 2640
 tgtctgtga tctgtgtttt catttacatc tctcttagac tccgctcttg ttctccaggt 2700
 ttccaccaga tagatttggg gttggcggga cctgctggtg acgtgcagggt gaaggacagg 2760
 aaggggcatg tgagcgtaaa tagagggtgac cagaggagag catgaggggt ggggctttgg 2820
 gaccaccgg ggccagtggc tggagcttga cgtctttcct ccccatgggg gtgggagggc 2880
 cccagctgg aagagcagac tcccagctgc taccctctc cttcccatgg gagggtgtt 2940
 ccattttggg cagaatgctg actagtagac taacataaaa gatataaaag gcaataacta 3000
 ttgtttgtga gcaacttttt tataacttcc aaaacaaaaa cctgagcaca gttttgaagt 3060
 tctagccact cgagctcatg catgtgaaac gtgtgcttta cgaagggtggc agctgacaga 3120
 cgtgggctct gcatgccgcc agcctagtag aaagtctcg ttcattggca acagcagaac 3180
 ctgcctctcc gtgaagtcgt cagcctaaaa tttgtttctc tcttgaagag gattctttga 3240
 aaaggctctg cagagaaatc agtacagggt atcccgaag gtacaaggac gcaattgtaa 3300
 agatgattaa aacgtatctt tcctttatgt gacgcgtctc tagtgcctta ctgaagaagc 3360
 agtgacactc ccgtcgtctg gtgaggacgt tcccgacag tgcctcactc acctgggact 3420
 ggtatccctt cccaggggtc accaagggtc cctgcttttc agacacccca tcatcctcgc 3480
 gcgtcctcac cctgtctcta ccaggagggt gcctagcttg gtgagggttac tcctgctcct 3540
 ccaacctttt ttgccaagg tttgtacacg actcccatct aggtgaaaa cctagaagtg 3600
 gaccttgtgt gtgtgcatgg tgtcagccca aagccaggct gagacagtcc tcatatctc 3660
 ttgagccaaa ctgtttgggt ctggttgctt catggtatgg tctggatttg tgggaatggc 3720
 tttgcgtgag aaaggggagg agagtgggtg ctgccctcag ccggcttgag gacagagcct 3780
 gtccctctca tgacaactca gtgttgaagc ccagtgtcct cagcttcatg tccagtggat 3840
 ggcagaagtt catggggtag tggcctctca aaggctgggc gcatcccaag acagccagca 3900
 ggtgtgtctt ggaaacgacc agagttaagc tctcggcttc tctgctgagg gtgcaccctt 3960

B0213WO seq list.ST25.txt

```

tcctctagat ggtagttgtc acgttatctt tgaaaactct tggactgctc ctgaggagggc 4020
cctcttttcc agtaggaagt tagatggggg ttctcagaag tggctgattg gaaggggaca 4080
agcttcgttt caggggtctg ccgttccatc ctggttcaga gaaggccgag cgtggctttc 4140
tctagccttg tctactgtctc cctgcctgtc aatcaccacc ttctctccag aggaggaaaa 4200
ttatctcccc tgcaagccc ggttctacac agatttcaca aattgtgcta agaaccgtcc 4260
gtgttctcag aaagcccagt gtttttgcaa agaataaaaa gggaccccat atgtagcaaa 4320
aatcaggggct gggggagagc cgggttcatt ccctgtcctc attggtcgtc cctatgaatt 4380
gtacgtttca gagaaatfff ttttctatg tgcaacacga agcttccaga accataaaat 4440
atcccgtcga taaggaaaga aaatgtcgtt gttgttgttt ttctggaaac tgcttgaaat 4500
cttctgttac tatagagctc agaaggacac agcccgtcct cccctgcctg cctgattcca 4560
tggctgttgt gctgattcca atgctttcac gttggttcct ggcgtgggaa ctgctctcct 4620
ttgcagcccc atttcccaag ctctgttcaa gttaaactta tgtaagcttt ccgtggcatg 4680
cggggcgcg cccacgtcc ccgtgcgta agactctgta tttggatgcc aatccacagg 4740
cctgaagaaa ctgcttggtg tgtatcagta atcattagtg gcaatgatga cattctgaaa 4800
agctgcaata cttatacaat aaattttaca attctttgg 4839

```

<210> 167
 <211> 200
 <212> DNA
 <213> Homo sapiens

```

<400> 167
cccagcaagg gatgcatca gggacttcag ggggttcacc cactttccag aggagaaact 60
ggggatgaga gaggtggaac atttgccgga ggccacactg cttgtcactg ccggtgtgaa 120
gagccacag cctattccgt cctccctcaa gtgctgggga gagtgacggt gcctggacat 180
tccagaaggc accagccctg 200

```

<210> 168
 <211> 355
 <212> DNA
 <213> Homo sapiens

```

<400> 168
aggggggaaa aggtgtctcc ttcggtaggg aatatataac gtggtgataa cctgtcacta 60
ggcagaagca tccactctgc agggacagtg gccctcggg aaagcccgcc gtccttgccc 120
aaggcctctc tgcagactcc acgggggctc accctctgcc gtcaggcgac tctgaaattc 180

```

B0213WO seq list.ST25.txt

cgacatttct cccttaaagt ctcaacagac acaagagaag ttccatcaa gcaagcactg 240
 acatatttat attaaaaaat agtgcaaaat ctcaacattt atataaataa ctctaaaccc 300
 ctgcttttga atttttttct ttacaaggta atacacactt tctgacttgg cactc 355

<210> 169

<211> 579

<212> DNA

<213> Homo sapiens

<400> 169
 ttcccagtat gcaagtcgca tcagcatcag gagtgaaga gtctctgctg gtccttaagg 60
 tctccaggag gggccagttc catcactggc tttgggagca tgaaagtgac aaatccagcc 120
 atgaatttgc ctgagtgtca gtggttaaga atacaaaag gggccccctt ctctcccaa 180
 ctgctccctc cctgggcccc taagaagggt ctgtgaccgt ctgcccagc ctttgcccag 240
 cgacaggagc cagtgcgcag ggctcccttt ctgccagtca gtcacgctg tgcactctgca 300
 gaacggctcc aggaggctct gagagcagag agcagggcct tcctcctgcc tgtcccgtta 360
 cctccttccg cggagctgga gtttggtcag atcatcatca tcgtggtggt gatgatggtg 420
 atggtggtg tgatcacgtg cctgctgagc cactacaagc tgtctgcacg gtccttcac 480
 agccggcaca gccaggggag gaggagagaa gatgccctgt cctcagaagg atgcctgtgg 540
 ccctcggaga gcacagtgtc aggcaacgga atcccagag 579

<210> 170

<211> 310

<212> DNA

<213> Homo sapiens

<400> 170
 tccttggtt cgggtgaaag cgcttgggg ttcagtgggc catgatcccc gagctgctgg 60
 agaactgaag gcggacagtc tcctgcgaaa ccaggcaatg gcggagctgg agtttgttca 120
 gatcatcatc atcgtggtg tgatgatggt gatggtggtg gtgatcacgt gcctgctgag 180
 ccactacaag ctgtctgcac ggtccttcac cagccggcac agccaggggc ggaggagaga 240
 agatgccctg tcctcagaag gatgcctgtg gccctcggag agcacagtgt caggcaacgg 300
 aatcccagag 310

<210> 171

<211> 301

<212> DNA

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 171
 ggacagggca tcttctctcc tccgcccctg gctgtgccgg ctgatgaagg accgtgcaga 60
 cagcttgtag tggctcagca ggcacgtgat caccaccacc atcaccatca tcaccaccac 120
 gatgatgatg atctgaacaa actccagctc cgctagacca gagcgaattc atcctgaaga 180
 actcagagaa agccggtgca ggaagtgggt tcccgcctctc cctgcacagg cacagtgatg 240
 ctgccagagc tctcccagaa agaccaggag gcttgttctg gagaagtcaa gcccagggat 300
 g 301

<210> 172

<211> 529

<212> DNA

<213> Homo sapiens

<400> 172
 ctctgggatt ccgttgccctg acactgtgct ctccgagggc cacaggcatc cttctgagga 60
 cagggcatct tctctctctcc gcccttggtg gtgccggctg atgaaggacc gtgcagacag 120
 cttgtagtgg ctccagcaggc acgtgatcac caccaccatc accatcatca ccaccacgat 180
 gatgatgatc tgaacaaact ccagctccgc tttttgtatt cttaaccact gacactcagg 240
 caaattcatg gctggatttg tcactttcat gctcccaaag ccagtgatgg aactggcccc 300
 tcctggagac cttaaggacc agcagagact cttccactcc tgatgctgat gcgacttgca 360
 tactgggaat ccatgacaac ctagaccaga gcgaattcat cctgaagaac tcagagaaaag 420
 ccggtgcagg aagtgggttc ccgttctccc tgacaggca cagtgatgct gccagagctc 480
 tcccagaaaag accaggaggc ttgttctgga gaagtcaagc ccagggatg 529

<210> 173

<211> 1429

<212> DNA

<213> Homo sapiens

<400> 173
 ttggaagtgt ccgtatcatg gaatcaatct ctatgatggg aagccctaag agccttagtg 60
 aaacttgttt acctaattggc ataaatggta tcaaagatgc aaggaaggtc actgtagggtg 120
 tgattggaag tggagatttt gccaaatcct tgaccattcg acttattaga tgcggctatc 180
 atgtggtcat aggaagtaga aatcctaagt ttgcttctga attttttcct catgtggtag 240

B0213WO seq list.ST25.txt

```

atgtcactca tcatgaagat gctctcacia aaacaaatat aatatttggt gctatacaca 300
gagaacatta tacctccctg tgggacctga gacatctgct tgtgggtaaa atcctgattg 360
atgtgagcaa taacatgagg ataaaccagt acccagaatc caatgctgaa tatttggtt 420
cattattccc agattctttg attgtcaaag gatttaatgt tgtctcagct tgggcacttc 480
agttaggacc taaggatgcc agccggcagg tttatatatg cagcaacaat attcaagcgc 540
gacaacaggt tattgaactt gcccgccagt tgaatttcac tcccattgac ttgggatcct 600
tatcatcagc cagagagatt gaaaatttac ccctacgact ctttactctc tggagagggc 660
cagtgggtgt agctataagc ttggccacat ttttttccct ttattccttt gtcagagatg 720
tgattcatcc atatgctaga aaccaacaga gtgactttta caaaattcct atagagattg 780
tgaataaaac cttacctata gttgccatta ctttgctctc cctagtatac cttgcaggtc 840
ttctggcagc tgcttatcaa ctttattatg gcaccaagta taggagattt ccaccttgg 900
tggaacctg gttacagtgt agaaaacagc ttggattact aagttttttc ttcgctatgg 960
tccatgttgc ctacagcctc tgcttaccga tgagaaggtc agagagatat ttgtttctca 1020
acatggctta tcagcagggt catgcaaata ttgaaaactc ttggaatgag gaagaagtt 1080
ggagaattga aatgtatatc tcctttggca taatgagcct tggcttactt tcctcctgg 1140
cagtcacttc tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc 1200
agtctacact tggatatgtc gctctgtcga taagtacttt ccatgtttta atttatggat 1260
ggaaacgagc ttttgaggaa gagtactaca gattttatac accaccaaac ttgttcttg 1320
ctcttgtttt gccctcaatt gtaattctgg tagagacgga gtttcaccgt gttagccagg 1380
atggtctcga tctcctgacc tcgtgatccg cccgccttgg cctccaaag 1429

```

<210> 174

<211> 462

<212> PRT

<213> Homo sapiens

<400> 174

```

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1           5           10          15

```

```

Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
20          25          30

```

```

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
35          40          45

```

```

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
50          55          60

```

B0213WO seq list.ST25.txt

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
 65 70 75 80
 Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
 85 90 95
 His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
 100 105 110
 Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
 115 120 125
 Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
 130 135 140
 Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
 145 150 155 160
 Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
 165 170 175
 Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
 180 185 190
 Gly Ser Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu
 195 200 205
 Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
 210 215 220
 Phe Phe Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro Tyr Ala
 225 230 235 240
 Arg Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro Ile Glu Ile Val Asn
 245 250 255
 Lys Thr Leu Pro Ile Val Ala Ile Thr Leu Leu Ser Leu Val Tyr Leu
 260 265 270
 Ala Gly Leu Leu Ala Ala Ala Tyr Gln Leu Tyr Tyr Gly Thr Lys Tyr
 275 280 285
 Arg Arg Phe Pro Pro Trp Leu Glu Thr Trp Leu Gln Cys Arg Lys Gln
 290 295 300
 Leu Gly Leu Leu Ser Phe Phe Phe Ala Met Val His Val Ala Tyr Ser
 305 310 315 320
 Leu Cys Leu Pro Met Arg Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met
 325 330 335

B0213WO seq list.ST25.txt

Ala Tyr Gln Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu
 340 345 350

Glu Val Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu
 355 360 365

Gly Leu Leu Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn
 370 375 380

Ala Leu Asn Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr Leu Gly Tyr
 385 390 395 400

Val Ala Leu Leu Ile Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys
 405 410 415

Arg Ala Phe Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe
 420 425 430

Val Leu Ala Leu Val Leu Pro Ser Ile Val Ile Leu Val Glu Thr Glu
 435 440 445

Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu Thr Ser
 450 455 460

<210> 175

<211> 1329

<212> DNA

<213> Homo sapiens

<400> 175
 atggaatcaa tctctatgat gggaagccct aagagcctta gtgaaacttt ttacctaataat 60
 ggcataaatg gtatcaaaga tgcaaggaag gtcactgtag gtgtgattgg aagtggagat 120
 ttgccaat ccttgaccat tcgacttatt agatgcggct atcatgtggt cataggaagt 180
 agaaatccta agtttgcttc tgaatTTTTT cctcatgtgg tagatgtcac tcatcatgaa 240
 gatgctctca caaaaacaaa tataatatTTT gttgctatac acagagaaca ttatacctcc 300
 ctgtgggacc tgagacatct gcttgtgggt aaaatcctga ttgatgtgag caataacatg 360
 aggataaacc agtaccacaga atccaatgct gaatatTTTg cttcattatt cccagattct 420
 ttgattgtca aaggatttaa tgttgtctca gcttgggcac ttcagttagg acctaaggat 480
 gccagccggc aggtttatat atgcagcaac aatattcaag cgcgacaaca ggttattgaa 540
 cttgcccgcc agttgaattt cattcccat gacttgggat ccttatcatc agccagagag 600
 attgaaaatt tacccttacg actctttact ctctggagag ggccagtggg ggtagctata 660
 agcttggcca cttttttttt cctttattcc ttgtcagag atgtgattca tccatattgct 720

B0213WO seq list.ST25.txt

```

agaaaccaac agagtgactt ttacaaaatt cctatagaga ttgtgaataa aaccttacct    780
atagttgccca ttactttgct ctccctagta tacctcgagc gtcttctggc agctgcttat    840
caactttatt acggcaccaa gtataggaga tttccacctt gggtggaaac ctgggtacag    900
tgtagaaaac agcttggatt actaagtttt ttcttcgcta tgggtccatgt tgcctacagc    960
ctctgcttac cgatgagaag gtcagagaga tatttgtttc tcaacatggc ttatcagcag   1020
gttcatgcaa atattgaaaa ctcttggaat gaggaagaag tttggagaat tgaaatgtat   1080
atctcctttg gcataatgag ccttggttta ctttccctcc tggcagtcac ttctatccct   1140
tcagtggagca atgctttaa ctggagagaa ttcagtttta ttcagatctt ttgcagcttt   1200
gcagatacc cagactgagct ggaactggaa tttgtcttcc tattgactct acttctttaa   1260
aagcggctgc ccattacatt cctcagctgt ccttgagttt aggtgtacat gtgactgagt   1320
gttggccag                                     1329

```

<210> 176

<211> 419

<212> PRT

<213> Homo sapiens

<400> 176

```

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1           5           10           15

```

```

Phe Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
20           25           30

```

```

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
35           40           45

```

```

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
50           55           60

```

```

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
65           70           75           80

```

```

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
85           90           95

```

```

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
100          105          110

```

```

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
115          120          125

```

```

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
Page 103

```

B0213WO seq list.ST25.txt

130						135						140					
Gly 145	Phe	Asn	Val	Val	Ser 150	Ala	Trp	Ala	Leu	Gln 155	Leu	Gly	Pro	Lys	Asp 160		
Ala	Ser	Arg	Gln	Val 165	Tyr	Ile	Cys	Ser	Asn 170	Asn	Ile	Gln	Ala	Arg 175	Gln		
Gln	Val	Ile	Glu 180	Leu	Ala	Arg	Gln	Leu 185	Asn	Phe	Ile	Pro	Ile 190	Asp	Leu		
Gly	Ser	Leu 195	Ser	Ser	Ala	Arg	Glu 200	Ile	Asp	Asn	Leu	Pro 205	Leu	Arg	Leu		
Phe	Thr 210	Leu	Trp	Arg	Gly	Pro 215	Val	Val	Val	Ala	Ile 220	Ser	Leu	Ala	Thr		
Phe 225	Phe	Phe	Leu	Tyr	Ser 230	Phe	Val	Arg	Asp	Val 235	Ile	His	Pro	Tyr	Ala 240		
Arg	Asn	Gln	Gln	Ser 245	Asp	Phe	Tyr	Lys	Ile 250	Pro	Ile	Glu	Ile	Val 255	Asn		
Lys	Thr	Leu	Pro 260	Ile	Val	Ala	Ile	Thr 265	Leu	Leu	Ser	Leu	Val 270	Tyr	Leu		
Ala	Gly	Leu 275	Leu	Ala	Ala	Ala	Tyr 280	Gln	Leu	Tyr	Tyr	Gly 285	Thr	Lys	Tyr		
Arg	Arg 290	Phe	Pro	Pro	Trp	Leu 295	Glu	Thr	Trp	Leu	Gln 300	Cys	Arg	Lys	Gln		
Leu 305	Gly	Leu	Leu	Ser	Phe 310	Phe	Phe	Ala	Met	Val 315	His	Val	Ala	Tyr	Ser 320		
Leu	Cys	Leu	Pro	Met 325	Arg	Arg	Ser	Glu	Arg 330	Tyr	Leu	Phe	Leu	Asn 335	Met		
Ala	Tyr	Gln	Gln 340	Val	His	Ala	Asn	Ile 345	Glu	Asn	Ser	Trp	Asn 350	Glu	Glu		
Glu	Val	Trp 355	Arg	Ile	Glu	Met	Tyr 360	Ile	Ser	Phe	Gly	Ile 365	Met	Ser	Leu		
Gly	Leu 370	Leu	Ser	Leu	Leu	Ala 375	Val	Thr	Ser	Ile	Pro 380	Ser	Val	Ser	Asn		
Ala 385	Leu	Asn	Trp	Arg	Glu 390	Phe	Ser	Phe	Ile	Gln 395	Ile	Phe	Cys	Ser	Phe 400		
Ala	Asp	Thr	Gln	Thr	Glu	Leu	Glu	Leu	Glu	Phe	Val	Phe	Leu	Leu	Thr		

405 B0213WO seq list.ST25.txt 415
410

Leu Leu Leu

<210> 177

<211> 940

<212> DNA

<213> Homo sapiens

<400> 177

tggaagtgtc cgtatcatgg aatcaatctc tatgatggga agccctaaga gccttagtga	60
aacttgttta cctaattggca taaatgggtat caaagatgca aggaagggtca ctgtagggtgt	120
gattggaagt ggagattttg ccaaattcctt gaccattcga cttattagat gcggctatca	180
tgtggtcata ggaagtagaa atcctaagtt tgcttctgaa ttttttcctc atgtggtaga	240
tgtcactcat catgaagatg ctctcacaaa aacaaatata atatttggtg ctatacacag	300
agaacattat acctccctgt gggacctgag acatctgctt gtgggtaaaa tcctgattga	360
tgtgagcaat aacatgagga taaaccagta ccagaatcc aatgctgaat atttggtctc	420
attattccca gattctttga ttgtcaaagg atttaagtgt gtctcagctt gggcacttca	480
gttaggacct aaggatgccg gccggcaggt ttatatatgc agcaacaata ttcaagcgcg	540
acaacagggt catgcaaata ttgaaaactc ttggaatgag gaagaagttt ggagaattga	600
aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg cagtcacttc	660
tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc agtctacact	720
tggatatgtc gctctgtctc taagtacttt ccatgtttta atttatggat ggaaacgagc	780
ttttgaggaa gagtactaca gattttatac accaccaaac tttgttcttg ctcttgtttt	840
gccctcaatt gtaattctgg tagagacgga gtttcaccgt gttagccagg atggtctcga	900
tctcctgacc tcgtgatccg cccgccttgg cctccaaagt	940

<210> 178

<211> 299

<212> PRT

<213> Homo sapiens

<400> 178

Met	Glu	Ser	Ile	Ser	Met	Met	Gly	Ser	Pro	Lys	Ser	Leu	Ser	Glu	Thr
1			5						10					15	

Cys	Leu	Pro	Asn	Gly	Ile	Asn	Gly	Ile	Lys	Asp	Ala	Arg	Lys	Val	Thr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Page 105

B0213WO seq list.ST25.txt

20

25

30

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
 35 40 45

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
 50 55 60

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
 65 70 75 80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
 85 90 95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
 100 105 110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
 115 120 125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
 130 135 140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
 145 150 155 160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
 165 170 175

Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu Glu Val Trp
 180 185 190

Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu Gly Leu Leu
 195 200 205

Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn Ala Leu Asn
 210 215 220

Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr Leu Gly Tyr Val Ala Leu
 225 230 235 240

Leu Ile Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys Arg Ala Phe
 245 250 255

Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe Val Leu Ala
 260 265 270

Leu Val Leu Pro Ser Ile Val Ile Leu Val Glu Thr Glu Phe His Arg
 275 280 285

Val Ser Gln Asp Gly Leu Asp Leu Leu Thr Ser
 Page 106

290 B0213WO seq list.ST25.txt
295

<210> 179

<211> 1388

<212> DNA

<213> Homo sapiens

<400> 179

```

tggaagtgtc cgtatcatgg aatcaatctc tatgatggga agccctaaga gccttagtga    60
aacttgttta cctaattgga taaatgggtat caaagatgca aggaagggtca ctgtaggtgt    120
gattggaagt ggagattttg ccaaattcctt gaccattcga cttattagat gcggctatca    180
tgtggtcata ggaagtagaa atcctaagtt tgcttctgaa ttttttcctc atgtggtaga    240
tgtcactcat catgaagatg ctctcacaaa aacaaatata atatttggtg ctatacacag    300
agaacattat acctccctgt gggacctgag acatctgctt gtgggtaaaa tcctgattga    360
tgtgagcaat aacatgagga taaaccagta ccagaaatcc aatgctgaat atttggcttc    420
attattccca gattctttga ttgtcaaagg atttaatggt gtctcagctt gggcacttca    480
gttaggacct aaggatgcca gccggcaggt ttatatatgc agcaacaata ttcaagcgcg    540
acaacagggt attgaacttg cccgccaggt gaatttcatt ccctattgact tgggatcctt    600
atcatcagcc agagagattg aaaatttacc cctacgactc ttactctctt ggagagggcc    660
agtgggtgga gctataagct tggccacatt tttttccttt attcctttgt cagagatgtg    720
attcatccat atgctagaaa ccaacagagt gacttttaca aaattcctat agagattgtg    780
aataaaacct tacctatagt tgccattact ttgctctccc tagtatacct tgcagggtctt    840
ctggcagctg cttatcaact ttattacggc accaagtata ggagatttcc accttggttg    900
gaaacctggg tacagtgtag aaaacagctt ggattactaa gttttttctt cgctatgggc    960
catgttgccct acagcctctg cttaccgatg agaaggttca tgcaaatatt gaaaactctt   1020
ggaatgagga agaagtttgg agaattgaaa tgtatatctc ctttggcata atgagccttg   1080
gcttactttc ctcctgggca gtcacttcta tcccgtcagt gagcaatgct ttaaactgga   1140
gagaattcag ttttattcag tctacacttg gatatgtcgc tctgctcata agtactttcc   1200
atgttttaat ttatggatgg aaacgagctt ttgaggaaga gtactacaga ttttatacac   1260
caccaaactt tgttcttgct cttgttttgc cctcaattgt aattctggta gagacggagt   1320
ttcaccgtgt tagccaggat ggtctcgatc tcctgacctc gtgatccgcc cgccttggcc   1380
tccaaagt

```

<210> 180

<211> 234

<212> PRT

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 180

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
 1 5 10 15

Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
 20 25 30

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
 35 40 45

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
 50 55 60

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
 65 70 75 80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
 85 90 95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
 100 105 110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
 115 120 125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
 130 135 140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
 145 150 155 160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
 165 170 175

Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
 180 185 190

Gly Ser Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu
 195 200 205

Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
 210 215 220

Phe Phe Ser Phe Ile Pro Leu Ser Glu Met
 225 230

<210> 181

B0213WO seq list.ST25.txt

<211> 1425

<212> DNA

<213> Homo sapiens

<400> 181

tggaagtgtc cgtatcatgg aatcaatctc tatgatggga agccctaaga gccttagtga	60
aacttgttta cctaattggca taaatggtat caaagatgca aggaagggtca ctgtaggtgt	120
gattggaagt ggagattttg ccaaattcctt gaccattcga cttattagat gcggctatca	180
tgtggtcata ggaagtagaa atcctaagtt tgcttctgaa ttttttcctc atgtggtaga	240
tgtcactcat catgaagatg ctctcacaaa aacaaatata atatttggtg ctatacacag	300
agaacattat acctccctgt gggacctgag acatctgctt gtgggtaaaa tcctgattga	360
tgtgagcaat aacatgagga taaaccagta cccagaatcc aatgctgaat atttggtctc	420
attattccca gattctttga ttgtcaaagg atttaagtgt gtctcagctt gggcacttca	480
gttaggacct aaggatgccg gccggcaggt ttatatatgc agcaacaata ttcaagcgcg	540
acaacagggt attgaacttg cccgccaggt gaatttcatt cccattgact tgggatcctt	600
atcatcagcc agagagattg aaaatttacc cctacgactc tttactctct ggagagggcc	660
agtggtggtg gctataagct tggccacatt ttttttcctt tattcctttg tcagagatgt	720
gattcatcca tatgctagaa accaacagag tgacttttac aaaattccta tagagattgt	780
gaataaaacc ttacctatag ttgccattac tttgtctctc ctagtatacc ttgcagggtct	840
tctggcagct gcttatcaac tttattatgg caccaagtat aggagatttc caccttggtt	900
ggaaacctgg ttacagtgtg gaaaacagct tggattacta agttttttct tcgctatggt	960
ccatgttgcc tacagcctct gcttaccgat gagaagggtca gagagatatt tgtttctcaa	1020
catggcttat cagcagggtc atgcaaatat tgaaaactct tggaatgagg aagaagtttg	1080
gagaattgaa atgtatatct cctttggcat aatgagcctt ggcttacttt ccctcctggc	1140
agtcacttct atcccttcag tgagcaatgc tttaaactgg agagaattca gttttattca	1200
gtctacactt ggatatgtcg ctctgctcat aagtactttc catgttttaa tttatggatg	1260
gaaacgagct tttgaggaag agtactacag attttataca ccaccaaact ttgttcttgc	1320
tcttggtttg ccctcaattg taattctgga gacggagttt caccgtgtta gccaggatgg	1380
tctcgatctc ctgacctcgt gatccgcccc ccttggcctc caaag	1425

<210> 182

<211> 461

<212> PRT

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 182

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
 1 5 10 15

Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
 20 25 30

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
 35 40 45

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
 50 55 60

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
 65 70 75 80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
 85 90 95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
 100 105 110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
 115 120 125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
 130 135 140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
 145 150 155 160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
 165 170 175

Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
 180 185 190

Gly Ser Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu
 195 200 205

Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
 210 215 220

Phe Phe Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro Tyr Ala
 225 230 235 240

Arg Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro Ile Glu Ile Val Asn
 245 250 255

Lys Thr Leu Pro Ile Val Ala Ile Thr Leu Leu Ser Leu Val Tyr Leu
 Page 110

B0213WO seq list.ST25.txt
265 270

260

Ala Gly Leu Leu Ala Ala Ala Tyr Gln Leu Tyr Tyr Gly Thr Lys Tyr
275 280 285

Arg Arg Phe Pro Pro Trp Leu Glu Thr Trp Leu Gln Cys Arg Lys Gln
290 295 300

Leu Gly Leu Leu Ser Phe Phe Phe Ala Met Val His Val Ala Tyr Ser
305 310 315 320

Leu Cys Leu Pro Met Arg Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met
325 330 335

Ala Tyr Gln Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu
340 345 350

Glu Val Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu
355 360 365

Gly Leu Leu Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn
370 375 380

Ala Leu Asn Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr Leu Gly Tyr
385 390 395 400

Val Ala Leu Leu Ile Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys
405 410 415

Arg Ala Phe Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe
420 425 430

Val Leu Ala Leu Val Leu Pro Ser Ile Val Ile Leu Glu Thr Glu Phe
435 440 445

His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu Thr Ser
450 455 460

<210> 183

<211> 18

<212> PRT

<213> Homo sapiens

<400> 183

Val Glu Thr Glu Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu
1 5 10 15

Thr Ser

80213wo seq list.ST25.txt

<210> 184

<211> 24

<212> PRT

<213> Homo sapiens

<400> 184

Ile Phe Cys Ser Phe Ala Asp Thr Gln Thr Glu Leu Glu Leu Glu Phe
1 5 10 15

Val Phe Leu Leu Thr Leu Leu Leu
20

<210> 185

<211> 8

<212> PRT

<213> Homo sapiens

<400> 185

Ser Phe Ile Pro Leu Ser Glu Met
1 5